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Acute Coronary Syndromes 
Introduclion 
Acute coronary syndromes (ACS), ·which include unstable angina, non-Q"wavc 
myocardial infarction eMI), Q-1vave MI, sudden ische1llic death and the acute 
c01llplicatiol1S resulting from interventional procedures, are the leading causes of 
morbidity and mortality in the Western world. 
In ''''estern European cDunhics, 14 % of all deaths (414 000 annually) have been 
attributed to acute MI and other ischemic heart diseases,l In the USA, 1110re than 
13 111i11ion people suffer froll1 ischemic heart disease, and ACS yearly account for 
ahnost 500 000 deaths. Each year, an estilnatcd 1.1 111illion Alnericans have a new 
of recurrent coronary attack, and about one third of thCll1 die. At least 250.000 
deaths attributed to i\1T occur 'within 1 hour of onset of Syl11ptOllls and before 
treahnent can be started.2 More than 650 000 Alnericans are discharged each year 
"with a prinl31J' diagnosis of unstable angina. This nlll11ber approaches that of 
patients discharged with a primary diagnosis of MI (747.000).' Over 10% of 
patients admitted to the hospital with unstable angina develop an MI within 2 weeks 
of diagnosis, and I-year nlortality of these patients ranges from 5% to as n1nch 
as 14%.' The ACS therefore have a considerable impact on public health and result 
in substantial n1edical expenditure . 
. Although CUITent interventional and phmTI1acologic therapies have been effective 
in reducing the incidence of ischemic events, novel therapeutic targets and 
strategies are urgently needed to in1prove further the clinical outc0111e in patients 
presenting with ACS. 
In the last decade) nunlerous studies have provided a more detailed 
understanding of the pathogenesis of ACS. Fr0111 these insights, new therapeutic 
targets and pharmacologic approaches to the treatment of ACS have emerged. 
Additionally, the results of these studies have led to an appreciation of the reasons 
for the drawbacks and shortcomings, including the relatively limited effectiveness, 
of the conlpounds used in the n1anagmllent of patients ,dth ACS. 
Pathophysiology of ACS 
ACS share the COlllnlon pathophysiology of 111yocardial ischelllia caused by 
varying degrees of coron31J' artery occlusion by platelet-rich thrOlnbi, initiated by 
the process of disruption or erosion of the covering endothelial layer of an 
atherosclerotic plaque.5.6 The two critical events in the pathogenesis of ACS, 
therefore, arc disruption or ulceration (erosion) of an atherosclerotic plaque and 
the subsequent superi1nposecl forn1ation of a partially or c0111pletely occlusive 
platelet-rich thrombus through the stages of platelet adhesion, activation and 
aggregation of individually activated platelets.56 The clinical presentation of the 
ischemia resulting frOlll the platelet-rich coronary thrombus depends on the 
extent and duration of obstruction of myocardial blood supply. 
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Disruption or erosion of atherosclerotic plaques 
Early plaque developnlent involves the proliferation of smooth 11111scle cells, 
the production of collagen and the accumulation of lipid lNithin macro phages/ as 
well as in the extracellular lnilien ·within the lesion.6 These initial plaques are often 
asynlptoll1atic uwing to the renlOdel1ing capacity of the affected coronary artery. 
An atherosclerotic plaque can beC01llC synlptomatic, either because additionallipid 
acquisition leads to plaque gt'U'\\Tth, causing chronic stenosis id1ich 111ay clinically 
lllanifest as stable angina, 01' because the plaque undergoes erosion or disruption 
oftlle covering enc1othelitll11, resulting in corowuy thr0111bosis ·which 1uay present 
as an acute ische111ic coronary syndrOllle.O.6 Not all plaque disruptions follo-wed by 
platelet thrombus formation, hOlNevel~ lead to an acute ischen1ic coronary event. 
Plaque nlptures \vith subclinical thr0111bosis result in the incorporation of thrombi 
into the lesion, stimulating plaque grmvth. In this way, plaque ruptures also 
contribute to the progression of the atherosclerotic process, 'which leads to the 
developnlent of the chronic stenoses that cause stable angina.s,6 The probability 
of plaque disruption is detern1ined by several factors, including the shape of the 
plaque, its composition, S0111e properties of the local circulation and external fhctors 
(e.g. blood pressure). 
Most patients vdth coronalJr artery disease have both concentric plaques, 
resulting in a fixed degree of obstruction) and eccentric plaques, ,\"'Ilkh may vary 
in the degree of stenosis owing to changes in coronary artery nlusc1e tone. 5 
Concentric plaques arc nlOre COll1111only associated 'with stable angina, while 
eccentric plaques carry an increased risk of disruption or erosion, resulting in an 
ACS. 5.7 
Susceptibility to disruption or fissuring is detennined to a great extent by the 
relative content of the major constituents of the plaque~namely intracellular lipid, 
extracellular lipid, collagen and proteoglycans. Fibrous plaques are composed 
primarily of collagen and proteoglycans and are considered 'stable' plaques. In 
contrast, high lipid content predisposes atherosclerotic plaques to an increased risk 
of disruption. These plaques contain a lipid-rich core that is separated from the blood 
by a fibrous cap "whose strength is proportional to its thickness. Therefore, the 
susceptibility of the lipid-rich plaques to rupture may vary depending on the 
thickness of the fibrous cap and the collagen content, which lends stability to the 
cap. Lipid-rich atherosclerotic lesions 'with a thin fibrous cap and a lack of collagen 
are Inore susceptible to disnlption and are therefore considered Ivulnerable' plaques.M 
High shear forces in the area of stenosis increase the probability of plaque 
rupture, especially if it concerns a vulnerable plaque that lacks a stable fibrous 
cap.8 Changes in coronary tone and pressure can also affect plaque susceptibility 
to rupture or fissuring by altering the degree of stenosis and the related local shear 
forces. 
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Thrombotic response to plaque rupture and platelet thrombus formation 
\\7}lcn an atherosclerotic plaque ruptures or ulcerates, platelets in the circulation 
arc exposed to the highly thrOlllbogcnic environnlel1t within the plaque or the 
snbendothelium. Platelet adhesion is the first step in platelet-mediated thrombosis. 
Platelet adhesion is mediated primarily by the binding of the platelet glycoprotein 
(GP) Ib receptor to the subendothelial form of von Willebrand factor (vWF).' 
Adhesion of platelets is followed by platelet activation. Adherent platelets aTe 
activated via several potent platelet agonists. The plaque and the subendothelial 
layer both contain large amounts of collagen "while lipid-laden l11acrophages in the 
plaque COfe produce large quantities of tissue facto!: Tissue factor stimulates the 
generation of thrombin (factor lIa) by initiating the coagulation cascade. 10 Thrombin 
and co11agen are two of the 111ajor inducers of platelet activation,ll An other potent 
platelet agonist is the high shear force of the circulation in the stenotic region,mll 
These platelet agonists activate several signal transduction pathways ·within the 
platelet. The final outcome of platelet activation includes a change in platelet shape 
and the secretion of additional platelet agonists (adenosine diphosphate [ADPj, 
serotonin and thrOlnboxane A2), adhesive glycoproteins (fibrinogen and vWF), 
clotting factors and other vasoconstrictors, thus promoting vasospasnl and further 
platelet accunlldation and activation.6,1O.11 Activation ofplate1ets by any agonist results 
in the expression of more than 50 ooo-ao 000 copies of the GP lIb/lIla receptor on 
the sln-face of each and every platelet, and its conversion to a high-affinity binding 
site for its pritllary ligands, fibrinogen and v'N"F. Bivalent 11101ecules of fibrinogen 
cross-link ligand-competent GP lIb/IlIa receptors on adjacent platelets. EvenhJally, 
bridging of platelets by their GP lIb/lIla receptors on a large scale generates a 
platelet-rich thrombus at the site of plaque injury." Additionally, the aggregate of 
activated platelets is the primary source of the negatively-charged phospholipid 
surface on \vhich the coagulation cascade proceeds, further increasing thrOlnbin 
generation and the conversion of fibrinogen to fibrin.? Local generation of thrombin 
and fibrin then fbrther enhance both platelet activation and aggregation. Most 
hnportant, regardless of the proaggregatory stinullus, the final COl11111on pathway 
to platelet aggregation and thus to the formation of the platelet-rich thrombus, a 
pivotal event in the developl11ent of ACS, involves a&~regation of activated platelets 
via their GP lIb/IlIa receptors. 
Clinical presentation 
The clinical presentation of the 111yocardial ischel11ia resulting fr0111 the 
platelet-rich coronary thrOlnbus depends on the extent and acuteness of l11yocardial 
blood flow obstruction, as well as on the duration of decreased ll1yocardial 
perfusion.6 
The magnitude of the plaque injmy determines the strength of the subsequent 
5 
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thT01nbotic response and is therefore related to the clinical Qutco111e. Minor 
plaque fIssuring usual1y results in the fOf1nation of 81na11 intrainti111aI platelet 
thrOlnbi, 'which aTC subsequently incorporated into the plaque. These thrombi 
usually rel11ai11 aSYlllptOlnatic but stilnulatc further plaque growth,M 1111e8ion8 
that have been disrupted 1110re deeply, increasing platelet activation results in the 
formation of larger thrOlllbi. These thr0111bi 111ay grmv intraluminally and can be 
either non-occlusive (111ura1) or occlusive.s The non-occlusive, intrahl111inal 
thrombi consist prilnarily of platelets and fibrin C'white' thrombi).5.1213 The outer 
surface of the 'Nhite thrOlllbus lU3SS consists of a layer of activated platelets.5 An 
occlusive coronary thr01nbns is compm;ed of a platelet-rich or ('ivhite' part located 
inside the disrupted atherosclerotic plaque and an inhalUll1ina1, occlusive 'red' part. 
The occlusive part ofthc thrOll1bus consists 111ain1y of fibrin and red blood cells, 
1Nhile platelets are scarce. 5.12,13 The transitional zone between the intraplaque 
white thrombus part and thc occlusive red thr0111bus is characterized by a layer 
of activated platelets, 'ivhich provide a highly active surface on which the occluding 
red thrombus layer is gencrated.5 Therefore, the aggregation of individual activated 
platelets by cross-linking of their GP TJb/IIIa receptors to form a white mural 
thr0111bus represents an cssentia1 step in the generation of the c0111pletely 
occlusive red thr01ubus. 
The presence 01' absence of a well-developed collateral circulation to the 
affected vessel is also an llnportant factor detennining the clinical outcon1e of 
intracoronary thr01ubosis. 5.14 Disruption of highly stenotic plaques is less likely to 
interfere significantly with myocardial perfusion since the distal territory is 
usually supplied by collaterals. 16. 16 In contrast, disruption of nlOderately stenotic 
plaques carries an increased risk of developing an ACS since the coll.ateral 
circulation has usually been less well-developed. 
Thc clinical nlanifestations of ACS depend primarily on the degree and 
acuteness of coronmy blood flow obstruction and the duration of decreased 
l11yocardial perfusion.6 At one end of the spectrum, patients presenting with the 
ACS of unstable angina usually have non-occlusive, intralull1inal thrombi, which 
are composed primarily of platelets (figures 1 and 2).1213 
Additionally, platelet aggregates may embolize distally, causing foci of 
l11yocardial necrosis.s These patients usually present with ST-segl1lent depression 
on their electrocardiogran1 (ECG) and elevated troponin T or troponin I levels. In 
non-Q"'wave infarction, the angiographic form of the responsible lesions is very 
shnilar to that 1:leen in unstable angina. In 25% of the non-Q1\raVe ~1I patients, 
howevCl~ the infarct-related artery is occluded but the distal 111yocardium retuains 
perfused by the collateral vasculature. In the remaining 75% of subjects, the nuual 
platelet-rich thrombus is l1on-occlusivc.6 The principal differcnce between unstable 
angina and non-Q-wave MI is the clevated level of cardiac enzymes (creatine 
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l<inase-1\1B) in the latter patient population, reflecting 111yocardial necrosis resulting 
from a longer duration of coronary blood flow obstruction. In Q"'1N8VC infarction, 
an occlusive thr0111bus on a deeply injured plaque leads to an abrupt, C0111pletc 
and prolonged cessation of lllyocardial perfnsion.6 This results in subsequent 
myocardial ischel11ia and necrosis of the Inyocardium supplied by the affected 
coronary artery. The intraltnllinal thr01nbi found in patients 'Ivith Q~wave 1\11 are 
occlusive and consist mainly of fibrin and trapped red blood cells (Figures 1 and 
2).12.13 The ECG sho·ws STsegn1Cnt elevation and subsequent developl11ent of 
abnormal Qwaves. As in non~Qwave MIl elevated levels of cardiac enzyrnes reflect 
the nlyocanlial necrosis. The pathophysiology of sudden ischemic death involves 
a rapidly progressing lesion with subsequent occlusive thrombosis.6 The abrupt 
and c0111plete obstruction of coronary blood flow results in severe ischemia and 
fatal ventricular arrhythmias.6 The probability of sudden ischemic death in 
patients with acute thrombotic occlusion is increased in absence of a wel1-
developed collateral circulation. 
Goals in the management of acute coronary syndromes 
In the l11ajority of patients presenting ·with the ACS of unstable angina and non-
Qwave MIl the platelet-rich thrombus is only partially occlusive. Antithrombotic 
(anticoagulant in cOlllbination 'with antiplatelet) agents ait11 to l11aintain vessel 
patency by preventing the progression of a non-occlusive thrOlnbus to an occlusive. 
thrombusl and to inhibit the generation of ne·w thrombi by preventing fmiher platelet 
aggregation. In patients ·with acute MIl characterized by STsegment elevationl the 
affected coronary atiery is completely occluded. Thereforel the first goal is to achieve 
rapid reperfusion by the adl11inistration of thrombolytic therapy. SecondlYI it is of 
utmost illlportance to l11aintain patency of the infarct~related artel"Y1 and to prevent 
recurrent thr01llbosis leading to reocclusion and recurrent ischClllia. For this reasonl 
thrOlllbolytic therapy is cOllnnonly used in combination with antithr01llbotic drugs,17 
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AngiopJasty has been used successfully in patients with all ACS. Although 
effective in establishing adequate Inyocardial reperfusioll , angioplasty does not 
affect the underlying pathophysiologic processes, platelet aggregation and 
thrornbns fOl'lnation. Drmvbacks of angioplasty include a significant incidence of 
both acute (abrupt vessel closure) and long-term (restenosis) ischemic 
cOlllplications, lNhich l11ay re~mlt in MI or c1eath. 18.19 These have been 111anaged by 
intracoronary stcnt i111plantatioll, but stenting is also accOlupanicd by adverse 
effects, 1110St notably stent thrombosis.20 
Although CUlTcnt interventional and phannHcological therapies have been 
effective in the treatJnent of patients 'with ACS, none of the current 111allagenwnt 
sh"atcgics effectively prevents platelet thrombus fonnatioll , and the l110TC thorough 
understanding of the pathophysiology of ACS has pointed to their drawbacks and 
Ihnited effectiveness. Additionally, studies have identified the pivotal role of the 
GP lIb/IlIa receptor in platelet aggregation and coronary th1"0111bosis. This receptor 
has Clnerged as a new therapeutic target and several inhibitors of its function have 
been developed and studied in large clinical trials." Based on the results ofthese 
trials, the GP lIb/lIla receptor inhibitors have 81101N11 prOlnising results in 
i111proving the DutcOlnes of patients lNith ACS and those cxpeliencing the ischetnic 
cOlllplications of the invasive therapies of these diseases. 
Anlilhrombotic therapy 
Antithr01llbotic therapy con::dsting of the intravenous infusion of 
unfractionated heparin plus the oral adnlinistration of aspirin is used routinely 
in the treatment of the variolls ACS. 
Aspirin 
In patients with a broad spectnnn of cardiovascular diseases, antiplatelet 
therapy offers protection against recunent adverse ischemic events,21 The Inost 
widely used antiplatelet drug today is acetylsalicylic acid (aspirin). Aspirin 
reduces the incidence of death) recurrent MI and shoke in patients presenting with 
acute MI (Figure 3).2122 
Aspirin also teduces mortality and MI lNhen used in the acute management 
of un stahle angina,23,26 The principal side-effects of aspirin include dose-dependent 
gastrointestinal symptorns and renal toxicity. Aspirin inhibits the synthesis of the 
potent platelet activator thromboxane A2 by blocking the cyc!o-m,j'genase pathway." 
HowevC1~ like many other platelet activation antagonists) aspirin inhibits only one 
of the pathways to platelet activation, leaving the others intact. Most ofthe platelet 
agonists can stimulate platelet aggregation by activating the GP lIb/IlIa receptor 
via 11111nerous alternate platelet activation patlrways,lO Although safe and very 
cost-effective, aspirin is therefore not a potent platelet antagonist. 
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Unfractionated heparin is a heterogeneous 111L-.:ture of polysaccharides ·with 
a molecular weight of 5000-30 000 Da. The mechanism of action of heparin 
involves binding to antithrombin III (AT-lII) , thereby greatly increasing its 
anticoagulant activities." AT-III is a protein capable of inhibiting multiple steps 
in the intrinsic and COll1111011 coagulation pathways, and of blocking the actions 
of free thrombin. Thrombin is thought to play an important role in the 
pathophysiology of coronary artery thr0111bosis. It promotes platelet activation and 
aggregation, cleaves tlbrinogen to fonn tlbrin, and catalyses the cross-linkage of 
the fibrin clot. Additionally, thrombin can self-amplif'y by means of a positive 
feedback loop. By binding to AT-Ill, heparin increases the affinity of AT-III for 
thrombin lOOO-fold. In this way, the heparin-AT-III complex is capable of blocking 
a higher level of thrOlnbin activity and increasing the time to clot f0T1nation. 28 
Heparin fragments 'with a 10'wer molecular "\veight hound to AT-III are 1110re 
capable of inhibiting factor Xa activity than blocking the actions ofthrombin.28 
Heparin is the lllOst widely used antithr0111bin therapy for patients with 
ACS. In clinical trials/ heparin, alone and in c01nbination with aspirin, has been 
effective in reducing the adverse ischemic ontcOlnes, including death and non-
fatal !vII al110ng patients with unstable angina and non-Q-wave lvII.25.26.29 A nleta-
analysis of 11111ltiple studies has shown a 33% reduction in MI or death during 
heparin therapy in patients with unstable angina treated with aspirin plus heparin 
9 
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COlllpared 'with those treated with aspirin a10ne.4 The uscfblness of un fractionated 
heparin in the managfnllcnt of patients presenting 'with acute ST-elevatioll IvII is 
not unequivocal. Acel AHA guidelines recornmend the lise ofintravenous hepmin 
in patients treated 'with tPA and in patients 'who do not receive tlu·Olnbolytics, 'while 
in those lNho are treated with streptokinase and are not at high risk for systclnic 
elnboli the addition of heparin is not rCCOlll111Cnded. 30.31 
The usc of unfractionated heparin is associated 'with several potential 
drawbacks. The effectiveness of heparin is lilnited by several factors, including 
its inability to inhibit clot-bound thr0111bin, its dependence on AT-III, its 
neutralization by protein binding and platelet factor 4, which is secreted by 
activated platelets and blocks the interaction between heparin and AT-III, and the 
rebound clinical events that fo11ow the discontinuation of un fractionated heparin. 
Unfractionated heparin is therefore inconsistent in its effect within and between 
patients. Furthennore, it leads to thrOlllbocytopenia in about 5% of patients, and 
requires hospitalization for frequent 11lOnitoring of the activated partial 
thromboplastin time (aPTT) and careful titration to achieve aPTT of 50-70 
seconds.32-35 In the GUSTO-I trial, aPTT values exceeding 70 seconds -were related 
to a progressively increased rate in 1110derate-to-severe bleeding and ,\"'ere also 
associated with higher 1110rta1ity and reinfarction rate. 36 In the GUSTO-ITa trial, a 
nlOre intensive heparin regimen was accOlllpanied by a 2-fold risk ofhaenlOrrhagic 
stroke in patients receiving thrOlnbolytic therapy.37 In patients with acute MI, 
fibrinolytic therapy exposes thrOlnbin, w-hich resl11ts not only in the autocatalytic 
fonnation oflllore thrombin but also in enhanced platelet activation. The thrOlllbin 
activity, but not the increasing fonnation of more thr01nbin, 111ay be inhibited by 
concOlnitant heparin during thro111bolytic therapy. FurthenllOfe, activated platelets 
create an environment that is potentially resistant to the effects of heparin. 
i,Vhen conlplexed vvith activated platelets, factor Xa is also relatively resistant to 
inactivation by the heparill-AT-ITI complex.33 
The need for increased efficacy and the Ihnitations ofllnfractionated heparin 
have led to the developillent of alternative and 1110re potent antithrOlllbotic 
drugs, including low-11101ecular--weight (LMVl) heparins and direct thrombin 
inhibitors. 
Low-molecular-weight heparin 
LM\V heparins are produced by depolYlllCrization of standard heparin, 
resulting in shorter polysaccharide fragll1ents '\\'ith a 11101ecular weight of 4000-
8000 Da. LM'V heparins have several potential advantages over unfractionated 
heparin. Owing to a higher resistance to inactivation by platelet factor 4 and a lower 
affinity for heparin-binding proteins, LMW heparins have a nl0re predictable 
pharmacokinetic profile, greater bioavailability and longer plasma halflife, all of 
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which result in more predictable and reliable levels of anticoagulant effect."" LMW 
heparins can therefore be administered once or twice daily as subcutaneous 
injections at fixed or lNcight-acljustecl doses! thus shnplifying treatlnent in the acute 
phase ·without the need for laboratory lllOnitoTing. The Imver-nlOlccular-1Neight 
distribution not only decreases the variability of the anticoagulant effectj but also 
l110difies the anticoagulant l11echa11i8111. LM\V heparins have a higher Xa/lla 
inhibition ratio I but a lesser platelet inhibitory effect. 40 
Several clinical trials have evaluated the efficacy and safety of LMW heparins 
in patients presenting ·with ACS. 
In the FRISC (Fragmin During Instability in Coronaty Artery Disease) study, 
1506 patients 'with unstable angina or llon-Q-wave infarction 'were randomised to 
rcceive subcutaneous dalteparin (Fragmin; 120 U/kg hvice daily for 6 days, 
followed by 7500 U once daily for the next 35-45 days) or placebo in addition to 
aspirin.41 The primary endpoint (death or new MI at 6 days) ",,"'as significantly luwer 
in the group taking dalteparin (1.8% versus 4.B%). The C0111posite endpoint of death, 
nc'w MI, revascularization or necd for intravenous heparin also shmved a significant 
diftcrcnce in favour of dalteparil1 (5.4 % versus 10.3 % ). These differences persisted 
at 40 days hut were no longer significant at 4-5 months after the end of treatment. 
HO"WeVCl~ survival analysis shmv"cd a risk of reactivation and reinfarction when 
the dose "was decreased. Thc trcahllent regimen was safe and c01npliance was 
adcquate. Of note, this study did not c01npare dHlteparin lNith unfractiollated 
heparin, but lNith placebo. 
In the ESSENCE (Efficacy and Safety of Subcutaneous Enoxaparin in NOll-(l-
Wave Corollmy Events) trial, the effect ofthe LMW heparin enoxaparin (lmg/kg 
every 12 h) i\7"8S c01npared with unfractionated heparin (a(,justed to achieve an 
aPTT of 55-85 seconds) in 3171 patients with unstable angina or non-Q-wave M1.42 
All patients received aspirin. The Inedian duration of treatment for both trial 
therapies was 2.6 days. At 14 clays, the risk of death, MI or recurrent angina lNas 
significant1y 10wer in patients assigned to enoxaparin than in those randOlllized 
to unfractionated heparin (Hi.6% versus 19.8%). The risk of this composite 
endpoint remained significantly lower at 30 days (19,8% versus 23.3%). Although 
the significance of the treahnent effect "was driven by the differences in the rates 
of recurrent angina, the risks of both death and MI at 30 days 'were reduced as well 
by 20% and 25%, respectively, 'Iteatment 'with enoxaparin did not increase the 
incidence of major blecding cOlnplications, a1though there were slightly more minor 
bleedings, primarily because of ecchymoses at injection sites. 
In the ESSENCE trial, the theoretical advantages of LMW heparin over 
unfractionated heparin have been translated into a clinical benefit. The Blore 
consistent anticoagulant effect together with the higher Xa/lla inhibition ratio nlay, 
in part, account for the better therapeutic index that LMV.,r heparin has over 
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unfractionated heparin. A 111(~jor advantage of LlvI\Y heparin is, hO"WCVC1~ that it 
can be used in fixed doses 'without the necessity of 111onitoring, thus shnplifjring 
therapy and aIIuwing its continuation beyond hospital discharge. I\1ore studies are 
needed to assess the optilnallcllgth of u'cahncnt and the long-tenn DutcOlnc. Future 
clinical trials will investigate the efficacy and safety of LMvV heparins in 11mv 
therapeutic settings and in cOll1bination 'with thT0111bolytic and other new potent 
antithrombotic and antiplatelet therapy. A slibstlicly in the GUSTO-IV trial will 
investigate the shnultallcous treahncnt of unstable angina patients 'with a GP 
lIb/IlIa inhibitor (abciximab) and LMW heparin. 
Direct thrombin inhibitors 
DiTcct thr0111bill inhibitors, such as hirudin and hirulog, have potential 
advantages over heparin. They do not require AT-III as a cofactOl~ are capable of 
inhibiting both free-circulating as well as clot-bound throlnbin and are not 
inactivated by plaslna proteins or platelet factor 4.43 
The TIMI 9Il trial compared the efficacy and safety ofhiruclin with intravenous 
heparin in 3002 patients with acute MI presenting 'within 12 h fronl onset and 
treated 'with streptokinase or tissue-type plasminogen activator.44.45 COlnparison 
of the prhnary endpoint of deathl MIl conge8tive heart failure or shock at 30 days 
betlNeen treatnlCnt groups did 110t show a significant difference (heparin 11.8% 
versus hinldin 12.8%). The incidence of major bleeding events including 
intracranial bleeding "was also silnilar between groups. 
The HERO (Himlog Early Reperfllsion/Occlusion) trial compared the efficacy 
of two doses of hirulog with heparin in achieving TIMI grade 3 flow at 90 min 
among 412 patients ,\\Tith acute ST-elevation MI 'who were treated \vith aspirin and 
streptokinase.46 TIMI grade 3 Howat 90 Ininutes was 35% with heparin 1 46% with 
low-dosel and 48% with high-dose hirulog. At 2 - 4 days after treatnlent, siInilar 
rates of TIMI grade 3 flow were present in the three groups, Hirulog was 1110re 
effective in producing early patency without increasing the risk oflllajor bleeding, 
In the large GUSTO-lIB (Global Usc of Strategies to Open Occluded Coronary 
Arteries) trial l 12142 patients with ACS were rando111ized to receive 72 h of 
therapy with either intravenous heparin or hirudin,47 At 24 hi the risk of death or 
MI 'was significantly lower in the hirudin group than in the group assigned to 
heparin (1.3% versus 2.1 %). This difference was still significant 48 h after the 
initiation of treatment (2.3% versus 3.1 %). Although hirudin dClllonstrated an 
iInportant effect in reducing early events) the extent of the benefit at 30 days was 
snla11 and of marginal statistical significance (incidence of death or MI at 30 
days: 8.9% versus 9.8% in heparin grouPI representing an 11 % risk reduction, P 
= 0.(58). The benefit was sitnilar in patients with Sl:'seguwnt elevation and in 
those without. Although there was no significant difference in the incidence of 
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severe bleeding complications, treatment "with hirudin was associated 'with a 
significantly higher incidence of 1110deratc bleeding (8.8% versus 7.7%, p = 
0.03). 
Results limn trials with direct thrombin inhibitors have questioned the hypothesis 
that potent direct inhibition ofthrombin results in a clinically ll1caningfuI long-term 
benefit in clinical outcome. Although thrOlllhin is one of the lllOSt potent platelet 
activators, inhibition of thrombin only targets a single platelet activation pathway, 
leaving nUlnerous alternate routes for platelet activation available. Furthe1~ it 'was 
demonstrated that) 'while capable of inhibiting thrombin activity, hirudin, like 
heparin, 'was incapable of blocking thrombin generation resulting in an accull1Ulation 
of thrOlllbin exceeding the ability of hirudin to block its activity.48.49 Thereforel 
antagonisln higher in the coagulation cascade I as achieved using UVIV{heparin l may 
appear to be morc effective. The lack oflong-term benefit may also reflect the lack 
of passivation of the vessel surface or the rebound hypercoagulability after the 
discontinuation ofh"eatment.f.I) Higher doses ofhinldinl howevel; resulted in excessive 
bleeding (including intracerebral haemorrhage) in the prematurely discontinued TIMI 
9A and GUSTO-IIA trials lNithout indication of hnproved efficacy.37.51 Thereforel 
like heparinl hirudin also requires careful titration to achieve aPTT of50-70 seconds. 
The GUSTO-IIB trial showed that patients treated with hirudin required significantly 
fe\ver dose acljustments to maintain therapeutic levels of anticoagulation than those 
heated 'with heparill.47 Most illlportantl future trials will have to find ways to iInprove 
the durability over titue of the therapeutic effect as observed in the early phasel and 
to assess the additional benefit ofa combination of direct thrombin inhibiting agents 
and platelet GP lIb/IlIa receptor blockers. 
Thrombolysis 
Thrombolytic therapy has been effective in reducing nlOrtality in patients 
presenting with acute MI with ST-segment elevation (Figure 3).2Z62 Although 
prinlary angioplasty is being used to an increasing extentl thrOll1bolysis is still the 
nlost widely used modality of reperfusion therapy. Neverthelessl throlllbolytic 
therapy has significant and relevant efficacy as we11 as safety liluitations. 
In patients with acute MIl achievement of rapidl complete and sustained 
restoration of coronary flow through the inf.:1.rct-related mtery (THvII-ThrOll1bolysis 
In Myocardial Infarction-grade 3 flow) results in lower nl0rtaHtYI irrespective of 
the thrombolytic regimen.SJ54 In the angiographic substucly of the landmark 
GUSTO-I trial, death OCCUlTed in 4.4% of patients \vith normal coronary flo'w at 
90 l11inl whereas nlortality 'was as high as 8.9% among patients with no flow. 53.54 
The n10st potent currently available thrOlnbolytic therapYI a c0111hination of 
accelerated alteplasel aspirin and intravenous heparinl produces conlplcte 
11lyocardial reperfusiol1 in only 53% of patients, howevcl:&3 
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Treatnlcnt with thrombolytics is associated i\'ith an increased risk of 
intracerebral bleeding, particularly in older patients and in those '''lith 
hypertension.55 In the recently completed GUSTO-III trial, the incidence of 
haclllOrrhagic stroke was 0.9%, or approxinlately 1 in 100 patients,56 
Furthermore, prhllary angioplasty for the treahncllt of acute 1\11 is capable 
of achieving higher rates of infhrct vessel patency (T[M! grade 3 flow approximately 
90%) and is associated "dth a significant reduction in l110rtality and recurrent MI 
as c0111pared ·w"ith phannacological reperfusion.57-60 
The primmy reason for the lack of efficacy and the relatively high failure rate 
of thrombolytic therapy is related to the prothrombotic effects of fibrinolytics and the 
lack of a potent anti platelet approach in the treatment of acute ML When fibrinolysis 
occurs, there is exposure of free thrombin, 'which not only increases its own production 
but also leads to platelet activation, thereby strongly prOllloting further platelet 
aggregation. The platelet-liell part at the core of the thrombus is, howevel; fully resistant 
to fibrinolytic therapy. In addition, activated platelets inhibit fibrinolysis by releasing 
large al110nnts of plasminogen activator inhibitor-l , the nlOst potent endogenous 
inhibitor of fibrinolysis, and by secreting rapid-acting a2-antiplasmin. Release of 
coagulation factor XIII further increases resistance to thrombolytics by cross-linking 
fibrin. 61 -63 
These interactions in response to fibrinolytic therapy stitnulate the fonllation 
of platelet-rich thr0111bi and contribute to the ongoing and recurrent thr01nbosis 
observed in the infarct-related coronary artery. Together ·with the inability of 
fibrinolytics to interfere with the forlllation of the platelet-rich (white) thrombi 
and the lack of a potent antiplatelet approach, they Illay contribute to the failure 
of reperfllsion and to the reocclusion that are present in many patients treated 
with thrombolytic therapy.64 
The prothr01nbotic state follmdng fibrinolytic therapy may not only account 
for the lack of benefit of fibrinolysis in patients with unstable angina and non-Q 
,\\Tave MI, in Wh0111 the thrOlnbus is conlposed prilnarily of platelets,"'S but also 
explain the adverse clinical effects of angioplasty after preceding thrombolysis in 
patients with acute MI.66-63 
The importance of a potent antiplatelet approach is endorsed by the results 
of the [8[S-2 hia1. Despite the fact that aspirin is a relatively weak antiplatelet agent 
and its antiaggregatory effect in the acute phase is only modest, this study showed 
that early adnlinistration of aspirin resulted in a 23% risk reduction in 1110rtality 
in patients with acute MI. This benefit was as large as the lllOrtality reduction 
achieved with the use of streptokinase alone (figure 3).22 
A Illore potent anti platelet therapy can be achieved with the use of GP 
lib/Ill a receptor antagonists. The addition of GP nb/Illa receptor blockade to 
thrombolytic therapy in patients presenting with acute M[ has the potential to 
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counteract the prothrombotic tendencies offibdnolytic agents, and to result in 1110re 
rapid, complete and sustained rcperf'usioll j and inlprovecl survival. 
Platelet glycoprotein lib/Ilia receptor inhibitors 
Based on a more thorough understanding of the pathogenesis of ACS and the 
identification ofthe platelet GP lIb/IlIa receptor as the final C0111mon pathway 
to platelet aggregatioll j a nC1\' class of therapeutic agents has cll1cTged j the GP 
IIb/ma receptor antagonists. 11 Several inhibitors of the GP IIb/IIIa receptor have 
been developed. They act either as irreversible) non-cOlnpctitive GP IIb/IIla 
receptor blockers (l11onoclonal antibodies) or as reversible, c01npctitivc GP Ilb/IlIa 
receptor antagonists (fibrinogen analogs). HOlNevcl~ -w1illc the C0111111011 Ihnitation 
of all antiplatelet agents that target the platelet activation stage of thrombus fonnation 
is the existence of nU111crous alternate platelet activation pathways, all of the GP 
lIb/IlIa receptor antagonists are potent inhibitors of platelet-platelet interaction 
and capable offully blocking platelet aggregation, which represents the final common 
pathway to coronary thr01nbosis and ACS.6? Several of these agents have been 
evaluated in large-scale, randOlnized, placebo-controlled clinical trials, and they 
have 8ho\\,11 to be effective in reducing recurrent adverse ischcl11ic events in the 
treatment of patients undergoing percutaneous intervention and in patients with 
unstable angina or non-Q'wave infarction. 
Abcixilnab, the Fab fraglnent of a chimeric hUman-1l10USC antibody (c7E3) 
directed against the GP Ilb/IlIa receptOl~ was the first to undergo clinical evaluation 
in the EPIC trial, and 'was approved for use in percutaneous coronary intclvcntion 
in HJ95. In the EPIC (Evaluation ofc7E3 for the Prevention ofIschemic Complications) 
trial, 2099 patients scheduled to undergo angioplasty who were at high risk of 
ische111ic complications (severe unstable angina, evolving acute IvII) or high-risk 
coronary morphologic characteristics) 'were randomised to placebo) a bolus of 
abcixh11ah just before the procedure) or a bolus and 12-hour infm;ion of abciximab.70 
The cOlnposite endpoint of death) non-fatal MI or urgent revascularisation at 30 days 
lNas reduced hy 35% (12.3% placebo versus 3.3% bolus/infusion ahciximab).70This 
benefit 'was sustained at 6 months) l11ainly due to lesser need for repeat 
revascularisation/1 and also at 3 years) most notably m110ng patients with unstable 
angina or evolving acute MI.72 Abcixilllab treat1llent resulted in particular and 
increnlental benefit for patients enroned 'with the Aes severe unstahle angina or 
evolving acute MI. In the subset of64 patients enrolled 'with acute MI) the composite 
endpoint 'Ivas reduced hy 83 % (26.1 % placebo versus 4.5% abciximab holus/infusion). 
At 6 nlOnths) ischemic events were significantly reduced fr0111 47.8% with placeho 
to 4.5% with abciximab bolus/infusion) with a significant reduction in reinfarction 
and a significantly lessened need for repeat revascularisation.73 Patients 'with severe 
unstable angina experienced particularly 11larked reductions in the risk of death and 
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IvII ,;\"rith abc:ixitnab treahnent during coronary intervention (62% reduction in the rate 
of the 30~day endpoint, mainly owing to reduction in the incidences of death and MI); 
by 6 111Onths, cU111ulative death and MI were further reduced by ahciximab. 74 Among 
patients ·who presented with ACS, the incidence of l1101tality at 3 years with abciximab 
was less than half that in the placebo group," The long-term results in the EPIC trial 
extended the benefits of abcixilnab £r0111 reducing the acute-phase ischemic 
complicatiom; from abrupt vessel closure to a diminished need for subsequent 
revasGuiarizatioI1.7l.76 These sllstained and, in some respects, incremental1ong-tenll 
benefits might be a result of the phenOlnenol1 of culprit vessel ·wall passivation, 
whereby the injured vessel ·wall is transformed from a platelet-reactive surface into 
one that does not support platelet thrombus formation and deposition.76 
The particular benefit of a potent anti platelet therapy in patients with ACS 
undergoing percutaneous intervention was further endorsed by the CAPTURE 
(c7E3 Antip1ate1et Therapy in Unstable Refi-actory Angina) triaL" In 1265 patients 
with refractory unstable angina for Wh0111 percutaneous coronary intervention ·W"3S 
planned, but not inunediately perfonned, there was a significant 30% reduction 
in the primary endpoint of death, MI or urgent intervention at 30 days in the 
abciximab group (11.3% versus 15.9% in the placebo group). In contrast to the EPIC 
trial, CAPTURE involved the administration of placebo or abciximab starting 18-
24 h prior to the percutaneous coronary intervention and continuing until one hour 
after completion of the intervention, A unique observation in the CAPTURE 
trial was the significant reduction of MI occurring before PTCA in patients 
receiving abciximab during the 24 h preceding coronary intervention (Figure 4).77 
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Development of mvocardial 
infarction during treatment with 
abciximab or placebo, before 
and In association with PTCA. 
Results from the CAPTURE study, 
Reprinted from the CAPTURE 
Investigators 1997 with permission 
from The Lancet, 
This finding also lends support to the hypothesis that GP IIb/IIIa receptor 
blockers can sthllulate culprit vesse1 passivation and stabilize patients ,;vith ACS, 
snch that subsequent coronary intervention l1laY even be avoided,771teatlnent with 
abchdtnab also sholNed to significantly reduce procedure-related infarctions, In fact, 
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most infarcts occurred during or within 24 h following PTCA (Figure 4). This 
suggests that longer treatment with potent GP IIb/IlIa receptor blockers without 
subsequent coronary intervention 111ight be an alternative or perhaps even the 
prefened option for patients with ACS, who are at patticular high-risk of procedure-
related thrOlllbotic cOlnplicatiolls such as MIl ·with early coronary rcvascularization 
rcc0111mended only for patients ·with recurrent ische1nia despite intensive medical 
therapy. This new concept of potent antiplatelet therapy with GP IJb/lIIa blockade 
being effective in achieving culprit vessel '\7a11 passivation and stabiliz.ing patients 
·with non-ST-segnlcnt elevation ACS on a durable basis, ·without systematic early 
coronar:y rcvascularizatioll, -will be tested in the forthco111ing large GUSTO-fll trial. 
The effectiveness of platelet GP lIb/IlIa blockade on adverse cardiac events 
in patients 1\7ith ACS undergoing coronary angioplasty 'Nas further Stl ppm'ted by 
the results of several large clinical trials using several othel' GP lIb/lIla receptor 
inhibitors: Eptifibatide (IntegtilinTM), a cyclic heptapeptide that mimics fibrinogen 
structure and acts as a reversible, conlpetitive GF IIb/Illa receptor antagonist , 
reduced the rates of early ischemic events at 30 days in the IMPAC1'II (Integrilin 
to Minimise Platelet Aggregation and Coronary Thrombosis-II) trial/' Analysis of 
the treated patient popUlation at (i 1110nths shmved a sustained reduction in the 
conlposite incidence of death and MI in patients who received eptifibatide. 
Tirofiban, another GP IIb/IIla blocker, was studied in the RESTORE 
(Randomized Efficacy Study of Tiro fib an for Outcomes and REstenosis) trial and 
provided protection against early cardiac events related to throlllbotic olosure.79 
At 30 days, the relative reduction 'vas sustained, although to a lesser extent. 
The efficacy of platelet GP IIb/llla inhibitors as primary therapy in patients 
lNith ACS 'without ST-segnlent elevation has also been investigated in clinical trials 
w"ithout protocol-nlandated revascularization strategies. 
In the PURSUIT (Platelet glycoprotein lIb/IlIa in Unstable angina: Receptor 
Suppression Using Integrilin Therapy) trial, more than 10 000 patients with 
unstable angina or non-Q'wave infarction 'were studied.w ~n'eatIllent with eptifibatide 
resulted in a significant 1.5% absolute reduction in the prin13ry endpoint (death/non-
fatal MI at 30 days) compared with placebo (14.2% versus 15.7%). This reduction 
was reached by 96 hand Inaintainecl for 30 days,W Using investigator-detennined 
infarctions, the 3D-day incidence of the primary endpoint was 8.1 % in the 
eptifibatide group versus 10% in the placebo group. This ahnost 2,0% absolute 
reduction was highly sigtlificant. In confonnity with the results from the CAPTURE 
study, eptifibatide reduced the event rate in patients treated ll1edically, \\"'ith an 
added benefit if they underwent coronary intervention while receiving study 
drug.77.W As with other antithrombotic therapies, eptifibatide \vas associated with 
increased bleeding and need for transfusion but not with an increased risk of 
haemorrhagic stroke. eo The PURSUIT trial represented the largest phase III study 
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of a GP lib/IlIa receptor inhibitor med as primmy ACS therapy in a setting that 
closely resembled clinical practice. The results from PURSUIT confirm that early 
treatment using GP IIb/lIla inhibitors improves QUtC01llCS in a broad spectrUlll of 
ACS patients presenting "without persistent ST-segnlent elevation.so 
Three other large studies have evaluated two other small-molecule GP lib/IlIa 
hihibitors as primary treatlncnt in patients presenting with unstable angina or non-
Qwave MT. Tirofiban was studied in the PRISM (Platelet Receptor Inhibition in 
Ischemic Syndrome Management) and PRISM-PLUS (Platelet Receptor Inhibition 
in Ischemic Syndrome Managclncnt in Patients Limited by Unstable Signs and 
Synlpto111s) trials. 81 .82 In both trials, treattllcnt ·with tirofihan was associated ,\'ith a 
significant reduction in adverse ischcl11ic events including death and non-fatal Ivn 
in the acute setting. At 30 days, the benefits had been eroded somewhat but the 
trcahllcnt effect sti11 favoured tirofiban, "'iNith a significant reduction in nlortality 
in the PRISM study and a significant reduction in death or MI in the PRISM-PLUS 
study. 
In the PARAGON-A study of 2282 patients with unstable angina or non-Qwave 
MI, lamifiban, a non peptide platelet GP lIb/IIIa inhibit01; showed no significant 
benefit for reduced death or MI in the overall study cohort at 30 days (10% 
relative reduction).8J At 6 nlonths, hm\rever, there was a highly statistically 
significant 40% reduction in death or MI for the low-dose 1a111ifiban/heparin 
group as conlpared with heparin alone. At 1 yeat~ mortality '>vas reduced frOl118.7% 
to 7.0% in the sanle low-dose latllifiban/heparin group. These findings of 
incremental late benefit suppoli the arterial passivation hypothesis. In agreement 
with other trials evaluating the efficacy of GP lIb/IlIa inhibitors in patients with 
ACS undergoing PTCA, lamifiban reduced the incidence of death and MI at 30 days 
in the subset of patients undergoing angioplasty (6.8% versus 15.8% 'NUh placebo).84 
Platelet glycoprotein IIb/nIa receptor inhibition has now- been evaluated in nine 
large rand0111ized clinical trials enrolling nl0re than 30 000 patients. In five trials, 
GP Ilb/IlIa receptor antagonists were cOlllpared with standard therapy in patients 
undergoing coronary revascularization, 70,77-79,&5 and in four tria1s GP IIh/IlIa receptor 
inhibition lNas evaluated as primary therapy in patients ,,\-.-ith unstable angina or non-
Qwave infarction.ro-a.3 "llhile the magnitude of benefit has varied, the results of these 
hials have all del1l0nstratecl a consistent benefit in the reduction of death and nonfatal 
MI for different GP IIb/IIla receptor blockers (figure 5). Four studies have 
demonstrated that GP lib/ilia inhibition therapy, added to heparin and aspirin in 
the acute-phase treatment of patients with unstable angina or non-Qwave MI, 
hnproves outc01lleS in these patients beyond the benefit offered by heparin and 
aspirin.ro-s3 A nleta-analysis of the nine trials sho'ws a very strong and highly 
significant 20% reduction in death or MI at 30 days (Figure 5).b3 Although in the first 
trial with GP IIb/IIIa blockers a doubling of significant bleeding complications 
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occurred/70 recent trials have only shown a slightly higher bleeding event rate in 
the GP lIb/lIla inhibitor group, mainly because of bleeding at the femoral access 
site in patients undergoing angioplasty. It has been demonsh'ated that bleeding 1isk 
can be reduced by using reduced heparin dosing on a weight-adjusted basis along 
\\'ith 1110re attention to the catheter-access site.85.86 
Trial N Odds Ratio & 95% CI Placebo Rx Figure 5 
EPIC 2,099 ~ 10.1% 7.0% Odds ratio's and 95% 
confidence intervals for the nine 
IMPACT-II 4,010 ~ 8.4% 7.1% large-scale (over 7000 patients), 
EPILOG 2,792 -a- 9.1% 4.0% randomized, p/acebo-contro/fed 
CAPTURE 1,252 ~ 9.0% 4.8% trials of platelet GPlib/llia 
RESTORE 2,139 ~ 6.3% 5.1% inhibitors for percutaneous 
PRISM 3,231 
-
7.0% 5.7% coronary intervention or 
PRISM Plus 1,570 -a- 11.9% 8.7% unstable onglna/non-Q-wave 
PARAGON 2,282 -0 11.7% 10.3% 
MI. Overall, In 30 323 patients, 
there Is a highly statistically 
PURSUIT 10,948 C 15.7% 14.2% Significant 20% reduction in 
Overall 30,323 + 
081 (0.75.0.83) 
10.9% 9.1% death or MI at 30 days. p <: 0_000000001 
0.1 10 . Low dose lam,fiban Reprinted from Topol 1998 with 
Rx Better R~WorsG 
",ith heparin permission from Circulation. 
Most importantly, GP lIb/IlIa inhibition therapy has not been associated with 
an excess of intracerebral bleedings in patients enrolled in the large intervention 
trials.'" Of note, all trials used aspirin in the placebo group. The effect ofthe GP 
Ilb/IIIa receptor inhibitors is therefore additional and ofa magnitude (25%) that 
is cOlnparable with that achieved -with aspirin nlOre than a decade ago. In additionl 
at least two trials with different GP nb/nla inhibiting agents have shuwn evidence 
for durability or incre111ental late benefit of the treatlnent effect achieved in the 
early phase. nS3 
GP lib/Ilia inhibitors in the treatment of acute MI 
As discussed/ platelet thr0111bus fornlation is a major contributor to both the 
failure ofthrOlllbolysis and the pathogenesis ofreocclusion in patients -with acute 
MI. Therefore, GP lIb/IlIa receptor blockade therapy adeled to thrombolytics or 
used as an adjunct to direct angioplasty l11ay significantly itllprove treatment 
outcomes in patients \\7ith acute ST·segnlent elevation MI. 
Thrombolytic therapy combined with GP lib/ilia receptor blockade 
Experimental/ preclinical studies have shmvn that combining GF nb/IIla 
inhibitors 'with thIOlnbolytic therapy results in lllOre rapid/ complete and sustained 
reperfllsion/ and that the dosage offibrinolytics can be decreased with concomitant 
use of GP lIb/IlIa receptor blockers." In the first clinical study, TAM! 3, 60 
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patients receiving full-dose aIteplascJ aspirin and heparin for acute MI received 
bolus injections of the 111luine 7E3 1110noc1onal antibody Fab at varying tinlc points 
after initiation of the thrOlnbolytic therapy. 87 Th11 control patients 'were treated 
with alteplase but not with m7E3 Fab. The infllrct-related artery was patent (TIMI 
grade 2 01':1 flow) in 92% of patients receiving 1117E3 Fab cOlnpared '\vith 56% of 
patients in the control group. There was no excess Of111qjor bleeding complications 
among patients treated with the combination of alteplase and m7E3 Fab. The 
IMPACT-AMI (Integrilin to Manage Platelet Aggregation to Combat Thrombus in 
Acute Myocardial Infarction) trial investigated the prclhnillary efficacy and safety 
of a combination of full-dose, accelerated alteplasc, aspirin and heparin 'with 
variable dosing of the GP IIb/IlIa inhibitor eptifibatide in a pilot study of 180 
patients with acute MI.'" Patients treated with the highest eptifibatide dose had 
a 69% higher rate ofTIMI grade 3 flo'w than placebo-treated patients (66% versus 
39 %) at 90 min) and a shorter Inedian til11e to ST-segnwnt recovery on continuous 
12-lead ST-segment monitoring. The combined use of alteplase and eptifibatide 
was not associated "'\7itl~ an excess of significant bleeding complications. In the 
PARADIGM (Platelet Aggregation Receptor Antagonist Dose Investigation and 
Reperfusion Gain in Myocardial Infarction) trial, 345 patients with acute MI 
treated with either alteplase or streptokinase were randOlllly assigned intravenous 
lan1ifiban at 3 different doses or placebo. -Vlhile there was no trend in reducing 
clinical endpoints between groups) the continuous 12-1ead ECG monitoring 
showed n10re rapid and stable resolution of the ST-segnlCnt elevation among 
patients treated Witll the cOlllbination oflamifiban and thrOlllbolytics) suggesting 
inlproved early and complete reperfusion.6.3.64 
Furthennore) concomitant use of potent antiplatelet therapy facilitating 
fibrinolysis lllay allow for 101Ner doses of fibrinolytics needed to achieve reperfusion. 
Lower doses of fibrinolytic therapy Ininin1ize the adverse prothrOlnbotic effects and 
could reduce the risk of significant bleeding c01nplications induding intracerebral 
haemorrhage.«3 The SPEED (Strategies for Patency Enhancement in the Enlergency 
Department) hial was a dose-finding, phase II study that compared abciximab alone 
\vith abcixi111ab plus reduced-dose reteplase in patients with acute ST-elevation :LvII. 
The dose of reteplase was escalated to establish the optimal dose of r-PA in 
combination with full-dose abciximab. Prelin1inary GO-min angiographic results 
showed a dose-response with increasing doses reteplase with a higher THvII 3 flo-w 
rate. 89 TIMI 3 fluw at 60 Ininutes '\Tas achieved in 52% of patients receiving 
abciximab plus 10 units r-FA versus 45% in the t-FA Ineta-analysis.89 The ongoing 
TIMI l4A trial evaluates the additional benefit of abciximab when used as adjunct 
to several fibrinolytic regimens in the n1anagmnent of patients 'with acute 1\.11. 
Preliminary data showed that treatment with abciximab alone was capable of 
achieving TIMI 3 flow Tates similar to those seen with a full-dose of streptokinase 
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in the GUSTO-I trial. When added to streptokinase and t-PA, abciximab increased 
the rate and extent of reperfusioll \\7ith reduced doses of the fihrinolytics. 90 The 
highest TIMI 3 flow rate (79%) "was achieved lNith a 60-111inute infusion of 50 l1lg 
t-PA in combination with abcLximab.'" Although the angiographic results and/or ST-
monitoring data [r0111 these studies suggest that the rate and speed ofreperfusion 
can be enhanced by c0111bining GP lIb/Ula receptor inhihitors with thr0111bolytic 
therapy, larger phase III trials are needed to assess further the ability of GP 
lIb/lIla inhibitors) alone or in combination "'\\7ith full- or reduced-dose fibrinolytics, 
to ilnprove clinical DutcOllles with fe1Ncr significant bleeding c01nplications in 
patients with acute ST·segll1cnt elevation MI. 
Combining direct angioplasly and GP lib/ilia blockade 
Initial data pointing to the beneficial effects of adding GP lIb/IlIa receptor 
blockade to direct angioplasty for acute Ml ,vere provided by the subgroup 
analysis of patients fr0111 the EPIC trial enrolled with acute MI and undergoing 
prilnary or rescue angioplasty. These have aheady been discussed in this chaptm: 
In the recent RAPPOKf (Reopro and Prima1Y PTCA Organization and Randomized 
Trial) trial, abcbdlnab was compared with placebo in patients undergoing prilnary 
angioplasty for acute ML Abciximab significantly reduced the incidence of death, 
reinfarction or urgent target vessel revasculaTization at 30 days (5.3% versus 
11.29-6).91 Furthennore, the need for unplanned, bail-out stenting was reduced by 
42% in the abcixilnab group. n'eatment with abcLxhnah was, howevel~ associated 
with an increased risk ofll1ajor bleeding (16.6% versus 9.5%). Larger trials i\'"ill 
have to confirm the beneficial effects of GP lIb/IlIa inhibition in patients 
undergoing direct angioplasty for acute ST-segnlCnt elevation MI. 
In the next few years, it is lil<cly that GP lIb/IlIa inhibitors will come to play 
an itnportant role in the treatnlCnt of patients ,dth acute ST-segnlent elevation 
MI. They have the potential to achieve high rates of reperfusion without an 
increased lisk of significant bleeding cOlnplkations when used cOlnbined with 10w-
dose fibrinolytics, and are capable of enhancing the safety of prbnary or 
(subsequent) rescue angioplasty. 
Oral GP lib/Ilia receptor antagonists 
'''There intravenolls GP lIb/IlIa receptor inhihitors l1ave shown significant effect 
in reducing acute ischf!1nic complications in patients undergoing angioplasty and 
in those w-ith ACS, additional and, potentially, increnlCntal long-ternl benefit 
lllight be obtained by subsequent, continuing longer-tenn treahnent with oral 
platelet GP lIb/IlIa antagonists. Howevel; whether prolonged administt·ation of oral 
GP IIb/IUa blockers is capable of preventing subsequent events in at-risk patients 
and providing secondary prevention awaits the results of large-scale trials. 
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This thesis addresses several aspects of the clinical evaluation of GP IIb/llla receptor 
bloci{ers in patients with acute coronary syndromes. A number of manuscripts 
described in this thesis have been based on data originating from the large Platelet 
glycoprotein IIblllla in Unstable angina: Receptor Suppression Using Integrilin 
(eptifibatide) Therapy (PURSUIT) trial. PURSUIT compared the GP IIblllla inhibitor 
eptifibatide with placebo in addition to standard therapy in 9461 patients with acute 
coronary syndromes who did not have persistent ST-segment elevation. 
In chapters 2 and 3, we reviewed the structure of the Clinical Events Committee and 
the event-adjudication process as used in the PURSUIT trial. 
In chapter 4, we reviewed the geographic variations in patient outcome and treatment 
effect as observed in PURSUIT. 
In chapters 5 and 6, we studied the safety of GP IIblllla receptor blockers with 
respect to the occurrence of bleeding complications and the risk of stral<e, respectively. 
Chapters 7 and 8 study the effects of GP IIb/llla receptor blockers during phannacological 
treatment relative to the effects during percutaneous coronary intervention. 
In chapters 9 through 12, we present some methods and decision models for risk 
stratification in patients admitted with a non-ST-segment elevation acute coronary syndrome. 
Finally, chapters 13 and 14 describe the phase II clinical development of an oral GP 
IIblllla receptor blocl<er. 
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Abstract 
Clinical Events C0l1l111ittees (GEe) are used routinely to a(~judicate slispected 
endpoints in clinical trials, but little information has been published about the 
various processes used for adjudication. In the Platelet glycoprotein lib/IlIa in 
Unstable angina: Receptor Suppression Using Integrilin (eptifibatide) Therapy 
(PURSUIT) trial, lO,H4B patients "'Nith acute coronary syndr01llCS i\7cre rand011l1y 
assigned in blinded fashion to eptifibatide or placebo. A centralized adjudication 
process lNas established prospectively to identify all suspected l11yocardial 
infarctions and to adjudicate the events based on definitions ofinfarctiol1 in the 
protocol. Suspected infarctions 'were identified by systetnatic rCViCi\'S of clinical 
infonnation on case report fon11s, of cardiac enzynle data, and of 
electrocardiographic information, All suspected events were independently 
rcviCi,"Tcd by t'iNO physicians. If the physicians disagreed about lNhether an 
infarction had occurred/ the case 'was adjudicated by a conllnittee of faculty 
cardiologists. The GEG identified 5005 (46%) suspected infarctions, of which 
1415 (28%) were a(\judicatecl as infarctions. 
,\<\,Te believe t11at endpoint adjudication by a Clinical Events COlll111ittee is 
ilnportant to provide a standardized/ systenlatic, independent/ and unbiased 
asseSSlllent of endpoints/ particularly in trials that include patients across 
geographic regions and clinical-practice settings. Understanding the CEC process 
is illlportant in interpretation of trial results and event rates, 
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Introduction 
Myocardial infarction is an important endpoint in clinical trials. In fact, the 
prevention of infarction has been the prim;:ny treatlnent effect assessed in recent 
trials of antiplatelet and antithrombin therapies. loll Clinical Events C0111mittees 
(CEes) are nuw conunonly used to adjudicate suspected endpoint events in 
clinical trials, but only limited information has been published about endpoint 
adjudication."·" In the Platelet glycoprotein JIb/IIIa in Unstable angina: Receptor 
Su ppression Using Integrilin (eptifibatide) Therapy (PURSUIT) tria1,6 a centralized, 
independent CEC systematically identified and adjudicated all suspected infarctions 
that occurred after enrollment and through 3D-day follow-up. The rationale for CEC 
adjudication lNas the need for a systenlatic, unbiased, independent, and standard 
assessment of this endpoint in a large, international trial. 'Ib understand the role 
of such a COl1l1uittcc, and to provide recol1ullcndations for futtuc efforts, ·wc 
reviewed the results of the CEC process used in the PURSUIT trial to identii:'y and 
adjudicate suspectcd endpoint infarctions. 
Methods 
PURSUIT Trial 
The PURSUIT trial 6 enrolled 10,948 patients at 726 hospitals in 27 countries 
from North Alllerica, Latin Anlerica, and Western and Eastcrn Europe. Patients 
'with acute coronary syndromes 'ivithout persistent ST-segnlent elevation 'were 
randOl111y assigned to placebo or eptifibatide. The inclusion and exclusion criteria, 
as well as treatment regimens, have been published.6 The primary endpoint was 
a composite of death or infarction by 30-day follow-up as adjudicated by a Clinical 
Events C0111111ittee. The C0111posite endpoint also was calculated using the site 
investigator deten11ination of infarction fr0111 case report forms. 
Endpoint Definitions 
The definition of infarction included clinical, electrocardiographic (ECG), and 
laboratory criteria (sec AppendLx). 
Data Collection 
Data were collected using standard case report fonns. Additional infonnation 
co11ected frOl11 all paticnts included cardiac enzynles, ECGs (perfonned at the tinlc 
of the qualifying cpisodc, at enrollnlcnt, at 24 hours, at first hospital discharge, 
and at 3D-day follow-up), rcvascularization procedure reports, details ofischel1lic 
episodes, clinical cOlllplications, Incdications, and reachnission records. All 
enzylnc valucs for each patient 'were to be reportedi study Inonitors then verified 
thelll against sourcc doclllncnts. Site investigators 'were asked to sublnit supp01ung 
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documents for patients 1\7ith suspected infarction, lNhich included discharge 
summaries and additional ECGs during the suspected event. Progrcl:is notes and 
procedure notes also "were collected if necessary. An independent, blinded ECG 
core laborator:y read the specified ECGs and identified suspected infarctions, 
defined as llC1N Q-"waves :2:0.04 seconds in t1\TO contiguous leads. 
Process for Event Adjudication 
The CEe 'was a group dedicated to event acljudication within the NOlth iuncrican 
Trial Coordinating Center at the Duke Clinical Research Institute. The group 
consisted of a Inanaging supervis01~ clinical coordinators 'with a nursing or clinical-
research background, administrative assistants, cardiology felluw8, and cardiology 
faculty members. The CEC helped define clinical endpoint events, helped develop 
COlnputer algorithms to identifY patients 'with suspected endpoint events from case-
report-foTIn data, worked 'with lllOnitoring groups to coneet supplclllentaimcdical 
records for event review, and adjudicated suspected c1inical endpoint events, 
A schmnatic of the clinical event adjudication process is Shm\Tll in Figure 1. 
Computerized algorithms systematically identified key variables from the database 
that could indicate the occurrence of an infarction. These variables, 'which were 
dctennincd frOll1 clinical expertise and previous trial experience, included elevated 
cardiac cllzynleS, ECG core laboratory identification of suspected infarction, 
reCUlTcnt ischcl11ic events, urgent rcvascularizations, or site investigator asseSSll1cnt 
of a post-enrolhncnt infarction, The systcnl 1vas designed for broad identification 
of all patients with possible infarction. 
Suspected myocord'ol infordons 
identified from: 
1. Case Report Form dolo 
2. Anc'!:ory Case Report Forms 
3. ECG Core Lob 
PHASE I: Independent Revi~~"1 by Two Physicians 
Disagree 
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Agree - ~ Done 
{1O%revie',ved for 
quo,ty assurance] 
Figure I: 
Process for review of 
suspected cfinical events in 
Ihe PURSUIT Iriol. 
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Each patient with a suspected infarction had a clinical folder prepared by CEC 
staff at the Duke Clinical Research Institute. Folders included the case report form 
and ancillary data fo1'1118, discharge 8n111111arie8, cardiac en7,ynlc results, ECGs, and 
a data "worksheet that summmized clinical events, procedures, and cardiac enzyme 
infonllatiOl1. i\1edical records ·were translated into English, if necessary; ·when 
possible, physicians literate in the other language 'were used, 
Each case "vas revie"wed independently by P;\"TO physicians blinded to trcaunent 
in the Phase I review. If the physicians agreed that an infarction had 01' had not 
occurred, the case ·was classified as resolved. Cases in \vhich there was 
disagreement between the two GEe physicians \vere forwaTCled to a second-
1evel (Phase II) review, fcu adjudication by consensus by a committee of facu1ty 
cardiologists (FiguTf', I). The comlnittee melnbeTs also 'i\Tere blinded to treatment, 
and to the result of the Phase I Tevie\\'. Physicians could request additional 
lnedical recoTds, if necessary, to adjudicate a suspected event. If additional 
recoTds were obtained, the case was rereviewed to ensure that decisions were based 
on shnilar doclllnents. For quality assurance, 10% of the cases with agTeement 
by the Phase I physicians wefe revic'wed in a blinded fashion by thc Phase II 
cOl1nnittee to determine if there weTe any systenlatic inconsistencies with the 
Phase I Teviews. 
Statistical Analysis 
VaTiables were summarized as percentages l' Of dichotOlnous variables or 
Inedians (2Sth and 75th percentiles) for continuous variables. The chi-square test 
'ivas used to calculatc p values. 
Results 
In the PURSUIT hial, eptifibatide reduced the incidence of death or infarction 
by l.S% (lS.7% vs. 14.2%; P = 0.042) at 3D-days. The benefit was driven prhnarily 
by a reduction in nonfatal infarction. Overall, SODS (46%) cases with a possible 
or suspected infarction were identified and adjudicated by the CEe. 1l1ble 1 
shows the lllllnher of patients enToIled, the number of patients with suspected 
infarction, and the nUlnber of patients with an endpoint infarction assessed by the 
CEC by geographic region. The prop011ioll ofpatiellts enl'Ollec1 who had a suspected 
infarction ranged fr0111 41 % in North America to SO% in \Vestern Europe. The 
propoTtion of patients with infarction H(1judicated by the CEC was similar in 
North America, Latin Anlerica, and 'A/estern EUfope but tended to be higher in 
Eastern Europe. 
As expected, because of the rigorous effort by the CEC to identiJ'y all suspected 
infarctions for adjudication, the process identified Inore endpoint events than did 
the site investigators (Thble 2). Smaller absolute and relative treatment effects were 
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Table 1 Cases Reviewed by the Clinical Events Commitlee 
Patients Enrolled Patients with Suspected Patients with Contlrmed 
Region 11 (%)' Infun;tion 1/ (%/' Infarction 11 (%/' 
Eastern Europe 1762 (16) R62 (49) 311 (17.7) 
Latin America 5H5 (5) 253 (43) 68 (11.6) 
North America 4358 (40) 1779 (41) 504 (11.6) 
Western Europe 4243 (39) 2111 (50) 532 (12.5) 
Ol'erall JO,948 5005 (46) 1415 (12.9) 
"Percentages are based on overall enrollment. 
hperccntages are based on number enrolled per region. 
Table 2 Efficacy Endpoints at 30-day Follow-up 
Eptifibatide" Placebo Absolute Relative 
(n~ 4722) (n~ 4739) Reduction Reduction 
% % % % p 
Death or Infarction 
Clinical Events Committee 14.2 15.7 1.5 9.6 0.042 
Site investigator 8.1 10.0 1.9 19.0 0.0007 
Myocardial infarction 
Clinical Events Committee 12.6 13.6 1.0 7.4 0.137 
Site investigator 6.2 7.8 1.6 20.5 0.002 
"High-dose group only. 
observed using the GEe-determined infarction rates c0111pared lNith the site 
investigator-deten11ined ratcs. 
Disagreements between the site invcstigator and CEC assessment of infarction 
occulTcd in 9lJb of all patients enrolled in the trial. Disagrecnlent betnrcen the site 
investigator and the CEC aSSeSS111ents ,\vas seen in 983 ofthc 5005 (20%) patients 
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with suspected infarction that were adjudicated by the CEC (Thble 3). Of these 983 
patients 'with disagTcclnents, 816 patients had an infarction assessed by the CEe 
but not by the site investigatOl~ and 167 patients had an infarction identified by 
site investigators but not by the CEe. 
Table 3 Disagreements Between the Site Investigator and the Clinical Events COlllmittee 
Patients'Vith Patients \Vith Disagreements 
Suspected Infarction Disagreement Commit tee No COlllmittee Yes 
Region II (%) II (%) Site Yes Site No 
Eastern Europe 862 (49) 206 (24) 24 182 
Latin America 253 (43) 52 (21) 8 44 
North America 1779 (41) 356 (20) 57 299 
\Vestern Europe 2111 (50) 369 (17) 78 291 
Overall 5005 (46) 983 (20) 167 816 
Discussion 
Review of the clinical events classification process in the current study raises 
80111e ilnportant issues for clinical investigators. First, the rates of infarction 'were 
higher than those repOlted in prior h·ials of patients idth acute coronary syndrOlllcs. 
Second, the Clinical Events COl1llnittee identified lnore events than the site 
investigators. Third, the site investigator and the CEC assessment of inf~1rction 
disagrecd for 20% of patients reviewed by the Conunittee. 
Clinical Events COll11nittees have bcc01ne an integral aspect of clinical trials 
of new therapies for patients with acute coronary syndr01nes. The pri1nary 
function of these cOl1unittees has been to systematically adjudicate nonfatal 
endpoints such as l11yocardial infarction. The first large trials in these patient 
populations used nlOrtality as the prim31Y cndpoint; thus, standardized asseSSlnent 
of patient outcome 'was not rcquired.24.26 More recent trials, hmvevet~ have included 
nonfatal endpoints such as infarction, congcstive heart failure, stroke, and safety 
lneasures as part of cOlnposite clinical endpoints. Myocardial infarction has been 
considered a IIhard" endpoint, but its asseSSlllcnt can be as difficult in clinical trials 
as in clinical practice, because clinical, laboratory, and ECG data n1ay conflict and 
physicians therefore often disagree as to whether a patient has suffered an 
infarction. An eXHlllple of this difficulty is the evaluation of low-level enzyll1e 
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elevations in patients undergoing percutaneous coronary intervcntion.21 Although 
these law-level enzyme elevations are defined as infarctions in many trial 
protocols, physicians do not consistently consider thenl to be infarctions in daily 
clinical practice. 
The rates of infarction as adjudicated by the CEC in PURSUIT were higher 
than reported in previous trials, I. 7, 8, 28 of patients with acute coronary syndro111cs, 
for severed reasons. The PURSUIT CEe effort "was 1110re liberal in its identification 
of possible events. COllUllittee physicians reviewed events for almost 50% ufthe 
patients in the PURSUIT trial, nearly double the percentage that undenvent 
adjudication by the smne CEe group for t';VD other trials: Integrilin to n1inimize 
Platelet Aggregation and Coronary Thrombosis (IMPAC1cII)', and the Global Use 
ofSh'ategies 1b open Occluded arteries in acute coronary syndromes (GUSTO-IIb).9 
The definition of infarction is evolving and has varied 31nong clinical trials in this 
patient population. For cXaIllple, in the GUSTO-lIb trial, criteria for infarction after 
bypass surgery were 1110rC stringent than in the PUR-SUIT trial and required two 
ofthrcc criteria (creatinc kinase or ME fraction at least fivc ti1nes the upper 1imit 
ofnornlal, two nm\7 Q"waves, and/or doculllentation ofnc1N regional wall-motion 
abnOr111alities). Finally, nlore cardiac enzynlc samples 'wcre col1ected per patient 
in PURSUIT than in GUSTO-IIb (median 4.5 [3, 7J vs. 3 [1, 4], unpublished data). 
Thesc factors, particularly the systetnatic collection of cardiac el17;ymes, contriliuted 
to a higher ascertahlll1Cnt of infarctions in the PURSUIT trial. 11'ials relying on 
investigator-reported infarctions likely unc1eresthnate the true event rate. 
Before the hnplelnentation of the CEC process, the International Steering 
Committee discussed and agreed upon the definitions for infarction using past 
experience and clinical expertise. Because of the global nature of the PURSUIT 
investigation, attelnpts "were Inade to model definitions after everyday clinical 
practice. The study protocol provided the endpoint definitions, so that the CEC 
and site investigators had the SaIlle set of criteria to classify infarctions. 
Nevertheless, lllyocardial infarctions "were undcrreported by site investigators. 
S1111ilar findings have been obscrved in prior trials. 1. 9. u n 31) 
The stratcgy used to idcntifY suspected infarctions can affect the proportion 
of events "with c1isagreetnents. Some trials havc confirmed evcnts reported only 
hy the investigators,5J,8.11.28.31 ",\\7hile others havc adjudicated all suspected evcnts 
identified by systematic screening of patient data. 1-3. 9. 29,31) In the first strategy, the 
CEC event rates will be the SaIne as or lower than the site investigator rates. In 
the second, the CEe event rates may be highel~ lowel~ or the same as the site 
investigator-reported rates, 
The itnpact of acljudication of cases fr01n other regions of the world by 
physicians based in North Alnerica is unknown. Howevel~ in the current study, 
nledical records were translated to English, physicians fluent in foreign languages 
36 
Clinical endpoint determination: methodology and Impact 
·w·ere used \\Thcn needed) and the criteria for reinfarction were based) for the most 
part, on objective data such as enzynle and ECG data. 
There are several key ilnplicatiol1S of these findings. The strategy used to 
identif~y and adjudicate endpoint events is one of many factors to be considered 
"when cOlnparing event rates bet'ween clinical studies. During trial planning, the 
events-classification strategy being considered also 1118Y have an ilnpOltant i1upaet 
on esti1nation of event rates and the sample-size and pOlNcr calculations. Education 
and training of clinical investigators regarding endpoint definitions and 
ascertainnlcnt lllaY help in 111iniIni7.ing differences behveen the CEe and site 
investigator asseSSl11ent of endpoints. Finally, the interpretation of trial results by 
the clinical and regulatory cOl1nllunities l11ay be influenced by the strategy and 
rigor of the clinical event adjudication process used. We believe that CEC 
Conllllittee adjudication of suspected nonfatal infarction endpoint events is 
important to provide independent, unbiased, standard, systenlatic assessl1lCnts, 
particularly in trials that include hroad geographic regions and different clinical-
practice settings. 
Conclusion 
Nonfatal lllyocardial infarction, inherently undesirable, is an ilnportant 
clinical event and an hnportant cOlllponent of c1inical trial endpoints. Clinical 
Events Conll11ittee adjudication of infarction is necessary and provides standardized, 
systematic, independent, and unbiased assessments of endpoints in clinical 
investigation. In PURSUIT, the assessment of infarction by site investigators 
versus a central CEC disagreed; nlore infarctions were identified by the CEe than 
by the site investigators. The impact of these findings affect the c0111parison of event 
rates between trials as ·well as the design of future trials. 
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Appendix 
Definition for Post-enrollment Myocardial Infarction 
Myocardial infarction is defined by either enzyme criteria or ECG. 
Enzyme Criteria: 
1. :Myocardial infarction (events without documentation of a prior infarction during the 
admission): creatine kinase (CK)-MB elevated above the upper limit ofnonnal (ULN) 
and ;:::3% of total CK IfCK-MB is unavailable, then total CK greater than twice the ULN. 
2. Myocardial infarction (events with documentation of a prior infarction during the 
admission, either before or at enrollment) 
Less thcm 18lJoHfs since previous infw'ction: Recurrent, severe ischemic discomfort and 
new or recurrent ST-segment elevation ::::0.1 I11V in at least t'wo contiguous leads, either 
persisting for ;:::'30 min. 
At least 18IJOlifS since previolls iilfm-cHon: Re-elevation of CK-MB to above the ULN (if 
prior CK-MB "'was within normal range) or > 50% above the prior level (if prior CK-
MB was above the ULN). IfCK-M13 is unavailable, then total CK at least twice the ULN 
and increased by ::::-:25%, or at least 1.5 times the ULN and increased by at least 200 
IU above the previous value. 
3. Periprocedural (percutaneous coronary intervention) infarction (events occurring 
during or "within 24 hours oran intervention): CK-MB at least three times the ULN and 
> 50% above the prior nadir value. If CK-MB is unavailable, then total CK at least 3 
times the ULN. 
4. Perioperative myocardial infarction (events occurring during or "within 36 hours of 
bypass surgery): CK-MB at least times the ULN (or CK, in the absence ofCK-MB). 
ECG Criteria: 
New, significant Q 'waves or Qwave equivalents ;::0.045 sec in at least two contiguous leads. 
If enzyme or ECG data are unavailable, an infarction is considered to have occurred when 
there is a preponderance of clinical evidence based on patient signs, symptoms, ECG 
changes, and pathological findings. When enzyme or ECG criteria are available, they take 
precedence. 
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Abstract 
Background 
Limited has been published about the specific processes for event adjudication 
and the ilnpaet on event rates in trials. \Ve rcvic'wed nonfatal 111yocardial infarctions 
(MI) reported by site investigators in the PURSUIT trial and those adjudicated by 
a centi'al Clinical Events Committee (CEC) to determine reasons for the differences 
in event rates. 
Methods and Results 
In PURSUIT, 10/94[3 patients "with acute coronary syndromes were randomized 
in blinded fashion to eptifibatide or placebo. The primaIY end point was death or 
MI at 30 days as assessed by the CEe. The prilnary end point aIflD 'was constructed 
using site investigator-reported events. The CEC identified suspected MIs by 
systClllatic revic'w of clinical, cardiac enzynlc, and electrocardiographic data, 
and l"igorously reviewed all suspected events. The CEC identified 5005 (46%) 
suspected MIs, of which 1415 (28%) were adjudicated as MI using prespecified 
criteria. Disagreenwnt between the site investigator and the CEC assessments of 
whether an MI had OCCUlTed was present in 983 (20%) of the 5005 patients with 
suspected NIT. -r..1ost disagTcclllcnts reflected investigator 111isclassification of post-
enrollment MIs (as enrollment MIs instead) or underreported periprocedural MIs. 
Conclusions 
The adjudication oEMI in clinical trials is complex and ll1irrors the difficulty 
often seen in clinical practice. vVe believe that GEe adjudication is itnportant to 
provide a standard, systematic) independent) and unbiased asseSSlllcnt of end 
points) particularly in tria1s that span geographic regions and clinical-practice 
settings, understanding the GEe review process and the reasons for disagreement 
between the CEe and site investigator assessments of MI is important to design 
future trials and interpret event rates between trials. 
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Introduction 
Myocardial infarction ()\1I) is a potentially catastrophic event in patients presenting 
'with acute coronary syndr01llCs. In recent trials of antiplatelet and antithrombotic 
therapies for such patients, prevention of M1 'was the primary treatment effect 
assessed. 1.4 Although MI has been considered a J1hard" end point, determination of MI 
end points in clinical trials can be difficult, just as in clinical practice. Because of 
conflicting clinical, laboratory, and electrocardiographic (ECG) data, physicians often 
disagree as to 'whether a patient has suffered an M1. The impOltancc oflm\r~level enzyrne 
elevations also has been controversial, particularly in aSY111ptomatic patients and in 
those undergoing percutaneous coronary intervention (PCI). 5 Although snch en7.yme 
elevations are defined as MIs in many trial protocols, physicians in clinical practice 
do not consistently consider them as such. In recent cardiovascular trials, the MI rates 
reported by site investigators have differed from rates adjudicated by a Clinical Events 
C0l111nittcc (CEC).6-? The reasons for the differences are ul1clem: 
Clinical Events COlnmittees are widely accepted to adjudicate suspected 
end point events in trials, but only limited infonnation has been published about 
end point adjudication.l~15 In the Platelet glycoprotein IJb/IIIa in Unstable angina: 
Receptor Suppression Using Integrilin Therapy (PURSUIT) trial,' a central, 
independent CEC systematically identified and adjudicated all sllspected MIs that 
occurred through 30 days. The rationale for CEC adjudication was the need for a 
systenlatic, unbiased, independent, and standard asseSSll1ent of NIls in a large 
international trial. In a previous analysis of the CEC proccss in PURSUIT, we found 
that in N 10% of patients the CEC and site investigator assessments of MI 
disagreed. 16 iNe retrmipectively revie'lNed these cases, to identify reasons for thenl 
and to understand their potential eftect on the trial results. 
Methods 
The PURSUIT trial 
The PURSUIT trial examined the role of eptifibatide, a platelet glycoprotein 
lIb/IlIa antagonist, in patients presenting 'with acute coronary syndrOlnes 1vithout 
persistent S'lcsegment elevation. The trial enrolledlO,fJ4B patients in 726 hospitals 
in 27 countries in NOTth Anlcrica, Latin America, 'Western EUTope, and Eastern 
Europe, using pTcviously reported inclusion and exclusion criteria and treatlnent 
reginlens.6 The prilnmy end point lNas a composite of death or MI by 30 days as 
acljudicated by a CEC. The cOlnposite end point also 'was constructed using the 
site investigator dctennination of MI. 
Definitions 
The protocol defined lvIl as an end point event based on clinical, ECG, and 
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laboratory criteria (Appendix); MIs that occurred before enrolhncnt were not to 
be included in the primary end point. The site investigators and the CEe used the 
Sel1ne MI criteria. These criteria ·were presented in the protocol, at investigatoT 
Incetings, and in trial l1laterials and nc"'wslcttcTs, 
Data Col/ection 
Data were captured on standaTd case-report fonns. Infornlation collected for 
all patients included cardiac enzymes, ECGs (at the time of the qualif'ying episode, 
at enrollment, at 24 hours, at initial discharge, and at 30 days), revascularization 
procedure reports, details of ischcll1ic episodes, clinical c01nplications, medications, 
and reachllission records. All cnzynw values for each patient were to be reported, 
and study 111onitors verified thenl against source documents. For patients "with 
suspected MI, site investigators "were to submit supporting documents, to include 
discharge sUllllllaries and additional ECGs during the suspected event. An 
independent, blinded, ECG Core Laboratory read the ECGs and identified suspected 
MIs, defined as ne"!;\" Q \\'aves ;::::0,04 seconds in two contiguous leads. 
Clinical Events Classification Process 
The structure of the CEC and the event-adjudication process have been 
reported in detail. 16 COluputeT algorithnls systematically identified key clinical, 
enzymatic, and ECG data frOlU the database that could indicate the occurrence 
of an MI. Each case of suspected MI "was revie"wed independently by two physicians 
blinded to treatment. If the physicians agreed that an MI had or had not OCCUlTed, 
the case was classified as resolved. A conllllittee of faculty cardiologists revie"wed 
cases about which the CEC physicians disagreed, for adjudication by consensus. 
Disagreements Between the Site Investigators and CEC 
A faculty cardiologist (KWM., RA.H., B.S.C.) rereviewed cases of disagreement 
betw"een the site investigator asseSSll1ent and CEC adjudication ofMI, to detennine 
reasons for the disagreement. This revie"w" occllned after the Inain hial results were 
presented, but the revie\vers were blinded to patient treatlnellt assignnlCnt. 
During the rereview, cases were categorized in clinically 11leanillgful groups: NIl 
at enrolhnellt (vs. post-enrollment MI); related to revascularization procedure; 
related to clinically evident ischemia; asymptomatic cardiac enzylue elevation post-
enrolhnent; clinically significant cardiac event resulting in death (vs. sudden death 
without evidence of MI), 
Despite Tigorous criteria to define MI, sonle cases required a subjective 
assessnlCnt by CEC physicians if cardiac enzyme, ECG, and clinical infonnation 
conflicted. Thus for MIs identified by the CEC but not by the site investigator 
(excluding events after PCI or bypass surgeW), we assigned a level of clinical 
certainty. \\1hen all clinicians would agree that an MI had occurred, a high clinical 
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certainty 'was assigned; a 10'1\7 clinical certainty 'was assigned 'when only 80111e 
clinicians lNould agree that an MI had occurred. 
Statistical Analysis 
Data regarding the nUl11ber of cases "with suspected events and cases "\Tith 
disagreenlents betw-een the site investigators and the CEe 'were fr0111 the entire 
PURSUIT study population; therefore, the data included patients assigned high-
close cptifibatide, lOlN-dose eptifibatidc1 or placebo. COlllparisons by trcat1ncnt 
assignments included only patients assigned to high-dose eptifibatide or placebo, 
to l11aintain consistency 'with the pri1nary efficacy analysis in PURSUIT.6 P-values 
were calculated using the X2 test. 
Results 
In all, 5005 (46%) cases of possible or suspected MI were identified and 
adjudicated by the CEC; the CEC identified more end-point events than did the 
site investigators (13.6% vs. 7.7% forplaceho; 12.6% VS, 6.2% for eptifibatidc). The 
CEe and site investigator asseSSlnents of MI disagreed for 9% of all patients 
enrolled in PURSUIT, Of the 5005 patients with suspected MI, the CEC identified 
MIs in 1415, The site investigator and the CEC assessments disagreed in 983 (20%) 
of these 5005 patients, Ofthese 983 patients with disagreements, BI6 patients had 
an MI identified by the CEC but not the site investigatOl; and W7 patients had an 
MI identified by site investigator but not the CEC, The proportion of cases that 
disagreed 'was similar mnong regions. 
In lnost cases where the site investigator identified an MI and the CEC did 
not, the site investigator had 111isclassified an MI at enrolhncnt as an end point 
MI, although by protocol these were not end point events CIable I), Recurrent 
ischemic events without elevated cardiac enzylnes or ECG evidence of MI also 
were incorrectly identified by site investigators as MIs (Thble 1), Ofthe cases in 
which the CEC identified an MI and the site investigators did not, one-third were 
MIs defined by enz.yme elevations without clinical or ECG evidence of ischemia 
or infarction (Thble 2). Enzynle elevations after bypass surgery accounted for 25% 
of these. Patients with clinically evident ischelllia reported by site investigator and 
associated with carcliac-enzynle elevations 'were not reported as MIs by investigators 
in 27% of the cases v'lith disagreelnents Crdble 2). Fmv infhrctions based on new 
Q ""waves without clinical evidence of rein fa ret ion "Nere identified by the CEC and 
not by site investigators. 
Thble 3 shows the cardiac enzyme elevation for MIs that the CEC identified 
and the site investigators did not. These data exclude MIs associatcd 'with PCI or 
bypass surgely; by definition, these required enzynle elevations greater than three 
or five times the upper limit ofnonnal (ULN), respectively, The ratio of creatine 
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TABLE 1. Myocardial Infarctions Identified by Site Investigators but not Confinned By the Clinical Events Committee 
Eastern Europe Latin America North America Western Europe Overall 
Clinical Scenario (n=24) (n=8) (n=57) (n=78) (n=167) 
Enrollment myocardial infarction* 8 (33) 4 (50) 24 (42) 28 (36) 64 (38) 
Ischemic event without infarction-j- 7 (29) 0(0) 8 (14) 19 (24) 34 (20) 
Peri-death infarction~: 6 (25) 2 (25) 13 (23) 8 (10) 29 (17) 
Percutaneous coronary intervention-related 0(0) I (12.5) 6 (II) 10 (13) 17 (10) 
Coronary artery bypass surgery-related 2 (8) I (12.5) 5 (9) 7 (9) 15 (9) 
Miscellaneous I (4) 0(0) I (2) 6 (8) 8 (5) 
*Not an end-point event per protocoL tClinical evidence of ischemia without EeG or cardiac enzyme evidence of infarction. 
:j:Infarction suspected at the time of death without supporting clinical EeG. or cardiac enzyme data. Data are number (%) of patients. 
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TABLE 2. Myocardial Infarctions Identified by the Clinical Events Committee but Not the Site Investigator 
Eastern Europe Latin America North America Western Europe Overall 
Clinical Scenario (n=182) (n=44) (n=299) (n=291) (n=816) 
Asymptomatic creatine kinase-ME elevation* 83 (46) 23 (52) 37 (12) 128 (44) 271 (33) 
Ischemic eventi" 89 (49) 12 (27) 48 (16) 68 (23) 217 (27) 
Coronary artery bypass graft-related 6 (3) 6 (14) 138 (46) 52 (18) 202 (25) 
Percutaneous coronary intervention-related 2 (1) 1 (2) 62 (21) 22 (8) 87 (11) 
Early myocardial infarction:j: 1 (1) 0(0.0) 3 (1) 3 (1) 7 (1) 
Isolated electrocardiogram (Q waves)§ 1 (1) 1 (2) 5 (2) 4 (1) 11 (1) 
Peri-deathl[ 0(0) 1 (2) 1 (0.3) 4 (1) 6 (1) 
Miscellaneous 0(0) 0(0) 5 (2) 10 (3) 15 (2) 
*No clinical symptoms or ECG evidence of ischemia. tClinical evidence of ischemia and ECG/cardiac enzyme evidence of infarction. 
:::Cardiac enzyme or ECG evidence of infarction <24 hours after enrollment. different from the enrollment event. §Identified by systematic 
review ofECGs without clinical evidence of reinfarction. 111v1I at the time of death with clinical. ECG. or cardiac enzyme evidence. Data 
are number (%) of patients. 
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TABLE 3. Enzyme Elevations in Patients with Myocardial Infarction Identified by the Clinical 
Events COlmniltee but Not the Site Investigator* 
11 PeakCKIULN n Peak CK-MB/ULN 
Eastern Europe 172 0.6 (0.3, l.2) 167 104 (1.2, l.9) 
Latin America 34 0.7 (004, l.2) 34 2.0 (1.3, 2.6) 
North America 112 l.6(l.0, 3.1) 106 2.9 (1.5, 5.5) 
\Vestern Europe 202 0.7 (004, 2.0) 196 l.7 (l.2, 3.0) 
Overall 520 0.9 (0.4, l.9) 503 l.6 (l.2, 2.9) 
"'Patients with poslprocedural infarction are excluded (see Methods), CK-MB = creatine 
kinase-MB; ULN, local upper limit of normal. Data are median (25th, 75th percentiles). 
TABLE 4. Level of Clinical Certainty*' [or Myocardial Infarction Identified by the Clinical 
Events Committee but not the Site Investigator 
High Certainty Low Certainty Total 
Eastern Europe 133 (76) 42 (24) 175 
Latin America 21 (58) 15 (42) 36 
North America 111 (98) 2 (2) 113 
\Vestern Europe 177 (82) 39 (I R) 216 
Overall 442 (82) 9R (18) 540 
*Sec Methods. Data presented arc number (%) of patients. 
kinase-MB (CK-MB) to its ULN was highest in North American cases (median 
1.6).12,29 Enzymes were similarly elevated bet'ween patients 'with MIs defined only 
by enzyme elevations (without symptoms or ECG changes) and patients with 
elevations associated with ECG or clinical evidence of ischemia. 
Thble 4 shows the level of clinical certainty for MIs not associated with PCI 
or CABG, as identified by the CEC but not the site investigators. Overall, 98 
(18%) of these cases of MI were assigned a low level of clinical certainty. The 
proportion of cases assigned a low level of clinical certainty varied among the 
regions, v'lith the lowest in North America. 
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TABLE 5. Event Rates at 30 Days 
All Patients With Reclassification* 
Eptifibatide Placebo P Eptifibatide Placebo P 
Death or myocardial infarction I~ 
Eastern Europe 21.0 19.7 18.0 17.9 I~ (0 
Latin America 16.1 15.7 14.1 13.2 I'" 
.g. 
North America 11.7 15.0 11.7 15.0 I ~. 
~ 
Western Europe 13.8 14.8 12.9 13.7 I~ 
CD 
Overall 14.2 15.7 0.042 13.3 14.9 0.021 13 
S-
Myocardial infarction I~ 
Eastern Europe 18.8 17.3 15.8 15.3 '" I·· 3 
Latin America 11.6 11.7 9.6 9.1 1(0 3' 
0 
North America 10.1 12.9 10.1 12.9 I§-
0 
Western Europe 12.6 12.9 11.7 11.8 I'Q 
Q 
Overall 12.6 13.6 0.137 11.6 12.7 0.08 liS. 
*See Methods: 98 cases with low clinical certainty reclassified as no infarction. Data are percentages. II A ..() 
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TABLE 6. 3D-Day and 6-Month Mortality for Cases of Dbagreement 
Mortality 
n 30 days 30 days to 6 months 6 months 
CEC No / Site No 9366 1.7 2.1 3.8 
CEC Yes I Site Yes 599 22.0 5.7 27.7 
CEC Yes I Site No 816 7.2 5.4 12.6 
CEC No I Site Yes 167 24.0 2.3 26.3 
Data arc percentages. 
The 30-day rates of MI and death or MI overall are shown in Table 5 by 
geographic region. The event rates also are 8ho'W11 for the analyses in lNhich the 
913 cases assigned a low level of certainty were reclassified as no infarction. 
The 10'west mortality rates wcre in patients for 1vh0111 the CEe and site 
investigators agreed that no MI had occurred by 30 days (Table 6). The highest rates 
'were in patients for whon1 there ,vas agreenlent that an MI had occulTed. 1\101tality 
'vas high in the group 'with !\'11 identified by the site investigators but not the CEe) 
but 111any of these patients had suspected sudden cardiac dcath as the event 
identified as an M1 by the investigator (Table 1). The absolute increase in mortality 
betlNcen 30 days and 6 1110nths lNas greater in patients idth CEC-detennined MIs 
not identified by the site invcstigators than in patients with MI identified by the 
site investigators but not the CEC. 
Discussion 
This analyses of the adjudication process of nonfatal MI by a central CEC in 
PURSUIT has five key findings. First, MI rates were higher than those reported 
in prior trials of acute coronary syndr01nes. Second, the site investigator and CEC 
assessments of MI disagreed for nearly 10% of all patients enrolled. Third, 
protocol-defined MIs were underreported by the site investigators. Fourth, the 
observed treatment effect was smaller using the CEC-adjudicated MI rates versus 
site investigator-identified event rates. Finally, in a retrospective analysis that 
excluded cases ofMI that, despite meeting the pre specified end-point criteria, had 
conflicting clinical, ECG, and cardiac-enzyme data, the treatlnent effect was 
larger than that seen ,,,,,hen such cases were included. In aggregate, these findings 
suggest that the use of a CEC is inlportant for systematic ascertai1ll11ent of 
nonfatal end points; howevel~ the definition ofMI and its application in CEC event 
adjudication in PURSUIT may have been too inclusive of MIs defined by low-level 
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8117,yn1e elevations, ·which either represented IInoise ll 01' clinically unimportant 
events. 
Event Rates 
The MI rates adjudicated by the CEC in PURSUIT were higher than those 
rep01ied in trials of shnllar patient populations.6.17.19 The reason for the higher rates 
have been detailed prcviously16 and include: reviev{ of nearly 50 % of patients by 
physicians to identify suspected events, 1110re liberal rvn criteria, and rigorous 
111CaSurenlent of cardiac enzymes in all patients. Studies that have used only 
invcstigatoT-reported events probably underestimate the true IvII rate. 
Lack of Concordance Between Site Investigator and CEC Event Rates 
Myocardial infarctions were underreported by site investigators. A sllnilar lack 
of concordance betv\Tcen events adjudicated by a CEC and those identifIed by 
clinical investigators has heen observed in trials in -which a siInilar CEC group 
adjudicated MIs1.8 and in other trials. 7.9 
The MI definitions in PURSUIT were formulated by the International Steeling 
Conl111ittee based on experience and clinical expertise. Because of the broad 
geographic emoIlment planned for PURSUIT, definitions were designed to be 
applicable in an array of clinical-practice situations. The definitions 'were detailed 
in the study protocol, in study nmvsletters, and in study materials, so that the CEC 
and site investigators had the SaIne set of criteria to c1assif~y f..lIs. 
The reasons for disagreenlents in MI m;sessment between the site investigators 
and the CEC in PURSUIT (Thbles 1 and 2) are similar to those seen in the GUSTO-
lIb and the IMPACT-II trials (unpublished data). Many of the disagreements 
reflect physician reluctance to diagnose MIs in patients they are treating, 
particularly 'when the definition of MI includes events ",vith low-level cardiac 
enz;yme elevations (often called ((enzynle leaks ll in clinical practice). This reluctance 
hy physicians also is apparent for patients undergoing PCI, in 'which the clinical 
significance of post-procedure enzylne elevations is controvcrsial, even though 
such elevations correlate with 'worse outcOlnes.5 
The disagreements also may partly reflect the definitions (AppendLx) of MI 
themselves. These definitions were designed to be applied to a broad set of 
clinical scenarios, including events after PCI or bypass surgery, and to events 
occurring early after enrollment, which needed to be differentiated frOlll pre-
enrolhnent MIs. Site investigators may have had difficulty applying these cliteria, 
particularly with conflicting cardiac enzynlC, ECG, and clinical infonnation. In 
addition, the enzyme criteria in PURSUIT required only one cardiac-enzynle 
value ahove normal to provide supportive evidence of ML Substantial clinical 
uncertainty exists about the need for Inore than one elevated cnzyll1c value and 
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whether the CK-MB criteria should spccifjr elevations greater than 011e or hvo titnes 
the local ULN. 
The strategy used by a CEC to adjudicate MIs can dramatically influence 
event rates and the propoTtion of events 'with disagreements bet",\\Tcen site 
investigators and a CEe. Son1C trials have confirmed only events reported by the 
investigators j 9,17-21 'while others have adjudicated all suspected events identified by 
systcillatic screening of patient data. 1.3.7.8,22 i/{hen only events reported by 
investigatoTs are reviewed by the GEe, the reported event rates lNill be identical 
to or la-wer than the site investigator rates. ,Yhen events arc identified 
independently by the CEe, the CEe event rates may be highel~ 101NCl~ or the SaIne 
as the site investigator-reported rates. 
Difference In Treatment Effect 
The absolute difference in the MI rates ,>,"'as 1.6% (6.2% for eptifibatide vs, 7,8% 
for placebo) as assessed hy the site investigators, and 1.0% (12,6% vs, 13.6%) as 
adjudicated by the CEC. As expected, the higher event rates in both treatment arms 
using the CEC data, despite the similar absolute difference, reduced the relative 
treatnlent effect (7.4% vs. 20.5% reduction). A sinlilar decrease in relative 
trcahnent cffect has been 110ted in some prior trialsL8 but not othcrs,17-19 
The MIs detennined by cardiac-enzyme elevations without clinical synlptOllls 
or ECG changes accounted for 33% of the disagreements in which the CEC 
identified an MI and the site investigators did not. The median CK-l'vIB elevation 
in these events was 1,6 titnes the ULN, Thus, about 50% of these events were 
defined by CK-MB values between 1 and 1,5 ti1nes the ULN, with normal median 
CK values (0.9 times the ULN) (Thble 3). 
A retrospective but blinded review of MIs identified by the CEC but not the 
site investigator found that 18% (98/540) of these cases were assigned a low level 
of clinical certainty becausc, although thc CK or CK-MB elevations Inet the end-
point criteria, the cardiac-enzynle data '>\"'ere considered inconsistent or unreliable 
or ,>vere associated with conflicting clinical and ECG data, 
'Ve noted regional differences in the proportion of cases with low clinical 
certainty, The highest proportions were in Eastern Europe and Latin Aillerica, 
where the observed treatment effect using the CEC definition '>vas negligible, 
Further, the magnitude of the enzyme elevations (Thble 3) parallels discrepancies 
in the assigned level of certainty, The highest enzynle elevations were observed 
in North Alllerica (nledian CK-MB elevation 2.9 ti111es the upper li111it of norn1al; 
111edian CK elevation 1.6 times the upper li1nit of nOl'lnal), where the treatnlent 
effect '>vas nlOst pronounced. In other regions, CK-MB elevations ,>vere less striking 
(lncdian 1.4 to 2,0 tirnes the npper linlit of nor111al). HowevCl~ the regional 
diffeTcnces in treatment effect are cOlllplex and include differences in patient 
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demographics; the use of cardiac procedures, l11cdications, and rcvascularization; 
and reliability of laboratory datan These findings support the hypothesis that 
including IvII end points defined by l01N-lcvcl cardiac-cllzYlllC elevations or events 
associated vdth conflicting clinical and ECG data l113Y dilute the actual treahncnt 
effect. 
Predictive Value of CEC-Identified Events 
The 3D-day treatment effect was reduced using CEC-adjudicated end points 
versus site-investigator asscSSl11cnts, but patients with events adjudicated by the 
CEC (but not identified by the site investigators) had greater mortality between 
30 days and 6 months than did patients with MI reported only by the site 
investigators (Thble 6). In addition, MIs identified by a similar CEC process have 
been associated "with ·worse long-term outcomes at 3-ye3r follow-up.24 These data 
suggest that events identified by the CEC alone are of prognostic importance. 
Implications 
Clinical Events C0111111ittee adjudication of suspected nonfatal MI end point 
events is ilnportant to provide independent, unbiased/ standard/ systematic 
asseSS111ent. The CEC adjudication does have certain lill1itations. The criteria used 
to define MI ll1ust be evaluated. In cases in ,vhich the clinical history/ the cardiac-
enzynle data/ and ECG inforn1ation are inconsistent/ or cardiac-enzyme data 
suspect/ the detennination of MI 111ay Tequire l110re clinical judgl11ent. We 
recognize that this 111ay decrease the objectivity that is ilnportant for event 
classification/ particularly in trials across geographic regions and clinical-practice 
settings. At a minimum/ events characterized by a lU'1N level of clinical certainty 
should not be classified as MIs. 
Although the absolute difference in infarction rates determined by the CEC 
versus site investigators was small/ the relative difference ·w-as nlO1'e substantial. 
This caused a substantial impact on the statistical outcOll1e of the trial. This 
phenOll1enon n1llst be considered in sample-size and power calculations during 
design of fuhue trials and also may influence how clinical and regulatory bodies 
interpret trial results. In addition/ the CEC process used must be considered/ among 
other factors/ ·when perfonning comparisons of event rates betlNeen trials. 
Conclusion 
Nonfatal MI is an ilnportant clinical outcome; its prevention is a key n1easure 
of efficacy in evaluating new therapies for acute coronary syndromes. The 
detenllil1ation ofMl can be difficult in clinical practice due to conflicting clinical/ 
cardiac enzyme, and ECG data. Clinical Events Committee (CEC) a(\judication of 
MI provides a standard, systematic, independent/ and unbiased assessment of this 
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end point in clinical investigations, In PURSUI~ the assessments of MI by site 
investigators and a central CEC disagreed; more MIs were identified by the CEC 
than by site investigators. Most disagrccll1cnts reflected underreporting of 
procedure-related events and misclassification of cnrollnlcnt MIs as post-enrolllllcnt 
(end point) MIs. Understanding the CEC process used in a trial is important in 
interpreting event rates, particularly \Vhe11 c01npaTing rates behveen trials. The 
type ofCEC process also has implications in sa111ple-sizc and po·wer calculations. 
Our review of the PURSUIT CEC experience has highlighted some of these 
i1llportant issues and the need to further evaluate the strategies used for event 
adjudication. 
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Appendix 
Definition for Post-enrollment Myocardial Infarclion 
Enzyme Criteria: 
Myocardial infarction (events without documentation of previous infarction during the 
admission): Creatine Ilinase (CI\)-MB level above upper limit of normal (ULN) and ~3 % 
of total CK If CI\-MB was unavailable, then total CI, > 2 times the ULN. 
Myocardial reinfarction (events with documentation of an infarction before or at 
enrollment) 
If < 18 hours since previous infarction: Recurrent, severe ischemic discomfort and 
new, recurrent ST-segment elevation ~O. I mV in at least two contiguous leads, either 
persisting ~30 minutes. 
If ~18 hours since previous infarction: Re-elevation of CI,-MB to above the ULN (if prior 
CI-('MB was within normal range) or > 50 % above the prior level (if prior CI\-MB was 
above-normal). If CI\-MB was unavailable, then total CI, ~2 times the ULN and 
increased by ~25 %, or ~1.5 times the ULN and increased by ~200 IU above prior value. 
Periprocedural infarction (events occurring during or within 24 hours of percutaneous 
coronary intervention): CI,-MB level ~3 times the ULN and> 50% above prior nadir 
value. If CI\-MB was unavailable, total CI, ~3 times the ULN. 
Perioperative infarction (events occurring during or within 36 hours of bypass 
surgery): CI\-MB ~5 times the ULN (or 0" in the absence of CI\-MB). 
ECG Criteria 
New, significant Q waves or equivalents ~0.045 seconds in at least two contiguous 
leads. 
When enzyme or ECG data were unavailable, an infarction was identified when the 
bull< of clinical evidence (patient signs, symptoms, ECG changes, and pathological 
findings) so indicated. 
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Abstract 
Aims 
Variations in ontc0111C of patients fro1H different geographic regions have been 
obscr,,Tcd in l1lany large international trials. I/{e analysed the factors that Inight 
contribute to the geographic variations in patient ontcOlllC and treatnlent effect 
as observed in the PURSUIT trial. 
Methods 
an In PURSUIT, 9461 patients 'with acute coronary syndrOllles 'without 
persistent ST.-elevation 'were rand01nized to the platelet inhibitor cptifibaticle or 
placebo for 72 hours in 27 countries in four geographic regions: Western (n ~ 3(197) 
and Eastern Europe (n~1541) as \Vell as North (n~3827) and Latin America 
(n ~ 396). The primaty end-point \Vas the 30-day composite of death or myocardial 
infarction. In the initial univariate analysis, the treatment effect appeared greater 
in N. AUlCrica than in 'Y. Europe, 'while no benefit 'ivas apparent in L. Alllerica 
and E. Europe. Howevel~ the confidence intenrals ,vere wide and overlapping. 
'Ib study these differences, a subdivision in an early and late patient outcome 
and treatnlCnt effect was made. Accordingly, we analysed the rate of death 
or infarction at 72 11 censored for percutaneous coronary intervention and the rate 
between 3 and 30 days, respectively. Additional analyses were perfornled with 
different definitions of nlyocardial infarction using progressively higher thresholds 
of eK(-MB) elevation. Multivariable analysis was used to evaluate the relation 
between region and outcOllle and to determine the adjusted odds ratios for the 
eptifibatide treatment effect. 
Results 
NIajor differences in baseline demographics 1Nere apparent anl0ng the four 
regions; in particula1~ nlOre patients from E. Europe had characteristics associated 
with itnpaired outcOl11e. Interventional treatnlCnt also varied considerably, "with 
more patients [TonI N. Al11erica undergoing Tevascularization. Despite differences 
in the 72 h event rate, eptifibatide showed a consistent trend towaTds a reduction 
in the cOlnposite endpoint among all four Tegions and for all definitions of 
infarction. Relative reductions ranged [TOlll17~42% in W Europe, 23~35% in N. 
Anwrica, 0-33% in E. Europe, and 55-82% in L. America. AfteT 111ultivariable 
adjustnwnt, the pattern of benefit with eptitibatide was consistent al1lOng the 
regions. In patients undergoing percutaneous coronary intervention during study 
drug infusion in W. Europe (n~2G(i) and N. America (n~r)31), the relative 
reduction in l11yocardial infarction during Inedical therapy ranged fr0111 56-75% 
in 'V. Europe and 14~67% in N. America, while the reduction in procedure-related 
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events ranged £1'0111 12-44% ancl25-fil % for different definitions of infarction. After 
llulltivariable adjustnlCnt neither benefit nor rebound 'were apparent after study 
drng discontinuation, or after 3 days in all regions, except in L. America. In 
general, the differences in outcome and treatll1cllt effect 'were greatest 'when the 
protocol definition ofmyocarclial infarction (CK-MB > 1 upper normal limit) was 
applied. Under stricter definitions, these differences became srnaIler and 
disappeared with the investigator's aSSCSSll1ent. 
Conclusion 
The analysis suggests that the apparent differences in patient QUtCOlllC and 
eptifibaticle treatment effect can be explainecllargely by differences in baseline 
dClllographks and adjunctive treatll1cnt strategies as ,veIl as by the lllethodology 
of 111 yo cardia I infarction definition and the adjudication process. 
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Introduction 
The PURSUIT trial (Platelet IIh/IIIa in Unstable angina: Receptor Suppression 
Using Integrilin Therapy) compared the glycoprotein lIb/IlIa inhibitor eptifibatide 
(Integrilinn,,, COR Therapeutics, Inc,) with placebo in addition to standard therapy 
in 9461 patients 'Ivith acute coronary syndr01nes who did not have persistent ST-
segment elevation, PURSUIT is the largest trial to date in this patient population, I A 
total of726 hospitals from 27 countries in four geographic regions (Vlrestern Europe, 
North Alnerica, Eastern Europe, Latin America) participated. Compared lNith placebo, 
treatment with eptifibatidc resulted in a significant 1.5% absolute reduction in death 
or myocardial infarction at 30 days. As in other large international trials, there ·were 
considerable variations in Qntc0111C of patients in different geographic regions. 1·5 
Due to the large llU1nbcr of patients treated in the various regions, this trial 
afforded a unique opportullitJl to gain insight into the heterogeneity of the disease 
and patient population, and to study differences in medical practice patterns and 
treatnlent strategies. Therefore, '\7e reviewed these regional differences and 
analysed the factors that 111ight contribute to the geographic variations in patient 
outconlC and treatInent effect. 
Methods 
The study design and results of the PURSUIT trial have been published in 
detai1. 1.6 Briefly, patients were eligible for enrolment if they had ischaemic chest 
pain within the previous 24 h and either ECG changes suggestive of ischaemia CST-
seglncnt depression, T-wave inversion, or transient ST-seglllCnt elevation) or a 
creatine kinase-:r..1B fraction above the upper li1nit of nonnal for that hospital. 
Patients with persistent ST-segment elevation were excluded since they should be 
considered for immediate reperfusion therapy.7 Patients were randomly assigned 
in double-blind fashion to an intravenous bolus and infusion of placebo or 180 ~tg 
,kg-1 bolus plus infusion of2,0 ~tg, kg-1 min-1 eptifibatide, study drug was to be 
infused over 72 h, but could be continued for up to 96 h if a percutaneous 
coronary intervention was perfonned at the end of the 72 h treatl11ent pcriod. All 
other treatlnent decisions, including the use of heparin, other anti-ischaenlic 
medications and coronary angiography as wen as the use and ti111ing of 
percutaneous or surgical coronary revasGularization, were left to the discretion of 
the treating physician, The prhllary end-point was the 30-day c01nposite of death 
or non-fatal myocardial (re)intarction as adjudicated by an independent Clinical 
Events C0l11111ittee blinded to treatnlCnt assignment. 
Additional data analysis 
Since the treatment effect at the end of the initial study drug infusion period 
provides the nlOst accurate esti111ation of the benefit of eptifihatide as well as an 
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even playing field for c01nparison of the treatment benefits of eptifibatide across 
the fonr geographic regions l h'cahnent effects at 72 h in the study were determined. 
For each region separately, the incidence of the composite end-point of death or 
non-fatal 111yocardial infarction ,>vas determined with the Kaplan-Meier ll1cthod 
during the scheduled 72 h study drug infusion period among all patients 
rand0111izcd, 'while patients were censored at the time ofintervention. In patients 
'who underwcnt a percutaneous coronary intervention during the Hrst 72 h/ the 
incidence of 111yocardial infarction 'was evaluated in the period before the 
intervention, 'while the rate of death or Inyocardial infarction -was assessed "within 
the first 48 h of the intervention as 'well as in the subsequent thue winduH"T up to 
30 days. In each period I only patients 'who 'were event-free at the beginning of that 
period 'were considered. Additional1y, in patients 'Nho did not reach a study end-
point and did not undergo a percutaneous coronary intel'lention during the first 
72 hi the rate of the end-point bet-ween day 3 and day 30 '\"'as detcnllined using 
the Kaplan-Meier esthnate. 
Definitions of myocardial infarction 
In the asseSSlnent by the Clinical Events Conullittee, l11yocardial (re)infarction 
was defined by ECG abnormalities or creatine kinase(-MB) elevatiol1.1.6 The 
definitions were specific to clinical scenarios of early or later l1lyocardial infarctions 
and to infarctions associated with cardiac revascularization procedures.1.6 A 
sensitive definition of cardiac enzyme elevation was applied: a single creatine 
kinase-I\.1B value elevated above the upper 1imit of normal was sufficient to 
diagnose a 111yocardial infarction. Following percutaneous or surgical intervention, 
the elevation of enzyn1C levels was required to be at least three or five times the 
upper limit of normal, respectively. 
Additional analyses were perfonned using the investigator's detenl1ination 
of lllyocardial infarction/ and the assessnlcnt by the Clinical Events COl11lnittee 
with application of higher thresholds of creatine kinase-MB (01~ in its absence/ 
crcatine kinase) of two/ three or five thnes the upper linlit ofnonnal. For defining 
a percutaneous coronary intervention-related 111yocardial infarction/ the creatine 
kinase-MB 'was required to be above three thnes the upper lhnit ofnonnal during 
the first 24 h following the intervention, while in the subsequent period up to 48 
h post-percutaneous coronary intervention a creatine kinase-ME value was 
required which exceeded one of the pre-specified thresholds as set for the other 
tinlc windows. 
Statistical methods 
Continuous variables are presented as nledians with 25th and 75th percentiles/ 
discrete variables as frequencies and percentages. Baseline characteristics and 
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treatment parameters among the regions ,vere c01nparcd univariably using the 
Kruskal-'i,Vallis test for all continuous variables and Pearson's chi-square test for 
all incidences. OutcOlnes between eptifibatide and placebo patients 1vithin each 
region were cornpared univariably using Fisher's Exact Thst. Statistical significance 
was determined to be P S; 0.05. A multi variable logistic regression lllOdcl ·was used 
to evaluate the relationship between geographic region and outcOInc for different 
definitions of myocardial infarction. The model was adjusted for variables found 
to be significant predictors of the 3D-day composite of death or non-fatal myocardial 
infarction in the overall PURSUIT population.8 Variables and their independent 
association ·with these QUtCOll1CS arc presented as odds ratios with 95% confidence 
intervals. Multivatiable regression was also performed to determine the interaction 
tel'ln bet'\7een region and eptifibatide treatment. Results of the l11ultivariable 
regression analysis were then used to calculate the new, muHivariab1e-adjusted 
odds ratios for the eptitlbatide treatment effect. 
Results 
Baseline demographics and adjunctive therapy 
A total of 9461 patients were enrolled in the placebo and the eptifibatide 
180/2.0 groups of the PURSUIT study.' Of these, 3827 (41 %) were enrolled in North 
America, 3697 (39 %) in Western Europe, 1541 (16 %) in Eastern Europe and 396 
(4 %) in Latin Anlerica. Major differences in baseline characteristics were apparent 
among these four geographic regions (Thble 1). For example, age was highest in 
European patients, while in Eastern Europe 1110re fmnale patients were enrol1ed, 
as well as more patients with heart failure. FurthenHore, patients fronl Eastern 
Europe had more severe angina preceding hospitalization, 1l1Ore often exhibited 
ST-segnlent depression on the qualifying clectrocardiograll1, and presented with 
a higher blood pressure, In contrast, patients frotH North AnlCrica had a higher 
body weight, were lnore frequent diabetics, and had 1110re frequently undergone 
Tevascularization procedures. In nlOre patients fr0111 North Al11erica the qualifying 
episode was classified as a 111,'jrocardial infarction. Medical and interventional 
treat111ent also varied all10ng regions, with nlore patients from North Alnerica 
receiving hepatin and undergoing angiography, percutaneous coronary intervention 
or coronary bypass surgel), (Fig. 1). The percentage of percutaneous coronal), 
interventions perfonued during the 72-h study drug infusion period was 
substantially higher muong patients enrolled in North America than in the other 
regions. In all regions, over 90% of all patients received aspirin during 
hospitalization. Beta-blockers were used Inore frequently in y\Testern EllTOpe, 
while 1110re Eastern European patients received ACE-inhiliitors, reflecting the higher 
rates of previous infarction and heart failure in this region. The different treattnent 
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Table 1 Baseline c1UlYacterisrics. concomitant therapy and treatment parameters by region 
Characteristic WE NA EE LA 
(n~3697) (n = 3827) (n= 1541) (n~396) 
Age (years) 65 (56, 71) 63 (54, 71) 65 (56, 71) 60 (51, 67) 
Female sex (%) 31 35 47 37 
Weight (kg) 76 (68, 85) 82 (71, 93) 75 (67, 85) 73 (63, 84) ~ Height (cm) 170 (164, 175) 172 (163, 178) 167 (161, 173) 165 (160,171) 
Systolic BP (mmHg) 130 (120, 145) 128 (113, 142) 135 (120, 150) 121 (110, 140) 0" 
Diastolic BP (mmHg) 80 (70, 84) 70 (61, 80) 80 (70, 90) 80 (70, 34) Q. 
Hypertension (%) 46 61 62 63 CO 
::0 Diabetes (%) 18 27 26 23 
.g. CHC in previous 6 weeks (%) 
0 lor II 36 41 33 45 
'S" 
III or IV 45 36 57 37 ~ 
Prior MI (%) 28 34 37 37 it 
Prior CHF (%) 8 10 20 8 CD 
Prior PCI (%) 10 21 3 5 3 Prior CABG (%) 9 20 2 6 
'S" 
MI at enrolment (%) 44 48 46 32 Q 
QualiJ'ying EeG changes (%) 8= 
ST-depression 54 40 66 44 ;e 
ST-elevation 13 16 9 16 3 
Concomitant medication (%) CO 
Aspirin 94 91 95 95 3' 
Beta-blockers (oral) 68 66 65 55 0 
ACE inhibitors 23 27 41 33 8-
Heparin infusion (%) 38 97 80 77 0-ro 
"<: 
For continuous variables, the median values are provided, with the 25th and 75th percentiles given in parentheses. P"" 0.0001 by Kruskall-Wallis test for dif- § 
ferences betvveen the regions for all continuous variables, P= 0.001 by Pearson's chi-square test for differences between the regions for all discrete variables; Q 
WE"" Western Europe; NA = North America; EE = Eastern Europe; LA", Latin America; ACE"" angiotensin convening enzyme; BP "" blood pressure; 3" CABG = coronary artery bypass grafting; CHC "" Canadian Hean Class; CHF= congestive heart failure; ECG "" electrocardiographic; MI = myocardial infarction; 
"0 
0- PCI = percutaneous coronary intervention. Q () ()1 ~ 
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Figure 1: 
Angiography and revQsGu/orization rates by region. 
Percentage of patients undergoIng angiography (A), percutaneous coronary inteNention 
(P) or coronary bypass surgery (C) during the 30-day follow-up are shown above the bars, 
with the percentages with procedures performed withIn the first 72 h shown separately 
within the bars, 
strategies were also apparent in the duration ofho.spital stay which was shortest 
in North Alnerica (median 6 days), and twice as long in Eastern Europe (median 
13 days) with intermediate figures for '''''estern Europe and Latin An1erica (median 
10 days, both). 
Early (<72 h) patient outcome and treatment effect 
In the PURSUIT study, the effect of eptifibatide on reducing death or 
myocardial infarction ,,"'as apparent at 72 h, 'while this treahnent effect reI11ained 
essentially unchanged during the subsequent 30 days.' At 72 h, mortality was 
highest among patients from Latin America followed by Eastern Europe (Thble 
2). Applying a variety of definitions ofnlyocardial infarction, patients enrolled in 
Eastern Europe and Latin Anlerica had a higher rate of death or infarction than 
those enrolled in Western Europe and North iUllerica. As expected, the nUlnber 
of end~points decreased in each region when a more stringent definition of 
Inyocarclial infarction ·was applied. By 111ultivariable analysis, the rate of death or 
Inyocardial infarction at 72 h according to the Clinical Events COll1nlittee was 
related to the geographic region (Thble 3). After adjustment for differences in 
baseline characteristics, patients enrolled in Latin America and Eastern Europe 
\vere at a higher risk of adverse cardiac events than those fr0111 Western Europe, 
\vhercas patients treated in North Alnerica were at a lower lisle. ""hen progressively 
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Table 2 Mortality and composite of death or Jnyocardial infarction at 72 h after randomization with censoring for 
percutaneous cOYOntoy intervention 
WE (n~3697) NA (n=3827) EE (n~1541) LA (n~396) 
E p D. RR E P D. RR E P D. RR E P D. RR 
Death 0.4 0.9 0.5 0.44 0.4 0.6 0.2 0.67 0.7 1.2 0.5 0.58 1.0 1.5 0.5 0.67 
Composite of death or MI 
according to:CEC 4.6 - 0 O.v 1.2 0.79 2.9 4.1 1.2 0.71 10.3 10.2 -0.1 1.01 3.7 8.2 4.S 0.45 
CEC>2 3.7 4.7 1.0 0.79 2.6 3.5 0.9 0.74 6.2 6.5 0.3 0.95 2.6 8.2 5.6 0.32* 
CEC>3 3.3 4.0 0.7 0.83 2.4 3.1 0.7 0.77 5.0 5.6 0.6 0.89 1.6 6.7 5.1 0.24* 
CEC>5 2.2 3.1 0.9 0.71 1.9 2.5 0.6 0.76 3.2 3.8 0.6 0.84 1.6 5.1 3.5 0.31 
Investigator 2.1 3.6 1.5 0.S8t 2.0 3.1 L1 0.65* 3.0 4.5 1.5 0.67 1.0 5.6 4.6 0.18* 
Values presented as percentages, relative risk as ratio. 
CEC = Clinical Events Committee; CEC > 2, CEC > 3, CEC >5 = composite end-point according to the Clinical Events Committee with 
application of thresholds of creatine kinase(-MB) of tvvo, three and five times the upper limit of normal in the definition of 
myocardial infarction, respectively; D = absolute difference benv-een P and E; E = eptifibatide; MI = myocardial infarction; 
P = placebo; PCI = percutaneous coronary intervention; RR=relative risk. *, t correspond to P < 0.05, < 0.005 by Fisher's Exact 
Test.Other abbreviations, see Table 1. 
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Thble 3 Multivariable-adjusted odds ratios for early (72 It) and late (3-30 days) event rate by region 
Death CEC CEC>2 CEC>3 CEC>5 Investigator 
Early event rate LA 3.76 (1.0 - 14) 2.01 (1.1 - 3.6) 2.78 (1.6 - 5.0) 2.75 (1.4 - 5.2) 2.93 (IA - 6.0) 2.62 (1.3 - 5.2) 
NA 0.77 (0.3 - 1.7) 0.60 (OA - 0.8) 0.69 (0.5 - 1.0) 0.76 (0.5 -1.1) 0.76 (0.5 - 1.2) 0.82 (0.5 - 1.2) 
EE 1.00 (OA - 2A) 1.65 (1.2 - 2.3) 1.21 (0.8 - 1.8) 1.27 (0.8 - 1.9) 1.09 (0.7 - 1.8) 1.15 (0.7 - 1.8) 
WE I 
Late event rate LA 1.37 (0.6 - 2.9) 1.12 (0.6 - 1.9) 1.20 (0.7 - 2.2) 1.02 (0.5 - 1.9) 1.06 (0.5 - 2.0) 1.13 (0.6 - 2.1) 
NA 1.10 (0.8 - 1.6) 1.07 (0.8 - 1.4) 1.16 (0.9 - 1.5) 1.16 (0.9 - 1.5) 1.26 (1.0 - 1.7) 0.98 (0.7 - 1.3) 
EE 0.80 (0.5 - 1.2) 1.00 (0.7 - 1.3) 0.88 (0.6 - 1.2) 0.77 (0.6 - 1.1) 0.75 (0.5 - 1.1) 0.96 (0.7 -1.3) 
WE I 
Multivariable-adjusted odds ratios relative to Western Europe are provided with their 95% confidence interval in parentheses. Early event 
rate represents the 72-h, Pel-censored end-point of death or composite of death or myocardial infarction (figures sho"Wll in Table 2), while 
the late event rate represents the 3-30-day end-point of death or composite of death or myocardial infarction in patients with no end-point 
or PCl during the first 72 h (figures presented in 'TItble 4). CEe = Clinical Events Committee; CEe > 2, CEe > 3, CEe > 5 = composite end-
point according to the Clinical Events Committee VlTith application of thresholds of creatine kinase(-MB) of two, three and five times the 
upper limit of normal in the definition of myocardial infarction, respectively; PCl = percutaneous coronary intervention. Other abbrevia-
tions, see '!able 1. 
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MulfivariabJe-adjusted odds ratios for the treatment effect on mortality and the composite of 
death or non-fatal myocordla/lnfarction at 72 h with censoring for percutaneous coronary 
intervention and between 3 and 30 days. 
Odds (atios are presented for each geographic region and for the various definitions of 
myocardial Infarction applied to the composite end-poInt. The horizon to/lines IndIcate 
95% confidence intervals. 
CEC = Clinical Events Committee: CEC>2, CEC>3, CEC>5 = composite end'polnt 
according to the Clinical Events Committee with application of thresholds of creatine 
klnose(-MB) of two, three and five times the upper limit of norma! In the definitlon of 
myocardIal Infarction, respecfivefy; Inv:= site investigator. 
higher thresholds of enzyme elevation were used in the definition ofnlyocardial 
infarction, North Al11crica and Eastern Europe were no longer statistically 
significant predictors of the cOlllbined QntcOll1C. In contrast, Latin Anlerica 
rCluainec1 an independent risk factor for the occurrence of death or infarction at 
nh, 
The absolute and relative reduction in the cOll1posite end-point of death or 
I11Jlocardial infarction after 72 hours in patients receiving eptifibatidc 'when 
cOlllpared lNith those in the placebo group appeared larger in Latin AnlCrica 
than in the other regions for all infarct definitions (1l1ble 2), This difference in 
treahnent effect 'vas) hOlNeVet~ not statistically significant. ,\Vithin each region 
separately as "well as al1lOng all four geographic regions there 'vas a relllarkable 
consistency with respect to the directionality ofthe treatment effect) independent 
of the definition of myocardial infilrction (Fig. 2). Although the magnitude of benefit 
differed and did not reach statistical significance in all c0111parisons) a beneficial 
effect of eptifibatide was apparent for all definitions of myocardial infarction 31uong 
all four regions. Only one exception was observed: the original assessment by the 
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Figure 3: 
Adverse cardIac events in patients from Western Europe (upper figure) and North America 
(lower figure) undergoing percutaneous coronary Intervention withIn the 72 h study drug 
Infusion period. 
In both figures, the {eft bar graphs show the percentage of patients suffering a mvocardial 
Infarction in the period prior to the Intervention. The middle graphs show the incidence of 
procedure~related death or infarction during the first 48 h (oHowing the intervention. The 
right grophs indicate the rate of death or non-fatal myocardial infarctIon from 48 h after the 
InteNentlon up to one month, The clinical event rates are depicted for the various 
definitions of myocardlallnfarctlon 
CEC = Clinical Events Committee: >2, >3, >5 = end-point according to the Clinical Events 
Committee with applicatlon of thresholds of creatine kinase(-MB) of two, three and five 
times the upper limit of normal in the definition of myocardIal infarction, respectively: Inv = 
site Investlgator. 
*, t, § correspond to P<0.05, <0,07, <0,005 by Fisher's Exact Test for comparison between 
eptifibatide CD) and placebo CD+ 0). 
Clinical Events COlllnlittee ofluyocardial infarction OcculTing in Eastern Europe 
(Thble 2). After multivmiable adjustment, the reduction in death or myocardial 
infarction at 72 h by eplifibaticle did not differ significantly between Western Europe, 
Eastern Europe and North Aluerica ·when the original Clinical Events C01111nittee 
adjudication \vas used or \vhen a definition of l11yocardial infarction with thresholds 
of creatine kinase(-l\1B) of hvo or three thues the upper limit of normal was 
applied (Fig. 2). In Western Europe, a slightly greater and statistically significant 
treatlnent benefit i\"'as observed on mortality and the c0111bined end-point with a 
threshold of creatine kinase(-MB) of five times the upper limit ofnon11al or the 
investigatorts assessment of infarction. Additionally) the odds ratios of the 
treatnlent benefit observed in Latin America were significantly lmver than in the 
other regions when a definition of myocardial infarction of creatine killase( -MB) 
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'Ikble 4 3 - 30-day mortality and composite of death or myocardial infarction in patients with no end-point or 
percutaneous coronary intervention in the first 72 It 
WE (n~3251) NA (n~2759) EE (n~ 1356) LA (n~ 359) 
E P D RR E P D RR E P D RR E P D RR 
Death 4.1 4.1 0.3 0.93 3.9 4.9 1.0 0.80 6.7 4.8 -1.9 lAO 13.5 5.2 -8.3 2.60* 
Composite of death or MI 
according to eEe 11.7 U.s -0.2 1.02 9.7 11.4 1.7 0.85 14.3 12.7 -1.6 Ll3 18.4 10.3 -8.1 1.79* 
CEC>2 9.9 9.7 -0.2 1.02 8.2 10.5 2.3 0.78'" 10.9 9.9 -1.0 LID 17.5 9.2 -8.3 1.90* 
CEC>3 9.1 9.5 0.4 0.96 8.0 10.3 2.3 0.78 10.4 8.5 -1.9 1.22 17.5 7.9 -9.6 2.22t 
CEC>5 8.1 8.4 0.3 0.96 8.0 9.6 1.6 0.33* 9.4 7.4 -2.0 1.27 16.4 7.2 -9.2 2.28' 
Investigator 3.2 8.5 0.3 0.96 6.8 7.9 LI 0.86 10.0 9.5 -0.5 LOS 14.7 7.3 -7.4 2.01 
Values presented as percentages, relative risk as ratio. 
eEe = Clinical Events Committee; eEe > 2, CEe > 3, CEC > 5 "" composite endpoint according to the Clinical Events Committee with 
application of thresholds of creatine kinase(-MB) of two, three and five times the upper limit of normal in the definition of myocar-
dial infarction, respectively; D "'" absolute difference between P and E; E = eptifibatide; MI = myocardial infarction; P = placebo; 
PCI = percutaneous coronary intervention; RR=relative risk.", t correspond to P<O.OS, <0.01 by Fisher's Exact Test. Other abbrevi-
ations, see Thble 1. 
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exceeding two or three titnes the npper linlit of normal \vas applied to the original 
adjudication by the Clinical Events C0l1ll11ittee or when the investigator's 
asseSSlllcnt \"\laS used. 
In patients undergoing early (Le. "within 7'2 h) percutaneous coronary 
intervention in Western Europe (n= 266) or North America (n = 931)1 there ",,"'as 
a consistent pattern of benefit \\7ith eptifibatide during luedical therapy, ·which \vas 
augmented by the use of eptifibatide during the intervention. Although only 
S0111C of the differences reached statistical significance, the directionality of the 
benefit ,vas again rClllarkably consistent and apparent for all definitions of 
l11yocardial infarction (Fig. 3). During l11edical therapy preceding percutaneous 
coronary intervention, the relative reduction in 111yocardial infarction ranged 
fronl 56 to 75 % in '''Test ern Europe and from 14 to 67% in NOlih Alnerica. The rate 
of nlyocardial infarction associated with percutaneous coronary intervention 
was higher than in the preceding clinical treatment period. The absolute and 
relative treatment benefit of eptifibatide was greater in patients undergoing early 
percutaneous coronary intervention, both in the lnedical treahnent period 
preceding the intervention and in association 'with the intervention, as cOlnpared 
-with patients in ",\\ThOlll no intervention was perfofllled in the first 72 h. Neither 
additional treatment effect nor rebound were apparent after discontinuation of 
eptifibatide or placebo. The nUlnbers of patients undergoing early coronary 
intervention in Eastern Europe (n = 31) and Latin AnlCrica (n = 16) were too snla11 
for a llleaningful analysis. 
Late (3-30 days) patient outcome and treatment effect 
In patients who did not reach a study end-point or undergo a percutaneous 
coronary intervention in the first 72 h, the subsequent incidence of the conlposite 
of death or myocardial infarction at 30 days was high (Tdble 4). In contrast to the 
early patient outcOlne, geographic region was not a significant predictor of cardiac 
events in these patients (similar odds ratios, Thble 3). Among patients enrolled 
in ""estern Europe, neither additional treatnlCnt benefit nor rebound effect v·ms 
apparent following the discontinuation of study drug. In North American patients, 
a consistent trend towards a treatment benefit with eptifibatide was observed. 
Additional analysis revealed that this benefit was mostly due to the favourable effect 
of eptifibatide on patients who were still receiving study drug in the period 
between 72 and 96 h. In contrast, negative treatlnent effects 'were observed in the 
other two geographic regions, '''lith a small disadvantage for eiJtifibatide in Eastern 
Europe and a largel~ statistically significant one in Latin Anlerica. By multivariable 
analysis, howevel~ odds ratios of the late treatnlCnt effect in ''''estern Europe, 
Eastern Europe and North America did not differ significantly and showed neither 
benefit nor rebound, although a trend towards a treatlnent benefit was apparent 
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in North America (Fig. 2). The odds ratios reflecting the negative treatment 
effect between day 3 and 30 in Latin AnlCrica ,vere significantly different from 
those observed in the other regions. 
Discussion 
In the initial univariate PURSUIT analysis, the treatment effect appeared 
greater in North America than in V\Testern Europe, while no treatlnent effect was 
apparent in Latin Al11crica and Eastern Europe,1 Howevel~ the confidence intervals 
for the treahncnt effects in these regions were ·wide and overlapping. The present 
analysis suggests that the apparent differences in patient outcome and treatlnent 
effect can be explained largely by differences in patient characteristics and 
treatillent strategies, and by the adjudication process. 
Baseline demographics 
and early « 72 h) patient outcome and treatment effect 
Patients enrol1ed in Eastern Europe were o]del~ had a history of 1110re severe 
coronmy artery disease including a worse angina pectoris class and heart failure, 
and more often exhibited ST-segment depression on the qualifying 
electrocardiogram. These factors are associated 'with a 'worse outcome in patients 
'with acute coronary syndrOllles.8-13 This is reflected in this analysis by the higher 
rates of Inortality and the cOlubined end-point at 72 h in Eastern European 
patients. After correction for baseline characteristics in the l11ultivariable analysis, 
Eastern Europe \\'as no longer a significant predictor of lllOrtality. Howevel~ 
differences in the cOlnbined event rate according to the Clinical Events Committee 
were maintained, with an increased risk in Eastern Europe as c0111pared with 
Western Europe and North America. Eastern European origin was not an 
independent risk factor with respect to the combined outc01l1e 1Nhen l110re 
stringent criteria of infarction were applied. Therefore, the original protocol 
definition of 111yocaTdiai infarction and the adjudication process should he 
considered in this context as discussed below. Furthermore, the developed 
l11ultivariable nlOdels concentrated on baseline characteristics and risk factors at 
the I110111ent of hospital adl11ission. Consequently, differences between countries 
and regions in applied l11anagement styles and treatment strategies arc post-
randonlization events for which it would be ilnpossible to control for adequately. 
Finally, the role of chance cannot be excluded. The high mortality rate in Latin 
AnlCrica remains an unexplained finding. 
Despite differences in adverse cardiac event rates among the four geographic 
regions, eptifibatide showed a consistent trend towards a reduction in 1l10rtality 
and the composite end-point at 72 h in each region and for each definition of 
111JTOcardiai infarction, Although most C0111parisons failed to reach statistical 
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significance, 1110St probably due to the 8111a11 nU111ber of patients per subgroup, only 
one exception "was observed: the original aSSCSSl11cnt by the Clinical Events 
COlnnlittee ofnlyocardial infarction occurring in Eastern Europe. This consistency 
with respect to the directionality of the treatlncnt benefit was Inaintaincd in the 
multi variable analysis. 
Impact of percutaneous coronary intervention 
In patients with acute coronary syndromes as well as in patients with stable 
angina, coronary intmvention is associated ·with a 596 to 1096 l11yocardial infarction 
rate. 14-19 Some of these infarcts can be avoided by treahncnt ·with a glycoprotein 
lIb/IlIa receptor blocker at the time of coronary intervention."'" The CAPTURE 
study denlOl1strated a significant reduction in adverse cardiac events he fore the 
percutaneous coronary intervcntion i,·;Then patients 'with refractory unstablc 
angina received a glycoprotein IIb/Illa inhibit01: 7,21 This prevention of myocardial 
infarction during medical therapy preceding percutaneous coronary intervention 
and protection from death or infarction during the proccdure were also apparent 
in PURSUIT patients undergoing intervention during the 72 h study drug infusion 
period.22 Despite the relatively slnall number of paticnts in ¥lestern Europe 
undergoing percutaneous coronar~y intervention during tltis tllneframe as c01npared 
to North Anwrica, the pattern of benefit was retnarkably silnilar in both regions. 
Recently, this pattern has also been observed in anothCl~ large clinical trial of 
g1ycoprotein IIh/IIIa inhibition in patients presenting i\Tith acute coronary 
syndromes without ST--elevation. 12 In patients undergoing percutaneous cOTonary 
intervention after discontinuation of study drug, no increlnental treahncllt effect 
is to he expected and none was observed. In facti coronary intervention in those 
patients \vas associated with an increased Inyocardial infarction rate. 
The observed treatlnent effect at 30 days is thus a cOlnbination of the 
preventive effect during initial medical therapy and the protection by glycoprotein 
IIb/IIla inhibition from thromhotic cOlnplications associated '''lith percutaneous 
coronary intervention. The large nUlnbcr of patients in North AUlclica undergoing 
percutaneous coronmy intervention while receiving study drug therefore enhanced 
thc apparent treatment effect in this region. In the other regions, coronary 
intcrvention was done less frequently and nlOstly after discontinuation of study 
drug. Accordingly, in these regions, the treatment effect as observed in the 
Oliginal repOlt merely reflectecl the effect of medical therapy without an additional 
effect during percutaneous coronary intervention. 
The increased benefit during the Inedical treatnlent period in Western 
European and North American patients subsequently undergoing an early 
percutaneous coronary intervention, as cOll1pared with the 72 h treattnent effect 
in the rell1aining patients enrolled in these regions, may reflect a patient group 
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at higher risk of thr0111hotic cOlnplications. It l11ay also reflect investigational sites 
with staffing and infrastructure capable of perfonning early coronaty intervention, 
allmving for optimal monitoring of patients and intervening in case of signs or 
s,Ylnptoms unfhvourably affecting the patientls prognosis (e.g. recurrent ischacnlia)", 
thus optimally exploiting the beneficial effects of eptifibatide. 
Late (3-30 days) patient outcome and treatment effect 
In patients without cardiac COll1plication or percutaneous coronary 
intervention in the first 72 h) the rate of clinical events reported between day 3 
and 30 was high in all regions. This may reflect the great effort expended in this 
trial to nlCasurc and collect data 011111yocardial enzylne levels in patients \vith 
suspected ischacillic events and in those undergoing revascularization. This is 
supported by the fact that the high event rate ,,"'as l11aintained when the Inore 
stringent definitions ofnlyocardial infarction of creatine kinase(-MB) above three 
or five tinles the upper nornlal linlit were applied. Smue of the events \vere 
associated with percutaneous coronary interventions performed after 
discontinuation of study drug. Contrary to its relation to the 72 h outcOlne, 
geographic region 'vas not an independent predictor ofIate outcome. This might 
suggest that the regional diflerences in treatluent strategies and management styles 
mainly influence the patienes prognosis during the acute and subacute phase of 
the acute coronary syndr0111e. After discontinuation of experimental therapy no 
increlnental treahllent benefit is to be expected since platelet function recovers 
rapidly after the infusion of eptifibatide has been stopped. Indeed, the high event 
rate associated w-ith late, unprotected coronary interventions may have diluted 
the actual treatn1ent benefit. The negative treatment effects between day 3 and 
30 in Eastern Europe and Latin America contributed to the absence oftreatnlCnt 
benefit in these regions at 30 days in the initial univariate analysis, However, in 
the multi variable analysis there were no significant differences in treatlnent 
effect bet\veen day 3 and 301 which shmved neither benefit nor rebound, aluong 
''''estern Europe, Eastern Europe and North Alnerica, although there was a trend 
tmvards more beneficial effect in the last region, The negative late treatnlCnt effect 
in Latin Anwrica is difficult to explain, HowevC1~ it should be appreciated that only 
a very li1nited number of patients -were enrolled in this region, Therefore, the role 
of chance cannot he excluded, 
Impact of myocardial Infarction definition and the adjudication process 
Since even small, aSYlnpt01natic Inyocardial infarctions detected on the basis 
of elevated cardiac-enzyme 1evels in senun portend an unfavourable short- and 
long-term outcome23-281 a sensitive definition of In yo cardia I infarction was appJiet'l 
by the Clinical Events Connnittee: any elevation of creatine kinase-MB above the 
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upper limit of 1101'1na1 'vas considered a l11yocardial infarction. Other recent 
studies investigating glycoprotein lIb/IlIa blockers have applied a threshold oftwo 
or three tinleS the upper limit of 110nnal for creatine kinase~MB or total creatine 
kinase as part of their definition of ll1yocardial infarction. 12,17.29 The greatest 
regional variation in treatment effect in PURSUIT and the present analysis was 
apparent ,dlen the original CEe definition of Inyocardial infarction was applied, 
while these differences becatuc 8111a11er \vhen 1110re stringent definitions ·were 
applied, and disappeared 'Nhen the clinical definition ofluyocardial infhrction was 
used as assessed by the local investigator. This might be explained in part by the 
fact that creatine kinase-MB measurement was introduced for the PURSUIT 
study in a number of hospitals 'INhere this n1C3suren1ent was not part of the 
routine clinical practice! particularly in Eastern Europe. This may have resulted 
in a nUlnber of erroneous abnormal creatine kinase-ME values. Re-screening of 
patients 'with a discrepancy between investigator and CEC assessment of 11lyocardial 
infarction resulted in identification of patients "with spurious creatine kinase-ME 
elevations, most likely not related to 11lyocardial necrosis.30 After application of 
a n10re strict threshold for n1yocardial infarction! treatnlent effects in al1 regions 
consistently favoured eptifibaticle. 
Although accumulating data support the notion that even minor elevations 
of creatine kinase-ME are prognostical1y illlportanf3-28, perhaps this level of 
elevation is too sensitive to a11m·v detection of slnal1 treatment effects \vl1Cn 
employed in a global mega-trial, especially when faced with the realities of 
collecting enzyme data in regions of the world that do not typically perfornl these 
laboratOly evaluations. Clearly, the inability to get reasonable creatine kinase-ME 
data is of concern for future global investigations unless standardization of 
methods (Le. a central core laboratory) can be assured. These factors all bear 
consideration when defining criteria for the diagnosis of 111 yo cardia 1 infarction in 
the context of clinical investigation and, especially! in the conduct of a 1arge 
international mega-trial. The present data imply that the adjudication process and 
the creatine kinase l11ethodologic problen1s Inay have had a InajaI' itnpact on the 
inter-region differences that emerged during the PURSUIT trial.'" 
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Conclusion 
In their attcl11pt to reflect actual clinical practice j the PURSUIT investigators 
chose the large simple trial model in the real-life clinical setting without mandated 
additional treatment assignments to study the effects ofeptifibatide. In choosing 
a global approach to the trial, including a broad spectrum of management styles 
and clinical practices from rural hospitals to 111ajor tertiary referral centers in 27 
countries, the investigators took the risk of seeing treatment outcomes and effects 
that would differ in the various regions. The initial PURSUIT analysis observed 
large differences in patient outcome and treatl11ent effect among the four 
geographic regions. The present analysis suggests that these apparent differences 
can largely be explained by differences in baseHne patient characteristics and 
treattnent strategies, particularly the use and timing of coronary intervention. The 
third major factor that contributed to the rcgiona1 variation was the adjudication 
process and the ll1ethodology of myocardial infarction definition. 
The present report should be considered as an explanatory analysis ailning 
to identify factors contributing to the geographic variations in outcOll1e and 
treatment effect. In order to explore these differences which result frOlll a cOlnplex 
interplay in each region betlNeen baseline characteristics, treatment strategies and 
results of the adjudication process as 'Nell as from the treatInent interaction as a 
function of these factors) the 30-day end-point 'was subdivided into early and late 
outcome. The effect ofloosing statistical pmver 'vas outweighed by the insight that 
was gained into the n1echanisnls involved in the geographic variations in patient 
outcOlne and treattnent effect. Clearly, the analyses presented should be viewed 
with the 1ilnitations germane to subgroup analysis ofrandOll1ized clinical trials. 31 
Yet, the differences in baseline denlOgraphics, the adjunctive treattnent strategies, 
and 111ethodologic aspects of how events are determined all bear important 
consideration when analysing data from large international trials. The nlOst 
important lesson ofthe present analysis is that global clinical trials should take 
into account these three important aspects ,vhen 11laking observations regarding 
differences in patient outcome and consistency of the treatment effect across a 
nlulti-national netwurk. 
Supported by COR Therapeutics, lnc. (South San Francisco, CA, U.S.A.) and 
Schering Plough Research Institute (Kenilworth, NJ, U.S.A.). 
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Abstract 
Context: 
AbcLximab, a potent inhibitor of the platelet glycoprotein lib/IlIa mceptm; reduces 
thrOlllbotic cOlnplications in patients undergoing percutaneous coronary 
intervention. Because of its potent inhibition of platelet aggregation) the effect of 
abcixhnab on the risk of stroke has been a concern. 
Objective: 
"Ib dctcnninc ,\"'11cthe1' abciximab is associated lNith an increased risk of stroke 
31uong patients undergoing percutaneous coronary intervention. 
Design: 
Four double-blind, placebo-controlled, randomized trials (EPIC, CAPTURE, 
EPILOG, and EPISTENT). 
Setting: 
A total of 257 academic and community hospitals in the United States and Europe. 
Patients: 
A total of 8555 patients undergoing percutaneous coronary intervention ';\Tith or 
-without stent dep10yment for a variety of indications were rando111ized. 
Interventions: 
Bolus and infhsion of abciximab or matching placebo. One treatment group in EPIC 
received a bolus of abcixiInab only. 
Main Outcome Measures: 
The incidences of henlOrrhagic and non-hetl1orrhagic stroke "were detennined. 
Results: 
Al110ng the 8555 patients randOl11ized) no significant difference in stroke rate "WBS 
apparent betv'leen patients assigned abcixitnab and those assigned placebo (0.40% 
versus 0.29%, l' ~ 0.46). With exclusion ofthe EPIC abciximab bolus-only group, 
there ·were 9 strokes m110ng the 3023 patients ".,Tho received placebo (0.30%) and 
15 in 4680 patients treated with abciximab bolus plus infhsion (0.32%), a c1ifterence 
of 0.02% (95%CI -0.23% to 0.28f}()). The incidence ofnon-henlOrrhagic stroke 1vas 
0.17% in abcixhnab-treated patients and 0.20% in placebo-treated patients 
(difference -0.03%) 95%CI -0.23% to 0.17%). The rates of hemorrhagic sh'oke were 
0.15% and 0,10%) respectively (difference 0,05%) 95%CI -0.11 % to 0.21 %), Muong 
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patients treated 'with abcL'(i111ab, the incidence ofhen10rrhagic stroke in patients 
receiving standard-dose heparin in EPIC, CAPTURE, and EPILOG was higher than 
in those receiving low-dose heparin in the EPILOG and EPISTENT trials (0.27% 
versus 0.04%, p=O.057). 
Conclusions: 
Abcixi1nab in addition to aspirin and heparin does not increase the risk of stroke 
in patients undergoing percutaneous coronary intervention. Patients undergoing 
percutaneous coronary intervention and treated 'with abcLxhnab should receive 
lO'w-dosc, i\"feight-adjusted heparin. 
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Introduction 
Intravenous platelet glycoprotein (GP) lIb/IlIa receptor inhibitors effectively 
reduce i8c11en1ic cOluplications in patients undergoing percutaneous coronary 
intervention and in those ,vith acute coronary syndrOlucs treated l11edically. 1-8 
Randomized studies have 8hO\\1n consistency mnong agents ·with respect to the 
directionality of the benefit, with the 1110st pronounced reductions achieved with 
abciximab (ReoPro TM, Centocor), a monoclonal antibody Fab fragment directed 
against the platelet GP lIb/IlIa receptor 9 In the EPIC (Evaluation of 7E3 for the 
Prevention ofIschemic Complications), CAPTURE (c7E3 Fab Antiplatelet Therapy 
in Unstable Refractory Angina), EPILOG (Evaluation in PTCA to Improve Long-
term Outcome with Abciximab GP lIb/IlIa Blockade) and EPISTENT (Evaluation 
of Platelet lIb/IlIa Inhibitor for Stenting) studies, treatment with abciximab 
resulted in an approximate 50% reduction in the cOll1posite of death or myocardial 
infarction at 30 days in the full spectnull of patients undergoing percutaneous 
coronary intervention. 1·4 
Inhibition ofplate!et aggregation by abciximab or other GP lIb/IlIa receptor 
blockers increases the risk of bleeding c0111plications, particularly when combined 
with conventional doses of heparin. loS Intracerebral he1110rrhage is potentially the 
m01:lt catastrophic and dreaded complication of antithronlbotic or anticoagulant 
therapy. The event usually results in fatality or disability.lO Because of its potent 
inhibition ofplatclet aggregation, the effect of abcL"imab on the risk of stroke has 
been a concern. Since stroke is infrequent, a conlbined analysis of 8555 patients 
from the EPIC, CAPTURE, EPILOG and EPISTENT studies was performed to 
C0111pare stroke rates between patients treated "\vith abcixhnab (in addition to aspirin 
and heparin) and those receiving placebo during coronary intervention, as well 
as to assess the predictive value of baseline clinical and denlOgraphic factors "with 
stroke. 
Methods 
Data were obtained from the EPIC, CAPTURE, EPILOG and EPISTENT trials, 
four studies conducted between November 1991 and October 1997. The protocols 
and results of the four studies have been published in detail.'4 In brief, the 
studies 1Ncre designed as large, double-blind, placebo-controlled, randomized 
trials to evaluate the efficacy of the GP lIb/lIla receptor inhibitor abciximab in 
reducing ischenlic complications in patients undergoing percutaneous coronary 
intervention for a variety of indications. The EPIC trial enrolled patients scheduled 
to undergo balloon angioplasty in high-risk clinical situations including unstable 
angina, evolving Inyocardial infarction, or high-risk coronary morphology.l 
CAPTURE evaluated the use of abcixhnab in patients with unstable angina 
refractory to conventional 111edical therapy for wh01n percutaneous coronary 
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intervention \vas planned and perf0f111Cd after approxhllately 24 houIs of pre-
treatment with abciximab.2 Patients undergoing elective balloon angioplasty were 
studied in EPILOG.', while EPISTENT evaluated the efficacy of abdximab as an 
adjunct to coronary stenting. This latter trial enrolled patients scheduled to 
undergo elective or urgent percutaneous coronary revascularization and tested the 
hypothesis that stenting or balloon angioplasty plus abciximab would be superior 
to stenting plus placebo.' All trials excluded patients with characteristics associated 
i .... ,-ith an increased risk of bleeding as \ve11 as those with a cerebrovascular accident 
1Nithin the preceding t1NO years. Patients were randomized to receive a bolus and 
an infusion of abciximab (0.25 ~lg/kg bolus, 10 mg/min infusion in EPIC and 
CAPTURE and 0.125 ~lg/kg.min (maximum 10 ~lg/min) in EPILOG and EPISTENT) 
or luatching placebo. One treatnlfmt group in EPIC received a bolus ofabcixhnab 
only. In EPIC, EPILOG and EPISTENT, study drug was administered from one hour 
before until 12 hours after the percutaneous coronary intervention, 1,,;'hile the 
CAPTURE trial required administration of placebo or abciximab starting 18 to 24 
hours prior to the coronary intervention and continuing until one h01lT after 
conlpletion of the intervention. All patients received aspirin as weH as intTavenous 
heparin at standard (EPIC) or weight-acljusted (CAPTURE, EPILOG and EPISTENT) 
dose. In addition to w-eight-adjustnlent, one abciximab treatment ann in EPILOG 
and both abcixilnab treabnent anns in EPISTENT received a low-dose heparin 
regilnen. The prilnmy endpoint in the three studies -was the cOlnposite of death, 
l11yocardial infarction or 1ugent (re)intervention at 30 days. The study protocols 
1\'ere approved by the institutional review hoard at each study center and all 
patients gave written infonned consent to participate. 
Stroke classification 
Patients with suspected strokes were identified n-Olll the Case Report Fonns. 
Clinical notes, hospital discharge snnunaries, neurological consultation reports, 
(results of) conlputed tomographic or nlagnetic resonance ilnaging studies, and I 
if applicable, autopsy reports were collected on all patients with suspected stroke 
for final classification. Any suspected stroke that occuned during the 30-day 
follow-up period was confirnled and adjudicated by a C0111nlittee blinded to 
treabnent allocation. Strokes w-ere classified as either henlOrrhagic or non-
hmnorrhagic. 
Statistical analysis 
The incidence of stroke and intracranial bleeding WBS detennined anl0ng all 
patients as randomized, as w-ell as all10ng all patients as treated/ with exclusion 
of the abciximah bolus-only group in the EPIC trial. This was done to provide an 
unbiased basis for comparison across the tOUT trials. Continuous variables are 
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presented as 111ca118 ""Tith standard deviation. Discrete variables are sho·w-n as 
frequencies and percentages. Baseline characteristics aluong patients "'with and 
without stroke ';vere c01npared univariably using the t-tcst for all reported 
continuous variables and Fisher's Exact Thst for all reported incidences. 
Results 
All patients 
AnlOng the 8555 patients randomized in the four trials, there 1Ncre 33 strokes 
reported in 31 patients (0.36%) within the first 30 days following emoliment. Stroke 
occurred in 9 (0.29%) ofthe 3079 patients assigned placebo and in 22 (0.40%) of 
the 5476 patients assigned abciximab (p ~ 0.46). Nineteen patients had a non-
hClllorrhagic stroke: (i placebo patients (0.20%) versus 13 abcLxhllab patients 
(0.24%), P ~ 0.81. Hemorrhagic stroke or intracranial bleeding occurred in 3 
(0.10%) patients assigned placebo and in9 (0.16%) patients assigned abciximab 
(p ~ 0.56). In one patient, the type of stroke could not be established. Among the 
695 patients in the EPIC abcixilnab bolus-only group, six strokes occurred in five 
patients. There 'were 2 stroke patients in the EPIC trial 'who were randomized to 
abciximab bolus plus infusion) but were not treated because the stroke occurred 
afteJ' randomization but before the angioplasty. One patient had a hemorrhagic 
stroke and the other had a non-hemorrhagic stroke. An patients 'who experienced 
strokes OJ' intracranial bleeding events in the CAPTURE, EPILOG and EPISTENT 
trials received the allocated study drug. 
Abc/x/mab bolus and infusion 
There were 24 strokes among the 7703 patients who received study drug bolus 
and infusion: 9 in 3023 placebo-treated patients (0.30%) and 15 in 4(JSO patients 
treated with abcbdmab bolus plus infusion (0.32%, Table 1). The difference in the 
incidcnce rate bch\"reen the groups 1\'aS 0.02% vvith an upper litnit to the 95% 
confidence interval eCl) of 0.28%. The incidence ofnon-helnorrhagic stroke "was 
0.17% in patients treated with abcixilnab bolus and infusion) cOlllpared with 
0.20% in paticnts receiving placebo (difference -0.03%) 95% Cl -0.23% to 0.17%). 
Among the 3023 patients treated with placebo there were 3 (0.10%) intracranial 
bleedings/hemorrhagic strokes compared with 7 (0.15%) in the 4680 patients 
receiving abcixilnab bolus plus infusion) a difference in incidence of 0.05% with 
an upper linlit to the 95% CI of 0.21 %. 
Heparin dosing 
After grouping the trials by heparin dosing) there was a higher incidence of 
henlOrrhagic stroke in patients receiving abcixhnab and standard-dose heparin 
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(patients from EPIC, CAPTURE, and the standard-dose heparin arm of EPILOG) 
as cOlnpared with those receiving ahciximab and Im\T~dose heparin (patients [r0111 
EPISTENT and the low-dose heparin arm of EPILOG). The difference in the 
incidence rates bct"\TCen these two groups achieved borderline statistical 
significance (0.27% versus 0.04%, respectively; p = 0.057). No differences lNcrc 
observed in the l1lCans of the maXinUll11 activated clotting time values achieved 
during the procedure between patients ""olith henlOrrhagic stroke and those 
without. A non-significant higher incidence of non-hen10lThagic stroke 'was 
apparent in patients receiving abcLxi1nab and law-dose heparin versus abcLxitnab 
and standard-dose heparin (0.24% versus O.099-fI, respectively; p = 0,30). 
Predictive value of baseline characteristics 
Patients ·w"ith a stroke ·were older (nlcan age 67 years versus 60 years in patients 
without stroke, p < 0.001), more often had a history of hypertension (77% versus 
549-(1, p = 0.012), but less frequently had a history of diabetes luellitus (7% versus 
21 %, P = 0.044). Non-significant higher incidences of peripheral vascular disease 
and prior revascularization procedures ·were apparent muong patients who 
experienced a stroke Crdble 2). 
Discussion 
This cOlubined analysis of more than 8500 patients implies that abcL-...:hnab 
in addition to aspirin and heparin does not increase the overall risk of stroke in 
patients undergoing percutaneous coronary intervention. The risk of stroke in 
patients receiving abcL-...:hnab on top of aspirin and heparin in the four trials 'Nas 
shni1ar to that in patients receiving standard therapy and the 95% confidence 
intervals exclude a clinically nlCaningful difference in stroke rate. The results are 
applicable to a diverse population of patients undergoing percutaneous corollaty 
intervention/ \vith or ·without stent deployment/ varying fr01n patients v.fith stable 
coronary artery disease and a IU'w risk profile to those at increased risk during 
coronary intervention because of unstable ischemic syndrolllCs or unfavorable 
lesionl110rphology on angiography.1-<l 
For cOlnparison, the incidence ofsh"oke in heparin-treated patients undergoing 
percutaneous coronary intervention for stable coronary artery disease as well as 
unstable coronary syndromes, including prhnary angioplasty for acute lnyocardial 
infarction, has been reported to be bet'lNeen 0% and 1 % .11-22 In patients with 
acute myocardial infarction with ST-segnlCnt elevation/ the incidence of stroke in 
the era before the routine use of thrOlllbolytic therapy was 1.7_3.2%.23.24 The 
majority of these strokes were ischenlic as inh"acranial henlorrhage was exceedingly 
rare. Intravenous thrombolytic therapy has reduced the incidence of 
nonhernorrhagic or ischemic stroke (0.1-1.3%), hut increased that of intracranial 
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AbcLximab Placebo Difference in incidence 95% CI 
Q 
l~ 
~ 
(J1 
n % n % % % 
Total 15/4680 0.32 9/ 3023 0.30 0.02 ~O.23, 0.28 
EPIC 3/678 0.44 4/681 0.59 -0.14 -0.91. 0.62 
CAPTURE 11 622 0.16 4/631 0.63 -0.47 -1.17.0.22 
EPILOG 61 1811 0.33 0/914 0.00 0.33 0.07. 0.60* 
Std-dose heparin 4/898 0.45 0/914 0.00 0.45 0.01. O.sst 
Low-dose heparin 2/913 0.22 NA 
EPISTENT Sf 1569 0.32 11 797 0.13 0.19 -0.18, 0.56 
Angiopl:lsty 2/785 0.25 NA 
Stcnt 3/784 0.38 1/ 797 0.13 0.26 -0.24. 0.75 
Intracranial bleeding / 
hemorrhagic stroke 7/4680 0.15 3/ 3023 0.10 0.05 -0.11. 0.21 
EPIC 2/678 0.29 21 681 0.29 0.00 -0.57. 0.58 
CAPTURE 0/622 0.00 11 631 0.16 -0.16 -0.47,0.15 
EPILOG 51 1811 0.28 Of 914 0.00 0.28 0.03. 0.52<-
Std-dose hep:uin 4/898 0.45 01914 0.00 0.45 0.01. O.SS~ 
Low-dose heparin 1/913 0.11 NA 
EPISTENT 01 1569 0.00 0/797 0.00 0.00 
Angiopbsty 0/785 0.00 NA 
Stent 0/784 0.00 0/797 0.00 0.00 
Non-hemorrhagic stroke 8/4680 0.17 61 3023 0.20 -0.03 -0.23, 0.17 
EPIC 11 678 0.15 21 6S1 0.29 -0.15 -0.64, 035 
CAPTURE 0/622 0.00 31 631 OAS -OA8 -1.01. 0.06 
EPILOG 21 1S11 0.11 0/914 0.00 0.11 -0.04. 0.26 
Std-dose heparin 11 898 0.11 0/914 0.00 0.11 -0.11. 0.33 
Low-dose heparin 11 913 0.11 NA 
EPISTEh'T 51 1569 032 11 797 0.13 0.19 -0.18, 0.56 
Angiopbsty 21 785 0.25 NA 
Stent 3/784 0.38 11 797 0.13 0.26 -0.24, 0.75 
Table L Incidence of stroke and intracranial bleeding (cont) 
Incidence of stroke and intracr-:mial bleeding among patients treated. only. and with exclusion of the abcix.inw.b bolUS-Only treatment group from EPIC. 
Difference in incidence denotes the difference between the incidence in abcix.inw.b patients and placebo patients. 95% CI denotes the 95% confidence 
interval of the difti....--rence in incidence between both groups. 
*. '1'. :~ correspond to p = 0.19. 0.06 and 0.18. respectively. by Fisher'S Exact Test for comparison of stroke rates between both treatment groups. The 
confidence interval of the difference correspond..;; to testing whether the difference in the incidence rates i,.;; equal to zero. The results from both tests do not 
correspond due to the fact that the event rate in the placebo ;rrm i..;; zero and the test of the difference is therefore testing the event rate in the abcLximab arm 
-{) 
being equal to zero. 
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Table 2. Baseline demographics by stroke status 
AU stroke No stroke I)-value 
(n=31) (n=8524) 
Age (yr) 67 (7) 60 (II) < 0.001 
Sex (% male) 65 73 
Weight (kg) 82 (17) 84 (16) 
Height (em) 171 (9) 172 (10) 
Hypertension (%) 77 54 0.01 
Diabetes mellitus (%) 7 21 0.0-1 
Current smoker or quit w/in I year (%) 27 35 
Prior CABO (%) 19 11 
Prior PCI (I/o) 24 20 
Prior CHF (%) 7 6 
History ofPVD «(,v) 17 8 O.OR 
Prior stroke (%) 3 2 
Continuous variables are shown as means (sl,mdurd deviation). 
CABG denotes coronary artery bypass gratling, CHF, congesth'e heart failure, per. percutaneous coronary 
intervention, PVD, peripheral vascular disea<;e. 
P-values fOf comparison ol't.:ontinuous variables according to I-test, for discrete variables according to Fisher's 
Exact Test. 
heIll0rrhage (0,07_1.5%).25-33 The overall stroke rate remained approxitnately 
stable with streptokinase and increased slightly "with alteplase. 33 In the current 
analysis, the rate ofnonhenlOrrhagic stroke as 'well as the incidence ofintracranial 
hmnorrhage in abcL,,(il113b-treated patients were cOlnparable to those for patients 
undergoing percutaneous coronary intervention receiving heparin, but lNere 
substantially luwer than those for patients with a lnyocardial infarction treated 
''lith thr01nbolytics. Therefore, unlike fibrinolytic therapy which carries an 
inlportant liability for intracranial hemorrhage, the present data observed in 
patients undergoing coronmy intervention in a variety of clinical settings support 
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the safety of abcLxhnab '''lith regard to the occurrence of intracranial hClllorrhagc. 
This finding is consistent with that of other intravenous GP lIb/IlIa receptor 
inhibitors in patients undergoing coronary intervention, In the IMPACT-II and 
RESTORE trials, the incidence of intracranial hCll10Trhage associated "with 
eptifibatide and tirofiban treatment ·w-as 0.1 %.5.6 This observation is especially 
llnpOliant in vie,v of the detriIncntal itnpact of shake and, in particlllal~ intracranial 
hClllonhage on mortality, disability, as 1Nell as 111cdical resource use and costS.lO 
In the present study, patients \\7110 cxpetienced a stroke were olc1et~ more often 
had a history ofhypertensiol1, but less frequently a history of diabetes mellitus. 
No previous study has detennined the risk factors for stroke anlOng patients 
undergoing percutaneous coronary intervention. I-Iowevel~ the present findings 
are consistent with the established risk factors for hoth nonhemorrhagic and 
hmllorrhagie stroke atnong paticnts with ST-elevation myocardial infarction 
treated with thrornbolytic thcrapy.26.28-34 
In patients treated "with abeL-dInah, a trend toward a higher incidence of 
intracranial bleeding ,\raS obscrvcd anlong patients receiving standard-dose 
heparin (patients enrolled in EPIC, CAPTURE, and the standard-dose heparin arm 
of EPILOG) compared 'w"ith thosc receiving the low-dose heparin reghnen in the 
EPISTENT trial and the low-dose heparin treatment ann in the EPILOG trial. As 
thc lu1n1ber of hemorrhagic strokes "was s111all and the difference only reached 
borderline statistica1 significance, definitive conclusions cannot be nlade about the 
potential risk of heparin dosing on the incidence of hClnorrhagic stroke in the 
patient population studied. Howevel~ other Inajor blceding cOlllplications are 
also reduced by the use of low-dose heparin versus standard-dose heparin in 
patients receiving abcLxhnab. 1-4 Furthermore, previous studies in paticnts with acutc 
myocardial infarction treated with thrombolytics have unequivocally show"11 that 
inappropriate high dosing of antithrombotic therapy has the potential to 
substantially increasc the incidence ofhemorrhagie stroke.35-37 
The TIMI 9A trial and the GUSTO-lla trial, which both compared intravenous 
hirudin with heparin as adjunctive therapy to thromb01ysis and aspirin in patients 
'with acute Inyocardial infarction, were tenninated prematurely because of an 
excess of intracranial henlOrrhagic cvents in both treatment arms.35.M These triah; 
achieved a high level of anticoagulation by using a high dose of hirudin and a 
heparin regimen with titration to a target aPIT of 60 to flO seconds. In both 
studies, an elevated aPTT w-as a significant risk factor for hetnorrhagic stroke in 
both heparin- and hirudin-treated patients. Both trials were re-initiated with 
lower doses of heparin and hirudin titrated to a Imver aPTT target range (50 to 
70 seconds). Silnilarly, a retrospective analysis fr0111 the GUSTO-I trial in 29,656 
patients with acute 111yocardial infarction revealed that the aPTT associated with 
the lowest 3D-clay lllOrtality, strokc, and bleeding rates was 50 to 70 seconds and 
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that aPTT values higher than 70 seconds were associated with higher likelihood 
of 111ortality, stroke, bleeding, and reinfarction. 37 These observations parallel 
those in the ASPECT trial, which investigated the efficacy of long-term aTal 
anticoagulant therapy in patients who survived a 111yocardial infarction.38 ''''hile 
oral anticoagulant treahncnt reduced the overall incidence of stroke in these 
patients, the risk of intracranial hemorrhage 'tv-as directly related to the intensity 
of the anticoagulant treattnent, measured by the international nonnalized ratio.39AO 
These data in a variety of patient popUlations treated "with different medications 
ilnply that caution should be exercised ·with respect to dosing of heparin in 
patients undergoing percutaneous coronary intervention and receiving ahcixinlab. 
In fact, the EPILOG and EPISTENT trials have shown that the clinical benefit of 
abciwnab can be uncoupled fronl the risk ofhenlOrrhage by using Imv-dose, weight-
adjusted heparin regil11ens. 3A Adherence to these guidelines should therefore be 
regarded as a standard treatl11ent strategy in the Inanagel11ent of patients 
undergoing percutaneous coronary intervention and treated with abcixil11ab. On 
the other hand, surveillance "with respect to the efficacy of the low-dose heparin 
regiluen in protecting patients fron1 non-henlorrhagic stroke is also needed. 
The safety profile of the GP lIb/IlIa inhibitors has the potential to reduce the 
risk of intracranial heIl10rrhage in patients with acute 111yocardial infarction 
'when cOll1bined with Teduced-dose fibrinolytic therapy and a lO'w-dose, weight-
ac,jnsted heparin reghnen. 41 -43 H()"wevel~ an adequate nUlllber of patients (tens to 
perhaps hundreds of thousands) need to be treated with this combination to be 
able to provide luore definitive assurance of the lack of Tisk of intracranial 
bleeding "with such treahnent strategy. A large trial to assess the risks and benefits 
of combined abciximab-thrombolytic therapy is ongoing (GUSTO IV-AMI). 
The present analysis of 8555 patients undergoing percutaneous cOTonary 
intervention and treated with either abcLxhnah or placebo "vms liluited by the very 
Imv incidence of stroke in this patient population. Continued surveillance with 
Tespect to the occurrence of stroke in patients treated with abciximab and systemic 
collectio11 of data in clinical trials are needed. Nonetheless, the present findings 
provide strong evidence that the efficacy of abciximah in patients undergoing 
peTcutaneous coronary intervention is not oveTshadmved by an increased risk of 
stroke. 
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Chapter 6 
Abstract 
Objective 
Th determine the clinical and demographic ri,k factors for bleeding in the 
population of patients with acute coronary sYlldrOlllcs lNithout persistent ST-
elevation. 
Background 
An accurate esmnation of the risk of bleeding based on clinicHI evaluation 11lay 
improve the risk-benefit ratio of GP nb/Illa inhibitors in patients 'with nOll-ST-
elevation acute coronary syndrOllles. 
Methods 
We studied bleeding complications among the 9375 patients with acute 
coronary syndrOlllcs 'Ivithout persistent ST-elevation receiving placebo 01' the 
platelet GP lIb/lIla inhibitor eptifibatide in the PUESUIT trial and determined the 
multivariable predictors of spontaneous or procedure-unrelated bleeding events 
as well as bleeding complications associated 'Nith percutaneous coronary 
procedures. 
Results 
Bleeding was increased ,\\7ith eptifibatide 31nong patients "who did not undergo 
bypass surgery during hospitalization (31 % cOlupared ·with 12% in placebo). In 
nlOst cases (B3 %) huwevel~ bleeding "'Nas 111ild. Patients undergoing bypass surgery 
during hospitalization had increased bleeding and accounted for approximately 
80% of the patients with Inajor bleeding conlplications. No increase in bleeding 
incidence ,\11th eptifibatide therapy was observed in patients who undenvent 
bypa" surgery. !{isk factor, for procedure-related bleeding included North 
Alnerican region, allocation to eptifibatide, feIuale gendcl~ the ll1aximal aPTT value 
and treahnent with ticlopidin. n-catment with eptifibatide was the most pmveTf'u1 
independent predictor of spontaneous bleeding, followed by older age, female 
gendet~ North American region, the maxhllal aPTT vahle, s1110king statns, usc of 
thrombolytics or ticlopidin, and non-caucasian ancestry. These factors "'Nere used 
to develop a scoring nomogra1n that can predict the patient's baseline risk of 
spontaneous bleeding and detennine to ,dIat extent this risk increases during 
antithrOlnbotic therapy. After c0111bining two risk lllOdels, no subgroups of patients 
could be identified with either a low risk of adverse cardiac events and a high 
bleeding risk or a low bleeding risk and a high risk of cardiac events. 
100 
Safety of Glycoprotein lib/ilia receptor blockers 
Conclusion 
Bleeding was a COll1l110n event in patients with non-ST-elevatioll acute 
coronary syndronlcs in the PURSUIT trial. The majority of the bleeding events 
"'was ll1ild. In detennining indications for GP IIh/rna inhibition therapy, the risk 
of bleeding is of secondary i111portance. 
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Introduction 
Intravenous platelet glycoprotein (GP) JIb/IlIa receptor inhibitors reduce 
ischemic c01nplications in patients "with acute coronary syndTOll1es without 
persistent ST-segnlent elevation undergoing percutaneous coronary intervention 
(PCI), as well as in those treated medically.'~ Inhibition of platelet aggregation by 
GP JIb/JIla receptor blockers increases the risk of bleeding complications.,s.?8 An 
accurate estimation of the Tisk of bleeding based on clinical evaluation at baseline 
may improve the risk-benefit ratio of GP JIb/IlIa receptor inhibition therapy in 
patients ';\Tith acute coronary syndr0111cs,9 ,Vhile the clinical factors associated 'with 
bleeding complications in patients with acute Inyocardial infarction eMI) treated 
with thrombolytic therapy have been "well described l 1G-12 the risk factors for 
bleeding in the population of patients -w-Hh acute coronary syndr0111cs without 
persistcnt ST-seglncnt elevation have not been prcviously analyzed. 
The PURSUIT (Platelet Glycoprotein JIb/IlIa in Unstable Angina: Receptor 
Suppression Using Integrilin Therapy) trial compared the GP JIb/IlIa inhibitor 
eptifibatide with placebo in addition to standard therapy in [J461 patients with acute 
coronary synclr01nes ·who did not have persistent ST-seginent elevation.3 Vle 
prospectively collected infoT1nation about patients who experienced heinorrhagic 
cOl1lplications in order to deternline the incidence and location of bleeding, as ·well 
as the independent clinical and demographic predictors of bleeding in this patient 
population. 
Methods 
Patients and treatment 
The study design and results of the PURSUIT trial have been published in 
detai1.3,13 In brief, patients "were eligible for enrolhnent if they had ischClllic chest 
pain within the previous 24 hours and either ECG changes suggestive ofischemia 
(ST-segl1ICnt depression, T-wave inversion, or transient ST-seginent elevation) or 
a creatine kinase-ME fraction above the upper linlit of n01"1nal for that hospital. 
Patients "\Tith persistent ST-seglnent elevation ·were excluded since they should be 
considered for itll1nediate reperfusion thcrapy. 14 0ther exclusion criteria included 
active bleeding, gastrointestinal or genitourinary bleeding within the previous 30 
days, a history of bleeding diathesis, Inajor surgery within 6 weel<s, systolic blood 
pressure above 200 rnrnHg or diastolic blood pressure above 110 nllllHg, renal 
failure, or treatnlCnt with thronlbolytic therapy within the previous 24 hours. 
Patients were rand0111ly assigned in double-blind fashion to an intravenous 
bolus and infusion of placebo, 180 mg/kg bolus plus infusion of 1.3 mg/kg.min 
of eptifibatide, or 180 mg/kg bolus plus infusion of2.0 mg/lcg.min of eptifibatide. 
As prespecified, after 32Hl patients had been randomized, an independent Data 
102 
Safety of Glycoprotein lib/ilia receptor blockers 
Safety Monitoring Board conducted an interinl rCViC1\T of safety data and 
reco111111cnded dropping the lower dose) because the high dose had an acceptable 
safety profile. Study drug was to be infused during 72 hours but could be continued 
for up to 96 hours if a PCl was performed at the end ofthe 72-hour treatment period. 
All patients received aspirin in an initial dose ofl60 mg followed by 75-325 mg 
daily thereaftcl: Patients who lNcre allergic to or intolerant of aspirin could receive 
ticlopidin. Heparin 'ivas recommended but not 111andatec1. Intravenous heparin "'INas 
to be given as a 5000 U bolus dose and 1000 U/hour infusion with adjustment to 
maintain a target activated parlial thromboplastin time (aPIT) of 50 to 80 seconds. 
The heparin regilnen in patients undergoing PCl consisted of an initial bolus of 
100 U/kg (maximum 10000 U) before the intervention, with additional weight-
adjusted boluses achninistered according to a nomogram intended to achieve 
and maintain an activated clotting time (ACT) of :lllll to 350 seconds. The protocol 
recol1ullcndcd that vascular sheaths be rCllloved 'when the aPTT 'was 45 seconds 
or less or "'when the ACT ,vas 150 seconds or less. All other treatnlCnt decisions 
including the use of other anti~ischenlic nledications, as well as the use and 
tiIlling of coronary angiography, and percutaneous or surgical revascularization 
were left at the discretion of the treating physician. The protocol "'was approved 
by the institutional review board at each study center and all patients gave 
infoflned consent. 
Bleeding complications 
Fol1owing enrolhnent, patients were continually assessed for the occurrence 
of bleeding c01nplications. Severity and location of bleeding ,vere determined by 
the site investigator and filled out in the Case Report Fonn. Site investigators used 
the scale from the Global Utilization of Streptokinase and Tissue Plasminogen 
Activator for Occluded Coronary Arteries (GUSTO) trial tor classification of the 
severity of bleeding events.l7,15 HClllorrhagic cOlnplications are scored as Inild, 
nlOderate, severe, or life-thrcatcning. Severe or life~threatening bleeding was 
deHncd as intracranial henlorrhage or bleeding that caused henl0dynmnic 
cOlnpr01nise and required intervention. Moderate bleeding was defined as bleeding 
that requiTed blood transfusion in the absence of hemodynalllic cOll1pr0111ise. Blood 
loss insufficient to meet criteria for 1110derate bleeding was classified as Inild. The 
Case Report Forn1 specified the following locations: oropharyngeal, puhnOnaIJT, 
brachial, upper or lower gastrointestinal and genitourinary tract helllOlThagc, as 
"'iNell as groin, retroperitoneal, coronal], artery bypass grafting (CABG)-related, and 
other bleeding and bleeding with an unidentifiable source requiring transfusion. 
The Clinical Events Comlnittee used the scale from the ThrOlllbolysis in I\1yocardial 
Infarction (TIMI) trial to classif'y bleeding complications on the basis of laboratory 
ll1easurenlents.3,16Hemorrhagic events are categorized as insignificant, IninOl~ or 
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l11ajOl: For this purpose l hospital discharge slIll11narics, laboratory printouts and 
transfusion reports ·were collected on patients \\"Tith bleeding c0111plications. 
Intracranial hmnorrhages observed in PURSUIT have becn reported previously 
and were not included in the present analysis. 17 
Additional data analysis 
In order to determine the predictors of distinct categories of bleeding) 
spontaneous or procedure-unrelated bleeding events and bleeding C0111plications 
associated 'Nith percutaneous COrOnm]T procedures were considered separately, 
Spontaneous bleeding was defined as oropharyngeal, pulnl0narYI brachial, upper 
or I01Ncr gastrointestinal and genitourinary tract hemorrhage, as -well as other 
bleeding and bleeding vdth an unidentifiable source requiTing transfusion, 
Procedure-related hemorrhage was defined as bleeding located at the groin or 
retroperitoneU111, In both categories j bleeding complications associated with 
CABG 'Nere excluded. The incidence of spontaneous bleeding ",\7as detennined in 
the 9375 PURSUIT patients receiving placebo or high-dose eptifibatide, whereas 
procedure-related bleeding ",vas analyzed in the subgroup fr0111 this population 
undergoing coronary intervention within 30 days ofrandOlnization) within the first 
72 hours) and between day 3 and 30) respectively. In addition) the incidence of 
spontaneous bleeding was detel'lnined in specific patient subsets to explore the 
relationship to coronary procedures. Patients receiving thrOll1bolysis and 
experiencing bleeding c0111plications were not excluded but the use of thrombolytics 
was included as a distinct detenninant ofbleeciing, 
Statist/cal analysis 
Continuous variables are shown as n1eans with standard deviations) discrete 
variables as frequencies and percentages. Logistic regression 1110deling techniques 
were used to detenlline the univariable and nmltivatiable risk factors for spontaneous 
as well as procedure-related bleeding events. All variables entered the l11ultivariable 
stage j irrespective of the results of the univatiable analyses. The 111ultivaliable 1110dels 
were constructed by backward deletion of the least significant characteristics) 
while applying a threshold of significance of p ~ 0.05. Predictors were tested with 
the use of the "Wald X2 test. Results are presented as odds ratios and 95% confidence 
intervals. The predictive accuracy of the ll1ultivariable rnodels is presented as the 
so-called concordance index (c-index}) which describes the discrhnillant power of 
the nlodel to reliably predict an outc0111e. A scoring nomogranl for predicting the 
likelihood of experiencing a spontaneous bleeding was created fr0111 the coefficients 
fr0111 the ll1ultivariable regression l1lodeling. Each independent predictor was 
assigned a score according to its predictive value. The sum of the scores indicates 
the probability of the occurrence of a spontaneous bleeding event. 
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Results 
Baseline results 
In PURSUIT, 4679 patients were treated with high-dose eptifibatide, while 4696 
patients received placebo. Bleeding '''BS increased "with eptifibatide among patients 
who did not undergo bypass surgery during hospitalization (Figure 1). In total, 
bleeding occurred in 1258 (31 %) of 4032 patients receiving eptifibatide compared 
with 498 (12%) of 4024 patients in the placebo treatment arm. In most cases (83%) 
however, bleeding ·was mild. Patients undergoing bypass surgery during 
hospitalization had increased bleeding and accounted for approximately 80% of 
Bleeding through hospitalization, non-CABG patients, patients as treated 
% 30 
26.0 o placebo, n=4024 
o eptifibatide, n=4032 
• 20 11 
~ 10.4 
=> 10 
" 4.1 
0 c¥==CJ 0.3 ~ 
mild moderate severe 
Bleeding through hospitalization, CABG patients, patients as treated 
% 60 
• 40 ] 
0 
t;; 
=> 20 
'" 
o 
g> 20 
1 
~ 15 
i j 10 
I , 
o 
~ ~ 
27.8 26.7 
mild moderate 
o placebo, 
o eptifibati 
4.2 4.2 
severe 
n=672 
de,n=647 
KaplaJ1-Meier estimate of time to occurrence of Spofltafle<Jus bleeding 
_~~~_~---------;:;;;;:::;:;::--- 24-2% Epttfibatide 
PlacebO 
-' __ --------------------72% 
14 
" 
28 
Figure 1 
Bleeding through 
hospitalization 
classified 
according to the 
scale of the Global 
Utilization of 
Streptokinase and 
TIssue PlasmInogen 
Activator for 
Occluded 
Coronary Arteries 
(GUSTO) trial In 
patients who did 
not undergo 
bypass surgery 
(upper paneO and 
in patients who 
underwent bypass 
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paneO· 
Figure 2 
Kaplan-Meier 
estimate of the 
time to occurrence 
of spontaneous 
bleeding in 
eptifibatide and 
placebo patients 
through 30 days 
follow-up. 
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Table 1 Unadju."tcd 30-day "pontancou." and procedure-related blcedin~ event rate and odd" ratios for baseline eharaeterit-tics 
Charaeteri~tie 
Demographics 
Age (year~i') 55 
64 
71 
Gender Female 
Male 
Ruoo Non-cauca"ian 
Caucasian 
Weight (kg/') 69 
78 
88 
Height (em)'" 163 
170 
176 
Region Nonh America 
Latin America 
Eastern Europe 
We~tern Europe 
Hisrory 
Hypertension Yo, 
No 
Diabete;. mellims Yes 
No 
Smoking ~r::ltus Current 
Former 
Never 
Family history Yes 
No 
Myocardial infarction Yes 
No 
Worst CCS--cluss in previous 6 weeks 30r4 
<3 
Congestive heart failure Yes 
No 
Perifcral ves."d disca.«e Yes 
No 
Sponmneous bleeding 
Rate (<;0) X: (OF) 
-------- ------
-------- ------
10.1 186 (1)" 
14.8 
23.9 
19.2 47 (1)# 
13.8 
18.2 6 (I)' 
15.4 
18.1 18 (1)# 
15.4 
13.7 
18.5 32 (1)" 
15.5 
13.0 
18.1 27 (3)" 
15.2 
14.3 
13.7 
16.9 13 (1)~ 
14.2 
IS.2 14 (1)~ 
14.9 
11.2 40 (2)# 
IS.1 
16.9 
14.1 9 (1)' 
16.4 
17.0 6(1)' 
15.0 
16.6 4 (I)~ 
IS.0 
19.6 13 (l)~ 
15.2 
19.5 11 (1)'l 
IS.3 
OR (9S% Cll 
0.72 (0.68 - 0.7S) 
1 
1.30 (1.25 - 1.35) 
1048 (1.33 - 1.66) 
1.23 (1.04 - 1045) 
1 
1.07(1.04-1.11) 
1 
0.92 (0.89 - 0.96) 
1.13 (1.08 - l.IS) 
1 
0.90 (0.87 - 0.93) 
1.39 (l.23 - 1.5S) 
l.12 (0.S4 - 1.50) 
1.05 (0.89 - 1.25) 
1.23 (1.10 - 1.3S) 
1 
1.27 (1.12 - 1.44) 
1 
0.62 (0.53 - 0.72) 
1.09 (0.96 - 1.24) 
0.84 (0.74 - 0.94) 
1.16 (1.03 - 1.30) 
1.12 (1.00 - 1.26) 
1.36 (1,15 - 1.60) 
1.37 (1.14 - 1.65) 
Procedure_related bleeding 
Rate (%) 
29.3 
1904 
27.8 
20.6 
21.9 
31.7 
2.9 
10.5 
11.7 
x: (OF) 
2S (1)" 
9 (1)\ 
113 (3)" 
4(3)t 
----- ------
---- ------
25.2 13 (1)'11 
19.1 
IS.S 6(2)"' 
24.5 
23.S 
OR(95%CI) 
1.72 (1,41 - 2.10) 
1 
1.11 (1.04 - 1.20) 
1 
0.91 (0.86 - 0.97) 
3.52 (2.79 _ 4.44) 
0.23 (0.06 - 0.94) 
0.89 (0.47 - 1.67) 
1,43 (1.18 - 1.74) 
1 
0.74 (0.58 - 0.95) 
1.04 (0.83 - 1.30) 
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Medication during hospirali::.ation 
A~pirin 
Beta-blocker 
Calcium antagonists 
Ticlopidin 
Muxim:ll uPTr value (scesi ll 
Dipiridamol 
Nitrates 
Thrombolytics 
Presenring characteristics 
Diastolic blood pressure (mmHg){i) 
Hcu.rt rate (bpm)(!) 
ST depression (>0.5 mm) 
PURSUIT study medication 
Yes 
No 
Yes 
No 
Yes 
No 
Yes 
No 
60 
86 
121 
Yes 
No 
Yes 
No 
Yes 
No 
67 
75 
83 
62 
72 
80 
Yes 
No 
-------
------
15.5 3 (I)-
18.1 
14.9 8 (1)' 
17.2 
16.9 60)" 
15.1 
18.6 6 (l)t 
15A 
14.2 2S (1)# 
15.5 
18.6 
20.7 3(1)-
15.6 
-------
18.1 13 (1)91 
14.8 
15.1 
14.1 13 (I)'" 
15A 
17.8 
17.3 18 (1)# 
14.1 
Eptiiibatide CHiC.gCh--:d-O,-o--- --"'-.-2- -4-6-8-0-'" 
Placebo 7.2 
0.83 (0.68 - L02) 
0.85 (0.75 - 0.95) 
1.15 (1.02 - 1.29) 
1 
1.26 (l.05 - 1.50) 
0.94 (0.91 - 0.96) 
1.09 (LOS - 1.13) 
l.41 (0.98 - 2.05) 
1 
1.06 (1.03 - 1.10) 
1 
0.94 (0.91 - 0.97) 
0.93 (0.90 - 0.97) 
1 
1.06 (1.03 - 1.09) 
1.27 (1.14 - 1.42) 
4.15 (3.65 - 4.72) 
*. t. :t. fl. 'lI. # correspond 10 p <0.1. <0.05. <0.01. <0.005. <0.001. <0.0001; only variables with p <0.1 arc shovvn. 
32.0 44 (1)" 2.01 (1.63 - 2A6) 
19.0 1 
19.3 7 (I): 0.94 (0.90 - 0.98) 
22.1 
25.5 l.08 (1.02 - LIS) 
51.1 19 (1)# 3.75 (2.07 - 6.78) 
21.8 
21.9 3 (1)- 0.75 (0.54 - 1.05) 
27.3 
31.1 3 (1)- 1.59 (0.96 - 2.63) 
22.1 
--------
--------
27.5 II (I)') 1.11 (1.04 - 1.17) 
20.0 1 
20.0 0.90 (0.85 - 0.96) 
27.2 30 (1)" 1.73 (1A2 - 2.09) 
17.8 
X~ = _210g likelihood; DF == degree(s) offrecdom; OR"" unadjusted odd" (atio; CI = eontldenee interval; High dose imegrdin == 180).lg/kg bolus followed by a 2.0 ).lglkgfmin continuous 
infusion 
(I) With respect 10 continuous variables (a) average event-r:nes ure pre~nted for the patient cohorts below the I" quartile. within the inK'I'quurtile range and above the 3'" quartile. while (b) 
odd.~ ratios are pre~ented for the I" and 3,d qu:rrti.le vs. the medi:m. respectively 
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the patients with major bleeding c01uplications. No increase in bleeding incidence 
with cptifibatide therapy \vas observed in patients who ulldcnvent bypass slugcry 
(Figure 1). In these patients, approximately 80% of bleeding was related to the 
bypass surgery, both in the eptifibatide and placebo treatment arm. 
Spontaneous bleeding as defined in the present analysis occurred in 14a:l (16%) 
of 9375 patients treated. Most spontaneous bleeding events occurred during the 
72-hour study drug infusion period during the initial hospitalization (Figure 2). 
Procedure-related bleeding complications were observed in 543 (22%) of 2430 
patients undergoing percutaneous coronary intervention during the 30-rl.:'lY [olIo\\'-
up period. 
Univariable analysis 
Among the patient dClllograpl1ics exanlined, older age, female gendel~ lighter 
body weight, shorter statue and North Al11crican origin were closely related to an 
increased risk of spontaneous bleeding (Thble 1, left panel). Patients with a 
history ofhypertensiol1, diabetes mellitus, congestive heart failure, or peripheral 
vascular disease, as 'well as those 'who presented i\'"ith a Imver diastolic blood 
pressure, higher heart rate, or ST-depression were also at an increased risk of a 
hemorrhagic event. In contrast, less bleeding was seen anlOng current sl11okers. 
Anlong the medications used during hospitalization, treatment 'with eptifIbatide 
was the most pmverful univariable predictor of spontaneous bleeding. Furthermore, 
the max1tnal aPTI~ value during heparin infhsion appeared to be significantly 
related to the occurrence of spontaneous bleeding. 
The nll1nber of factors closely associated with hemorrhagic events related to 
coronary intervention was considerably lower than for non-procedure-related 
bleeding (Thble 1, right panel). Furthermore, there were differences in the ranking 
order by the degree of risk stratification with North Anlerican origin now as 
nlOst powerful univariable predictor (X2 113 versus X2 27 for spontaneous bleeding), 
while the administration of ticlopidin and eptifibatide ranked second and third, 
respectively. Other factors associated with an increased Pel-related bleeding rate 
included fClnale gender, a lower diastolic blood pressure, treatlnent with 
dipiridm11ol, and a higher maxitnal aPTT value. Age had no predictive value for 
the occurrence of intervention-related bleeding cOlnplications. 
Multlvariable analysis 
Many of the univariahly significant predictors of spontaneous bleeding 
remained important in the l1lultivariable model (Thble 2). ll-eatment with 
eptifibatide was the nlUst pmverful independent predictor of spontaneous bleeding, 
while higher age was the secondlnost il11portant independent predictOl: Other 
variables that added significantly to the l1lUdel 'were felnale gendel~ the Inaxitnal 
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Table 2 Independcnt predicturs uf spontaneolls bleeding 
Variable Category Spontaneoos bleeding 
x' OR (95~) en 
Eptinbatidc therapy High dose 476# 4.50 (3.'J3 - 5.15) 
Placebo I 
Ago 10 years 123# L36 (1.29 - 1.42) 
Gender Pemale 28# 1.42 (1.25 - 1.(2) 
; .... hlle I 
Region Nurth America 25> 1.39 (1.22- 1.5~) 
Other 
b.t.L'dmai aPlT value Each 10 seconds 17# 1.02 (1.01 - \.(3) 
Smoking ~tutus Former 13§ 1.31 (1.13 - 1.51) 
Never 
U~e of thrombol}'1ks Yes 9:} 1.90 (1.20 - 2.R7) 
No I 
Usc ofticlopidin Yes 9+ 1.3(' (I 
" 
- 1.65) 
No 
Race Non-caucasian 'J:j: 1.34 (1.10 - 1.61) 
Cauea~ian 
ST depression (>0.5 Illlll) yO' S-t 1.20 (1.06- 1.35) 
No 
Heart rate IObpm 7t 1.06 (1.02 - I 101 
Variables have been run ked uccording to their independent contribution to the bleeding model. 
t,.:j:, §, ffcorrespoml to p <0,01, <0.005, <O.OUI, <0.0001 
OR = odds ratio, adjusted for all variables in the model, Cl = Confidence interval 
Table 3 Independent predictors of procedure-related bleeding 
Variable Category procedure-related hleeding 
-/ OR (95% eI) 
Region North America 111# 3,62 (2.S5 - 4.0 I) 
Other I 
Eptifibatide therapy High do<;e 3D> 1.77 (1.44 - 2.18) 
Placebo 
Gender Female 19# 1.61 (1.30 - 1.99) 
rVfale 
l\laximal aPIT value 10 se(onds 16# 1.lJ.1 (1.02 - 1.06) 
Use of ticiopidin Yes lOt 1.44 (1.15- 1.80) 
No 
Smuking status Former 9t 1.40 (1.12 - 1.75) 
Never 
Use of dipiridamul Yes 4' 2.00 (1.05 - 3.84) 
No 
Variables have been ranked according to their independent conlribHlion to the bleeding model 
"', t, t, *, # correspond to p <0.05, <0.01, <0.005, <0.001, <0.0001 
OR == odds ratio, adjusted for all variables inlhe mode[, CI == Confidence interval 
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aPTT value during heparin infusion, smoking status, usc of thrOlllbolytics or 
ticlopidin during hospitaHzation, and non-caucasian ancestry. Adjustment for 
differences in baseline characteristics and concOlnitant phannacological therapy 
did not clintinatc North Alllcrican origin as a risk factor in the llmltivmiablc 1110deL 
There "'INas no interaction between treatment with eptifihatide and the use of 
thr01nbolytics during hospitalization indicating that there 'was 110 inCIClllcntal 
increase in the incidence of spontaneous bleeding for the cOlllbination of these 
two therapies. 
In confonnity ,vith the results £r0111 the univariable analyses, North lUllclican 
origin 'was the lllOSt puwerful independent predictor of procedure-related bleeding 
(I'dble 3). Other important risk factors were allocation to eptifibatide, female 
gendel~ the Inaxhnal aPTT value during heparin infiulion l and treat1nent 'with 
ticlopidin. The sanle variables 'were also 1110st significantly associated with 
procedure-related bleeding conlplications in the patient population undergoing 
percutaneous coronary intervention 1Nithin the first 72 hours. In patients 'who had 
an intervention between day 3 and 30 1 treattnent with eptifibatide and the 
maxinlal aPTT value 'were no longer independent risk factors. 
The c-index corresponding \\Tith the spontaneous bleeding model and the 
procedure-related bleeding model were 0.739 and 0.715, respectively, reflecting 
good ability to discriminate between patients who had and did not have a bleeding 
event. 
Spontaneous bleeding: relation with geographic region and procedures 
The incidence of spontaneous bleeding was detennined in specific patient 
subsets to explore the relationship to geographic region and coron31)7 procedures 
(TIlble 4). Although the incidence gradually decreased when patients undergoing 
CABG I PCI and coronary angiography were successively excluded l spontaneous 
bleeding persisted to occur more frequently in North Alnerican patients than in 
patients enrolled in one of the other geographic regions (V\Testern and Eastern 
Europe l Latin America). I-ImvevC1~ the increase in the incidence of spontaneous 
bleeding associated with eptifibatide therapy did not differ between the two 
groups (no statistically significant differences in Breslow-Day test for homogeneity 
of the odds ratios). 
Prediction of bleeding 
The predicted value for the probability of experiencing a spontaneous bleeding 
event in this patient population can be calculated by using the nomogram in Figure 
3. The n01110gra111 can be used to assess the patient's baseline risk of spontaneous 
bleedi ng and to detennine to what extent this risk increases with antithrOlnbotic 
therapy. The n01110granl was created fronl a separate multivariable analysis 
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Table,", Sponlane-ous bleeding in relation with region and coronary procedures by trealment 
Incidence of spontaneous bleeding (17,,) 
Patient subgroup Region Placebo Eptifibatide Odds ratio (95Q. CI) Bre'ilow-Day 
All patients NA (0=3827) 8.9 27.5 3.9 (3.2-4.7) 
(0:=946l) p=O.33 Olher ("=56);) 6.0 no 4.4 (3.7-5.3) 
PIS \\ithoul CABU NA ("=3042) S.O 27.1 4.3 (3.5-5.3) 
("=7998) p=O.60 Other (0=04956) 5.8 22.3 4.7 (3.8-5.6) 
PIS \\ilhout CABG, pel NA (n=1758) 6.1 26.6 5.6 (4.[-7.7) 
(n=5637) p=0.55 Other (n=3879) 5.6 22.8 5.0 (4.0-6.3) 
Pts \\ithout CABO,peI,CAG NA (0=695) 5A 31.1 7.9 (4.7-13.2) 
(n=336.l) p----o.25 Other ("=2669) 5.4 24.2 5.6(4.3-7.4) 
CABG == coronary artery bypass gmfting, CAG = ({)fonaT)' angiography, CI = wnfidence inte-mil, NA = North America, Other == one of 
the other three ge<lgraphic regions (We~tern Europe, Eastern Euro~, Lllin America), PCl == percutaneous coronary intcrwnti(ln, 
Breslow-Day f(lr homogeneity of oJds ratios. 
which excluded the region of enrollment to allow applicability beyond the context 
ofthe PURSUIT trial. The predictive accuracy of the model was only little affected 
by this step: the c-index decreased from 0.739 to 0.736. There was a close 
relationship between the actual bleeding rates observed in each risk categOlY and 
the expected bleeding rates obtained from the nomogram, calculated by using the 
average score in each category (Figure 4). 
Risk-benefit ratio 
The risk of spontaneous bleeding (with and without eptifibatide) and the risk 
of the composite of death and MI ,\rere calculated for each patient using the scoring 
nomogram presented in Figure 3 and that for predicting the likelihood of death 
or MI based on an established risk model in the PURSUIT population (18) (Figure 
5). No cut-off values could be identified separating subgroups of patients with either 
a Imv risk of adverse cardiac events and a high risk of bleeding or a luw risk of 
bleeding and a high risk of cardiac events. 
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1. Find points for each baseline risk factor 
Age Pulse Gender Caucasian Smoker ST -depression 
years Points hpm Points Points Points Points Points 
--
40 0 60 0 Female 4 Yes 0 Former 3 Yes 1 
SO 4 SO 1 Male 0 No 4 Current -I No 0 
60 8 100 2 Never 0 
70 12 120 3 
XO 16 140 4 
80' 20 160 5 
160' 6 
2. SUlll points for all h'L~ellne risk factors 
+ + + + + ~ 
--
---
----
Age Pulse Gender Caucasian Smoker ST -depres~ion Point Total of baseline risk 
3. Look up baseline risk corresponding 10 point tolal 
Points Risk 
0- 11 <5 % 
12 - 19 5 - 10 % 
20 - 24 lO-15% 
25 - 27 [5 - 20 '70 
28 - 30 20-25% 
31-:13 25-30170 
W >30% 
4. To determine to Ilhat extent the risk of bleeding increases with antithrmllhutil' therapy, add points fur: 
Eptitlbatide Thrombolytic Ticlopidin Max aPTT 
Points Points Points seconds Points 
y" 15 Yes 6 Yes 4 SO 0 
No 0 No 0 No 0 100 I 
150 2 
21J{) 3 
250 4 
250+ 5 
5, Add points for treatmcnl parnmc-ters 10 Poiul Tolal of bawlille risk 
+ + + + ~ 
Point Total ofba~eline risk Eptifibatide Thromholytic Ticlopidin Max aPTT Overall Point Total 
6, To detcrmlnc lolal hleeding risk during trealmcnt, luok up risk corresponding to overall point tolul 
Points Risk 
0- II <5 '/b 
12 - 19 5- 10% 
20 - 24 10 - 15 % 
25 - 27 15 - 20 '/b 
28 - 30 20-25% 
31 - 33 25-30% 
J4' >30 % 
Figure 3 
Nomogram for estimating the risk of spontaneous bleeding at baseline (panels 1 through 3) 
and offer pharmacologic therapy (panels 3 through 6), fn panels 1 and 4, find the values 
most closely matching the patient's risk factors and circle the corresponding point 
assignment, In panels 2 and 5, sum the points for 01/ predictive factors. In panels 3 and 6, 
determine the probabffity of spontaneous bleeding. 
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Spontaneous bleeding 
40,-------------------------~ 
• 
30 
~ Figure 4 
• 
Validation plot of actual 
u incidence versus predIcted c 
• ~ probobflify of spontaneous '0 20 
.• bleeding, respectively obseNed ~ 
• and expected In each risk e 
.!l category of the scoring 
0 nomogram (Figure 3). 10 
o 10 20 30 40 
Expected Incidence based on nomogram (%l 
% 0.6 
c 
OJ 
" 
0.5 CY 
e> 0.4 '=-
:2 0.3 5 
.c 0.2 1ii 
OJ 
" 0.1 15 
-'" 0 I 
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Risk of spontaneous bleeding 
. __ with~ut eptifibalide (frequency) 
oc 0 0.2 0.4 0.6 0.8 
>; 0.6 0 
c 
Q) 
" 
0.5 CY 
e> 
'=- 0.4 
:2 
5 0.3 
~ 0.2 
Q) • 
" 0.1 15 
+ 
+ Risk of spontaneous bleeding 
-'" 0 
'" oc 0 
-----. 
~th ,eptifibalide (frequency) 
0.2 0.4 0.8 0.6 
Figure 5 
DIstribution plot of risk of the composite of death or myocardIa/Infarction (M/) versus risk of 
spontaneous bleeding without eptitibatide treatment (upper panel) and with eptifibatide 
treatment (lower paneO. 
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Discussion 
In this trial of almost IO/GOO patients 'with non-ST-elevatiol1 acute coronary 
synclrOlnes 'who 'were treated according to an array of managclnent strategies) 
including allocation to GP IIb/I1Ia inhibition with eptifibatide, bleeding was a 
C0l111110n adverse event. The large sample size and t11C broad spectnul1 of 
managC111cnt 8tyles and treatnlcnt strategies allowed the baseline den10graphic 
and clinical risk factors to be detenllinec1 faT distinct categoTics of bleeding) 
including procedure-related as ,veIl as procedure-lulTclated or spontaneous 
bleeding. 
Spontaneous bleeding 
AnlOng the patfent characteristics at baseline) age and female gender l"leIC 
the most i111portant detenninants of spontaneous bleeding in this patient 
population. This finding is consistent with the established risk factors for bleeding 
among patients with ST-elevation MI treated \\7ith thrOlnbolytic therapy.10-12 1n 
contrast to the increased risk of bleeding in patients oflighter weight observed 
in studies of thrOlllbolytic therapy for acute MI) weight was not a predictor of 
bleeding in the present patient population. This might be explained by the fact 
that bolus and infusion of both eptifibatide and heparin were adnlinistered on a 
weight-adjusted basis. An additional finding is the higher likelihood of bleeding 
in patients of non-caucasian ancestr~y which persisted even after nlultivariable 
adjushnent. Previous studies ofthrOll1bolysis 'with alteplase for acute 1vn have found 
an increased bleeding risk in patients of African anccstry) 12,19 possibly related to 
an enhanced sensitivity to alteplasc resulting in increased thro111bolytic efficacy 
and 1110re pronounced systelnic fibrinogenolysis. 19 
As expectcd) however) most predictive infornlation 'was captured in the 
pharmacological therapy administered during the initial hospitalization) including 
GP IIb/IIIa inhibition with eptifibatide, the use of thrombolytic agents 01' ticlopidin, 
as ,ye11 as the intensity of anticoagulant treatnlent) l11casured by the aPTT. 
Accordingly) the occurrence of spontaneous bleeding coincided with the 
administration of these agents, 
Recent trials have demonstrated an association bctween high aPTT and 
bleeding and intracranial hemorrhage in patients with acute coronary syndromes 
treated with heparin:'O-22Lower doses ofhcparin nlight therefore reduce the risk of 
bleeding in patients treated with eptifibatide without reducing the clinical efficacy/3 
as suppOltcd by the experience in patients undergoing percutaneous rcvasculmization 
and receiving a GP nb/IIla receptor blocket:2J,2S 0ther possibilities include the use 
of an aut0111ated heparin control systmn to improve aPIT control of intravenous 
heparin/6 or the use onow-molecular-weight heparins which have a nl0re predictahle 
pharmacokinetic profile resulting in a 1110re stable level of anticoagulation. 
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The finding of increased bleeding in patients enrolled in North Anwrica is 
inh-iguing. Although the definition ofspontaneOllS bleeding in the present analysis 
ai1ned to exclude bleeding cOlllplications resulting fronl coronary procedures) the 
observation of an increased risk of spontaneous bleeding in North AnlCrican 
patients cOll1pellcd an exploration of the relation bet-w-cen bleeding, geographic 
region and coronary procedures (111ble 4), the hypothesis being that procedure-
unrelated bleeding could also have been increased by the enhanced pmi-procedural 
level of anticoagulation. Howevel~ even in patients 'without any invasive procedure 
during the first 3n days, a higher incidence OfspolltaneOl1s bleeding1vas observed 
in North AlllCrica . 
Procedure-related bleeding 
Bleeding occurred at the fenlOral access site in ahnost one quarter of all 
patients undergoing coronary intervention. North AU1erican region \vas the most 
important predict01~ with only two other baselinc denlOgraphic variables (fenlale 
gender and smoking status) independently related to this type ofbleecling. All 
remaining nlultivariable predictors "w"ere related to the antithrOlnbotic therapy such 
as the antiplatelet agents eptifibatide, ticlopidin and dipiridamol. In contrast to 
their association 'with procedure-related bleeding evcnts during the first 72 hours, 
eptifibatide and the l11aximal aPTT value ,,,'ere no independent predictors of 
procedure-related bleeding in patients undergoing coronmy intervention between 
day 3 and 30. V\1ith respect to eptifibatide, this finding is reassuring and consistent 
with its short half-life. While the results of the 111uItivariable asseSSll1cnt during 
the 72-hour study drug infusion period confirm previous observations of a 
synergistic effect of GP Ilb/Illa receptor blockers and heparin dosing with respect 
to the occurrence of blceding cOlllplications in patients undergoing PCI/,24 the 
prescnt analysis "was liInited by the fact that no data on peri-procedural ACT values 
,,,'ere collected in the Case Report Fonns. This nlight explain "why the intensity 
of hcparin anticoagulation was not a predictor of procedure-related bleeding in 
patients undergoing coronary intervention at a later stage. 
As the recommended heparin reghnen in patients undergoing PCT aimed to 
achieve and l11aintain an ACT of at least 300 seconds, it is likely that the number 
of procedure-related bleeding complications can be reduced \vhen eptifibatide is 
cOlllbined \,,7ith low-dose heparin with a target ACT of 200 seconds.8N27 In fact, the 
EPILOG and EPISTENT triah have recently shown that the clinical benefit of the 
GP lIb/IlIa inhibitor abciximab can be uncoupled from the risk of hemorrhage 
by using low-dose heparin regimens.24,25 Another possibility to reduce the incidence 
of access site bleeding complications in patients with acute coronary syndr01nes 
undergoing coronary intervention l11ight be to pcrfon11 the procedure fr01n the 
radial instead of femoral access site. 28 
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Bleeding in CABG patients 
Patients undergoing bypass stugmy eluTing hospitalization had an increased 
bleeding risk and accounted for approxhnately 80% of the patients \v"ith l11ajoT 
bleeding c0111plications. In these patients, approxhnately 80% of bleeding lN8S 
related to the bypass surgery, both in patients assigned eptifibatide and those given 
placebo. No increase in bleeding incidence with eptifibatide therapy ... vas observed 
in patients \vho underwent bypass surgery. This finding is reassuring, consistent 
with the short half-life of eptifibatide and parallels the observation in a previous 
study of abciximab.29 
Prediction models for risk stratification 
Patients who present 'with chest pain or other sylnptoms suggestive of an acute 
coronary syndrome and do not have persistent ST-segment elevation, encompass 
a heterogeneous group that varies considerably 'with respect to diagnosis as well 
as future risk for cardiac events. Early risk stratification in these patients is 
i1nportant to tailor pharmacological and invasive treatment to an individual need 
based on the expected prognosis as well as the benefit-risk ratio of the applied 
treatlnent strategy. The admission lZ-lead ECG and troponin status have 
independently proven useful in stratifying patients according to their risk of 
future adverse cardiac events as well as to the expected benefit of enhanced 
antiplatelet therapy with GP IIb/nla inhibitors. 3o-:n 
Recently, a risk-nlOdel has been developed to detennine the prognosis of 
patients "with non-ST-elevation acute coronary syndrOlnes on the basis of an 
evaluation of dClnographic and clinical characteristics at hospital adnlission.18 In 
the present analysis, a silnplc scoring nOl1lOgrmn "was developed 1Nhich can be used 
by physicians to detennine the probability of cxperiencillg a spontaneous bleeding. 
In the present papel~ these two lllOdels ,\7ere integrated by calculating for each 
patient the risk of death or MI and the corresponding risk of experiencing a 
spontaneous bleeding, both with and without eptifibatic1e, by entering the baseline 
prognostic factors in the respective scoring 1l0l110grams. "i!le aimed to identify 
subgroups of patients 'with either a low risk of adverse cardiac events accompanied 
by an increased risk of bleeding or vice versa. These two groups would then 
represent patients in whom the use of GP TIb/ITIa receptor blockers should be 
discouraged or rather recommended, respective1y. Such patient subsets could, 
howevel~ not be identified. 
As most b1eeding events were mild or clinically insignificant and did not 
require any intervention, and considering the trade-off in terms of reducing 
death and MI, the baseline assessment of the patient's risk of bleeding will 
therefore be of secondary importance to the estimation of the risk of adverse cardiac 
events in the decision whether or not to administer a GP lIb/IlIa receptor blockm: 
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Furthermore, it is likely that the risk of bleeding can be reduced by additional 
l11easures including IO'w'-dose hcpaTin regi1ncns/24,26 meticulous care of vascular 
access sites.24.25.27) and reduced-dose thrombolytic therapy in patients experiencing 
an MI while receiving a GP lIb/IlIa inhibitof.34 Accordingly, the rCCOlll1llClldation 
to use a GP IIb/IIla inhibitor like eptifibatide in the management of acute 
coronary syndr0111c patients should be made on the basis of the expected prognosis 
and treatlllcnt benefit assessed by the baseline denlographic and clinical factors, 
including 12-lead ECG and tropollin status. 
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Chapter 7 
Abstract 
Background 
Glycoprotein (GP) lIb/IlIa receptor blockers prevent life-threatening cardiac 
complications in patients "with acute coronary syndrOllles ·without ST-scglllcnt 
elevation and protect against thrombotic c0111plications associated 1v-ith 
percutaneous coronary interventions (pels). The question arises as to ,vhcther 
these 2 beneficial effects are independent and additive. 
Methods and Results 
We analyzed data fi'om the CAPTURE, PURSUIT, and PRISM-PLUS randomized 
trials, which studied the effects of the GP lIb/IlIa inhibitors abcL'(imab, eptifibatide, 
and tirofiban, respectively, in acute coronary syndrOlne patients "'without persistent 
ST-segment elevation, with a period of study drug infusion before a possible PCL 
During the period of pharnwcological treatment, each trial demonstrated a 
significant reduction in the rate of death or nonfatal Inyocarclial infarction in 
patients randomized to the GP lIb/lIra inhibitor compared with placebo. The 3 
trials combined showed a 2.5% event rate in this period in the G-P lIb/lIla 
inhibitor group (N~6125) versus 3.8% in placebo (N~6171), which implies a 
34% relative reduction (P< 0.001). During study 11ledication, a PCI was perfof1ned 
in 1358 patients assigned GP lIb/IlIa inhibition and 1396 placebo patients. The 
event rate during the first 48 hours after pel 'was also significantly Im\7cr in the 
G-P lIb/IlIa inhibitor group (4.9% vs. 8.0%; 41 % reduction; P< 0.001). No fhrther 
benefit or rebound effect was observecl beyond 48 hours after the PCr. 
Conclusions 
There is conclusive evidence of an early benefit of GP nb/Illa inlubitors during 
Incdical treatl1lCnt in patients with acute coronary syndrOlnes 'without persistent 
ST-segnlent elevation. In addition, in patients subsequently undcrgoing PCI, GP 
IIb/IIIa inhibition protects against 111yocardial danlage associated with thc 
intervention. 
124 
Glycoprotein lib/ilia receptor blockers and coronary intervention 
Coronary thr0111bosis is a pivotal event in the pathogenesis of acute coronary 
syndr0111eS and ischclnic cOlllplications resulting fr0111 coronary interventions. l 
Activation of the platelet glycoprotein (GP) lIb/IlIa receptor is the final common 
pathway in the process leading to platelet aggregation, coronary thr0111bus 
formation, and ll1yocardial ischenlia. Accordingly, inhibitors of the platelet GP 
lIb/IlIa receptor arc potent agents to prevent progression to 111yocardial infarction 
(M!) and death,' Indeed, in recent randomized clinical trials, GP lIb/IlIa inhibitors 
effectively reduced life-threatening cOlnplications in patients \\7ith acute coronary 
syndr01llCS 'without ST-segn1ent elevation, ',4 Furthermore, these agents protect 
against life-threatening thr0111botic c0111plications associated 1Nith percutaneous 
coronary intervention (PCI).5 The question arises as to lNhether these 2 beneficial 
effects are independent and additive. Th date, 3 clinical trials can contribute to 
answering this question (Thble 1),""" 
CAPTURE studied the effects of abciximab in patients with unstable angina 
refractolyto conventional 111edical therapy.6 A reduction ",vas observed in the rate 
of death or nonfatal MI during the 24-hour period of pharmacological treatment 
preceding PCl all10ng patients rand0111ized to abciximab versus placebo (KRplan-
Meier estilnates 1.3% versus 2.8%; log-rank P= 0.032; Figure). The event rate during 
the first 48 hours after PCI "'\\"'as significantly lower in abcixhnab patients (2.8% 
versus 5.8% in placebo; P= 0.009). In the period starting 48 hours after PCl, only 
a few events occurred, with silnilar rates in both groups. 
Observations in PUR...SUIT con finned these findings.3 Acute coronary syndr0111e 
patients randOll1ized to eptifibatide had a 3.2% event rate after the scheduled 72 
hours of study drug infusion, versus 4.4% in placebo (P= 0.003). There were also 
fewer procedure-related events in eptifibatide patients undergoing a PCI during 
this period (7.6% versus 10.3% in placebo; P= 0.105). In the subsequent 
postprocedural period (all patients were off study 111edication), event rates were 
low and similar in both groups. 
PRlSM-PLUS also confirmed the beneficial effects of GP lIb/ilia inhibition 
before and during PCr.4 Patients assigned tirofiban had fewer events during initial 
Inedicalll1anagement (1.8% versus 3.8% in p1acebo; P= 0.016) as well as fewer PCI-
related events (2.9% versus 8.0%; P=0.O(2). 
There was no evidence of a differential effect of the GP lIb/ilia blockers 
between the trials, in any of the 3 stages, because all tests for hOll1ogeneity of 
treatlnellt effect were nonsignificant. Therefore, the separate trial data could be 
combined (Figure and l1tble 2), The 3 h"ials together denlOnsh'ated a 34% reduction 
in the composite of death or nonfatal MI during pharmacological therapy preceding 
PCl (if any) by GP lIb/IlIa inhibition [2,5% versus 3,8% in placebo; odds ratio (fJ,5% 
CI) 0,66 (0,54 to 0,81)] and an additional 41 % reduction in PCI-mlated events [4,fJ% 
versus 8,0%; odds ratio 0,59 (0.44 to 0,8])]. Mortality was low but was still affected 
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Enrollment criteria 
Mean (SD) age, y 
Male, % 
Prior MI, % 
Prior CABG, % 
Prior PTCA, % 
Study medication 
Duration of study 
drug infusion 
Cardiac comedication 
Further management 
CAPTURE (n~ 1265) 
Recurrent ischemia under 
medical treatment including heparin 
and nitrates 
61 (10) 
73 
40 
3 
13 
AbcLximab (0.25 rug/kg bolus plus 10 
mg/mill infusion) vs placebo 
PURSUIT (n ~ 9461) 
Ischemic chest pain within 
previous 24 hi with ECG or 
enzymatic evidence of 
myocardial ischemia; no 
persistent ST-segment elevation 
63 (II) 
65 
33 
12 
13 
Eptifibatide (180 J..Lg/kg bolus plus2.0 
J..Lg • kg-l • min-l infusion) 
V$ placebo 
PRISM-PLUS (n ~ 1570) 
Ischemic chest pain within 
previous 12 hi with ECG or 
enzymatic evidence of myocardial 
ischemia; no persistent 
ST-segment elevation 
63 (12) 
68 
42 
14 
9 
Tirofiban (0.4 )..lg/kg infusion for 30 
min followed by 0.1 )..lg. kg-l • 
min-l infusion) vs placebo 
Ih after percutaneous 72 h after randomization. In case of a 48-96 h post randomization. In case of 
intervention, which was scheduled at PCI, for an additional 24 h a PCI, for an additional 12-24 h 
18-24 h after randomization 
Aspirin, heparin, nitrates 
Percutaneous intervention at 18-24 h 
after randomization 
Aspirin, heparin 
At discretion of treating physician 
Aspirin, heparin 
Coronary angiography at 48-96 h after 
randomization; coronary intervention at 
discretion of treatingphysician 
9 
-8 
~ 
'-J 
'" '-J 
Thble 2. Mortality and Composite of Death or Nonfatal j\U 
n 
Placebo 
Death, 
% 
Death or 
Nonfatal 
MI, % n 
GP lIb/lIla Inhfbitor 
Death, 
% 
Death or 
Nonfatal 
MI, % 
Period: Randomization to randomization + 24 h or until PCI or surgical coronary intervention (if any) 
Patients: All randomized 
CAPTURE 635 1 (0.2) 16 (2.5) 630 0 6 (1.0) 
PURSUIT 4739 13 (0.3) 75 (1.6) 4722 6 (0.1) SO (1.1) 
PRlSM-PLUS 797 1 (0.1) 7 (0.9) 773 1 (0.1) 5 (0.6) 
All 6171 15 (0.2) 93 (1.6) 6125 7 (0.1) 61 (1.0) 
Period: Randomization to end of study drug infusion or until PCI or surgical coronary intervention (if any) 
Patients: All randomized 
CAPTURE 
PURSUIT 
PRlSM-PLUS 
All 
Period: pcr to PCI + 43 h 
635 
4739 
797 
6171 
1 (0.2) 
40 (0.8) 
5 (0.6) 
46 (0.7) 
16 (2.5) 
190 (4.0) 
29 (3.6) 
235 (3.8) 
Patients: Undergoing pcr during the scheduled study drug infusion period 
CAPTURE 623 3 (0.5) 36 (5.8) 
PURSUIT 622 7 (1.1) 64 (10.3) 
PRlSM-PLUS 151 1 (0.7) 12 (7.9) 
All 1396 11 (0.8) 112 (8.0) 
Period: pcr + 48 h to PCI + 25 days 
630 
4722 
773 
6125 
616 
606 
136 
1353 
Patients: Undergoing PC! during study drug infusion and surviving the first 48 h after pcr 
CAPTURE 620 3 (0.5) 7 (1.1) 614 
PURSUIT 615 4 (0.7) 10 (1.6) 602 
PRlSM-PLUS 150 1 (0.7) 1 (0.7) 135 
All 1385 8 (0.6) 18 (1.3) 1351 
Breslow-Day indicates Breslow-Day test for homogeneity of odds ratios (P). 
o 
21 (0.4) 
2 (0.3) 
23 (0.4) 
2 (0.3) 
4 (0.7) 
1 (0.7) 
7 (0.5) 
2 (0.3) 
9 (1.5) 
o 
11 (0.8) 
6 (1.0) 
137 (2.9) 
13 (1.7) 
156 (2.5) 
17 (2.8) 
46 (7.6) 
4 (2.9) 
67 (4.9) 
4 (0.7) 
14 (2.3) 
4 (3.0) 
22 (1.6) 
Odds ratio (95% CI) BreslOW-Day 
0.37 (0.15-0.96) 
0.67 (0.46-0.95) 0.502 
0.74 (0.23-2.33) 
0.62 (0.45-0.86) 
0.37 (0.15-0.96) 
0.72 (0.57-0.90) 0.201 
0.45 (0.23-0.38) 
0.66 (0.54-0.81) 
0.46 (0.26-0.83) 
0.72 (0.48-1.07) 0.307 
0.35 (0.11-1.12) 
0.59 (0.44-0.81) 
0.57 (0.17-1.97) 
1.44 (0.64-3.27) 0.199 
4.55 (0.50-41.2) 
1.26 (0.67-2.36) 
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CAPTIJRE 
10% N~I,265 N~I,239 N=l,234 
8% p=O.032 p=O.OO9 p=0.371 
6% E"' 4% 28% 2.8% 2% I.l% 1.3% 
0% < : 0.7% 
PURSUIT 
10% N=9,461 10.3% N=1,217 
8% p=O.OOJ 7.6% p=0.383 
6% 
4% 4.4% 
3.2% N=1,228 2.3% 
2% 
---
1.6% p=O.105 r 0% 
IRISM·ILUS 
10% N=I,570 N=287 N=285 
8% p=O.016 p=O.062 R07c· p=O.l40 
6% 
4% 18% 29% 3.0% 2% 1.8% 
0.7% 
0% 
All 
10% N~12,296 N=2,754 N=2,736 
8% p=O.OOl p=O.OOl 8.0% p=O.474 
6% 
4% 4.3% 4.9% 
2% 2.970 1.6% 
0% ,L 1.3% 
i +24h t48h +72h i +24h t48h +7(l.1y +14day +21day 
Start GP IIb'lIIainhibitor I pltrdJo fucuttlllfflUS Coron..1rY Intervention 
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Figure legend 
Kaplan-Meier curves showing cumulative Incidence of death or nonfatal myocardIal 
(re)lnfarction in patients randomly assigned to glycoprotein IIb////a inhibition (bold lines) or 
placebo. 
Data were derived from CAPTURE, PURSUIT, and PRISM-PLUS, Left, Event rates during Initial 
period of pharmacological treatment until moment of a PCI or coronary bypass grafting, jf 
any, Middle, Event (otes among PCI patients during 48-hour period affer procedure. During 
ond shortfy after PCf, all patients were on study medication. RIght, Event rates in period 
starting 48 hours after PCf, during which 011 patients were off study medIcation. At beginning 
of each period, event totes were (re)set ot 0%. Any patient still alive contributes to event 
estimates in each period fn PURSUIT, procedure-unrelated MI was defined as any elevation 
of creatine kinase (CK)-MB above upper limit of normal (ULN), For consistency with CAPTURE 
and PRISM-PLUS, In present analyses only CK or CK-MB elevations >2xULN were considered 
to be infarctions during medical therapy. fn 011 3 trials, procedure-related infarcts were 
defined by on elevation of CK or CK-MB >3xULN, 
by GP IIb/IIIa inhibition, The incidence of death during medical therapy waR 0,4% 
among patients randOlllized to GP I1b/Ula inhibition cOlllparcd with 0.7% mnong 
placebo patients [odds ratio Q,SO (0,30 to 0,83)], The procedure-related death 
rates were 0,5% and 0,8%, respectively [odds ratio 0,65 (0,25 to 1,69)J, 
Intracoronary stcnts '\Tcre used in 10.5% of the CAPTURE patients. In PURSUIT 
and PRISM-PLUS, stcnting 1vas done in 50.2% and 20.3% of patients undergoing 
PCl during study drug infusionl respectively. Irrespective oftreatlncnt assignl11Cnt, 
the overall procedure-related event rates 'were higher in stented patients (9.3% 
versus 5,3% in ba1100n angioplasty; X'l P< 0.001). Howevel~ the beneficial effect of 
GP lib/lIla inhibition was similar in stented and balloon-only patients, with odds 
ratios (95% CI) of 0,61 (0,38 to 0,99) and 0,58 ((US to 0.88), respectively 
(hOlnogeneity test: P= 0.863). Late event rates 'were si1nilar in patients -w-ith and 
1\Tithout stents (1.6% versus 1.4%) and were not influenced by the initial GP lIb/IlIa 
treai1nent. 
In contrast to CAPTURE, in which all patients 'were to undergo PCI, in 
PURSUIT and PRISM-PLUS the decision to perfoY1n an intervention was at the 
discretion of the treating physician. Patients undergoing a PCI in these latter trials 
were possibly at higher-than-average risk. Indeed, cOlnpared with CAPTURE, 
procedure-related event rates in the placebo anns were higher than expected on 
the basis of the preprocedural event rates. These higher event rates, huwevel~ did 
not affect the benefit of GP lIb/IlIa blockade, because there was no evidence of 
a differential effect between the 3 trials, Still, the observed reduction in procedure-
related events hy GP lIb/IlIa treatment in PURSUIT and PRISM-PLUS might 
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have been biased because ofindistillct selection criteria. Howeve1~ the incidence 
of per in both hcahncnt anns ofthese h'ials was well balanced, as were the baseline 
characteristics of the patients conccrned.3.4 
The definition of non-PC I-related Ml varied among the trials. In particulm; the 
criteria applied in PURSUIT 'were 1110re sensitive, resulting in a relatively high event 
ratc,3 In the present analysis, similar infhrct definitions ,\7ere applied to all 3 trials 
(sec Figure caption). Supplementary analyses (not presented) demonstrated that 
the early beneficial effects were consistent for different definitions of MI. 
In contrast to CAPTURE, the PURSUIT and PRISM-PLUS studies showed a 
slightly higher event rate among patients randomized to GP IIb/IIIa inhibition in 
the period starting 43 hours after PCI. This might be a result of differences in 
phannacodynamics between the agents and between the degree, duration, and 
specificity of the GP IIb/TIla inhibition, although there is no statistical evidence 
of a differential late treatment effect between the trials (and thus between the 
agents). Additional investigations are needed to clarifY this issue. 
In all 3 trials, bleeding complications 'were 1110re C0111111011 in patients treated 
'with GP lIb/IITa inhibitors than with placebo.3.4.6 In 1110st cases, 11O'wevel~ bleeding 
"was Inild and occurred at the arterial puncture site. The EPILOG trial has sho'wn 
that the benefit of GP lIb/IlIa inhibition can be uncoupled from the risk of 
hel110rrhage in PCl patients by low-dose, weight-H(1justed heparin, adherence to 
strictcr anticoagulation guidelines, and careful vascular access-site management.? 
We conclude that enhanced platelet inhibition with a GP lib/IlIa blocker in 
addition to aspirin and heparin, starting immediately after admission, is beneficial 
to patients 'lVith acute coronary syndrOlnes 'without persistent ST-:;.;egment elevation. 
In addition, in those undcrgoing PCl, intensive platelet inhibition protects against 
myocardial da111agc associated "with the intervention. Thus, to fully explore their 
beneficial effects, GP IIb/IIIa inhibitors should be initiated early after hospital 
admission and continued until after the procedure in patients undergoing PCL 
130 
Glycoprotein lib/ilia receptor blockers and coronary intervention 
References 
1 Fustcr V, Bmlimon L, Badimon J.J, Chesehro .ill. The pathogenesis of coronary artery disease 
and the acute coronary syndromes. N Ellgl , Mcci. H.l92j326:242-2S0,310-318. 
2 Coller TIS. Blockade of platelet GP lIh/fIla Tf~ceptors as an antithrombotic strategy. 
Circulation. 1995;92:2373-2380. 
3 The PURSUIT Investigators. Inhibition of platelet glyr:oprotein lIb/IlIa lNith cptifihatide 
in patients with acute coronary syndromes. N Eng1 J Med. 1998;339:436-443. 
4 PRISM-PLUS Investigators. Inhibition of the platelet glycoprotein lIb/IlIa receptor with 
tirofiban in unstable angina and non-Q wave myocardial infarction. N Engl J Med. 
1998;330,1433-1497. 
5 Kong DF, CaliffMI, Miller DP, Molitcrno DJ, White HD, Hanington RA, TI::hcng JE,Lincoff 
Ai .... l, Hassclblad \~ 'IhpoJ E.T. Clinical outcomes oftherapeutic agents that block the platelet 
glycopmtein IIb/nIa integrin in ischemic heart disease. Circlilatinll. 1993;98:2829- 35. 
(j The CAPTURE InvestigatorI'. Randomized placebo-controlled trial of abciximab before 
and during comnary intervention in refractory unstahle illlb';na: the CAPTURE shldy. 
Lancel. 1997;349:1429-1435. 
7 The EPILOG Investigators. Platelet glycoprotein lIb/IlIa receptm hlockade and lnw-dose 
heparin during percutaneous coronm:,y revil};cuiari:tBtion. New Ellgl J Mcd. 1997;33(j:16B9-1696. 
131 

Minor Myocardial Damage and 
Prognosis: 
Are Spontaneous and 
Percutaneous Coronary 
Intervention-Related Events 
Different? 
IC Martijn A7c1cerhllis, MDj 
John H. Ale,Yandel, MDj 
Barbam E. Thrdiff, MDj Erie Boersma, 
PhDj Robert A. Harrington, MDj 
A. Michael Lineoff, MDj 
l'iaarten L. Simoons, MD 
Thoraxcentet~ Erasmus University and 
University Hospital Rotterdam, The 
Netherlands (KMA, EB, MLS); Duke 
University Medical Centel; Durham, NC 
(JAA, BET, RAH); Cleveland Clinic 
Foundation, Cleveland, OH (AML) 
Submitted for publication 
Chapter 8 
Abstract 
Background 
The relevance of the adverse prognostic implications of CK~NIB elevation 
fonowing percutaneous coronary intervention (PCI) rel11ains a controversial 
issue. Therefore, "nrC cOlllpared the relationship between the level of post-
procedural CK-MB elevation and the risk of death after 6-111onth follow-up with 
the relationship bet\veen the level of CK-MB elevation and 1110Ttality in patients 
"with acute coronary syndromes without persistent ST-clcvation treated l11cdically. 
Methods and Results 
In the PURSUIT trial, 5583 of 9461 patients who presented with a non-ST-
elevation acute coronary syndrOlllc did not undergo PCl or coronary artery 
bypass grafting and had at least 1 CK-MB sample collected during index-
hospitalization, In these patients, there lNas a gradual increase in fi-1110nth 
111ortalitY'Nith higher CK-l\1B levels: 4.1 %) 8.6%) 9.0%) 14.3%) 15.5% for CK-MB 
ratios 0-1) > 1-3) >3-5) > 5-10) and> 10 titnes the upper limit ofnollnal) respectively. 
The prognostic significance of cardiac enzynlC elevation after PCl 'was 
assessed in a combined analysis using data from the CAPTURE, EPIC, EPILOG, 
IMPACT-II and PURSUIT h-ials_ In all studies, the peak CK-MB value within 48 hours 
after PCI '\7as considered to represent procedure-related 111yocaTdiai dmnage. 
This combined analysis in 8838 patients revealed a direct) proportional relationship 
between post-procedlual CK-MB levels and 6-rnonth nlOrtality. In patients with 
CK-MB ratios 0-1) > 1-3) > 3-5) > 5-10 and> 10) the risk of death was 1.3%) 2.0%) 
2.3%) 4.3% and 7.4%) respectively. The 6-1110nth nlOrtality rates were lower after 
procedure-related cOl11pared with spontaneous infarcts. Yet) the relative increase 
in 6-nl0nth mortality with each increase in the category of peak CK-1\1B level was 
of the same magnitude for cardiac enzynlC elevations after PCl and those occurring 
spontaneously in the setting of acute coronary syndr01nes. 
Conclusions 
The strong dose-response relationship between the Inagnitude of post-
procedural CK-MB elevation and 6-111onth 111ortality) as well as the consistency of 
this finding among the different studies strongly indicate that peri-procedural 
11lyocardial dmllage is an important l11arker of subsequent adverse outconle. 
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Creatine kinase (CK) or CK-lvIB isoenzynle elevations occur in 5% to 30% of 
patients undergoing percutaneous coronary intervention (PCI).1.4 Recent studies 
have shmvn a direct , proportional relationship between the level of post-procedural 
CK-MB elevation and the risk of an adverse clinical DntcOlllC during long-term 
follow-up including death, myocardial infarction (MI) and need for repeat 
rcvascularization procedures.2-5 Post-proccduralliscs in cardiac cnzynlcs appeared 
to be an independent predictor of adverse outconIC) even in patients lNith an 
othenvisc apparently unco111plicated and successful coronary intervention and after 
adjushncnt for other prognostic factors.2-5 
Nevertheless) the relevance of these aSYll1ptonlatic procedure-related rises in 
cardiac cnzynlcs rClllains a controversial issue in interventional cardiology. In 
contrast j the prognostic significancc of sl11a11 MIs occulTing spontaneously in the 
setting of unstable angina or after acute MI has been '\'lell established,6-8 
\Vc investigated whether the adverse prognostic iI11plications of CK-MB 
elevation follmdng PCI are sinlilar to those of spontaneous j non-procedure-
related Ml. Accordingly, we cOl11pared the relationship betv·,Teen the level of post-
procedural CK-MB elevation and the risk of death after 6-month follow-up with 
the relationship between the level of CK-MB elevation and nl0rtality in patients 
with acute coronary syndrOl11es treated nledically. 
Prognostic significance of CK-MB elevation in acute coronary syndromes 
The relationship between peak CK-l\1B level and outcOI1le in paticnts lNith 
acute coronaty syndrOl1lCS 1'las investigated in a retrospcctivc analysis of data fr0111 
the large PURSUIT triaL' PURSUIT compared the glycoprotein lIb/IlIa inhibitor 
eptifibatide with placebo in addition to standard therapy in 9461 patients with 
unstable angina or evolving IvII without persistent ST-segll1ent elevation.6 
Mortality at 6 months was assessed in five groups of patients categorized hy 
peak CK-MB level (0-1, > 1-3, >3-5, >5-10, or> 10 times the upper limit of normal) 
at the index-hospitalization in the 5583 PURSUIT patients who did not undergo PCI 
or coronary artery bypass grafting and had at least I CK-MB sample collected. 
Mortality at G months was 4.1 % in patients with normal peak CK-MB levels, and 
increased to B,G% at peak CK-MB levels 1 to 3 times normal, 9.0% at peak CK-MB 
levels 3 to 5 times normal, 14.3% at peak CK-MB levels 5 to 10 times normal j and 
15 .. ')% at peak CK-Mil levels greater than 10 times normal (Thble). The relation 
between peak CK-MB level and G-month mortality remained highly statistically 
significant (Wald x' 74.4fi; P < 0.001) after adjustment for other haseline predictors.' 
Prognostic significance of CK-MB elevation following PCI 
The prognostic significance of cardiac enz;yme elevation after PCI V·laS 
assessed in retrospective analyses using data from the IMPACT-II and PURSUIT 
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Table. Mortality at 6-month follow-up by C:l.t~ory of peak CK-:MB level 
eK-ME 0-1 x ULN CK-l\1B >1-3 x ULN 
n Death (%) n Death (%) Odds Ratio (95% el) 
Spontaneous 2658 109 (4.1) 1567 135 (8.6) 2.21 (1.70-2.86) 
Post-PCI (Combined) 6548 85 (1.3) 1376 27 (2.0) 1.52 (0.98-2.36) 
Post-PCI (C-E-E) 4034 44 (1.1) 662 14 (2.1) 1.96 (1.07-3.60) 
Post-PCI (IMPACT-II) 1779 27 0.5) 323 4 (1.2) 0.81 (0.28-2.34) 
Post-PCI (PURSUIT) 735 14 (1.9) 391 9 (2.3) 1.21 (0.52-2.83) 
CK-:MB >3-5 x ULN 
n Death (%) Odds Ratio (95% el) 
Spontaneous 498 45 (9.0) 2.32 (1.62-3.33) 
Post-PCI (Combined) 303 7 (2.3) 1.80 (0.83-3.92) 
Post-PCI (C-E-E) 114 2 (1.8) 1.62 (0.39-6.76) 
Post-PCI (L'1PACT-II) S4 2 (2.4) 1.58 (0.37-6.77) 
Post-PCI (PURSUIT) 105 3 (2.9) 1.52 (0.43-5.36) 
CK-l\IIB >5-10 x ULN 
n Death (%) Odds Ratio (95% CI) 
Spontaneous 461 66 (14.3) 3.91 (2.83-5.40) 
Post-PCI (Combined) 301 13 (4.3) 3.43 (1.90-6.23) 
Post-PCI (C-E-E) 110 4 (3.6) 3.42 (1.21-9.70) 
Post-PCI (IMPACT-II) 86 5 (5.8) 4.01 (1.50-10.7) 
Post-PCI (PURSUIT) 105 4 (3.8) 2.04 (0.66-6.32) 
CK-MB >10 X ULN 
n Death (%) Odds Ratio (95% CO 
Spontaneous 399 62 05.5) 4.30 (3.09-6.00) 
Post-PCI (Combined) 310 23 (7.4) 6.09 (3.79-9.80) 
Post-PCI (C-E-E) 105 7 (6.7) 6.48 (2.85-14.7) 
Post-PCI (IMPACT-II) 69 6 (8.7) 6.18 (2.46-15.5) 
Post-PCI (PURSUIT) 136 10 (7.4) 4.09 (1.78-9.40) 
Odds ratio for risk of death at 6 months relative to ri$k in catcgory without CK-MB elcvation (CK-MB ratio 0-1). 95% CI denotes 95% confidence interval. Bre$low-
Day indicates Breslow-Day test for heterogeneity of odd.~ ratios ofpost-PCI cardine enzyme elevation vcrsU$ odcL~ rntio of spontnneous enzyme elevntion within each 
enzyme eategory (P). C-E-E = combined data from CAPTURE, EPIC and EPILOG studies; CK-MB = creatine k:ina~e-MB: PCI = percutaneous coronary 
intervention; ULN ;;;0 upper limit of nonnal. 
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trials, as well as from a combined analysis of the CAPTURE, EPIC and EPILOG 
trials.3.4 These studies were conducted between NOVe111ber 1991 and January 
1997. The protocols and results of the studies have been published previously.3A6 
In brief, CAPTURE, EPIC and EPILOG were large, double-blind, placebo-controlled, 
randomized trials evaluating the efficacy of the glycoprotein lIb/IlIa inhibitor 
abciximab in reducing ischenlic cOlllplications in patients undergoing PCI for a 
variety of indications.' The IMPACT-II trial evaluated the efficacy of eptifibatide 
in patients scheduled for electi'llc, urgent, or enlcrgency PCr.3 A silnilar analysis 
was done in the subgroup of PURSUIT patients who underwent PCI in the first 
30 days following enrollment and had at least 1 CK-MB sample collected in the 
first 48 hours following the intervention. In all studies, the peak CK-MB value within 
48 hours after PCI was considered to represent procedure-related 111yocardial 
da111age. 
The combined analysis in 5025 patients enrolled in CAPTURE, EPIC and 
EPILOG demonstrated a gradual increase in 6-month mortality with higher post-
procedural CK-MB levels: 1.1 %/2.1 %/ 1.8%/3.6%/6.7% for CK-MB ratios (relative 
to the upper limit of normal) 0-1, >1-3, >3-5, >5-10 and >10, respectively 
(TIlble).4 The CK-MB ratio remained an independent predictor of outcome after 
nulltivariable adjust1ncnt for clinical as lNc11 as angiographic characteristics.4 
Similar analyses of data from the IMPACT-II trial and in the subgroup of 
PURSUIT patients undergoing PCI within 30 days confirmed this observation. In 
IMPACT-II, the risk of mortality at 6-month follow-up increased from 1.5% in 
patients ·without post-procedural CK-1VIB elevation to 8.7% in patients with a 
peak CK-MB level exceeding 10 times the upper limit of normal CPable).' In 
PURSUIT patients undergoing PCI, these figures 'Nere 1.9% and 7.4%, respectively 
CPable). 
In order to provide an accurate aSSeSSlllent of the 6-l1l0nth 1110rtality rate in 
each category of post-procedural peak CK-MI3 level, the data from all PCI trials 
were c0111bined. This cOlllbined analysis in 8838 patients undergoing PCl for a 
variety of indications revealed a direct) proportional relationship between post-
procedural CK-MI31evels and 6-month mortality. In patients with CK-MB ratios 0-
1, >1-3, >3-5, >5-10 and >10, the risk of death ",vas 1.3%,2.0%,2,3%,4.3% and 
7.4 % I respectively, 
In each categ01J' of peak CK-MB level, 1110rtality at 6-11lOnth folluw-up ·was 
substantially Imvcr in patients after PCl cOlnparcd "with patients presenting 1\Tith 
an acute cOTonaTY syndTOnle and treated Inedically. Acute coronary syndrOl1le 
patients had a "worse cardiovascular baseline risk profile including older age 
(median 65 years versus 61 years in the PCI patient population; P< 0.001), higher 
heart rate (72 versus 69 years; P< 0.001) and a higher percentage of WaHlen 
(40.0% versus 27 .5%i P< 0.001). In contrast, patients undergoing PCI had a higher 
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frequency of previous MI (33.5% versus 43.3%; P<O.OOl). Howeve1~ the relative 
increase in 6-11lOnth 1110rtality ·with each increase in the category of peak CK-lvIB 
level (as represented by the odds ratios) \vas of the SaIne ll1agnitude for cardiac 
cnzylnc elevations after PCI and those occurring spontaneously in the setting of 
acute coronary syndrOll1cs (Figure), as all tests for heterogeneity of the odds ratios 
were non-significant (Thble), 
100 
CK-MBratio >1-3 CK-MB ratio >3-5 CK-MB ratio >5-10 CK-MB ratio> 1 0 
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FIgure 
Odds ratios for mortality at 6-month follow-up presented for four categories of peak CK-MB 
level for cardiac enzyme elevations following PCI and those occurring spontaneously In 
patients with acute coronary syndromes treated medically. Odds ratios for risk of death at 6 
months relative to risk In category without CK-MB elevation (CK-MB ratio 0-1), Peak CK-MB 
level shown as ratio relative to upper limit of normal. Vertical lines Indicate 95% confidence 
intervals. 
C-E-E ~ combined data from CAPTURE, EPIC and EPILOG trials: CK-MB ~ creatine kinase-MB: 
PC! = percutaneous coronary intervention. 
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Discussion 
This combined analysis in flB3B patients undergoing PCI for a variety of 
indications clearly demonstrates that the risk of death at 6-month follow-up is 
directly proportional to the extent of post-procedural CK-MB elevation. Fmthenllore, 
although the absolute 1110ftality rates differed) the relative risk for adverse DutCOlllC 
at 6 111011th8 after peri-proccduralillyocardial damage 1\7as similar to that observed 
for MI occulTing spontaneously in the setting of acute coronary syndr01ncs, The 
increased absolute risk of 6-month mortality might be explained by the fact that 
patients 'who presented 'with an acute coronary syndrOlue represented a population 
at increased risk of adverse thr01nbotic cOlnplicatiolls) 1\7hile 1110re elective and 
lmv-risk patients were included in S0111C of the PCI trials. This was also appaTcnt 
in the differences in baseline variables knO"w11 to be illlportant predictors of 
Inortality. 
As MI is clefinecl as myocardial cell death which results in the release of specific 
bi01narkers into the circulation, the present findings hnply that any abnornlal 
elevation of cardiac Inarkers, 'whether associated with PCl and regardless of 
Inagnitude, should he interpreted as an MI. 
Most procedure-related infarcts are slna11 and result fronl nlicroernboli frOl11 
the atherosclerotic plaque that has been disrupted during angioplasty, or from 
thrOl11bus particles,2 As these s1ua11 infarcts do not illlpair myocardial function, 
pathophysiologicallnechanis111s other than heart failure may explain the 11npaired 
long-tenll prognosis associated with post-procedural cardiac enzyme elevation. It 
is conceivable that 1uicroinfarcts provide a nidus for ventricular arrythnlias via 
a 1uicrOTeentry or a focal 111echanisnl.1.24.5 Indeed, previous studies have 
denlonstrated the association between sma11 procedure-related infaTcts and 
subsequent sudden death. 1.4 
Furthenllore, 111yocardial damage occurring during the procedure 111ay be an 
expression of vascular instability. Although myocardial cell injury during 
angioplasty 111ay be a one-time event cOlllpared with the often repetitive nature 
of spontaneously occurring episodes of myocardial ischetnia and necrosis, it is likely 
that patients -who develop coronary elnboli and slna11 infarcts have atherosclerotic 
lesions which are apparently unstable and continue to represent a substrate for 
plaque rupture ",yUh subsequent thro111hosis resulting in adverse events such as 
MIl sudden death or death during revascularization procedures. 
Post-procedural enz;yme elevations, or rather peri-pTocedural MIl should be 
interpreted with consideration of lesion nl0rphology and the clinical setting. 
The present analysis solidly supports the need for syste1uatic asseSS111ent of 
cardiac l1wrkers after all PCls. Measures for secondary prevention, including 
aspirin, statills, beta-blockers, and ACE inhibitors, should be recol1uuended for 
patients with post-procedural elevation of cardiac ellZY1nes, shuilar to the guidelines 
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for Inanagetllcnt of other infarcts. Furthermore, patients \\Tith peri-procedural 
l11yocardial danlage should be instructed to seek inl111cdiatc 111cdical help ·whenever 
.symptoms reoccur after hospital discharge. Perl1aps 1110re ilnportant l therapeutic 
.strategies that reduce the incidence and severity of peri-procedural MI arc likely 
to improve the long-term QUtC0111C of patients undergoing PCl. Antiplatelet agents, 
particularly the glycoprotein lib/IlIa receptor blockers have been shown to 
reduce the incidence of recurrent: acute coronary events.9 A recent uleta-analysis 
of all studies with abciximab in patients undergoing PCI supports the above 
concept by showing a 3096 relative reduction in mortality at G-month follow-up 
in patients treated with this glycoprotein lib/IlIa inhibitor. 1O 
The strong relationship between the magnitude of the post-procedural CK-
ME elevation and 6-11lOnth mortality as ,>vell as the consistency of this finding aIuong 
the different studies indicate that peri-procedural 111yocardial danlage is all 
inlportant l11arker of subsequent adverse outcOllle. Therefore, measures to avoid 
or prevent such peri-procedural myocardial da111age are ·warranted. 
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Abstract 
COlllputer-assisted continuous 1110nitoring of the ST-scgnlel1t allows detection 
and quantification of recurrent ischenria in patients with acute coronary syndrOlnes. 
In a substudy ofthe PURSUIT (Platelet glycoprotein lIb/IlIa in Unstable angina: 
Receptor Suppression Using Integrilin Therapy) trial, this technique ,vas used to 
evaluate the effects of the glycoprotein lIb/IlIa inhibitor eptifibatide on the 
incidence and severity of recurrent ischcll1ia, and to investigate the relationship 
bet\veen recunent ischcnlia and the occuncnce of subsequent death or l11yocardial 
(re)infarction. A total of258 patients with unstable angina or evolving 111yocardial 
infarction without ST elevation were lllOuitored for 24 hours during infusion 
with either eptifibatide or placebo with a computer-assisted 12-lead ECG-ischemia 
monitoring device. ReeuTrcnt ischemic episodes ,\'ere identified by an automated 
computer algorithn1. 'I\vo hundred and sixteen patients (84%) had ECG recordings 
suitable for analysis. Ischemic episodes were detected in 35 (33%) of the 105 
eptifibatide patients and in 32 (29%) ofthe III placebo patients (not significant). 
No difference in ischen1ic burden was apparent between both treatnlent groups. 
Patients ,vho exhibited 2 or 1110re episodes of recurrent ischeIllia 1110re frequently 
died or suffered a l11yocardial infarction, both at 7 and 30 days, as well as through 
the G-Illonth follow-up. A greater ischenlic burden was significantly related to 
adverse outconlC during the 6-n10nth follow-up period. Real-tin1e c0111puter-
assisted continuous nnlltiIead ECG-ischclllia 111Onitoring Inay help to identif~y 
patients w"ith unstablc coronary syndrOllles at increased risk of adverse outconlC 
and, thus, allow for better prognostic triage and nlOre appropriate selection of 
therapeutic strategies. Integration of these systen1s in coronary care units and 
cnlcrgcncy wards should, thereforc, be recommended. 
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Introduction 
In patients 1vith unstable angina pectoris or myocardial infarction 'without ST-
seglnent elevation) recurrent ischemia may reflect episodes of platelet thrombus 
formation at the culprit lesioll. 1-3 C0111puter-assisted continuous lllOuitoring of the 
ST-segment allm\"Ts detection and quantification of recurrent ischmnia and 
111yocardial infarction,4-8 As such l continuous 12~lcad or vectorcardiographic ST 
111onitoring Inight be suitable to evaluate the efficacy of 11mv pharmacological 
therapies such as platelet glycoprotein lIb/IlIa Teccptor inhibitors in patients with 
acute coronary syndromes. The CAPTURE (c7E3 Fab Anti Platelet Therapy in 
Unstable REfractory angina) ECG-ischemia monitoring substudy showed that 
treahnent "with ahciximab reduced recurrent ischclnia and total ischclnic burden 
in patients with refi"actory unstable angina.' In the PURSUIT (Platelet glycoprotein 
lIb/IlIa in Unstable angina: Receptor Suppression Using Integrilin Therapy) 
study, h'cahnent \"lith eptifibatide, a synthctic inhibitor of the platelet glycoprotein 
lIb/IlIa rcccpt01~ resulted in a 1.5% absolute reduction in the 30-day conlposite 
endpoint of death or myocardial (re)infarction in patients \"lith unstable angina 
or evolving nlyocanlial infarction without ST-segnlent elevation.9 T\velve-lead 
cOlllputer-assisted ECG-ischelllia nlonitoring was conducted as a substudy "\Nithin 
the PURSUIT study to evaluate the effects of eptifibatide compared with placebo 
on the incidcnce and severity of recurrent ischClllia. 
Recurrcnt ische111ia, as detected by continuous ECG nlonitoring in patients 
with unstablc anginal has been reported to carry an incrcased risk of unfavorable 
outcome, including death and myocardial infarction.5.1o-17 A secondary objective 
of the present PURSUIT substudy was to verify this relationship between recurrent 
ischemia and ischclnic burden as detected during cOlnputcr-assistcd standard 12-
lead ECG-ischelllia nlonitoring and the occurrence of subscquent death or 
myocardial (re )infarction. 
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Methods 
Study Organization 
The PURSUIT ECG-ischc111ia 111onitoring substudy involved patients fr0111 
the main PURSUIT study from 10 hospitals in The Netherlands and 16 in the 
United States, The protocol and the results of the PURSUIT study have been 
published previously,',18 All patients enrolled in the substudy underwent 
continuous ECG 1110nitoring using a 12-1eacl ECG-ischenlia 111onitoring device as 
described later, 
Patient Population and Treatment 
Patients presenting 'with unstable angina or l11yocardial infarction i\"Tithout 
persistent ST-segtl1cnt elevation wcre eligible for inclusion in PURSUIT. 9.18 Inclusion 
criteria 'were: sylnpt0111s of 111yocardial ischemia at rest 'within 24 hours of 
e11rolh11e11tl and either transient « 30 111inntes duration) ST-segmcnt elevation 
0.5 111111 or greater 01' transient or persistent ST-seglllcnt depression 0.5 11Ull or 
greater or definite T-"wave inversion ofl 111m or greater during or within 12 hours 
of (an episode of) chest pain, or subsequent creatine kinase-ME above the upper 
lilnit ofnorn1a1. Patients 'were randOlllly assigned to receive a bolus and infusion 
of either eptifibatide (180 ~lg/kg bolus, 2,0 ~lg/kg/min infusion) 01' matching 
placebo in addition to standard therapy for up to 72 hOlus or 96 hours if coronary 
intervention was perfortlled. 
All patients selected for enrollment in PURSUIT were eligible for participation 
in the ECG-ischeillia monitoring substudy, except those 'with ECG abnormalities 
interfering 'with ST-segl11ent interpretation such as left bundle branch block, 
third-degree AV-block, persistent arrhytlnnias, or pacemakers. All patients gave 
informed consent before enrolln1ent. 
Continuous ST-Segment Monitoring 
Continuous ECG nlOnitoring ,vas preferably started at the beginning of study 
drug infusion and continued for 24 hours. Patients were Inonitored with the ELI-
STIOO (Mortam Instruments, Milwaukee, WI) continuously updated standard 12-
lead ECG recording systell1. This SysteIll autOlnatically calculates nledian ECG 
cOlllplexes of the 12 ECG leads every 20 seconds. The patient's own baseline ECG 
was used as a template for cOlnparisol1 of subsequent ST-segtl1ent levels. The systClll 
was programmed to store ll1edian ECG cOlnplexes every 20 seconds if 100pV or 
greater ST-segment shift was present in 1 lead relative to the baseline ECG of that 
patient, or if 50 l1V or greater ST-shift was present in any 2 leads of the 12-lead 
ECG. A baseline median ECG 'Nas stored evel"}T 20 minutes ifST change 'vas belmv 
these levels or absent altogether, 
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Data Management 
All recordings 'were stored on a hard disk. Once lllOnitoring was c0111pleted l the 
data were downloaded to a floppy disk and sent either to the Cardia lysis core 
laboratory in Rotterdam, The Netherlands (European centers) or to the Duke core 
laboratory in Durham, NC. (U.S. sites). The final analysis of the recordings was 
performed at the Cardialysis core laboratory. The timing of the start of study drug 
illfbsion and the 1110111cnt of angiography, as well as the presence of episodes of chest 
pain during ST monitoring) ,vere obtained from the case report forms. All personnel 
involved in the ST-segment analysis remained blinded to treatment assignment. 
Editing and Analysis of Recorded Data 
The procedures of editing of the continuous ECG monitoring data and the 
analysis with an automated cOlnputer-driven ischenlic ST episode detection 
program, as developed and applied by the Cardialysis core laboratory, have been 
described in detail.A.5 
In the present study, patients ·were excluded from the analysis if the recording 
started Inure than 12 hours after the start of study drug infusion or contained no 
analyzable ST monitoring data during the first 12 hours. Recordings with less than 
50% analyzable ST 111Onitoring data or ·with a duration ofless than 12 hours were 
also excluded. The period of study drug infusion was analyzed only) ·whereas ST 
episodes occllrring during coronary procedures were exc1uded. 
The onset of an ST episode ,vas defined as a change of ST anlplitude in 1 or 
more leads of at least 100 IlV from the baseline ST level, developing within a 20-
111inutc period and persisting for at least 1 Ininute. The end of an episode was 
defined as a return of the ST level within 100 ~lV of the baseline ST level) again 
lasting for at least 1 Ininute. If 100 ~lV ST change or greater was present in 
multiple leads simultaneously, the onset ofthe ST episode was defined by the lead 
exhibiting the first significant ST change. Shnilarly) the end of an episode "was 
defined by the lead exhibiting the latest 1110111ent of return to baseline ST level. 
Episodes had to be separated fr0111 each other by at least 1 ll1inute. 
Ischemic burden was calculated in different ways) such as the total duration of 
all ST episodes pel' patient, the sum of the area under the curve of a1112 ECG leads 
during ST episodes per patient) and the area under the curve of the de11ved ST vector 
magnitucle CST-I'M) of all episodes per patient, calculated from the 8 independent 
leads using the inversed Dower transformation formula. 19 The area under the curve 
,vas measured from the baseline ST level directly preceding the episode. 
Study Endpoints 
The endpoints in this substudy were the nlu11ber of patients 1Nith recurrent 
ischemia) the time fr0111 start of study drug to start of the first ischell1ic episode) 
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and the time until a second ischenlic episode after a first one, as ,veil as the 1111111ber 
ofischelllic episodes and the ischenlic burden in patients "with recurrent ischenlia. 
Furthennorc, recurrent ischemia was investigated in relation to the occurrence 
of the composite endpoint of death or myocardial (re)infarction as defined in the 
PURSUIT trial at 7, 30, and 180 days after randomization. All suspected myocardial 
infarctions 1Nithin 30 days 1Ncre adjudicated by a Clinical Events COlllmittee 
blinded to treatnlcnt assignnlcnt.9.18 
Statistical Analysis 
The vVilcoxon Rank SU111 test estimated that at least 200 patients were required 
per treatlncnt group to provide 80% pmvcr to detect a relative reduction of 66% 
in ischenlic burden in the total group of patients and a relative reduction of 5096 
in the subgroup of patients 'With ischemia.s Continuous variablcs are sUl111narized 
using the median and interquartile range (25th and 75th percentiles) and were 
c01npared using the Mann-vVhitney test. Discrete variablcs are described as 
pcrcentages and "n-'cre cOlnpared using Fisher's Exact Thst. The Kaplan-Meier 
l1lcthod 1Nas used for the evaluation of the titne to the OCCUITence of the first and 
second ST episode, "with censoring of data. Statistical differences 'vere tested 
with the log rank test. A 2-sided P-value of less than .05 was required for 
significance. The re1ationship between recurrent ischmnia parameters and adverse 
outcOllle ,vas evaluated univariab1y, as well as after adjustment for baseline 
variables found to be the strongest independent predictors of the 3D-day composite 
endpoint in the overall PURSUIT population"', including age, geographic region, 
enro1hllent diagnosis (non-ST-segnwllt elevation l1lyocardial infarction versus 
unstab1e angina), sex, and worst Canadian Heart Class of angina pectoris in the 
6 weeks before enrolhllent. Variables arc presented as odds ratios with 95% 
confidence intervals. 
Results 
The PURSUIT trial enrolled 9,461 patients.' A subset of 258 patients (2.7%) 
were included in the ECG-Ischel1lia Monitoring Substudy. TWD hundred and 
sixteen patients (84%) had continuous ECG recordings suitable for ST analysis. 
A total of 42 patients (16 %) were excluded frOlll analysis because the recording 
began l110re than 12 hours after the start of study drug infusion or contained less 
than 12 hours ofanalyzable ECG data (n ~ 19), because of technical failures owing 
to incorrect user operation of the l11onitoring syste111 (n = 20), whereas 3 patients 
had a left bundle branch block that prevented reliable interpretation of the ST-
segnlCnt. 
Of the 216 patients, 105 received eptifibatide and III received placebo. The 
2 treahnent groups w"ere well balanced with regard to baseline characteristics that 
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were representative of the baseline data of the PURSUIT patients enrolled in 
Western Europe and North America CIable 1). Thtal recording time suitable for 
analysis ,vas silnilar in patients receiving eptifibatide and those \\Tho received 
placebo (median 24 [25th and 75th percentiles 22,33] hours vs 24 [22,30] hours). 
Baseline characteristics did not differ significantly between patients ,vith and 
-without ST episodes during ECG 111onitoring except for age; patients with ST 
episodes 'were older than those without recnrrent ischelnia (n1cdiall 67 [61,77] years 
versus 61 [54,68] years, P < .001). 
Incidence and Severity of Ischemia by Treatment Allocation 
Ischemic episodes were detected in 35 (33%) of the 105 eptifibatide patients 
and in 32 (29%) of the 111 placebo patients (not significant). The Kaplan-Meier 
estimates offreedom f1'0111 recurrent ischclllia did not shuw- significant differences 
between both treatment groups, though a trend favoring eptifibatide was apparent 
'IItble 1. Baseline C/l£lmcteristics by '1l'catlllellt Allocation 
Eptifibatide Placebo 
(n ~ 105) (n ~ lll) 
Age (y) 62 (56, (9) 64 (55, 71) 
Women (%) 24 27 
Systolic blood pressure 
(I11mHg) 130 (115, 140) 130 (120, 140) 
Diastolic blood pressure 
(mmHg) 75 (65, 3D) 75 (65, 80) 
Weight (kg) 81 (74, 87) 32 (73, 91 
Body ll1ass index 
(kg/m2) 27 (25, 29) 27 (25, 30) 
Prior MI (%) 31 27 
Prior CABG (%) 14 12 
Hypertension (%) 45 49 
Diabetes (%) 13 21 
Hypercholestcroien1ia (%) 41 39 
Current sl1lOker (%) 31 29 
Family history of CAD (%) 41 44 
Congestive heart failure (%) 5 5 
Angina before qualifying 
episode (%) 87 35 
For continuous variables l the Inedian values are providedl 1Nith the 25th and 
75th percentiles given in parentheses, MIl myocardial infarction; CABGI 
coronary artery bypass grafting; CADI coronary artery disease. 
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Kaplan-Meier estimates of the probability to remain free from an Ischemic episode during the 
course of the monitoring period: (A) The probability to remain free from Q recurrent ST episode 
from the start of study drug, (8) The probability to remain free from a second ST episode after 
the ending of a prevIous first one. For both comparisons, no statistically significant differences 
were apparent between the eptifibatide and placebo treatment groups. 
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Un/variable and mult/variable-adjusted odds ratios for the composite of death or 
myocardia! infarction at 7, 3D, and 180 days. Odds rot/os are presented for the various 
parameters of recurrent /schemla detected during ECG monitoring. The horizontal/ines 
indlcote 95% confidence InteNols. 
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'Rihle 2. EGG-Ischemia Monitoring Results by 'JJ-eatment Allocation 
Eptifibatide Placebo 
n % n % P Value 
Patients 105 III 
~ 1 ST episode(s) 35 33 32 29 NS 
~ 2 ST episodes 17 16 18 16 NS 
~ 1 Episode(s) of chest pain 19 18 18 16 NS 
~ 2 Episodes of chest pain 5 5 1 1 NS 
Patients with ~ 1 ST episode(s) 
~ 1 Episode(s) of chest pain 11 31 8 25 NS 
~ 2 Episodes of chest pain 3 9 0 0 NS 
Ischemic burden' 
Total duration / patient (min) 10 23 NS 
ST-VM (~V:min) 455 369 NS 
12-lead ST-area (~V:min) 7815 9439 NS 
, For ischemic burden variables, the median values are provided only for 
patients with recurrent ischemia (ie, ~ 1 ST episode). NS, not significant; ST-VM, area under the curve of the 
ST-vector-magnimde during ST episodes per patient; 12-lead ST-area, sum of the area under the curve of all 12 EeG leads 
during ST episodes per patient. 
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Table 3. Relation Between Recurrent Ischemia During ST Monitoring and Clinical Endpoints 
7 Days DeathIMJ 30 Days DeathlMI 180 Days DeathIM} 
n n % P n % P n % P 
Patients 216 
No ST episode 149 14 9 
.81 20 13 .31 22 15 .12 ~ 1 S T episode 67 7 10 13 19 16 24 
< 2 ST episodes 181 15 8 
.12 23 13 .04 26 14 .008 ~ 2 ST episodes 35 6 17 10 29 12 34 
Pain absent 179 15 8 
.22 25 14 .31 29 16 .24 Pain present 37 6 16 8 22 9 24 
Patients ~ 1 ST episode 67 
Pain absent 48 2 4 
.02 6 12 .04 8 17 .05 Pain present 19 5 26 7 37 8 42 
P values provided for Fisher's Exact Test. MI, myocardial infarction. 
(y, 
(y, 
Table 4. Relation Between Ischemic Burden and Clinical Endpoints 
7 Days 30 Days 180 Days 
No DeathIMI Yes Death./MI P No Death/M] Yes DeathfMI P No DeathlM1 Yes DeathIMI P 
(n~60) (n~7) (n~54) (n~13) (n~51) (n~16) 
Ischemic burden 
Duration I patient (min) 10 46 .06 9 35 .04 7 30 .03 
ST-VM (flY.min) 288 2716 .02 267 2.098 .007 232 1.290 .003 
12-1ead ST-area (flY.min) 5.943 43.514 .02 4.762 22.078 .02 3.923 17.571 .02 
For ischemic burden variables. the median values are provided only for the 67 patients with recurrent ischemia (ie. ~ 1 ST episode). 
ML myocardial infarction~ ST-VM. area under the curve of the ST-vector-magnitude during ST episodes per patient~ 12-lead ST-area, sum of the area under the 
curve of all 12 ECG leads during ST episodes per patient. P values provided for Mann-Whitney Test. 
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in the tin1e until a second ischemic episode after a first epi1wde (Figure 1). No 
significant differences '\\'cre apparent between patients treated with eptifibatide 
and those assigned placebo for a series of indicators of ischemia (Table 2). 
Relationship Between Recurrent Ischemia and Outcome 
TIventy-one patients enrolled in this sl1bstl1dy (9.7%) developed a myocardial 
infarction (n ~ 17) or clied (n ~4) within 7 days of follow-up. At 30 days, 33 (15.3%) 
of the 216 patients had died (n~8) or developed a myocardial (re)infarction 
(11= 27), and at six months, death or Inyocardial infarction had occurred in 38 
patients (17.6%). The endpoint rates of the 2Hi patients participating in this 
substudy "were similar to those oEthe overall PURSUIT population.9, and did not 
differ between the eptifibatide and placebo treatment groups. 
In both univariable and ll1ultivariable analysis, there "'INas a remarkable 
consistency ·w-Hh respect to the directionality of the relationship between recurrent 
ischenlic episodes and adverse DUtC0111C (Figure 2). For all 3 follow-up periods! 
patients 1Nho exhibited frequent recurrent ischemia! as represented by 2 or n10re 
ST episodes during ECG n1Onitoring! n10re often died or suffered a myocardial 
infarction (,Illble 3). Significance was greatest after 6 months oflollow-up (P ~ .008, 
TItble 3). Furthermore/ in the subgroup of patients \vith ST episodes! the presence 
of at least 1 episode of chest pain during the monitoTing period in addition to 1 
Of more ST episodes appeared an independent predictor of subsequent advcrse 
outcome (Figure 2). Paticnts "with recurrent ischel11ia with a greater ischc111ic 
burden more often died or developed a myocardial infarction compared with those 
with a lower ischCl11ic burden. This association reached statistical significance in 
all but 1 comparison (Thble 4). At 6 months, death or myocardial infarction most 
frequently OCCUlTed in patients with a total duration of ischemia of 10 l11inutes or 
1110re (incidence of the composite endpoint 40% vs 13% in patients \\'ith ischemia 
duration less than 10 minutes, P ~ .0(03); an ST vector magnitude 450 f.lVmin or 
gTeatcT (43% vs 13%/ P = .0001); or a 12-lead ST area 820 ~lV.l11in or greater (41 % 
vs 13%/ P = .0001). 
Discussion 
In the PURSUIT trial, treatment with eptifibatide in addition to aspirin and 
heparin resulted in a statistically significant/ but modest/ 1.5% absolute reduction 
in the 3D-day composite endpoint of death or nonfatal myocardial (re)infarction 
in patients with acute coronary syndrol11es without persistent ST-segment 
elevation.' Yet, the present substudy failed to show a beneficial eflect of eptifibatide 
on reducing the incidence of reCUlTcnt ischemia or the an10unt of ischen1ic 
burden during the first 24 hours of study drug infusion. These data contrast with 
the results of a pilot study of eptifibatide in patients with unstable angina that did 
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show a reduction in the frequency and duration of Holter-detected ischcll1ia 
associated 'with eptifibatide treatnlCnt. 21 
Several possible explanations for the observed results deserve consideration. 
First, this substudy ,,"ras powered to detect the predefined (lnajaI') reductions in 
recurrent ischcl11ia and ischenlic burden if ST 111Onitoring data of 200 patients per 
trcahnent group 1\'ere suitable for final statistical analysis. I3ecause only 258 
patients 'were enrolled \v"ith 216 ECG recordings suitable for analysis, statistical 
pO'weT to detect a difference behvecn hoth treatl11cnt groups was significantly 
decreased. Using the clirrent salnple size, only a relative reduction in ischemic 
burden of at least 70% 'lVould have been identified as statistically significant. 
Fluthennore, patients 'were lllOnitored only during the first 24 hours of the 72-hour 
study drug infusion period. At 24 hours, the treatment benefit of eptifibatide was 
a 0.85% absolute reduction in the composite of death or myocardial infarction 
ccnsored for percutaneous coronary intervention.22 This represented a 26% 
relative reduction. The clinical benefit of eptifibatide in PURSUIT was seen 
pTinlarily 'within 24 to 72 hours after enrollmellt.9; the duration ofECG monitoring 
Inight have been too short and the relative difference between the eptiftbatide and 
placebo treatment groups at 24 hours in the main PURSUIT trial may have been 
insufficicnt to shm\T a rcduction in recurrent ischemia during continuous ST-
segll1Cllt 111011itoring in thc s111a11 series of patients studied. For conlparison, in the 
CAPTURE ECG-ischclnia nlOnitoring substudy, frequent recurrent ischetnia and 
total ischclnic burden 1Nerc significantly reduced by abcLxilllab in 332 patients ,;vith 
refractory unstablc angina.5 This 1Nas associated with a 54 % relative lmver rate of 
death or Inyocardial infarction censored for coronary intervention at 24 houIs in 
that trial.22"rt should be noticed, however; that CAPTURE had very different design 
features than PURSUIT.'9." CAPTURE included patients with unstable angina 
refractory to standard medical therapy 1N110 undel'Ncnt pcrcutaneous coronary 
intervention within 24 hours after study enrolhncnt. 
Megatrials are conducted to assess reliably the impact of different therapeutic 
regilnens on hard clinical endpoints, such as death, Inyocardial infhrction, or stroke. 
Substudies in the context of such megatrials may help to verify and understand 
the pathophysiological Inechanisms involved. 24 For exalnple, the angiographic 
substudy in GUSTO-I helped to link differences in early coronary patency between 
4 reperfusion strategies to differenceR in survivaL25.26 These differences in early 
coronary patency appeared related to differences in infarct size and residual left 
ventricular function. 2627 The ECG-ischemia monitoring substudy in PURSUIT was 
designed v·,lith a shnilar purpose, to analyze the effect of eptifibatide on recurrent 
ischetnia as a pORsihle explanation for the expected and observed reduction in the 
prhnary endpoint of death or myocardial infarction. Regrettably, the start of the 
ischetnia monitoring substlldy was de1ayed considerably until the larger trial 
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'was "'iNcH unden\Tay. An immediate start resulting in an adequately powered 
substudy 1\Tould have been the preferred arrangement. 
The present study did confirm that patients 'w-Hh frequent recurrent ischeIllic 
episodes and a greater ischemic burden in the first 24 hours after adillission are 
at increased risk to die or develop a l11yocardial infarction during follmv-up, 
1vhen compared with those \\Tithout recurrent ischcll1ia. In particulal~ the presence 
of 2 or l110re ST episodes or the recurrence of chest pain as reported by the 
investigator in addition to at least 1 ST episode had a profound impact on outcOInc. 
Although the association bet-w-cen recurrent ischclllic episodes and adverse 
outcOInc did not reach statistical significance in all cOluparisons, there 'was a 
remarkable consistency 'with respect to the directionality of the relationship, 
both in univariable and nlultivariable analysis. This huplies that the presence of 
ischemic episodes during luultilead ECG monitoring has predictive value additive 
to that afforded by baseline characteristics. 
It might be suggested that the relation between recurrent ischeluic episodes 
and outcome has been biased by cardiac events occurring during percutaneous 
coronary intervention pcrfonued because of findings during ST monitoring. This 
is unlike1YI howevCl~ because nlonitoring was pcrfonned as a b1ack box with the 
results analyzed aftep;vards at the core laboratories. 
Several other studies have shown that recurrent ischemia, either silent or 
symptOl11atic, during the first days after ad111ission for unstable angina portends 
an unfavorable outcOllle. ti.1G-17. 28 This has been sho'wn for ischemia detected during 
2- or 3-lead Holter nlOnitoring, as 'well as for ischeluia during cOlllputer-assisted 
vectorcardiographic 1110nitoring.o,1G-17 Hm\reVel~ the present study is the first to 
ShO'IN the direct relationship between recun .. ent ischemia and adverse outcome for 
ischenric episodes detected by C0111puter-assisted continuous standard 12-lead ECG-
ische1uia lllOnitoring. 
In contrast to Holter monitoring \"-]lich al1mvs for retrospective analysis 
only, C0111puter-assisted continuous 12-lead and vectorcardiographic ECG-ische111ia 
nlonitoring offer an accurate continuous real-tit11e nleaSUren1ent of the QRS-
cOl11plex and ST-segment, and can, therefore, be used for on-line risk prediction 
of imminent cardiac events. Thus, the present study el11phasizes the usefulness 
of these techniques as a noninvasive tool for fbrther risk assessnlent and selection 
of the optimal treatl11ent strategy in patients treated for unstable coronary 
syndromes.29 
Patients presenting with unstable angina without elevated troponin T or 
troponin I levels who stabilize onluedical treailnent after admission and do not 
exhibit recurrent ischetnia duTing continuous ECG 111Onitoring have a low Tisk of 
death or myocardial infarction) especially 'when treai1nent includes a glycoprotein 
lIb/IlIa receptor inhibitOl:5,17.30-37 In these patients, noninvasive InanagenlCnt 1uay 
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be 1110St beneficial aUG'wing further plaque stabilization.38 In contrast, patients who 
present 'with elevated troponin T or I levels on adlnissi01\ as \vell as those who 
subsequently develop recurrent ischenlic episodes during continuous ECG 
monitoring, aTe at high risk of adverse cardiac events.S,17,30-35Such patients lllaY 
particularly benefit fronl a more aggressive therapeutic approach including 
administration of a glycoprotein lIb/IlIa receptor inhibitor like eptifibatidc and 
an early percutaneous coronary intervclltion,22.23.3S.39.40 
Alllong patients treated for acute coronary syndromes, the profound itnpact 
of recurrent ischetnia on survival and the incidence of 111yocardial infarction 
enlphasizes the need for continuous ECG-ischemia nlonitoring, Therefore l 
integration of continuous multilead ECG-ischemia monitoring systeuls in coronary 
care units j mnergency wards/ and mnbulance services 111ay identifY patients at 
increased risk of an unfavorable outcOlne/ and ann\\' for better prognostic triage 
and lnore appropriate se1ection of therapeutic strategies. 
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Appendix 
Investigators and Clinics Participating in the PURSUIT 12-Lead ECG-Ischemla 
Monitoring Substudy: 
The Netherlands 
Thoraxccntel~ University Hospital Rotterdanl~D~jkzigt: C. van def ZW(lCHl, 
i',1.L. SimooHs; Ziekenhuis St. Jansdal, I-Iarderwijk: R. Dijkgnwf; Mariaziekenhuis, 
Tilbllrg: ILF Baars; Ziekenhuis De Tjongcrschans, Hcerenveen: G.lvl. JocJw11lsen; 
11edisch Centrlllll Alkmaat~ AIkmaar: v: Ul1ums; Maasziekenhuis, Boxll1ccr: vI?: 
Smits; Medisch Centnt111 LeeUWaTdcll, Leeu1\"rarden: R. W: Breedveld; 
Spaarneziekcllhuis, Hecmstede: E.J. M.iWer; Ziekenhuis HilverSU111, HilverSll1n: P 
de A1illimw; Mcdisch Spectnl1ll 'I\\Tcntc, Ellschede: f. c. Poorterma11S. 
United States 
Baptist Hospital Montclah~ Birminghanl, AL: R. Reeves; Huntsville Hospital, 
Huntsville, AL: D. Drenning; University of Arkansas for Medical Science and 
John L. McClellan VAMC, Little Rock, AR: D. Tl!lIey; St. Elizabeth's Medical Cente!; 
Boston, MA: D, Losordo; Northern Michigan Hospital, Petosky, Ml: H~ lVleengs; 
Michigan Heart and Vascular Institute, Ypsilanti, MI: J. Bengtson; Oak"'wood 
Hospital and Medica1 Centcl; Dearborn, Ml: A, Riha; University Hospita1 and Clinics, 
ColU111bia, MO: R. 11fehe7; Duke Medical Centm~ Durham, NC: R,lL Harn'l1gton; 
MenlOrial Hospital-UNC, Chapel Hill, NC: B. Crells1ww; Moses Cone MenlOrial 
Hospital, Greensboro, NC: E Nislul1l; Alamance Regiona1 Medical Centel~ Burlington, 
NC: 11. PamscJws; Margaret Pardee Memorial Hospital, Hendersonville, NC; E 
Goodfield; Durhatn VluVlC, Durhmn, NC: .M, W: Knlcoff; Lancaster Heart Foundation, 
Lancastel; PA: R. Small; Cleveland Clinic Foundation, Cleveland, OH: A.M. Lincoff 
Coordinating Centers and ECG Core Laboratories 
Cm"dialysis B'~ Clinical Research Managenlent and Core Laboratories, 
Rotterdam, The Netherlands: A.PJ. Klootwijk, KM. Akkerlmis, S. Meij, A Spielings, 
E, UWl de Leur; 
Duke Clinical Research Institute, Durham, NC: M. W Kl'Ucojf, C. Gmen, A. c.p 
Mews, S. Sowc1wk. 
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Abstract 
Background 
Appropriate treatment policies should include an accurate estimate of a 
patient's baseline risk. Risk lllOdcling to date has been underutilized in patients 
with acute coronary syndr01ncs \\Tithout persistent STsegment clevation. 
Methods and Results 
VVe analyzed the relation bet";\TCCll baseline characteristics and the 3D-day 
incidence of death and the composite of death or 111yocardial (re)infarction in 9461 
patients v·lith acute coronary syndr0111CS "without persistent ST-segt11cnt elevation 
enrolled in the PURSUIT trial [Platelet glycoprotein lIb/IlIa in Unstable angina: 
Receptor Suppression Using Integrilin (eptifibatide) Therapy]. Variables examined 
included demographics, history, henlOdynamic condition, and sylnptOlll duration. 
Risk models ,;vere created with l11ultivariable logistic regression and validated hy 
bootstrapping techniques. There 'was a 3.6% mortality rate and 11.4% infarction 
rate by :10 days. More than 20 significant predictors for mortality and for the 
composite end point 1\"-ere identified. The most i1nportant baseline determinants 
of death were age (adjusted X'~95), heart rate eX2~32), systolic blood pressure 
eX' ~ 20), ST-segment depression eX' ~ 20), signs of heart failure eX' ~ 18), and cardiac 
enzymes (X2 = 15). Determinants ofnlOrtality were generally also predictive of death 
or nlj,rocardial (re)infarction. Differences were observed, hO'wevel~ in the relative 
prognostic inlportance of predictive variables for 1110rtality alone or the composite 
end point; for example, sex was a more important deternlinant of the c01nposite 
end point (X' ~ 21) than of death alone eX'~ 10). The accuracy of the prediction of 
the COlllposite end point was less than of l110rtality (C-index 0.67 versus 0.81). 
Conclusion 
The occurrence of adverse events after presentation with acute coronary 
syndronles is affected by n1l1ltiple factors. These factors should he considered in 
the clinical decision-nlaking process. 
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Patients '\vith acute coronary syndr0111cs have a range of therapeutic 
alternatives. The decision of,vhich therapy to use for individual patients dependf\ 
on the clinical presentation and the estilllated treatlnent benefits. Such benefits 
usually are proportional to the risk of adverse outcome in the absence of a 
specific therapy.1,2 An appropriate treat111cllt policy should include an estimate of 
this baseline risk) "which can be achieved by appHcation of a risk nIodeI that 
integrates itnportant prognostic features. A number of such 1110dels have been 
developed for acute Inyocardial infarction (MI) 'with ST-segl11cnt elevatio11) 2-5 but 
fe,v slich tools exist for patients 'with unstable angina pectoris (OAP) or suspected 
MI 'Nithout persistent ST~seg11le11t elevation.6.7 
The Platelet glycoprotein lIb/lIla in Unstable angina: Receptor Suppression 
Using Integrilin (cptifibatide) Therapy (PURSUIT) trial studied the effects of 
eptifibatide versus placebo in 9461 patients "with acute coro11aTY syndrOllleS 
'without persistent ST-seg11lent elevation.8 This popUlation coveTS a variety of 
patients l hospital settings l and treatlllent policies and therefore is suitable for 
development of a clinical risk 1110del. \Ye assessed the relation beh\7ee11 the 
baseline characteristics and the OCCUlTence of death and of death or nonfatal (re )MI 
at 30 clays. 
Methods 
Patient Population 
The design and methods ofthe PURSUIT trial have been described in detail.' 
In sU111111aTYI patients "were eligible if they presented 'within 24 hours of an 
episode ofischC111ic chest pain (> 10 111inutes) and had either transient ST-segment 
elevation (> 0.5111111)1 transient or persistent ST·seglllent depression (> 0.5 111m)1 
T-"wave inversion (> 1 ,0 mm)1 or elevation of the creatine kinase-MB fraction 
(CK-MIl) above the upper limit of normal (ULN). Patients with persistent (> :10 
minutes) ST-segtl1ent elevation were excluded. There "were no Testrictions regarding 
age. Eligible patients 'were Tandomiy assigned to treatll1cnt "with eptifibatide aT 
placebo. PURSUIT enrolled 94(i! patients in 726 hospitals in 28 countries in 
,,,Testern and Eastern Europe and North and South Aillerica, There ,vere 4308 
patients (45.5%) with elevated CK-MB at adl11ission; these were classified as 
having MI. The other 5129 patients (54.2%) were classified as having UAP. In 24 
cases (0.3%)1 the qualifYing ischenlic episode was undefined, 
Definition of MI 
The primmy efficacy encl point of PURSUIT was a composite of death or 
nonfatal (re)MI at 30 days. Within 1H hours of enrollment, MI was diagnosed on 
the basis of ischelnic chest pain and new ST-segnlCnt elevation. After 18 hours l 
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MI ,vas diagnosed on the basis of ne1,"' Q waves or l1e"'1 or repeated CK-MB 
elevations above the ULN. For patients undergoing percutaneous intenrcntion or 
coronary bypass surgery, CK-MB elevation above 3 or 5 times the ULN ,vas 
required. End points "were adjudicated by a central Clinical Events Committee 
(CEC). A computerized algorithm was used to review the raw data. If a possible 
event was identified, additional dOGUlllCntation was collected and the case 
revie"wed in detail. Local investigators also reported whether the patient had had 
an acute MI. Discrepancies that appeared between the CEC opinion and that of 
the investigator have been investigated and discussed in detail. 9 This analysis 
presents data based on the CECjudgment. Differences with analyses based on the 
investigators I opinions arc discussed, but data i\ril1 not be 8hO\\'l1. 
Statistical Analysis 
Univariable and ll1ultivariable logistic regression analyses lNcre applied to 
evaluate the relations bet~\7cen baseline characteristics and the 3D-day occurrence 
of death alone and the composite of death or nonfatal (re)MI. All variables 
entered the 111ultivariablc stage, irrespective of the results ofunivariable analyses. 
The final multivariable model was constructed by backward deletion ofthe least 
significant characteristics) "while the Akaikc information cdtcrion ·was applied (that 
is, the applied threshold of significance depended on the degrees of freedom [df) 
associated with the variable at hand; if df~ 1, then p z O.157).'o 
The shape of the relation between continuolls variables and outcome ,vas 
examined by a 111odcl-fitting technique involving cubic spline functions,l1 A 
disadvantage of this approach is the complexity of the resulting regression 
function. Therefore, 'when the relation appeaTcd to be nonlinear, the cubic 
POlYllOl11ial was approximated by a linlited nU111bcr of high-order terms. 
Flnthennore, 'Ne evaluated "whether the prognostic relation of any predictive 
characteristic differed for patients enrolling with UAP or MI: we tested for 
interactions bet\\reen prognostic factors and the enrollment diagnosis. Th prevent 
false-positive findings I we did not test for other interactions alnong prognostic 
vmiables. An unexpected finding in PURSUIT "was the interaction between sex and 
study llledication ·with respect to the C0111posite end point.8 vVe evaluated the extent 
to lNhich the lHodel perfonnance ·would have changed had this interaction been 
incorporated. 
Clinical variables were lnissing for 8% of the patients. This subset had a higher 
3D-day mortality rate than patients with complete data (4.7% versus 3.5%; P~ 0.08). 
The exclusion of patients "with mi::lsing datal therefore, could lead to biased risk 
estilnates. 12 Th partly conect for this , all l11ultivariable analyses ·were perfornled 
on a data set that included imputed predictive variables. The applied iterative 
i1nputation technique estitnated the missing value of a given predictor on the basis 
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ofnlultivmiable regression on all other predictors. 12.13 End point data were not used 
in this process. Computations '>vere perfoflned with S-PLUS statistical soft\\"rare 
(version 3.3).14 
The predictive accuracy of 11111ltivariable models ",\\7as evaluated by the C-
index. 15 The 1110dels developed in the full study population ·were further evaluated 
by bootsh'apping techniques: 100 bootsh'ap samples i\"'ere drawn, with replaceJncnt, 
to estitnate the extent to 1vhich the predictive accuracy of the models based on 
the entire population ·was Dveroptinlistic. 16 
Results 
Baseline characteristics of the population are described in Thble 1. Data for 
the 30-day occurrence of death or nonfatal (re)MI were complete. A total of 342 
patients (3.6%) died, anel another 1075 (11.4%) had a nonfatal (re)M!. 
Univariable Analyses 
Thble 2 presents the univariable relations bctween dichotOllloUS baseline 
characteristics and 30-day OUtC0111C. The relations between continuous variables 
and outcome are described in Figures 1 and 2. Age "lNaS sh'ongly related with death) 
as were l11easures of left ventricular function (mles and history of heart failure)) 
ST-seglnent depression on the presenting ECG) and adlnission heart rate. Other 
inlpOliant risk fhctors "'Nere diabetes luellitus) prior rvII) previous anginal SYll1ptoms) 
and CK-MB level at emollment (enrollment MI versus UAP). The region of 
enrolhuent appeared to be prognostic! with higher 1110liality rates in Latin Alnerica 
and EasteTn Europe relative to Western EllTOpe and North Alnerica. Systolic and 
diastolic blood pressures "lNere only 'Neale predictors. There 'vas a significant 
nonlinear relation between v·,reight and Inortality. Patients taking cardiac 
luedications had a worse prognosis than patients not taking such medication 
before enrolhllent. 
Clinical characteristics that predicted 30-day mortality generally also predicted 
the occurrence of eitber death or nonfatal (re)M!. The ranking meler according 
to prognostic ilnportance! howevC1~ was sOll1ewhat different! lNith enrolltuent 
diagnosis atuong the 1110st iluportant risk factors for the conlposite end point, 
whereas heart rate was of only 1110dest predictive value. Unlike death alone) the 
C0111posite event rate in Latin Alucrica was rather close to that ofV{cstern Europe 
and North America. 
'Vith respect to 30-day mortality, there 'were interactions betw-een enrollment 
diagnosis and the variables age, heart rate, mles, and PURSUIT study Inedication. 
As far as the C0111posite end point was concerned, interactions were observed 
between enrolhuent diagnosis and the variables diabetes, histor:.y of heart failure, 
rales, and T-v'lave inversion. 
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Thble 1.Baselinc C/zametcristies 
Demographics 
Age, Y 
Male sex! % 
\"'hite, % 
Weight, kg 
Height, en! 
64 (55,7l) 
65 
89 
78 (69,88) 
170 (163,176) 
Region of enrollnlent, % 
Latin Alncrica 4 
40 
16 
39 
North Alnerica 
Eastern Europe 
Western Europe 
HistOlY 
Hypertension) % 
Diabetes Incllitu8, % 
Snloking status, % 
Current 
Former 
Never 
Hypercholesterolclllia, % 
Fmnily history of CADI % 
55 
23 
28 
33 
39 
42 
36 
32 
\"'lorst CCS class past 6 lNceks, % 
No angina 19 
I 12 
II 26 
III 18 
IV 25 
CHFj % 11 
Stroke j % 4 
PVD, % S 
Bypass surgelY, % 12 
Angioplasty, % 13 
170 
Prior l11e(lication 
Aspirin, % 
p~Blockers, % 
Calciu111 antagonists, % 
Nitrates j % 
ACE inhibitors, % 
Presenting characteristics 
Enrolhnent diagnosis, % 
64 
43 
33 
69 
24 
MI 
UAP 
SBp, mmHg 
DBP, l1UllHg 
Heart rate) bpnl 
Rales, % 
46 
54 
130 (116,145) 
75 (67,83) 
72 (63,80) 
<1/3 
8/3 
ST depression, % 
ST elevation, % 
T-\vave inversion) % 
Titne course 
Synlpt0111 onset to 
8 
1 
50 
14 
51 
randomization, h 11.1 (5.7,18.8) 
PURSUIT study medication 
Eptitlbatidc, % 
Data presented are median (25th, 
75th percentiles) or percentages. 
CAD indicates coronary artery 
disease; CCS I Canadian 
Cardiovascular Society; CHFj 
congestive heart failure; PVD, 
peripheral vascular disease; SBPj 
systolic blood pressure; and DB~ 
diastolic blood pressure. 
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'Ihble 2. Ullivariable Relatioll Between Dichotomous Baseline Characteristics and 30-Day Outcome 
Deilth Death or Nonfatal (Ru)MT 
R1t~, % X' (tin OR (95% Cl)' Rate:, % t (dl) OR(HS% CW 
Demographics 
Se.'i: 
Female 3.8 < 1 (1) l.06 (0.85-1.33) 14.3 2 (I) 0.92 (0.m-L03) 
Male 3.5 15.4 
Racr: 
Nonwhite :l.B <1 (1) 1.0~) (O.7fl-1.."i2) 12.B .') (1)§ O,BZ (O.b7-O.U9) 
White 3,6 I 15,3 
Region of enrollment 
Latin Amctica 7.6 20 (3)\ 2.42 (1.60-3.67) 15.9 42 (3)+ 1.14 (O.nS-15l) 
NOith Anwrka .1.2 0,97 (0.75-1.26) 13.4 0.93 (D.m-I.Oll) 
Eastern Europe 4.5 1 .. 1~) (1.02-1.87) 20.4 1.54 (1.32-1.79) 
Western Europe 3.3 I 1·1.3 
History 
Hypertension 
Yps 43 Hi (1)+ J.S9 (}.20-1.99) 10.2 B(l)~ 1.24 (1.l(}-1.3U) 
No 2.il 13.5 
Diabetes mellitns 
Yes 5.6 30 (1)t: 1.92 (1.53-2.41) Hl.S 25(1)* UAP: 1.16 (O.9r)-I,42) 
i\1J : UiO (U5-1.!JO) 
No :Ul 14.0 I 
Smoking status 
CtlrTt::nt 2.2 23 (2):1= 0.55 (0.41-0.75) 12.3 25 (2):1= 0.77 (0.60-0.1'17) 
ForJlwr 4.4 1.10 (0.36-1.39) w.n 1.11 (O.H7-12!i) 
Never ".0 IS.4 I 
Hypercholesterolemia 
Yes 3.2 4 (I)§ 0.80 (0.64-1.00) 15.0 < 1 (1) 1.00 (0.fi9-1.12) 
No .1.9 IS.O 
Family history of CAD 
Yes 3.1 4 (l)§ 0.79 (0.63-1.00) 14.2 3 (11 0.90 (0.80-1.02) 
No 3.9 15.5 
'II 
Yes 5.1 28 (1)* 1.112 (1.4li-2.26) 17.8 27 (1)* 1.37 (1.22-1.54) 
No 2.9 1 13.6 
",Yomt CCS class past 6 wr:r:h 
Tn or IV ".B 27 (l)t 1.7fl (1."~-2.22) 17.9 "g (1)t I.S0 (1.33-1.08) 
Uther 2.7 12.7 
CHF 
Yes 9.0 73 (1):1= 3.25 (2.54-4.15) 21.6 37 (1):1= UAP: 1.22 (O.94-1.s1l) 
MT; 2.0" (1.66-2.52) 
No 2.U 14.1 
Stroke 
Yes 5.B 4 (I)§ 1.69 (1.06-2.69) 20.1 7 (1)# 1.45 (l.ll-U)[J) 
No 3.S 14.B 
l'VD 
Yes 6.1 13 (1)\ l.il6 (1.36-2.55) 21.7 23 (1):1= 1.66 (1.38-1.98) 
No 3.4 14.4 
Bypass surgr:J"y 
Yes 52 
" (I )11 1.511 (1.l7-2.{Hl) 15.9 <1 (1) LOB (0.91-1.28) 
No 3.4 I 14.9 
171 
Chapter 70 
'TIlblc 2. Cunt Ullj-Yariablc Relation Between DichotolllDUs Baseline Chamcteristics and 30.0ay Outcome 
Death Deilth Of Nonfatal (Re)~n 
R1t~, % X' (dll OR (!=J5% GI)' Ratr:, % X' (dt) OR (9.'1% el)' 
AIl),rioplasty 
Yes 2.0 12(1)\ 0.50 (0.33-0.77) 13..1 3 (1) 0.fi6 (0.72-1.03) 
No 3.9 15.2 
Prior medication 
Aspirin 
Yes 4,0 
" (1 )11 lA:~ (l.U-1.IIl) lfU 17 (l)t 1.2~J (1.14-1.45) 
No LUi 13.0 
J1-fI1ocker 
Yes 4.1 5 (I)§ 1.27 (1.02-1.58) 16.0 18 (l)t 1.28 (1.14-1.43) 
No .13 13.7 
Calcium antagonists 
Yes 5.1 26 (l)t 1. 70 (1..13-2.21) 17.U 21l {l)t 1.:.17 (1.22-1.54) 
No 2.9 13.6 
Nitrates 
Yes 4.2 2.'1 (I)t 1.92 (J.4G-2.SJ) 16.4 32 (1)+ 1.44 (1.27-Ui4) 
No 2.:~ 1 12.0 1 
ACE inhibitors 
Yes 4.6 o (1)11 1.42 (1.12-1.79) 17.0 9 (1)11 1.22 (1.013-1.39) 
No .1.3 14.3 
Presenting characteristics 
Enrollment diagnosis 
'!l 4.7 26 (l):t- 1.77 (1.42-2.21) HlA 73 (I)t- 1.64 (1.46·UI4) 
UAl' 2.7 12.1 
Rales 
;cl/3 10.5 lUll (2)f 5.U5 (3.32-1O.3) 23.2 63 (2)~ 2.77 (1.01-4.26) 
<1/:-1 15.1 UAP: 2.34 (1.40-3.69) 31.1 UAP: 1.21 (0.63-1.68) 
MT: 4.9:-1 (3.58-6.711) ~n: 2.19 (1.70-2.73) 
None 2.11 n~J 
ST depression 
Yf:S 5.1 65 (l)t 2.54 (2.00-3.21) 17.9 63(1)t 1.59 (1.42-1.78) 
No 2.1 12.1 
ST elevation 
Yes 2.U 2 (1) 0.7U (0.5S-1.011) 13.0 5 (I)§ 0.113 (0.70-0.99) 
No 3.7 15.3 
"Fwave inyersion 
Yes 2.U I(i (l)t n.bS (O.52-(UIOJ 14.1 5 (1)§ liAr: n.m (0.70-O.9U) 
MI: 1.07 (0.92-1.25) 
No 4.4 15.B 
PURSUIT study lllf:diration 
Eptifibatide :~.5 <1 (1) UAP: 1.25 (0.9-1.11) 14.Z 4 (l)§ o.m) (O.7l1-1.00) 
MI: 0.74 (OA-1.6) 
Placeho 3.7 15.7 
X" indicates -2 log likelihood of the univariahle model without interaction terms. 
'If a significant interaction was obseryed between the variable and enrollment diagnosis (Ml or UAI'), 2 sepa-
rate OR,> a\"(~ presented. 
tP<lJ.nOOlj §P<O.05; !1P<O.005; ~P<O.OOI; #P<O.Ol. 
Abbreviations as in Thhle 1. 
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Risk assessment 
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Univariobfe relations between continuous baseline characteristics and 30-daV mortality. If 2 
curves are presented, bold curve indicates MI pat/ents and light curve IndIcates UAP 
patients. X21ndicates -2'og-likelfhood of the un{voriabJe model without Interaction terms; 
OR, unadjusted odds ratio,' CI, confidence inteNal; bpm, beats per mInute. 
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Univariable relation between continuous baseline characteristics and 30-day rote of death 
or nonfatal Ml. Abbreviations os in Figure 1. 
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TABLE 3, Mu1tivuriahly Adjusted Effec.t'! of Baseline Chamcteristics 011 30.Day OutC::OllW 
Oemographirs 
Age, yt 
Se.'{ 
55 
64 
71 
Female 
Male 
Weight, kgt 
!iU 
7" 
8" 
Hdght, emt 
163 
170 
176 
Region of cl\I'ol1mcnt 
Latin Amerira 
North America 
Eastern Europe 
'Yestern Eutopr: 
History 
Hypertension 
Yes 
No 
Diabetes mellitus 
Yes 
Nu 
Smoking status 
Current 
Former 
Never 
Worst CCS class past (j weeks 
III or IV 
Other 
CHF 
Yes 
No 
1'\'lJ 
Yes 
No 
Bypass surgery 
Yes 
Nu 
All/:,.-ioplasty 
Yes 
No 
us (1)t 
9 (l)§ 
14 (2)11 
f) (1)~ 
2.1 (.1):1: 
3 (1) 
6 (1)\ 
3 (1) 
14(1)t 
5 (1)1 
5 (1)\ 
~J (1)§ 
Death 
OR (95% CI)* 
UAl': 0.63 (0.53-0.74) 
111: 0.47 (0.40·0.55) 
UAP; 1.44 (1.26·1.05) 
r-.1I: 1.BI (1 .. ')9.2.05) 
0.61 (0.44..{).B4) 
1.04 (0.95-1.15) 
1.05 (0.96-1.14) 
un (1.[J4-1.:r~) 
0.B7 (D.7fi-D.9?) 
3.04 (1.9.1·4.78) 
0.90 (O.6£l-1.21) 
1.03 (O.74~1.43) 
1.25 (0.97~1.62) 
1.J8 (1.07-1.76) 
1.2~J (O.91-un) 
1.27 (0.97-1.66) 
1.56 (1.23-UJ7) 
1 .7.1 (1 .. 11-2.2fl) 
1.44 (1.04-2.00) 
0.s1 (0.33-0.110) 
Death or Nonfata! (H.e}\l1 
75 (1)* 
21(1)* 
7 (2)1 
12 (l)1I 
22 (~)t 
6 (1)1 
3(1) 
20 (l)t 
7 (l)1t 
OR (95% CI)' 
0.77 (D.73-0.B2) 
1.23 (1.17-\.28) 
0.56 (O.4S-0.59) 
1.02 (O.H7·1.07) 
1 
1.01 (0.97·1.06) 
1.12 (1.0.'1-1.20) 
0.91 (0.1J6-0.96) 
1.31 (0.9[3-1.77) 
0.~5 (0.U2-UO) 
lAO (1.l9~1.65) 
1.18 (1.0J-1.36) 
1.09 (0.92-1.29) 
1.14 (0.99-1.32) 
1. Hj (1.2U-1.5J) 
1.29 (1.06~1.56) 
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'l~\'llLE 3. Cont i\lultiyariahly Adjusted Effects of Baseline Chamctcristks on :m·Day Outcome 
Death Death ur Nonf:1.tai (Rep.U 
X2 (df) OR (95% GI)' X, (dt) OR (95% GI)' 
Prior 11H~diratioll 
p.-lllockers 
Yes 6 (l)§ lAO (1.10-1.79) 1·1 (IP 1.26 (1.1I-1.4.1) 
No 1 
Calcium antagonists 
Yes 6 (1)\ L1S (1.01l-1.70) U (l)§ 1.20(1.06·],,16) 
Nu 1 1 
Nitrates 
Yes 3 (1) 1.34 (0,99·1.111) , (1)1 1.16 (1.0l-1.34) 
No 
Presenting chardctcristics 
Diagnosis 
~II 15 (1}1= 6ll {l)t-
OAP 
SlH~ mmHgt 
116 20 (I)t 1.21 (U2-1.:11) 7 (1)1t 1.08 (1.02.1.13) 
\.10 
145 0.82 (0.7.'1·0.89) 0.92 (0.87-0.97) 
DriP, mrnHgt 
67 , (l)1 0,95 (0.91-1.00) 
75 t 
83 LOS (1.00-1.10) 
Heart ralr:, hpmt 
62 32 (l)t UAP: 0.90 (o.no·l,Ol) 
:..11: 0.73 (O.67-0.ll0) 
n 
60 OAP: l,Og (O,9g.1.HJ) 
111: 1.28 (1.19-1.37) 
Rales 
;d/3 III (2)+ 1.B5 (1.36-2.51) 17 (2)+ 2.00 (1.27<U3) 
< 1/3 2.05 (1.0S-3.[l[l) UAI': 0.U6 (0.69-1.34) 
~n: 1.59 (J.2o-2.0l) 
None 
,sT depression 
Yes 20 (1)+ l.ao (1.40-1.JJ) 14 (1)+ 1.27 (1.l2-1.,j'l) 
No 
Time course 
Symptom onset to randomization, ht 
.'1.7 :l (1) 1.05 (0.99-1.12) 2 (I) 1.02 (0.99-1.06) 
11.2 
HUJ O.tlJ (0.115--1.02) 0,97 (O.H3-1.01) 
PURSUIT study medication 
Eptifibatide < 1 (l) UAP: 1.2fl (o.H1-1.H1) " (1) 0.90 (0.30-1.01) 
~II: 0.79 (0.53-1.07) 
Plar.eho 
Rcsults are based on the imputed data set (sec i\lethods). X2 indicates dilference between -2 log likf!!ihood of 
the fullmotlel and the modd with the variahle at hand renlm'ed, both without interaction terms. 
>If a significant interaction was seen hf:twf:f:n the variable and enrollment diilgllOSi.~ (i\I1 or UAI'), 2 separate 
ORs arf: prf:sf:nted. tfor continuous variables, OHs are pre:;ented for the tirst and third quartiles vs the nwdian. 
H'<O.OOO1; §P<n.o[)s; 111'<n.o01; ~l'<0.05; #P<O.Ol. "Tiw rontrihution of enrollment diagnosis should he 
interpreted in combination with all interaction terms. Theff'!fore, the OR for diagno:;is separatdy is not present-
ed. Abbreviations as in 'lable 1. 
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Mulfivariable Models 
1\1a11Y of the univariably significant 1110rtaHty predictors remained ilnportant 
in the muItivariable models (Thble 3; the mortality model is described in detail 
in the AppenrlLx). After correction for other detcnninants, age sho\ved the 
strongest relationship with 3D-day lllOrtality; baseline heart rate ·was the next-
strongest predict01: The interactions between enrollment diagnosis and both age 
and heart rate "were maintained. The ac,jnsted 3D-day mortality rate for Eastern 
Europe ·w-as shnilar to ,\Testcrn Europe and North America, but patients treated 
in Latin Anlcrica still had a higher risk of death. Other important Tisk factors ·were 
(lower) systolic blood pressure j ST-segnlcnt depression, and signs of heart failure 
(rales). Sex also appeared to be an important determinant of 3D-day mortality in 
the ll1ultivariate analysis: 'V01115n were at luw'cT 1'i8k than l1lCn. This observation 
,",vas not nlade in the univariable analysis: the crude 3D-day lllOrtality rates of ll1C11 
and \\'OI11e11 lNcre similar (TIlble 2). The prognostic importance of systolic blood 
pressure lATas 1110re pronounced in 111ultivariable than in univariahle analyses. 
In c0111bination 'with other hase1ine infon11atio11 1 age ,\vas again the strongest 
predictor of the composite of 30-day death or nonfatal (re)MI, but the relative 
contribution of age in the cOlllposite end point 1110del 'was 8111a11er than in the 
1110rtality 111Odel. In contrast, the relative contribution of enrolhllcnt diagnosis was 
greater in the c01nposite end point model. Again, there was a difference hetween 
ullivariable and 111ultivariable analyses "with respect to the sex~outconle relation: 
after correction for differences in baseline characteristics, wonlen appeared to be 
at Imver risk for the conlposite end point than l11en. 
Predictive Accuracy 
The C;-index for the mortality model was 0.814, reflecting good ability to 
discrinlinate betw"een patients "who did and did not have a fatal ontcOlne. The 
correction factor deteIlllined by bootstrapping "was 0.01 (reducing the C-index to 
0.804), hnplying that there was little overoptimism in the estimated predictive 
accuracy of the model. The composite end point model had a 'weaker discrinlinativc 
po"wel~ with a C>index of 0.669 (correction factor also 0.01). The perfonnance of 
the latter 1110del shm\7ed only minimal hllprovement after incorporation of the 
interaction between sex and eptifibatide (C-index 0.(70). If events "were ignored 
that occurred \vithin 43 hours of an invasive procedure, the C-indices of both the 
mortality and the composite end point model increased to D.H44 and 0.736, 
respectively. 
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Discussion 
The prognosis of patients with acute coronary syndTOlllcs generally depends 
on the occurrence and extent of myocardial damage. Patients presenting ,\"'ithout 
persistent ST-segnlcnt elevation or a typical cnzYlne rise have the lowest incidence 
of lllOrtality and 111orbidity.7 Intermediate C0111plication Tates are secn in those 
presenting without ST-scgnlcnt elevation but ';\Tith a rise in cardiac enzylnes j 7 
"'whereas prognosis is ,;vorst in patients with ST-segment elevation and substantial 
ll1yocardial damage.1.3 Apart from this silnplc classification! analyses of the 
GUSTO·l (Global Utilization of Streptokinase and Tissue plasminogen activator 
for Occluded coronary arteries) population have denlO11strated that age, heart rate l 
blood pressure, and signs of heart failure (Killip class) are the key factors in 
predicting outcome in patients "with ST-segnlCnt-elevation MI.3 The present 
analysis in non-ST-seglncnt-clevation acute coronary syndrOlnes sho\\rcd a 
rClllarkablc hOlllo1ogy with ST-segmcnt-elevation patients, as basically the SaIne 
prognostic factors ,vere detcnnined. 
Demographics 
Age "was the most i1nportant detenninant of outcome in this non-ST-segtnent-
elevation populationl as i\7"3S the case in a population with ST-segment elevation.3 
The contribution of age to l110rtality 'was 11101'e pronounced in patients i\Tith MI 
rather than in those i\rith UAP. This suggests that the relation between age and 
ontcOll1e depends on the presence and extent of myocardial necrosis at adillission. 
The results with respect to sex (and blood pressure) emphasize that possible 
prognostic factors should be considered in association with other DUtCOlllC predictors, 
In univariable analysis, no relation 1\'aS observed between sex and mortality, 
whereas l11ultivariable analysis revealed ·women to be at 100\Tcr risk than rncn. 
The difference in QUtC0111C bct\\Tcen regions of enrolhncnt could not be 
explained fully on the basis of other baseline differences. Univmiable analysis 
shmved an increased risk for adverse events in Eastern Europe cOlllpared ·with 
\Vestern Europe and North Alllcrica. After correction for differences in haseline 
characteristics! 111orta1ity rates in these regions 1'lcre similat~ but the difference 
in the COlllbil1cd end point rCll1ained. The definition of MI should be considered 
in this respect. Particularly in Eastern Europe, the ntll11bcr of MIs differed 
according to the definition of the GEG versus the local investigator.9 Eastern 
European origin 'was not a risk factor for the combined outcOlne of death or 
nonfatal (re)MI ivhen MI1Nas classified by local investigators. Furthermore, there 
were interregional differences in applied treahnent strategies. 17 Percutaneous 
interventions were much nlore common in North America than in Eastern 
EtlTope, These variations in treahnent may have caused differences in outcOlne, 
The high nlortality rate in Latin America is still an unexplained finding, 
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Presenting Features 
The cOllh-iblltion ofhemt rate to the mortality 1110dcl"was of similar impOliance 
as in patients with persistent ST-segment elevation,3 In contrast to observations 
in ST-segl11cnt elevatioll,3 hm\TeVel~ no U-shapcd relation between heart rate and 
1110rtality was observed, although the l1l1111bers of patients with very 101\7 01' velY 
high values were too 8111a11 to draw strong conclusions. 
The en1'011111cnt diagnosis was the second 1110St inlportant predictor of the 
C0111posite end point. Patients presenting 1-\lith MI had an almost 50% increase in 
the 30-day (re)infarction rate compared with UAF. According to local investigator 
reports, the prognostic i1nportance of cnTo1h11cl1t diagnosis ,vas less pronounced. 
Patients classified as having MT by the CEC who were not labeled as such by the 
investigators represent a subgroup 1\7ith l11inor CK-MB elevations. These patients 
arc probably silnilar to patients 1\"rith elevated cardiac troponin levels, who arc at 
increased risk for repeat thrombotic cvcnts. 18 
History 
Anlong the histOT,Y variables, the prognostic contribution of prior 
revascularization lNas 1110St interesting. Patients who had undergone angioplasty 
generally had a better survival rate than those 'who had not, but previous bypass 
surgery was associated with worse prognosis. Most likely, the type of prior 
revascularization procedure is a marker of coronary disease ::;everity, \\7hieh is less 
severe in the angioplasty group (single-vessel disease) and more severe in the 
bypass group (rnultivcsscl disease and ilnpaired left ventricular function). 
Treatment In-Hospital Course, and Modeling Aspects 
The treatnumt of acute coronary syndrOlne patients is an interactive process 
that is guided by the physician)s perceptions of patient risk and risk reduction by 
available therapies and by the response to such therapy. Because we concentrated 
on risk esti111ation at hospital adl11ission) response to treahllent 'vas not part of 
the 1110del) nor 'were l11arkers of changes during hospitalization) such as recurrent 
ischelnia. An exception was assignnlCnt to eptifibatide) which OCCUlTed at random 
in PURSUIT. 
The predictive power of the 1110rtality nlOdel was substantial and was similar 
to an established model for patients with S1'segment elevation.' Prediction of (re )MI 
was less accurate) which reflects the fact that disruption of atherosclerotic plaque) 
which ultilnately leads to MI) often occurs at l11ultiple locations in the coronary 
systen1) independently of prior ische111ic events. 19 MIs caused by percutaneous 
interventions are even nlOre difficult to predict fron1 infonllation known at 
hospital adlnission. Indeed) if these events are ignored) the predictive power of 
both the 1110rtality and the cOlllposite end point 1110dels i111proved significantly. 
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Score 
Mortnlity 
only 
Age (year) 50 0 
60 2 (3) 
70 4 (6) 
80 6 (9) 
Gender Female 0 
1<faie 
Worst CCS-c1ass in previous 6 weeks No angina; I or II 0 
III or IV 2 
Heart rale (bplll) 80 0 
100 I (2) 
120 2 (5) 
Systolic blood pressure (nmli-Ig) 120 0 
100 
80 2 
Signs of heart failure (mles) No 0 
Yes 3 
ST-depression on presenting ECG No 0 
Yes 3 
25% 50% 
c 
20% 40% a ·2 g ;0 0 
t! '"" ~ 
0 15% 30% {j :E-
o o 0 
S "" ~. 10% 20% ~. g 
0 <il 
M 0 b 
5% 10% M 0 c 
0% 0% 
0 4 8 12 16 20 
Risk score 
Figure 3. Simple scheme to estimate risk of30-day compikiltiolls in 
individual patients. Points are given for each predictive factor. With rc~pcct 
to age and heart rate, there urc separate points for enrollment diagnosis of 
VAP und IvIT (between parentheses). Summed points will provide a risk 
score, which can be converted into a probability with help of the graph. 
CCS indicates Canadian Cardiovascular Society. 
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1-fortality or 
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8 (11) 
9 (12) 
II (13) 
12 (14) 
0 
0 
2 
0 
0 
0 
0 
0 
0 
0 
2 
-----
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C/inicallmp/ications 
Although the developed risk models can be helpful for evaluating a patient's 
prognosis at hospital adlnissioll , these l11ay be too cOlllplex to be integrated in 
clinical practice. \Ve therefore present in Figure 3 a silnple risk~evaluation sehenIC 
based on the 1110St inlportant prognostic factors. The observed 3D-day 1110rtality 
rates in the first quartile of predicted 1110rtality according to this SChClllC (:51 %), 
the interquartile range (> 1 % and :-:;;4 %), and the highest quartile (> 4 %) "were 0.6% I 
2.2%, and 8.9%, respectively. The observed event rates in the first quartile of the 
predicted C0111posite end point (::=;10%), the interquartile range (> 10% and ::;19%), 
and the highest quartile (> 19%) were 8.2%, 16.5%, and 24.1 <}b. 
It is beyond the scope of the data presented in this article to l11ake fin11 
statenlents about the appropriate treatment of patients in the several risk 
categories. Still, we may indicate how knowledge of the risk profile may affect the 
clinical decision-making process. For patients at low risk for reClIlTent events/ early 
discharge seems 'tvarranted. The intermediate-risk group l11ay benefit fr0111 a 
strategy of II watchful waiting": close observation in intensive or l11ediU111-carc units 
lNith ischemia 111Onitoring and serial cletennination of l11arkers of l11yocardial 
da1nage. Some of these patients will be candidates for additional, invasive therapy; 
others may be treated medically. Antiplatelet therapy should be considered for 
high-risk patients/ especially in case of elevated levels of caTdiac troponins. 
Platelet glycoprotein IIh/IIIa inhibitors can reduce the probability ofMI beyond 
that achieved by aspirin and heparin. 8,20,21 Percutaneous revasculaTization nwy be 
of particular henefit in this group." Again, platelet glycoprotein Ilb/IlIa receptor 
blockers should be given to reduce the Tisk of procedure-related thrOlnbotic 
cOll1plications.2J Bypass surgery should be considered in patients ""Tith impaired 
left ventricular function and 111ultivessel disease. 
Conclusions 
By systel11atic analysis of the PURSUIT database/ several pivotal factors were 
identified that have a profound l111pact on clinical outcome. Knowledge of these 
factors luay facilitate the clinical decision-l11aking process. 
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Appendix 
The probability of 3D-day mortality is [1 + exp( + 8.9294 - S)r I 'idlere S is the sum of: 
0.0483x[age (years)] + 0.0317x[age (years)]x[enrollment MI] 
-O.4787xlfemale sex] 
0.1608x[weight (kg)]-2.8481x + [weight (kg)] 
-0.02I6x[hcight (em)] 
-O,1048x[North AmericaJ+ 1.0978x[Latin Americaj+ O.033Gx[Eastern Europe] 
Q.2247x[histofyofhypertension] 
O.3197xfdiabetes mellitus] 
O.2508x[ current smoker] + O.2185x[foIlller smoker] 
0,4418x[worst Canadian Cardiovascular Society class in previous 6 'weeks = III or IV] 
O.3517x[history of heart failure] 
0.3771 x[history of angioplasty] 
-O.6552x(history of bypass surgery] 
0.3SlOx[b-blocker use] 
O.Z977x[calciu111 antagonist use] 
O.2744x[nitrate use] 
-3.0787x[enrollmcnt infarction 1 
-O,0127x[systoHc blood pressure (111111 Hg)] 
0.0088x[hcart rate (hpm)] + 0.0204x[heart rate (hpm))x[cnrollment M I) 
0.61S0x[ra1es < 1/3) + o. 7174x[ra1es <:1/3] 
Q,S906x[ST-segment depre:->sion] 
-O,Q09ax[timc from onset of symptoms] 
0.2635x[cptifibatide )-0.4 7GOx[ eptifibatide ]x[ enrollment MI) 
Age, weight, height, systolic blood pressure, heart rate, and time from onset are continuous 
variables; all other determinants are Oil variables, with 0=110 and 1 =ycs. 
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Abstract 
Background 
A proportion of patients 'who present ,\"'ith suspected acute coronary syndr0111cs 
(ACS) are found to have insignificant coronary artery disease (CAD) during 
coronary angiographYI but these patients have not been 't\Tcll characterized. 
Methods and Results 
Of the 5767 patients with non-ST-segment elevation ACS enrolled in the 
PURSUIT trial who underwent in-hospital angiography, 88% had significant CAD 
(any stenosis >50%)16% had mild CAD (any stenosis >0% to :::;509'&)1 and 6% had 
no CAD (no stenosis identified). The frequency of death or nonfatal myocardial 
infarction at 30 days \vas reduced 'w"ith eptifibatide treatlllcnt in patients with 
significant CAD (18.3% VS. 15.6% for placebo, P= 0.006)1 but not in those \vith !llild 
CAD (6.6% vs. 5.4%, p~ 0,(;2) and no CAD (3.0% vs. 1.2%, p~ 0.28). We identified 
independent, baseline predictors of insignificant CAD (mild or no CAD) and 
used them to develop a simple, predictive nomogram of the probability of 
insignificant CAD for use at hospital presentation. This 1l0l1logranl 'was validated 
in a separate population of patients "with non-ST-segment elevation Aes, 
Conclusions 
Patients '''lith suspected ACS found to have insignificant CAD have a low risk 
of adverse outcOlnesl do not appear to benefit fr0111 treatment with eptifibatide l 
and can be predicted with a sitnple nomograI11 using baseline c11aracteristics. Since 
patients with significant CAD appear to have an enhanced benefit from eptifibatide 
treatlnent l the predictive nonlogram developed can he used to detennine 
indications for glycoprotein lIb/IlIa blockade. 
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Introduction 
Acute coronary syndrOlllcs (ACS) lllOst commonly begin 'with atherosclerotic 
plaque rupture and intracoronmy thr0111bus formation.! Whereas occlusive 
inh'acoronmy thrombi arc present in 1110St cases of ST-segment-elevation 111yocardial 
infarction (MI), the degree of coronary blood-flow disruption and the morphology 
ofilltracoronmy thrombi are more diveTsc in patients 'who present 'with non-ST-
scglllcnt elevation ACS (unstable angina or non-Q1vave MI).2 Thus, angiographic 
fhidings in non-ST-clevation ACS range £r0111 cOlnplex, ulcerated lesions to 110 
significant coronary disease, 'which occurs in up to 1596 to 2096 of patients ,\1"110 
undergo angiography.3A 
C0111plex lesion 111Orphology is a powerful predictor of adverse QntcOlnes in 
unstable angina, but the i1npact of insignificant coronary-artery disease (CAD) in 
unstable angina is not clearly understood.5-8 In thc ThrOll1bolysis In Myocardial 
Ischemia (TIMI)-IIIA trial, 53 of 391 patients with unstable angina (14%) had no 
critical coronary lesions during angiography and had a la-w incidence of in-
hospital adverse outcOlnes.9 Howevel~ longer-ternl outcOlnes and the efficacy of 
anti-ischclnic thcrapies have not been well charactelized in patients 'with ACS found 
to havc insignificant CAD. 
The recent Platelet glycoprotein lIb/lIla in Unstable Angina: Receptor 
Suppression Using Integrilin (eptifibatide) Therapy (PURSUIT) trial is the largest 
trial to date ofnon-ST-elevation ACS with almost 11,000 patients enrolleel.1O In this 
trial, eptifibatide significantly reduced the composite incidence of death or 
nontatal MI at 30 days. We evaluated patients from the PURSUIT trial who 
undenvent angiography and cOlllpared the clinical profiles, treatl11ent responses, 
and outcomes of those with insignificant versus significant CAD, 
Methods 
Patient Enrollment 
The enrolhllent criteria for the PURSUIT trial have been reported. lO.11 Patients 
'were enrolled among 28 counhies if they presented < 24 hours after ischelllic chest-
pain onset 'with either ECG signs of ischemia or an elevated creatine kinase 
(CK)-MB level. Patients with persistent ST-segment elevation, active bleeding, or 
recent l11ajor surgery 'wcre excluded from enrolhllent. The study protocol was 
approved by the institutional reviev.,T committee of each participating institution, 
and all patients gave infornlCd consent before enrolhnent. 
Randomization and Treatment 
Patients were randOlllized in a double-blind fashion to placebo or one of two 
doses of eptifibatiele. 1O In a protocol-specifled analysis of the f,rst 3218 patients 
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enrolled, a safetY-ll1onitoring C0l111uittee dctCTlllincd that the higher eptifihatide 
dose had an acceptable safety profIle; thercaftcl~ the lO'IN-dose ann 'was discontinued. 
The study drug was to be infused until discharge or for 72 hours, whichever 
occurred first. Aspirin and intravenous heparin 'were encouraged, and other 
l11cdications 'were not restricted. 
Coronary Angiography 
Decisions about the usc of coronary angiography and revascularization 'were 
not restricted and lNcrc Iuade by the treating physician. The maXinlU111 percent 
stenosis of allillajor epicardial coronary arteries and bypass grafts 'were recorded 
on the case-repOlt f01111, Angiographic characteristics of coronary plaques (including 
intracoronm]T thrOlubus) 'were not recorded. 
Patient Selection 
The study group consisted of patients who underwent coronary angiography 
during the initial adnrission. "Ve excluded patients who did not undergo angiography 
during the initial hospitalization, those who did not receive study drug after 
rando111ization, and those randOlllized to lo·w-dose eptifibatide treatnlent. 
Patients ,\7ere separatcd into three groups, based on the severity of CAD 
identified on the baseline diagnostic angiogram. Patients in the significant-CAD 
group had at least one stcnosis > 50% in a Inajor epicardial vesse1. Patients in the 
111ild-CAD group had at least one stenosis> 0% to"";; 50t}6. Patients in the no-CAD 
group had no coronary stenosis recorded. 
After angiography, nine patients in the 111ild-CAD group underwent 
revascularization (eight undell\7ent angioplasty, one underwent bypass surgery), 
as did three patients in the no-CAD group (two underwent angioplasty, one 
unden\7ent bypass surgery). These 12 patients were excluded £r0111 fmther analyses 
due to concerns that the angiographic findings were not recoTdcd accuTately. After 
exclusion of these 12 patients, the final cohort for this analysis cOl11prised 5767 
patients, 62% of the 9375 patients ranc1Ol11ized to and receiving placebo or high-
dose eptifibatide, 
Endpoints 
The primary endpoint of the PURSUIT trial (and of this analysis) was a 
composite of all-cause mortality or nonfatal 111 at 30 days, The criteria for 111 have 
been reported.1O In brief, all suspected infarctions that occurred within 30 days 
of randOl11ization were independently reviewed and adjudicated by a clinical-events 
conu11ittee blinded to treatment assignnlCnt. Investigators at enrolling sites also 
detennined whether an MT had occurred through 6-111onth follow-up. 
\,"'le also analyzed the fol1owing endpoints: 6-11lOnth 111Ortality, nonfatal MI at 
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30 days as adjudicated by the clinical-events cOll1111ittee, nonfatal MI at 6 1110nths 
as dctcTlnined by investigators, and a C0111posite of death or nonfatal, investigator-
determined MI at 6 months. Bleeding complications were classified by the 
Thrombolysis in Myocardial Infarction (TIMI) scale,12 and significant 
thr0111hocytopenia was classified as described. 13 
Statistical Analysis 
Baseline characteristics lNcre sUllu,narlzed as frequencies and percentages for 
categorical factors and as medians (25th, 75th percentiles) for the continuous 
factors. We calculated Kaplan-Meier event rates for patients 1Nith significant, 
mild, or no CAD for the endpoints evaluated, overall and by treahncnt assignment. 
Log-rank tests 'w-ere used to c0111pare event rates muong the three disease groups 
and the treatment elfect of eptifibatide within each group. 
',\7e used step'wise logistic-regression techniques to identif3r baseline variables 
that 'were independent predictors of insignificant CAD, defined as nlild or no 
coronary disease. Data £:r0111 patients in these two groups 'Nere pooled for this 
analysis. Candidate vmiables included den10graphic, clinical, and ECG fhctors; initial 
cardiac enzyn1e results; and llledications used before randOl11ization. The variable 
"Enrollment IvII" ,,"'as adjudicated by the clinical events conlll1ittee and was 
defined as any elevation of creatine kinase (CK) greater than twice the upper limit 
of normal (ULN) or CK-MB above the ULN within 16 hours of randomization. 
Multivariable predictors were tested with the i/{alcl X2 test and retained when 
P< 0.05. Results are presented as odds ratios (OR) and 9Sc}() confidence intervals 
(Cl). We used the coefficients from the full model (as shown in 'Pdble 5) to create 
a shllple predictive nomogram. 14 The sum of the scores for each independent 
predictor represents the probability that a given patient has insignificant CAD. 
A C-index value (area under the receiver-operator characteristic tROC] curve) 
was generated for the regression nl0del, to 111CaSure the concordance of predictions 
of insignificant CAD with actual angiographic findings. The regression lllOdel 
created from the PURSUIT population in this study was validated against patients 
with non-ST-clevation ACS enrolled in the Global Use of Strategies to Open 
Occluded Coronary £cliClies in Acute Coronary Syndromes (GUSTO-IIb) hial." The 
C-index was recalculated to detenninc how well this 1l1Odel could discrin1inate 
between patients with and without significant CAD in the separate population of 
patients froll1 GUSTO-lIb who underwent angiography. Finally, another regression 
model was generated in the GUSTO-IIb population to evaluate all 16 tactors in the 
original PURSUIT lllOdel and to detenlline whcthcr any factors had a different 
multivariable relationship with the OlltCOlllC of insignificant CAD than was found 
in the PURSUIT population. 
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Results 
Patient Characteristics 
As seen in 1),hle 1, of the 5767 patients who underwent angiography during 
the initial hospitalization, 5071 (88%) had significant CAD, 366 (6%) had mild CAD, 
and 330 (6%) had no CAD. Patients with significant CAD were older; more often 
TABLE 1. Baseline Chal'act~ristics by Degree of Coronary Artery Disease (CAD) 
Signiticant CAD Mild CAD No CAD 
(n = 5071) (n = 366) (n = 330) P* 
Male sex 70.1 52.2 48.2 <0.001 
Caucasian 88.4 84.1 74.8 <0.001 
Age, y 63 (55, 70) 58 (50, 67) 54 (47, 63) <0.001 
Diabetes 23.9 l3.1 10.3 <0.001 
Hypertension 55.6 55.2 50.3 0.17 
Current smoking 30.1 31.1 30.3 0.92 
Hypercholesterolemia 46.5 39.9 30.9 <0.001 
Family history of CAD 38.7 39.6 36.3 0.64 
Congestive heart failure 8.2 7.4 5.5 0.18 
Prior myocardial infarction 33.8 20.5 5.5 <0.001 
Prior angina 83.3 72.7 69.5 <0.001 
Prior angioplasty 18.2 15.6 1.2 <0.001 
Prior bypass surgery 15.9 0.3 0.3 <0.001 
Enrollment infarction 48.1 23.6 19.7 <0.001 
EeG changest 
ST-segmenl depression 47.1 32.2 28.5 <0.001 
ST-segmenl elevation 15.5 14.8 13.0 0.45 
T-wave inversion 50.4 60.9 67.0 <0.001 
Data are presented as percentnges or median (25th, 75th percentiles), *Across the three 
groups. i"Not mutually exclusiye. 
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lnalc, and luore often had diabetes l1lellitus, hypercholesterolemia, prior MI, 
prior angina, prior rcvascularization procedures, enrollment MI, and ST-I:lcgmcnt 
depression c01npared \vith patients with mild or no CAD. 
In the group with mild CAD, one patient had prior bypass surgery, yet all 
recorded native coronary stenoses were ~50%. In the group ",\\rith no CAD, four 
patients had prior angioplasty and one had prior bypass surgery, yet there lNcre 
no recorded stenoses (0%). No adverse clinical events (death or nonfatal MI) 
occurred in these patients by 6 months. 
Medical Treatment 
study drug was infused for a median 72 (52, 72) hams in patients with 
significant CAD, 72 (30, 72) hours in patients with mild CAD, and 70 (24, 72) hours 
in patients 'with no CAD. Aspirin ",vas used dlning the first adlnissioll in about 95% 
of patients in all three groups. b-blockers were used in 79% of patients 'with 
significant CAD) 69% of patients -with luild CADI and 63% of patients ·with no CAD. 
Intravenous heparin ·was used in 96%) 93%1 and 92% of patients I respectively. 
Outcomes 
As seen in Table 2) adverse ischeluic events occurred nlore often in the 
TABLE 2. Outcomes by Severity of Coronary Artery Disease (CAD)* 
SignifIcant CAD Mild CAD No CAD 
(n ~ 5071) (n ~ 366) (n ~ 330) 
30 Days 
Death 3.3 0.5 0.6 
Nonfatal MI (by CEC) 15.3 5.7 1.5 
Nonfatal MI (by investigators) 8.0 0.8 0.6 
Death or nonfatal MI (by CEC) 17.0 6.0 2.1 
Death or nonfatal MI (by investigators) 10.0 1.4 0.9 
6 Months 
Death 5.5 0.6 1.2 
Nonfatal:MI (by investigators) 9.9 1.7 1.2 
Death or nonfatal MI (by investigators) 13.4 2.2 2.2 
Data presented are percentages. fvfI, myocardial infarction; CEC, clinical events committee. 
*AlI P<O.OOI across the three groups for each outcome analyzed. 
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group with significant CAD. Patients with mild CAD had a lower adjusted risk of 
the composite of death or nonfatal Mr at 30 days than patients with significant CAD 
(hazard ratio lHRj, 0.45; rJ5% cr, 0.25 to 0.80; P~O.007). The group with no CAD 
also had a lower adjusted risk of this composite endpoint (HR, 0.20; 95% cr, 0.08 
to 0.49; P<O.OOl). At 6mol1ths, patients with mild or 110 CAD continued to have 
a lower risk of adverse events than did those with significant CAD. 
Treatment Efficacy 
As seen in Table 3, the frequency of the composite endpoint of death or 
nonfatal MI at 30 days 'was reduced fr011118.3% to 15.6% in patients lNith significant 
CAD treated with eptifibatide (absolute risk reduction [RR]) 2.7%; relative RR) 15%; 
P~0.006). The Kaplan-Meier event curves for the frequency of the composite 
endpoint separated early during the study drug infusion in the group lNith 
significant CAD and thereaftel~ fC1\7c1' events 'were seen in eptifibatidc-trcated 
patients through 30 days (Figure 1). By contrast, no apparent treatment benefit 
was seen in patients 'who did not have significant CAD. The frequency of the 
composite endpoint lNas si1niIar mnong patients treated ';\Tith placebo and those 
treated with eptifibatide in the group with mild CAD (6.6% vs. 5.4%; P~ 0.63) and 
the group with no CAD (3.0% vs. 1.2%; P~ 0.28). 
Safety 
In all patientf> treated with eptifibatide! the incidence of n1<ljor or minor 
bleeding was highest in the group with significant CAD compared with the groups 
'with lnild CAD and no CAD (34.5% vs. 9.7% VI:>. 8.1 %! respectively; P< 0.001). Most 
bleeding events in patients 'with significant CAD treated with eptifibatide! howevel~ 
'NeTe related to revascularization procedures. The incidence of major or minor 
bleeding \\Tith cptifibatide treattnent in patients \vith significant CAD \vas 25.8% 
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Figure I. 
Kaplan Meier plot of 
death or nonfatal 
myocardial infarction 
through 30 days in 
patients with significant 
coronary artery disease 
receiving eptifibatide 
(solid line) or placebo 
(dashed line). 
TABLE 3. Outcomes at 30 Days* by Severity of Coronary Artery Disease (CAD) and Treatment Assignment 
Significant CAD Mild CAD No CAD 
Placebo Eptifibatide Placebo Eptifibatide Placebo Eptifibatide 
(n=2548) (n=2523) P (n=181) (n=185) P (n=169) (n=161) 
Death, % 3.7 2.9 0.11 0.6 0.5 0.99 1.2 0.0 
Nonfatal MI % 16.6 14.1 0.01 6.1 5.4 0.77 1.8 1.2 
Death or nonfatal MI. % 18.3 15.6 0.01 6.6 5.4 0.62 3.0 1.2 
* As adjudicated by the clinical events conuuittee. MI, myocardial infarction. 
c:s 
P 
0.16 
0.68 
0.28 
~ g 
~ 
CD 
:0 
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TAULE 4. Independent Uaseline Predictors of Insigniticant Coronary Artery Disease 
Wald X2 p Odds Ratio (95% CI) 
No enrollment MI 178.2 <0.001 4.24 (3.43-5.24) 
Age (per lO-year decrease) 143.6 <0.001 I. 72 (1.57-1.88) 
Female sex 94.7 <0.001 2.51 (2.09-3.03) 
No angina <6 weeks before entry 63.5 <0.001 2.39 (1.93-2.96) 
No diabetes 39.6 <0.001 2.36 (1.81-3.08) 
No ST -segment depression 37.7 <0.001 1.82 (1.51-2.21) 
No current smoking 29.2 <0.001 1.77 (1.44-2.17) 
No previous MI 25.6 <0.001 1.97 (1.51-2.55) 
No previous hypass surgery 25.2 <0.001 35.86 (8.86--145.1) 
No hyperlipidemia 12.9 <0.001 1.40 (1.17-1.69) 
Non-Caucasian race 11.4 <0.001 1.50 (1.19-1.90) 
No peripheral vascular disease 7.4 0.007 2.16 (1.24--3.76) 
No P-blocker treatment before cntry 6.9 0.009 1.28 (1.07-1.54) 
No previous angioplasty 6.3 0.012 1.49 (1.09-2.03) 
No ST-segmcnt elevation 4.6 0.032 1.32 (1.03-1.71) 
Congestive heart failure 4.3 0.039 1.48 (1.02-2.14) 
Model X2, 947.025; C-uldex, 0.827. Of the 5767 patients included in the model, 696 had 
insignificant CAD. cr, confidence interval; MI, myocardial infarction. 
for patients "nrho underwent 311gioplasty, 81.7% for those who had bypass surger:y, 
and 13.0% for patients 1Nho did not undergo revascuiarization. AdditionallYI 
thrOlnbocytopcnia was nlore con1nlOn in the group with significant CAD cOlnpared 
"with the other groups (10.49-6 vs. 1.2% vs. 0.79-6 1 respectively; P<O.OOl). 
Predictors of Insignificant CAD 
As seen in Table 41 several baseline characteristics were found to predict 
insignificant CAD (l11ild or no disease) versus significant CAD. The strongest 
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independent predictors of insignificant CAD included younger age; fe111ale sex; 
and the absence of enrolhncnt MI, plior angina, diabetes, or ST-scgtllcnt depression. 
The overallmoclel X' was 947 (P< 0.001) and the C·index value was 0.827, indicating 
that the model can reliably predict the presence ofinsignificant CAD. An estimate 
of the probability of insignificant CAD can be calculated for individual patients 
by using the nomogram created from this model (Figure 2). 
When the predictive model was applied to the GUSTo·IIb population, the C· 
index value was 0.796. The validation plot of actual incidence versus predicted 
probability of insignificant CAD in the GUSTo·nb population illustrates the 
excellent discrimination of this model when applied to a different population 
1. Find Points for Each Predictive Fador 
Age Points Other Baseline Clinical Factors Points ECG Factors Points 
20 100 No enrolling MI 38 No ST Elevation 
30 86 Female sex 24 No ST Depression 
40 71 Non-Caucasian 11 
50 57 Congestive heart failure 10 
60 43 Absence of: 
70 29 Hyperlipidemia 9 
80 14 Previous MI 18 
90 0 Previous bypass surgery 94 
Diabetes 23 
Current smoking 15 
Peripheral vascular disease 20 
Previous angina (within 6 weeks) 23 
Previous ongioplasty 10 
Belo·blocker use before hospitalizotion 7 
2. Sum Points for All Predictive Factors 
+ + ~ 
A" Other Boseline ECG Factor~ Point Total 
Clinicol Foctors 
3. Look Up Probability of Insignificant Coronary Disease Corresponding to Point Total 
Tolol Points Probability Tolal Points Probability 
223 2% 286 18% 
242 4% 289 20% 
253 6% 303 30% 
261 8% 315 40% 
268 10% 326 50% 
273 12% 336 60% 
278 14% 348 70% 
282 16% 362 80% 
Figure 2. 
Nomogram to predict the probability of insignificant coronary artery disease (CAD) from 
baseline clinical characteristics. In panel 1, find the vafues that most closely match the 
patient's baseline characteristics and determine the corresponding point assignment. In 
panel2, add the points for alf predIctive factors. In panel 3, determine the likelihood of 
inSignificant CAD based on the total poInts. 
7 
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Figure 3. 
Validation plot for the actual 
incidence versus predicted 
probability of insignificant CAD in 
the GUSTO·llb population. by 
deciles of probability. This plot 
shows the excellent concordance 
of the PURSUIT model for 
insignificant CAD in a separate 
patient population 
(Figure 3). Most of the 16 l;,ctors in the model derived from the PURSUIT 
population remained significant when the model was applied to the GUSTO·IIb 
population. No previous angioplasty and congestive heart failure 'were not 
predictors of insignificant CAD in the GUSTO·IIb population, but these two 
factors 'were at110ng the least powerful predictors of insignificant CAD in the 
PURSUIT population. 
Discussion 
Even in this clinical hial that lIsed oqjectivc evidence of ischetnia as enrollnlcnt 
criteria (chest pain, ECG changes, and cardiac enzynlC elevations), a sizable 
proportion of patients 'with non-S1~clevation ACS were found to have insigni ficant 
CAD during coronary angiography. Patients ,\\Tith insignificant CAD had a low 
incidence of adverse outcomes and did not benefit from treatment with the 
glycoprotein (GP) 1I1l/IlIa inhibitor eptifibatide. By conti'ast, an enhanced treatment 
effect was demonstrated in patients with significant CAD treated with eptifibatide. 
Baseline clinical characteristics were used to create a silnple nlodel that accurately 
predicted the probability of insignificant CAD in a separate population of patients. 
Although patients with ACS and insignificant CAD have been shown to have 
better in-hospital outcOlnes than ACS patients with significant CAD, longer-tenn 
Qutc0111es have not been closely examined.? Our results shO'w a 1m\' incidence of 
death or nonfatal MI through 6 months in patients with insignificant CAD. In 
previous angiographic studies, hm\Tevel~ progression of coronary lesions in unstable 
angina has been con1n10n and associated w"ith an increased incidence of ischelllic 
events. 16,17 In this analysis, \ve could not evaluate angiographic progression of 
disease, but patients \vith insignificant CAD had a low risk of adverse clinical events 
through 6 111Ouths. Further evaluation is needed to detennine whether patients with 
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insignificant CAD have a shllilar prognosis through longer-term follow-up. 
The underlying mechanisll1s that conhibute to the clinical presentation of ACS 
in patients 'Idth insignificant CAD are not '\ve11 understood. Since allllOst 25% of 
the patients with insignificant CAD in this analysis presented "\1ith Inyocardial 
infarction at cnrolhnent, inh"acoronary throll1bus 111ay have first fanned at the site 
of a minilllal coronary lesion, as descnbcd by Pecora ct a1. 18 Embolization of platelet-
fibrin thrOll1bi to the 111icrovascular circulation, endothelial dysfunction caused 
by abnonnalities in distal coronary flow, or both also l1my be present in patients 
with ACS 1Nho have no significant coronary epicardial 1e8io118.9.19.20 Elevated 
troponin levels are a possible marker oflesion cOlnplexity, thrOlnbus burden, and 
microvascular obstruction in patients with non-ST-segment elevation ACS.1O, 21 
Howevel~ troponin levels ,vere not routinely 111easured in the PURSUIT trial, so 
we could not assess their predictive and prognostic abilities in patients "with 
insignificant CAD. Finally, given the limited prognostic significance of T-wave 
changes in patients with unstable angina, the high prevalence ofT-wave inversion 
in patients with insignificant CAD suggests these ECG findings may have 
contributed to the incolTect diagnosis of ACS in a certain proportion ofpatients.22 
Since 1ve have denlOnshated that patients with insignificant CAD do not benefit 
from treatment with GP lib/IlIa blockade, early identification of patients with 
suspected ACS 1'vho have insignificant CAD may help to guide therapeutic 
decisions in this low-risk cohort. The probability of insignificant CAD can be reliably 
predicted before angiography using baseline characteristics, so the nOlllogrmll we 
created can potentially be used to identifY patients who are not likely to benefit 
fl.·onl treatnlCnt with a GP Ilb/IlIa inhibitor upon hospital presentation,2J.24 The 
clinical significance of this predictive n01llogranl was denlOnstrated by our finding 
that patients with significant CAD treated with eptifibatide had an enhanced 
reduction in the frequency of the primary cOlnposite endpoint cOlnpared with the 
overall PURSUIT trial (2.7% vs. 1.5%).)0 Elevated troponinlevels also appear to 
identifY patients with ACS who have enhanced benefit fr0111 treatment with GP 
lIb/IlIa blockade.23.24 However, furtl1f~r studies are needed to determine which 
conlbination of high-risk features (CK-lvIB, troponins, ischC111ic ST-seglnent 
changes) should be used together with our predictive n01110grmn to select patients 
with suspected ACS for treatment with a GP lIb/IlIa inhibit01: 
Limitations 
Only patients who underwent angiography were eva1uated, so a selection bias 
relating to the decision to perfonn angiography Inay have influenced the results. 
The angiographic infoI1nation recorded ,vas linlited and did not include assessnlents 
oflesion characteristics, intracoronary thrOlllbus, or coronary flmv, Additionally, 
there -was no verification of the severity of coronary lesions in an angiographic 
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core laboratory. The PURSUIT trial! howevcl; 'was designed as a 1m-gel usinlplc l1 
trial that enrolled almost 11,000 patients with nOI1-S'f.elevation ACS." Detailed 
angiographic analysis and verification of the findings in a core laboratory 'would 
have been inlpractical in a trial of this size. Finally, the enrolhncnt criteria of 
PURSUIT were designed to select a moderate- to high-risk group of patients with 
non-ST-elevation ACS, so the patient popUlation studied in this analysis may 
have been j1cnrichedll compared ·with that seen in typical clinical practice. 
Conclusions 
Patients \\Tith ACS found to have insignificant CAD eluTing coronary 
angiography have a low· risk of adverse outcome.s. While patients with insignificant 
CAD did not appear to benefit from treatment with eptifibatide, those with 
significant CAD ·were shuwn to have an enhanced treattncnt benefit. Bascline 
clinical characteristics ,;\'ere used to accurately predict the probability of 
insignificant CAD using a sitllplified nOlnogratll. Thereforc i early identification 
of patients with suspected ACS who have insignificant CAD l11ay help refine 
triage algorithn1s for acute ischelnic chest pain and detenlline indications for GP 
IIb/IIIa inhibitors. 
Acknowledgments 
The PURSUIT trial was funded by grants from COR Therapeutics, Inc, South 
San Francisco l Califl and Schering-Plough Research Institute l Kenilworth l NJ. The 
authors wish to thank mel11bers of the PURSUIT Steering C0l11111ittee for their 
C0l11111cnts and suggestionsl Pat French for expert editorial assistancel and Suzanne 
'Ibrner and Anthony Doll for their assistance in preparation of the figures. 
198 
Risk assessment 
References 
Fuster'~ Baclimon L, Baclimon .TJ, Chesebro JH. The pathogenesis of coronary artery 
disease and the acute coronary syndromes. N Engl J Mal. 1992;326:242-250. 
2 IvfizUll0 K, Satomma K, ~vIiyamot(j A, Aralm'lva K, Shibuya T, Ami T, Kurita A, Nakfl1111Wl H, 
Ambrose lA. Angioscopic evaluation of coronary-artery thrombi in acute coronary 
syndromes. N Engl! Merl. 1992;326;287-291 . 
.1 Freeman i\·lR, Williams AE, Chisholm RJ, Armstrong pw. Intr<lcorol1alY thrombus and 
complex morphology in unstable angina. Circulation. 19f19j80:17-23. 
4 "Williams AE, Freeman MR, Chisholm RJ, Patt NL, Armstrong rw, Angiographic morphology 
in unstable angina. Am J Cardiol. 1988;62:1024-1027. 
5 Bugianlini R, Pozzati A, Borghi A, Morgaglli GL, Ottani F, ivfu;o;i A, Puddu E Angiographic 
morphology in unstable angina and its relation to transient myocardial ischemia and 
hospital outcome. Am J Cardiol. 1991;67:460-464. 
f) Dangas G, iVlehran R, Wallenstein S, Conrcoutsakis NA, Kakarala V, Holly-wood.l, Ambrose 
.lA. Correlation of <lngiographic morphology and clinical presentation in unstable angina. 
I Am Coli Cardiol. 1997;29:519-52,1). 
7 Ahmed "WFI, Bittl JA, Braunwald E. Relation between clinical presentation and angiographic 
findings in unstable angina pectoris, and comparison ·with that in stable angina. Am I Cmdiol. 
1993;72:544-550. 
8 Rupprecht HJ, Solm HY, Kearney P, Bickel C, Nafe B, 1'leyer J. Clinical predictors of 
unstable coronary lesion morphology. Eur lIenrt J. 1995;16:1526-5.14. 
9 Diver D, Bier.l, Ferreira P, Sharaf B, McCabe C, Thompson il, Chaitman B, Williams D, 
BraunwalJ E. Clinical and arteriographic characterization of patients with unstable angina 
without critical coronary arterial narrowing (from the TIMI-IIIA trial). 11m I Cm-diol. 
1994;74:531-537. 
10 The PURSUIT Investigators. Inhibition of platelet glycoprotein lIb/lIla with eptifibatide in 
patients with acute coronary syndromes. N Engl I Med. 1998;339:436-443. 
11 Harrington RA. Design and methodology of the PURSUIT trial: evaluating eptifibatide for 
acute ischemic coronary syndromes. Am J Cmdiol. 1997;80:34B-SB. 
12 Ran AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, Bell WR, Knatterud G, Robertson 
TL, 'Terrin J'vlL. Tluombolysis in Myocardial Infarction (TI1vlI) TI-icll- phase I: hemorrhagic 
manifestations ,md changes in plasma fibrinogen and the fibrinolytic system in patients 
treated with recombinant tissue plasminogen activator ,ll1d streptokinase. I Am Col! Cardiul. 
1988;11:1-1l. 
1:1 McClure ~'lW, Berkowit? SD, Sparapani R, Thttle R, Kleiman NS, Berdan LG, Lincoff AM, 
Deckers J, Diax R, Karsch KR, Grctler D, Kitt M, Simoons M, Tbpol EJ, Califf RM, Harrington 
RA. Clinical significance of thrombocytopenia during a non-ST·e!evation acute coronary 
syndrome. Circulation 1999;H9:2892-2900. 
14 Harrell FE. Design: S plus functions for biostatisticall epidemiologic modeling, testing, 
estimation, validation, graphics, prediction, and type-setting by storing enhanced model 
design attributes for the fit. UNIX version available from statlih@lib.stat.cmu.edu; 1996. 
15 The GUSTO-lib Investigators. A comparison of recombinant hirudin with heparin for the 
treatment of acute coronary syndromes. N Engl! Merl. 1996:335;775-782. 
16 Chen L, Cllf'!ster MR, Redwood S, Huang J, Leatham E, K.aski Je. Angiographic stenosis 
progression and coronary events in patients \vith 'stabilized' unstable angina. Circulation 
1995;91 :2319-2324. 
17 Ambrose J, ,\Tinters S, Arora R, Eng A, Riccio A, Godin R, Fuster v: Angiof.:,'Taphic evolution 
of coronary artery morphology in unstable angina.! AnI Call C(mliul. 1986;7:472-478. 
13 Pecora MJ, Roubin GS, Cobbs BW Jl~ Ellis SG, Weintraub WS, King SB III. Presentation and 
late outcome of myocardial infarction in the ,lbsence of angiographically significant 
coronary artery disease. Am I Cardiol. 1988;62:363-367. 
199 
Chapter II 
19 Hasdai D, Holmes DR, Higano S, Burnett J, Lerman A. Prevalence of corollary hlood flow 
resen'c abnormalities among patients with nOl1ohstructive coronm;y attery disease and chest 
pain. Mayo Clin Fmc. 1998;73:1133-1140. 
20 Egashira K, lnou T, Hirooka Y, Yamada A, Thkcshita A. Evidence of impaired cndothcliu1l1-
dependent coronary vasodilatation in patients with angina pectoris and normal coronary 
angiograms. N Eng1 J Mell. 1993;32B:16S9-1664. 
21 Heeschcn C, van den Brand MJ, Hamm CW, Simoons ML. Angiographic findings in patients 
with refractory un.stable angina according to troponin T status. CirclIl(llion 1999;104:1509-14. 
22 Cannon Cp, IvlcCabe CH, Stone PH, Itogers WJ, Schactman i'vI, Thompson BW, Pearce DJ, 
Diver DJ, Kells C, Feldman T, Williams 1'1, Gibson RS, Kronenberg MW, Ganz LI, Anderson 
HV, Braunwald E. The clech'ocardiogwm predicts one-year outcome of patients with 
unstable angina and non-Q-wave myocardial infarction: results of the TIMI III Rcgistry 
Ancillary Study.! Am Col! CunHa1, 1997;30:133-1':10. 
23 Hanull CW, Heeschcn C, Goldmann B, Vahanian A, Adgcy ,I, Migucl eM, Rutsch ,\~ Berger 
J, Kuotsh'a J, Simoons ML. Benefit of abciximab in patients "'with refractor:y unstable angina 
in relation to serulll troponin Tlevels. N EHgl/ Mea. 1999;340:1623-1629. 
24 I-Iceschen C, Hamm CW, Goldmann 13, Deu A, Langenbrink L, Whitc RD. Troponin 
concentrations f01' stratification of patifmts 'Nith acute coronaty syndromes in relation to 
therapeutic efflcacy of timflban, Lancet 1999;354:1757-1762. 
25 'Ibpol EJ, Califf RM. Ans"\,'crs to complex questions cannot bc derived from "simple" trials. 
Br Heart J. 1992;6B:34fl-351, 
200 
Recurrent Ischemia During 
Continuous Multilead ST -segment 
Monitoring Identifies Patients With 
Unstable Angina at High Risl< of 
Subsequent Cardiac Events: 
Meta-analysis of Three Studies 
Involving 995 Patients 
J(. M.artijn Aldcerlzuis, MDj Peter A.J. 
K[ootwijl(, MD, PhDj TVietze Lilldeboolll, 
MSCj l1ictor A. W:M·. Umans, MD, phDj 
Simon Meij, MScj Peter-Paul Kint, RNj 
klaarten L. Simoons, M.D, PhD 
From the Thoraxcenter, University Hospital 
Rotterdam, The Netherlands (KMA, PAJK, 
SM, MLS); Cardialysis, Clinical Research 
Management and Core Laboratories, 
Rotterdam, The Netherlands (WL, PPK); 
Division of Cardiology, Medical Center 
Alkmam; The Netherlands (VAWMU); 
Submitted for publication 
Chapter 72 
Abstract 
Background 
Recurrent ischemia detected by continuous ECG monitoring in patients -with 
unstable angina carries an increased Tisk of unfavorable QutcOlne. Studies that 
evaluated this relationship have been Ihllitcd by 8111a11 series of patients. By 
c01ubinillg data of three studies, the present analysis aims to provide an accurate 
asseSSlllcnt of the illlpact of recurrent ischclllia detected by 111ultilead ECG~ 
ischmnia 1110nitoring on the occurrence of death and 111yocardial infarction in 
patients 'with acute coronary syndromes. 
Methods and Results 
Data were obtained frol11 CAPTURE, PURSUIT and FROST, three trials 
evaluating glycoprotein lIb/IlIa blockers in patients with non-ST-elevation acute 
coronary syndrOll1cs. Patients were 111Onitored for 24 hours after enrohl1cnt 'with 
a COll1puter-assisted 12-lead or vectorcardiographic ECG-ischemia Inonitoring 
device. In a retrospective blinded analysis, recurrent ischernic episodes ... vere 
identified by a cOlllputer algorithm. The nUlnber of ischemic episodes was 
normalized to 24 hours. Ischemic episodes were detected in 271 (27%) of 995 
patients. There was a direct proportional relationship between the ntllllber of 
ischemic episodes per 24 hours and the probability of cardiac events at 5 and 30 
days. The 3D-day composite of death and 111yocardial infarction occurred in 5.7% 
of patients w-ithout episodes and increased to 19.7% in patients -with:? 5 episodes. 
After adjustment for baseline predictors of adverse outc01ne, the relative risk of 
death or myocardial infarction at 5 and 30 days increased by 25% for each 
additional ischemic episode per 24 hours. 
Conclusions 
This analysis elllphasizes the need for integration Oflllultilead ECG-ische1nia 
l11onitoring systC1ns in coronary cafe units and mnergency -wards to inlprove early 
risk-stratification in patients with acute coronary syndrOlllcs. 
202 
Risk assessment 
Introduction 
Recurrent ischenlia detected by Holter 111onitoring or C0111puter-assisted 
ECG analysis in patients 'with unstable angina carries an increased risk for an 
unfavorable ontcoll1C, including death and Inyocarclial infarction,I.? C0111puter-
assisted lludtilead ECG 111onitorillg offers an accurate continuous real-titne 
111CaSUymnent of the QRS-COlllplcx and the ST-flcgment 10,11 and can be used as a 
non-invasive tool for on-line risk stratification in patients 1Nith acute coronary 
syndr0111cs 4·9 In contrast, Holter l11onitoring is limited by a restricted nU111bcr of 
two or three ECG leads and allmvs for retrospective analysis only.lO.n 
Studies that evaluated the Telationship between recurrent ischclnia detected 
duting continuous l11ultilead ECG-ischetnia monitoring (or Holter lllOnitoting) and 
adverse outcOllle have been lhllited by small series of patients. 1-9 By c0111bining 
data of 3 studies l the present analysis aims to provide an accurate asseSSlnent of 
the itnpact of recurrent ischel11ia detected by multilead ECG-ischel11ia lllOnitoring 
on the occurrence of death and l11yocardial infarction in patients adl11itted "with 
an acute coronary syndr0111e. 
Methods 
Patients and Treatment 
Data were obtained fr0111 the ECG-ischemia monitoring sub studies of the 
CAPTURE (c7E3 Fab Anti Platelet Therapy in Unstable REfractory angina) and 
PURSUIT (Platelet glycoprotein lIb/IlIa in Unstable angina: Receptor Suppression 
Using Integrilin Therapy) trials ,59 as well as from the FROST (FfiJrinogen Receptor 
Occupancy STIldy) trial." The protocols and results of the 3 studies have been 
published.s,9.12 All patients were tllonitored using a nlultilead ECG-ischemia 
monitoring device as described beluw. 
In brief, the studies were designed as double-blind, placebo-controlled, 
randomized hials to evaluate glycoprotein lIb/lIla inhibitors in patients presenting 
lvith an acute coronary syndrome without persistent ST-elevation. CAPTURE 
evaluated abchdll1ab in patients with unstable angina refractory to conventional 
lnedica1 therapy for 1\'h0111 percutaneom; coronary intervention was planned and 
performed after approxit11ately 24 hours of pretreat111ent lNith abcixhnab. 13 
PURSUIT tested the hypothesis that inhibition of platelet aggregation with 
eptifibatkle would have an incrmnental benefit beyond that of hepatin and asphin 
in reducing the incidence of adverse outcomes in patients with unstable angina 
or non-ST-segnlCnt elevation ll1yocarclial infarction. 14 A sit11ilar patient population 
'was studied in FROST 'which assessed the safety and prelh11inary efficacy of onc-
month treatment with the oral glycoprotein lIb/IlIa blocker lefi-adafiban," 
An ECG-ischcnlia 1110nitoring studies excluded patients who presented with 
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ECG abnonnalitics interfering with ST-segnlent interpretation such as 1eft bundle 
branch block) third-degree AV~blockl persistent arrhytlullias) or pacelnakers. The 
protocols "were approved by the institutional rCVie1\"T board at each center and all 
patients gave infbnllcd consent. 
Continuous ECG-ischemio Monitoring 
ECG l11onitoring 'was started at the beginning of study drug adlllinish'ation and 
continued for 24 hours in all studies, and at least until G hours after c01nplction 
of the percutaneous coronary intervention in CAPTURE. 5,9,12 In the latter study! 
ECG 111onitoring was performed using the MIDA-lOOO vectorcardiographic ECG 
monitoring device (Ortivm; Ivledica1, T~ibYI S·weden).5,1l This system calculates and 
stores averaged QRS-T complexes from the Frank orthogonal X-Y-Z leads at I-minute 
intervak 15 In PURSUIT and FROST, patients were monitored with the ELl-STlOO 
continuously updated 12-1ead ECG reconting system (Mortara Instnuncnts! 
Milwaukee, U.S.A.).9.1O This system automatically calculates median ECG cOlllplexcs 
of the 12 ECG leads every 20 seconds. The systenl was programmed to store 111cdian 
ECG complexes and ST-trend data every 20 seconds if::> 100111' ST-segment shift 
was present in one lead relative to the preceding ECG of that patient, or if::> 5°111' 
ST-shift was present in any two leads of the 12-lead ECG. A baseline median ECG 
was stored every 5 minutes if ST-change was below these levels or absent 
altogether. 
Data Management 
Recordings ,vere stored on a hard disk) subsequently dO'wnloadcd to floppy 
disk and sent to the Cardialysis ECG core laboratOlY for editing and analysis. The 
tinling of the start of study drug adlllinistration and the 1110111cnt of coronary 
procedures, as well as the presence of episodes of chest pain during ECG 
111onitoring 'were obtained fr0111 the Case Report Fonns. All personnel involved in 
the analysis relnained blinded to study treatlncnt and patient outcOll1e. 
Editing and Analysis of Recorded Data 
The procedures of editing of the continuous ECG nlOnitoring data and the 
analysis 'with an auto111ated conlputer-driven ischelnic ST-episode detection 
prograln havc been described in detail. 5.9,10 After editingl trends of the ST-segment 
levellneasured at J-point + 60 Inseconds wcre generated for each single lead of 
the I2-lead ECG (except aVR) in PURSUIT and FROST, and for each single lead 
of the derived I2-lead ECG (except aVR) in CAPTURE, which was calculated 
£1.'0111 the X-Y-Z leads using the transfonnation £or11u11as of DOlNer.16 
The onset of an ST-episode was defined as a change of ST-amplitude ::> 100[11' 
£:1.'0111 the baseline ST-level in one or 11lOrc of the 12leadsl developing 1Nithin a 10-
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minute period in CAPTURE and a 20-minute period in PURSUIT and FROST, and 
persisting for at least 1 Inillutc. The end of an episode ,;vas defined as a return of 
the ST-level within 100~{V of the baseline ST-level, again lasting for at least one 
Ininute, if;:::': 100~V STchange ·was present in lllultiple leads simultaneously! the 
onset of the ST-episode was defined by the lead exhibiting the first significant ST-
change. Similarly, the cnd of an episode ·was defined by the lead exhibiting the 
latest moment of rctuTll to baseline ST~lcvcl. Episodes had to be separated from 
each other by at least one Ininute. A C01llputer algorithm progranullcd according 
to these criteria for ischenlia ·was used for detection of ST-episodcsJ lNith visual 
confirmation afterwards. Examples of the ST-trend analysis have been published 
previously.5.10 
Patients wcre excluded frOl11 the present analysiS if the recording staTted > 12 
hours after the start of study drug administration in PURSUIT and FROST and> 1 
hour in CAPTURE. Recordings ·with < 50% analyzable data or ·with a duration of 
< 12 hours were also excluded. ST-episodes occurring during coronmy procedures 
·were excluded. 
Ischemic burden was calculated in different ways: the total duration of all ST-
episodes per patient, the SUll1 ofthe area under the curve of a1112 ECG leads during 
ST-episodes per patient, and the area under the curve of the ST-vector Inagnitude 
(ST-VM) of all episodes per patient, calculated from the X-Y-Z leads (CAPTURE) 
or the 8 independent leads ·with subsequent use of the inversed Dower 
transformation fonnula (PURSUIT and FROST).16 The area under the curve was 
measured from the baseline ST-Ievel directly preceding the episode. 
Endpoints 
The relationship bet\\7cen recurrent ischC1nia and mortality, as 'Nell as the 
COll1posite of death and nlyocaTdial infarction was investigated at 5 and 30 days 
following randomization. In all studies, a blindcd Clinkal Events COlluuittee 
adjudicated suspected 11lyocardial infarctions within 30 days according to 
previously-published criteria. 12-14 
Statistical Analysis 
Continuous variables arc sUlllll1arized using the Inedian and interquartile range 
(25th and 75th percentiles) and were compared using Wilcoxon Tll'o-sample Test. 
Discrete variables are described as percentages and ·were c01npared using Fisher's 
Exact Thst. A two-sided p-value of less than 0.05 was required for significance. The 
number of ST-episodes was 110T1nalized to a period of 24 hours. Patients were 
subsequently classified by the nlnnber of ST-episodes per 24 hours into one of the 
following categories: 0, 0-1, 1-2, 2-3, 3-4, 4-5 and;:, 5. The relationship between 
recurrent ischetnia and adverse outcome "was evaluated univariably and after 
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adjushnent for baseline variables known to be independent predictors of death 
and Illy-acardial infarction in patients with l1on-ST-elevation acute coronaTjT 
syndr0111CS, based on an established risk IllOde! for this patient population. 17 
These included age, gendm~ pulse, ST-depressioll at enrolnlcnt, sl1lOking status, 
history of diabetes 111Cllitus or congestive heart failure, as 'well as previous 
Inyocardial infarction, percutaneous coronary intervention or bypass surgery.17 
Variables aTC presented as odds ratios lNith 95% confidence intervals. 
Results 
A total of 1181 patients were enmlled in the three trials togethee One hundred 
and eighty-sLx (16%) patients 'were excluded fr0111 the present analysis for the 
Table l.llaseline Charactel"istics 
Patients without ischemic Paticnts with any ischemic P-nlue 
episodes episode 
(n=724) (n=271) 
Age, yr 62 (54,69) 66 (58,71) <0.001 
Male sex, % 69 75 O.Q7 
Current smoker, % 35 37 0.55 
Diabetes, % 14 16 0.69 
Previous MI, % 32 38 0.10 
Previolls Pcl, % 14 19 0.07 
Previolls CABG, % g II 0.18 
Congestive heart fililure, % 3 5 0.19 
Heart rate, bpm 70 (64,79) 72 (64,83) 0.06 
For continuous variables, median values are provided, with 25th and 75th percentiles in parentheses; 
CABG = coronary artery bypass grafting; f,,1I = myocardial infarction; PCT = percutaneous coronary 
intervention. P-value hy Fisher's Exact Test for discrete variables and hy Wilcoxon Two-sample Test for 
continuous variables. 
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following reasons: 1) the recording began too late or contained < 12 hours or < 50% 
of analyzable ECG data (n ~ 58), 2) technical failures clue to incorrect lWeI' operation 
of the monitoring system (n~ 124), and 3) left bundle branch block that prevented 
interpretation of the ST-segment (n~4). Thus, ECG recordings suitable for Sl' 
analysis ",\\Tcrc available in 995 (84%) patients. The 111cdiall total recording thne 
suitable for ST-analysis was 25 hours (25th ancl 75th percentiles, 24 and 28 hours). 
IschClllic epilmcles during continuous ECG 111Onitoring ,vere detected in 271 
(27%) of the "lI5 patients. Almost half (49%) of the patients who exhibited 
recurrent ischemia had tlNO or 1110re ischclllic episodes per 24 hours. Patients with 
reCUITcnt ischemia had a -wurse cardiovascular baseline risk profile including older 
age, higher heart rate and a higher frequency of previous InyocaTdial infarction 
and coronary revasc111arization when c0111parcd 'with patients 1\Tithout ischcl11ia 
(Thble 1). Episodes of recurrent chest pain during 111Onitoring ",'ere reported by 
the investigator in 216 (22%) of the 995 patients. 
Relationship Between Recurrent Ischemia and Outcome 
Eight patients (0.8%) died within 5 clays of folloW-Up. The incidence of the 
c01nposite of death and luyocardial infarction was 4.7%. At 30 days, the incidence 
of death 'was 2.2%1 'while the composite of death and myocardial infarction 
occurred in 76 patients (7.6%). 
Patients 'who exhibited recurrent ischelllia during ECG 1110nitoring 11lOre 
f\-equently died or suffered from an myocardial infarction (Thble 2). The differences 
in cardiac event rates hetween patients with recurrent ischeIllia and those without 
were substantial, and all compmisons 'were statistically significant. The results were 
consistent for death alone and for the composite of death and myocardial 
infarction I as well as for events occuning during short-tenn (5 days) and long-ternl 
(30 days) follow-up. The association between recurrent ischeIllia and adverse 
outcome 'was even nlOre apparent in patients with frequent recurrent ischemia, 
as represented by two or more and three or more ST-episodes during ECG 
nl0nitoring ('TItble 2). In facti there lNas a direct relationship bet'lveen the number 
of recurrent ischemic episodes per 24 hours and the probability of adverse cardiac 
events (Figure 1). At 5 days, the incidence ofthe composite of death and myocardial 
inE:uction was 3.3% muong patients w"ithout ST-episodes which increased up to 
15.5% in patients 'with nlom than 5 ST-episodes. At 30 days, these figures were 5.7% 
and 19.7%1 respectively. 
Both in univariable and 111ultivariable analysis, the relationship het\veen 
reCUITent ischemia and unfavorable outcOIne was rClllarkably consistent (Figure 2). 
All ischenlia parameters univariably associated with impaired outcOIlle remained 
independent predictors in the multivariable analysis, with cD111parable odds 
ratios. After multivariable adjustment, the relative risk of death or myocardial 
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Table 2. Relation Between Recurrent Ischemia During ECG~ Ischemia Monitoring and Clinical Outcome 
1;;0 
5 days 30 days 
Death Death/MI Death Death/MI 
n n % P n % P n % P n % P 
Patients 995 
No ST -episode 724 1 0.1 <0.001 24 3.3 0.001 10 1.4 0.006 41 5.7 <0.001 Any ST-episode 271 7 2.6 23 8.5 12 4.4 35 12.9 
<2 ST -episodes 861 3 0.3 0.002 31 3.6 <0.001 14 1.6 0.005 54 6.3 <0.001 
;:Q ST -episodes 134 5 3.7 16 11.9 8 6.0 22 16.4 
<3 ST-episodes 885 3 0.3 <0.001 33 3.7 <0.001 14 1.6 0.001 57 6.4 <0.001 
<:3 ST -episodes 110 5 4.5 14 12.7 8 7.3 19 17.3 
No pain episode 779 6 0.8 0.69 30 3.9 0.02 18 2.3 0.80 53 6.8 0.08 
Any pain episode 216 2 0.9 17 7.9 4 1.9 23 10.6 
<2 pain episodes 963 6 0.6 0.03 43 4.5 0.06 20 2.1 0.16 72 7.5 0.30 
::?:2 pain episodes 32 2 6.3 4 12.5 2 6.3 4 12.5 
Data have been normalized to 24 hours. MI = myocardial infarction. P-values provided for Fisher's Exact Test. 
Risk assessment 
5 days 
15.5 
Chi-Square Test p< 0.001 
MI 
5.1 
1.5 1.6 Death 
30 days 
Chi-Square Test p< 0.001 
12.7 MI 
9.9 
Death 
n=:724 (73%) n=137 (14%) n=63 (6%) n=71 (7%) Number of pts ('Yo of lotal) 
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Figure 1 
Incidence (%) of death and compos;te of death ond myocardIal infarction of day 5 ond 30 
in patients w;th a non-ST-elevatlon acute coronary syndrome cfassified according to the 
number of ischemic episodes per 24 hours as detected by continuous multi/ead ECG-
ischemia monitoring. Mf =; myocardial infarction. 
Odds ratlos and 95% Cl for mortality and composite of death or myocardial (re)lnfarclion 
unlvariable multivariable 
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Figure 2 
Univarlable and muftivarlable-adjusted odds ratios for mortaUty and composite of death 
and myocardial infarction at 5 and 30 days. Odds ratios presented for various parameters 
of recurrent ischemIa. Horizontaf Unes indIcate 95% confIdence inteNa!s (CI). /category = 
for each increase In category of the number of ischemic episodes per 24 hours (0, (}-7, 7-2, 
2-3, 3-4, 4-5, ;::5). Number of deaths in first 5 days was too low for a meaningful multivariable 
assessment. Ml = myocardIal infarctiOn. 
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Table 3. Relation Between Ischemic Burden and Clinical Outcome in Patients With Recurrent Ischemia 
5 days 30 days 
No Yes No Yes No Yes No Yes 
death death deathIMI deathIMI death death deathlMI death/Ml 
(n=264) (n=7) P (n=24S) (n=23) p (n=259) (n=12) P (n=236) (n=35) P 
Frequency of ischemia 
Number of ST -episodes 2 (1.5) 6 (2.11) 0.09 2 (1.5) 5 (1.9) 0.14 2 (1.5) 7 (1.11) 0.06 2 (1.5) 3 (1.7) 0.14 
Ischemic burden 
Duration (min) 6 32 0.47 6 4 0.62 5 44 0.03 6 10 0.24 
ST-YM (~Y.min) 2052 7722 0.03 1745 15573 <0.001 1957 6867 0.004 1632 7505 <0.001 
12-1ead ST-area (~V.min) 8550 46259 0.02 8048 112217 <0.001 8261 37500 0.002 7617 46259 <0.001 
Data provided only for patients with any ischemic episode per 24 hours. Number of ST -episodes presented as median value with 25th and 75th percentiles 
in parentheses. Median values provided for ischemic burden variables. MI = myocardial infarction; ST -VM = area under curve of ST -vector-magnitude 
during ST -episodes per patient: 12-lead ST -area = sum of area under curve of all 12 ECG leads during ST -episodes per patient. P-values provided for 
Wilcoxon Two-sample Test. 
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Risk assessment 
infarction both at 5 and 30 days increased by 25% for each increase in the 
categOlY of ischemic episodes per 24 hams (Figme 2). The risk of death at 30 days 
increased by ahnost 40%. The nU111her of deaths in the first 5 days was too 101\' 
fbI' a 111caningful 111ultivariable asseSSl1wnt. 
Patients lNith recurrent episodes of chest pain exhibited a trend tmvards an 
increased risk of death and myocardial infarction (Thblc 2). Although the association 
between chest pain and adverse cardiac QutcOlne did not reach statistical 
significance in 1110St cOll1parisons, the directionality of the effect on ontc01nc 
parallels that of recurrent ischenlia detected by ECG-ischenlia 111onitoring. 
In patients \\7ith ischclllia) those ·who had a greater ischcnric burden more often 
died or developed a luyocardial infarction as conlpared 'with those "with a lower 
ischemic burden Clable 3). 
Discussion 
The present analysis in al11lOst 1000 patients with acute coronary synclrOlnes 
without persistent ST-elevation currently represents the largest asseSSl11ent of the 
prognostic i1nplications of recurrent ischemia as detected by cOlllputer-assisted 
continuous nlultilead ECG-ischelnia monitoring in this patient popUlation. The 
results confinn that recurrent ischemia is an independent and ilnportant predictor 
of death and lnyocardial infarction. In addition, the present analysis demon.strates 
that ahnost 75% of all patients admitted 'with a non-ST-elevation acute coronary 
syndrOlne do not exhibit any episode of recurrent ischClnia. Despite the fact that 
these patients nlet the electrocardiographic or enzY111atic criteria for enrolhnent 
in the respective studies, they had a relatively 10'1\7 risk of death and nlyocardial 
infarction (3.3% at day 5 and 5.7% at day 30). The results also confirnl previous 
observations that recurrent ischmnia detected by nlultilead ECG monitoring is a 
nlore sensitive and better prognostic l11arker than recurrence of chest pain.l.$ 
Several previous studies have shmvn that recurrent ischenlia, either silent or 
symptomatic and detectecl by either Holter or computer-assisted 11lultilead ECG 
monitoring, during the first fC1N days after admission for an acute coronary 
syndrome portends an unfavorable outcOl11e. 1•Q In S01ne of these studies, the 
prognostic infonnation of reCUlTent ischell1ia appeared to be independent f1'0111 
and additive to that of the baseline characteristics as well as to the presence of 
ST-depression on the enrohne11t ECG and to the biochel11ical nlarkers of Inyocardial 
necrosis at achnission, including the creatine kinase-MB and troponin levels,7.$ 
HO\vevel~ the 8111a11 sanlplc sizes ofthe individual shldies v,lith relatively fe'w cardiac 
events during follmv-up lhnited the assessment of the nlagnitude of the risk 
associated with recurrent ischclllia after l1lultivariable adjushnent. Consequently, 
the odds ratios varied considerably across the studies and the 95% confidence 
interva1s ,;vere wide. Accordingly, all previous studies evaluating llulltilead ECG-
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ischemia 111onitorillg in acute coronary syndr01nc patients failed to dCll10nstratc 
a direct relation between the 11l111lber of ische1nic episodes and the risk of adverse 
outcOIne. By cOlnbining three studies on l11ultilead ECG-ischcnlia lllOnitoring in 
almost 1000 patients, the present analysis \vas able to provide an accurate 
asseSSlnent of the ilnpact ofreculTcnt ischmnia on QntcOlllC and to establish a direct 
proportional relationship between the number of recurrent ischenl1c episodes and 
the risk of death or myocardial infarction. After 111ultivaTiable adjustnlfmt, the 
relative risk of death or ll1yocardial infarction both at 5 and 30 days increased by 
25% for each additional ischenlic episode per 24 hours. The large sanlple size also 
alluwed a risk aSSeSSl1lCnt far death alone: the risk af death at 30 days was 
particularly high in patients "·lith ~ 5 episades afrecunent ischemia (5.6% at day 
5 and 9.9% at day 30). The results were obtained in a diverse population of 
patients presenting 1\Tith nan-persistent ST-elevatian acute coronary syndromes! 
vat"ying from patients lNith unstable angina accOlnpanicd by T-wave inversion and 
a low risk profile to those at increased risk of adverse outcOlne because of 
refractory unstable angina or nan-Q-wave 11lyacardial infarction. 
Patient admitted with chest pain suspected 01 an acute corona!), syndrome. 
,--_ccE"Cc:G __ !-- ST-e!evation ------J> I Acute M! I 
Start standard medical therapy 
-Aspirin 
T-wave changes 
Non-diagnostic EGG 
ST·d"",,[oo l 
- Unfractionated or LMW heparin 
• Bela-b!ockers L_",T..:"",-P<>:::O:::'O,---...J!-- Elevated -> 
• Nitrates . 
UAPI 
Non-ST-t M! 
at high risk 01 
adverse 
• (Ca-antagonlsts) 1 
Start multilead ECG monitoring ---
~==~I"~h='m='~'=:':;!-- Ye, ___ ---.Jt 
Non-elevated 
outcome 
-- Elevated ------
UAP 
Thrombolys!s 
Direct PC! 
More Intensive treatment: 
In addition to 
standard medical therapy 
- add GP IIblllla blocker 
- consider early PCI 
I Non-elevated at low risk 01 Non-Invasive management 
adverse Stress test I discharge 
outcome 
Figure 3 
Protocol for triage of patients admitted with chest pain suspected of an acute coronary syndrome. 
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Incorporation of 
Continuous Multilead ECG-ischemia Monitoring in Patient Triage 
Patients 'who present with chest pain or other synlptOllls suggestive of an acute 
coronary syndr01uc and do not have persistent ST-segment elevation 011 the 
electrocardiogrmll, encompass a heterogeneous group that varies considerably \vith 
respect to diagnosis as weH as future risk for cardiac events. Early 11Sk stratification 
in these patients is inlportant to tailor phanllacological and invasive treatment to 
an individual need based on the expected prognosis. Baseline characteristics, the 
admission 12~lead electrocardiogrmn, biochclllical 111arkers ofluyocardial necrosis 
as 'well as continuous l11ultilcad ECG-ischclllia 111onitoring have all independently 
proven useful in risk stratification and could he combined in an emergency 
departlnent protocol for patient triage as suggested in Figure 3,4-9JJ.23 
Recent clinical trials suggest that patients identified as having a high risk of 
subsequent cardiac events based on STdcpression on the adlnission EGG or an 
elevated troponin T or I level, l11ay particularly benefit fronl a nlOre aggressive 
therapeutic approach including administration of a glycoprotein lIb/IlIa receptor 
inhibitor and an early percutaneous coron311' intervention,22-26 In patients with an 
elevated troponin level, glycoprotein lIb/lIla receptor blockers have been shown 
to reduce the high risk of cardiac events to that of patients without elevated troponin 
levels,22.23 This applies to thrOlllbotic COll1plications arising froll1 spontaneous 
plaque disruption as wen as those associated "''lith intervention~induced plaque 
ruptures,22.23 
If it is inlpossible to perfo1'1n i111111ediate percutaneous coron31j' intervention, 
high-risk patients may still receive a glycoprotein lIb/IlIa blocker as there appears 
to be a benefit of these agents during phannacological treatnlent only,22-24 A 
recent 111eta~analysis showed a 34% relative reduction (frol11 3.8% to 2.5% at 72 
hours) in the COll1posite endpoint of death or ll1yocardial infarction duTing 
phannacological treat111ent among the full spectnull of patients w-ith non-ST 
elevation acute coronary syndromes,24 In retrospective studies, the benefit appears 
even greater in patients with an elevated troponin level at adlnission. 2223 However, 
this observation is investigated in a prospective -way in the forthcoming GUSTO-
IV-ACS study. 
Patients admitted with a lo-w-risk profile and a non-elevated troponin level 
should undergo continuous nntltilead EGG-ischemia 111011itorillg \vhile receiving 
standard 111edical therapy (Figure 3).21.27 MeasurenlCnt oftroponinlevel should be 
repeated after approxilnateiy g hours, Patients who stabilize and do not exhibit 
recurrent ischemic episodes have a low risk of death and lllyocardial infarction. 
In these patients, a non~invasive managell1ent strategy 111ight be preferred.7,21-23,26 
Early transfer to a low level of care and early hospital discharge may result in 
econOll1ic gains without jeopardizing the safety. By contrast, in patients with an 
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initial Im\T-risk profile 1Nho do exhibit recurrent ischemia/ the risk of adverse 
outcome increases 'with the 1111111bcr of ischclnic episodes. These patients should 
be considered high-risk even 'when the sennn troponin level is not elevated.7.8.27 
Glycoprotein lIb/IlIa inhibition therapy and an early revascularization should he 
considered. This lNDUld apply even 11lOfe to patients who exhibit frequent recurrent 
ischclllia as the present analysis shmvs that the 3D-day event rate of alnlost 20'-)6 
in this group surpasses the risk associated with an early intervention protected 
by a glycoprotein IIblIIIa blockelc Clearly, the above protocol for patient triage 
needs to be evaluated for its safety and efficacy in prospective studies. 
The present analysis was litnited by the fact that the troponin level at 
adlnission could not be included in the l11ultivariable analysis as this infonnation 
was not systematically available in the three studies. Howevel; two recent studies 
have denlonstrated that the presence ofischelnic episodes during l11ulti1ead ECG 
Inonitoring has predictive value additive to that afforded by tile troponin leve1.7.8 
A potential limitation of the ECG monitoring studies is that the S'Hrend data could 
not be blinded during the recording. Hm\"TevCl~ clinicians 'were only instructed on 
hm\"' to operate the nlOnitoring function of the ECG systel11 and no infonnation 
was provided on hm\"T the ST· trend data could be retrieved. Furthermore l the 
nlOnitoring devices 'were specifically introduced in most investigational centers 
for these studies and 'were not used for routine 1110nitoTing of patients. FinallYI 
decisions based on ST-trend data or the on-line observation of ischenlic episodes 
1\70uld more likely have resulted in an underesthnation rather than an 
overestimation of the prognostic value of ischmnic episodes detected by nulltnead 
ECG-ischClnia Inonitoring. 
In conclusion l the profound inlpact of recurrent ischemia on survival Hnd the 
incidence of l11yocardial infarction among patients treated for acute coronary 
syndr01nes elnphasizes the need for continuous on-line ECG-ischenlia Inonitoring. 
Therefore l integration of continuous multilead ECG-ischemia l11onitoring systClns 
in coronary care units and enwrgency 'Nards 'will identify patients at increased 
risk of an unfavorable outcOlne l and allm\T for better prognostic triage and 1110re 
appropriate selection oftherapeut1c strategies. 
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Abstract 
Background 
Oral platelet glycoprotein lib/IlIa receptor blockers might enhance the early benefit 
of an intravenous agent. Lefradafiban is the orally active prodrug of fradafiball, 
a glycoprotein lib/IlIa blocker. 
Objective 
To determine the dose of lefradafiban that provides 8096 blockade of the 
glycoprotein lIb/lIla receptors (FRO ~ Fibrinogen Receptor Occupancy) by 
fTadatlball and to study the pharmacodynamics and safety of different doses in 
patients with stable angina undergoing angioplasty. 
Design 
A double·blind, placebo·controlled, dose·finding study. 
Setting 
FOllr acadcl11ic and cOllll11unity hospitals in The Netherlands. 
Patients 
A total of 64 patients "'!;v-ith stable coronary artery disease undergoing elective 
percutaneous translllluinal coronmy angioplasty. 
Interventions 
30 mg, 45 mg and GO mg lefradafiban tid or placebo was administered for 48 hours. 
Main Outcome Measures 
The pritnary safety endpoint "'was the occurrence of bleeding classified as 111ajOl~ 
minor or insignificant according to the TIMI criteria. Efficacy par3111cters included 
the % FRO, ex-vivo p1atelet aggregation and plasilla concentrations of fradafiban. 
Results 
Levels of FRO increased in a dose-dependent 111anner: adnlinish'ation of lefradafiban 
3D, 45 and 60 111g tid resulted in l11edian FRO leve1s of 71 %, 85% and 889-6, 
respectively. Inhibition of platelet aggregation was closely related to FRO. There 
were no major bleeding events. Lefradafiban GO mg tid resulted in a high (7196) 
incidence ofnlinol' and insignificant bleeding. The incidence of bleeding was 44% 
in the lefradaflban 30 and 45 mg tid groups, cOlllpared with 9% in placebo 
patients. Puncture site bleedings were l1lost COllllllOll. The odds of bleeding 
increased by 3 % for every increase in FRO by 1 %. 
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Conclusions 
Lefradatlban is an effective oral glycoprotein Ilb/Illa receptor blocker. The 
clinical effectiveness of dosages up to 45 mg tid should be investigated. 
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Introduction 
Platelet adhesion) activation and aggregation arc pivotal events in the process 
leading to coronary thrOlnbosis in patients "with unstable coronary artery disease. 1 
This process is also activated during percutaneous transhuninal coronary 
angioplasty (PTCA) by local vascular injmy which exposes circulating platelets 
to various prothrombotic stimuli within the subenclotheliU111.2.3 The final C011111lOn 
pathway to coronary thrOlllbus fOflnation involves aggregation of platelets via cross-
linking of their glycoprotein (GP) lIb/lIla receptors by the primmy binding 
ligand fibrinogen.4 
Several inhibitors of the GP lIb/lIla receptor have been deVeloped. The 
tllonoc1onal antibody c7E3 (abcixinlab) has been ShmV"ll to reduce the incidence 
of death and luyocardial infarction in patients undergoing PTCA) ·with or ·without 
stent deployment.56,.8Smallmolecules (eptifibatide, tirofiban) given intravenously 
also reduce c01nplications associated with PTCA, although their effects 'were of 
borderline significance,9.10Furthennorc, these intravenous GP lIb/Ula receptor 
blockers have recently been sho'wn to reduce the incidence of death, recurrent 
luyocardial infarction and recurrent ische1nia in patients with unstable angina or 
non-ST-segnlcnt elevation 111yocardial infarction. 11.12.13. 
The clinical use of monoclonal antibodies and small molecules as GP lIb/lIla 
receptor blockers is lhuited to the treatment of acute episodes of unstable angina, 
or treatlnent during coronary procedures, since oral administration is not feasible. 
Lefradafiban (Boehringer Ingelhci111, Genllany) is an orally active prodrllg 1Nhich 
is metabolised in two steps to fradafiban, an intravenously-active, non-peptide GP 
Ilb/IIIa receptor inhibitoc 14 In studies "with healthy volunteers, fradafiban as 
well as lefradafIban lead to a reversible and dose-dependent inhibition of platelet 
aggregation,14 
The ailn of the present, first phase II study was to detennine the dose 
regimen of Ie fradafiban that provides 80% bloclmde of the platelet GP lIb/lIla 
receptors (FRO ~ Fibrinogen Receptor Occupancy) by fradafIban as well as to study 
the phannacoclYl1mnics and safety of different doses in patients with stable 
coronary artery disease undergoing elective PTCA to select the appropriate range 
of dose regimens for subsequent larger studies. 
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Methods 
Study population 
Patients aged benvccl1 1 Band 80 years with stable coronary artery disease ,ycre 
eligible for enrolment if they were scheduled for elective PTCA. Patients were 
excluded if they suffered I\·om unstable angina or if there was a total occlusion 
of the vessel to be treated. Other criteria for exclusion included myocardial 
infarction within the preceding 14 days/ planned stent hllplantatiotl, Inajar 
surgery or traU111a 'within the preceding 6 'weeks/ any history of cerebrovascular 
hael1l0rrhage or hacmorrhagic diathesis, cardiopu1monary TCSllscitation or 
cOlnplicated puncture of a l11ajor vein or artery within the preceding 6 1\7Cek81 
retinopathy grade 3 or greatel~ gastrointestinal or genitourinary bleeding 1vithin 
the preceding 6 weeks, peptic ulcer disease, platelet count < 100x109/1, uncontrolled 
hypertension (systolic blood pressure > 200 mmHg andlor diastolic blood pressure 
> 100 111111Hg), current therapy 'Nith oral anticoagulants or any antiplatelet agent 
other than acetylsalicylic acid, including any non-steroidal anti-inflanlmatory agent, 
pregnant or nursing 'women or 'won1en not using Inedically approved l11ca118 of 
contraception, knmvn hepatic or renal insufficiency or any other COnCOlllitant 
serious illness 'which would Iinlit life expectancy or interfere 'with the study 
endpoints. The study protocol 1\78S ravie'wed and approved by each hospital's 
Institutional Revic'!N Board, and infonned consent '>vas obtained £r0111 each patient 
prior to participation in the trial. 
Study design and dose selection 
The initial protocol envisaged a dosc-esca1atioll, starting with lcfradafiban 60 
mg tid or placebo and subsequent series of 75 ll1g tid and 90 ll1g tid. Based on phase 
I data in healthy volunteers, the latter dose was expected to achieve FRO levels 
of 1110re than 80% .14 H01Nevm~ after COlllpletion of the first group of 21 patients 
treated with lefradafiban 60 mg tid, it became apparent that this dose was 
associated with a high incidence of bleeding and FRO levels o[more than 80% (see 
results). Therefore, the dose for the next group was reduced to 30 mg tid. After 
the safety of this regimen had been established, a third group was investigated 
receiving lefradafiban 45 mg tid or placebo. 
Within each dose level) patients WCfe randomised in a 4:1 ratio to receive 
lefradafiban or placebo in a double-blind manner. Study medication was 
adillinistered as an oral solution 3 times a day for two days, It \vas not to be taken 
'within 2 hours aftcT or 1 hour prior to a l11cal. The first dose was given 2 hours 
before the start of the PTCA. An additionalloac1ing dose was administered 3.5 
hours following the first dose 'while subsequent doses ,vere given at 8-hour 
intervals. 
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Concomitant therapy 
Before the start of the PTCA, all patients received an intravenous bolus of 
heparin of 5000 IU as well as an intravenous bolus of 250 mg acetylsalicylic aciel. 
During the procedure, heparin was repeated in boluses of 5000 IU after 30, 60 anel, 
ifllccessary, 120 l11inutes. Aspirin ';;vas continued in a dose of 100 lUg daily. The 
use ofticlopidin together with lefradafiban was excluded by the protocol because 
no interaction data ,,\"'ere available at that tiIlle. Therefore, if stenting 'was perfonncd, 
study drug was discontinued and ticlopidin (250 mg once a day or bid) was 
initiated. Other 111edications were continued as before randOll1isation and adjusted 
as required by the clinical status of the patient. 
Clinical and laboratory monitoring 
A corollary angiogrmn was perfonned hll111cdiately before and after PTCA, 
Coronary flO'w was classified according to the Th rOlllbolysis 111 Myocardial 
Infarction (TIMI) Study classification by a central angiographic core laboratory 
(Cardialysis BY)." Sheaths were removed 4-6 hours after discontinuation of the 
heparin infusion and as close as possible before the next intake of study Inedication) 
asslllning that the platelet inhibitory activity of fradafiban ,\70uld be at its nadir. 
Patients underwent daily clinical asseSSlnent for the occurrence of bleeding 
cOlnplications and other adverse events as well as extensive laboratory evaluation 
for hae111atology) coagulation and biochemistr:y. Patients returned for a follow-up 
visit two weeks after hospital discharge) which was not to take place lvithin 4B hours 
frOlll first study drug administration. 
Samples for determination of FRO and fradafiban plasma concentration were 
drawn at baseline and 2, 4, 12, 24, 36 and 48 hours after study drug initiation. Blood 
for detennination of FRO v·,ras stored in a Monovette prefilled with ACD (trisodium 
citrate) citric acid) dextrose). Platelet-rich plasma was prepared by centrifugation 
and mixed with labelled fradafiban. After incubation and centrifugation, the 
supernatant as well as the platelet pellet were counted for fiee ligand in 4 ml 
scintillation cocktail. Unspecific binding was determined in the presence of 
unlabelled fradafiban. The specific binding was calculated using corrections for 
spill-Dvm; extracellular space and unspecific binding. The percentage of FRO 
was then calculated frOll1 the specific binding data using corrections for receptor 
affinity and dilution of ACD. 
Blood for detennination of fradafiban plaSll1a levels \vas drawn into tubes with 
EDTA. PlaS111a was prepared inul1ediately through centrifugation and stored at 
_20 0 C until analysis. plasllla concentrations of fradafiban were measured using a 
validated high-performance liquid chromatographic method with fluorescence 
detection. Til The lower lhnit of quantification was 1 ng/ml. 
Ex-vivo platelet aggregation was assessed in a subgroup of 32 patients at 
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baseline ancl2, 4, 24 and 48 hours after study drug initiation. Platelet aggregation 
was measured in citra ted platelet-rich plasma and recorded by a Chrono-Iog 
aggrcg0111cter during a 6-8 111innte interval after induction by two agonists: 1 1111110111 
ADP and 2 mg/ml collagen, respectively. Results arc expressed as maximum 
percent aggregation achieved in platelet-rich p1a8111a, using platelet-poor plasma 
as reference 0[100%. 
Ivy bleeding tiines dctcnnined '''lith standard techniques 'were obtained at 
baseline and at the end ofthe 48-hour treatment period. Measurement of bleeding 
titnes was discontinued at 15 ll1inutes. 
Safety and efficacy parameters 
The prhllary safety endpoint in this trial 'was the occurrence of bleeding 
complications classified as InajOl~ minor or insignificant according to the criteria 
of the Thrombolysis in Myocardial Infarction (TIM!) Study Group." Milior bleeding 
'was defined as intracranial or bleeding associated 'with a decrease in haenlOg10bin 
of more than 3.1 n11n01l1 (5 g/dl) or a drop in hematocrit of more than 15%. Minor 
bleeding was detlned as observed blood loss with a decrease in haemoglobin of 
I.H-3.1 mm01l1 (3.1-5.0 g/dl) or a drop in hematocrit oflO-15%. Spontaneous gross 
haematuria or haelllatelllcsis as 'well as a decrease in haenlOg10bin of 2.5-3.1 1111110111 
or a drop in hell1atocrit of12-15% without an identifiable bleeding site ,\7ere also 
considered to indicate lninor bleeding. I3loodloss insufficient to 111eet criteria for 
nlinor bleeding was classified as insignificant. Haemoglobin values were adjusted 
if patients received packet red blood cells or whole blood within 48 hours prior 
to the ll1eaSUrenlent. l 7) 
The primary efficacy para111Cter was the FRO level in percentages expressed 
as area under the curve nonl1alised pcr hour. Secondary efficacy variables 
included the ex-vivo platelet aggregation and plasma concentrations of fradatlban. 
Statistical analysis 
Descriptive analyses of angiographicl aggregation and safety data are presented. 
The association of % FR01 expressed as Area Under the Curve (AUC)I with the 
first bleeding event was assessed using logistic regression analysis l the null 
hypothesis being that the risk of bleeding was not afrected by FRO levels. The AUC 
was calculated until the first b1eeding l as well as over the whole treatnlCnt 
interval. The relationship bet\veen bleeding and heparin adlninistration as well 
as aPTT AUC was investigated with logistic regression analysis in a shnilar way. 
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Results 
A total of64 patients were enrolled: 16 patients received lefradafiban 30 mg 
tid, 16 lefradafiban 45 mg tid, 21 lefradafiban 60 mg tid and 11 placebo. The 
Inajority (73%) of the patients were male (Table 1). The 111ca11 age i\73S 61 years 
(range 39-79 years). A previous l11yocardial infarction 'was present in 15 patients 
(23%), 'while 3 patients (5%) had undergone coronary artery bypass surgery and 
7 (11 %) PTCA. All patients received study drug and underwent PTCf\ as scheduled. 
The treated scgtllcnts ivere in the right coronar:.v artery in 14 (22%), the circumflex 
coronary artery in 19 (30%), and the left anterior descending coronary artery in 
31 (4B%) patients. Coronary flow was normal (TIMI grade III) in;)4 patients (84%). 
Following PTCA, TIMI grade III flow was achieved in all patients, except 2 in the 
placebo group (TIMI 0), both caused by dissection. A stent was placed in 9 
patients. In these patients, study Incdication ,\'-as discontinued and ticlopidin (250 
mg once a day or bid) 'was initiated, 
Pharmacodynamics and inhibition of platelet aggregation 
plasma concentrations offi:adafiban increased in a dose-dependent 111allner 
in patients treated with lefradafiban, GCOlnetric 111eans of the maXinlUl11 plasll1a 
concentration of fradafiban at steady state were 158, 314 and :194 ng/ml during 
treatment with lefradafiban 30, 45 and 60 mg tid, respectively (Table 2). The 
phannacokinetic profile of lefradafiban was predictable and no significant 
deviations £r0111 dose-proportionality ,\"'ere observed, 
There was a close correlation between the p1asma concentrations of fradafiban 
and the FRO levels (Figure 1). Levels of FRO increased in a dose-dependent 
l11anner in patients treated with lefradafiban, Median levels of FRO were 0% in the 
placebo group! 71 % in patients treated with lefradafiban 30 111g tid! 85% in patients 
treated with lefradafiban 45 mg tid and aB% in patients on Lefradafiban 60 mg tid 
(Thble 2). Mini1nu1l1! luean and maximum values of FRO i\7ete also dose-dependent. 
Fradafiban plasma levels of170 ng/ml were required to achieve 80% FRO (Figure 
1). There was little variation in FRO level within each patient (Figure 2), while the 
interpatient variability was greater among patients receiving the lower dose than 
among those treated with the higher dosages (Figure 2 and Table 2), reflecting the 
plasma concentration-FRO relationship (Figure 1). 
Ex-vivo platelet aggregation was Ineasured in 32 patients and decreased with 
higher FRO levels (Figure 3). In placebo patients, platelet aggregation was 
approximately 60% of normal. Inhibition of platelet aggregation to values below 
20%! or greater than 80<)-() inhibitiol1! was observed in all patients with FRO levels 
higher than 80%. 
Bleeding til11es measured at 48 hours were in the n01'1nal range for all patients 
with FRO values below 70%! wl1i1e prolonged bleeding thucs 'were observed in the 
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majority of patients with higher FRO levels (Figure 4). 
Adverse events 
Adverse events resulting in discontinuation ofstndy medication occulTed in 
4 patients: angina "with cardiogenic shock in one (30 l11g), leucopenia in one (30 
mg) and bleeding in two other patients, both receiving 45 mg. No major bleeding 
events ·were reported. Minor and insignificant bleeding cOlllplications were 
/i'equent in the highest dose group ((iO mg tid) in which 15 out of 21 patients (71 %) 
experienced such events ('Table 2). There -was one haC111atOl113 in the placebo group, 
while bleeding was reported in 7 (44%) of 16 patients receiving lef'radafiban 30 
mg tid as well as in 7 (<14%) ofl6 patients receiving lefradafiban 45mg tid (Thblc 
2). Arterial and venons puncture site bleedings lNCTe 1110St C0111111011. All bleeding 
events occurred later than 2 hours follmving adnlinistration of the first dose. 
By logistic regression analysis, higher levels of FRO were found to be 
significantly related to an increased incidence of bleeding. The odds of bleeding 
increased lNith a factor of 1.03 for every increase in FRO level "Tith 1 % point 
(I' < 0.01). The relationship bet",'cen bleeding and heparin administration as well 
as the aPIT Aue \vas explored in a sitnilar \vay. When heparin administration and 
aPIT Aue 'were restricted to observations prior to the bleeding event, the relation 
with bleeding was statistically significant lor heparin (p ~ 0.04) but failed to reach 
conventional statistical significance for aPIT (p ~ O.OH). 
A clinically relevant drop in leukocytes «3.0xIO'/I) was observed in 3 
patients, 2 of lNh0111 'were treated \vith lcfradafiban (iO 111g tid, and one with 
lcfradallban 30 mg tieL The lowest values were 0.9xI0'/1 (from 5.9xl09/1 at 
baseline), 1.9xl09 II (from 4.7xl 0'/1) and 2.3xl09 II (from 7.4x109 II), observed at 4, 
24 and 48 hours after first study drug adnlinistratioll, respectively. After 
discontinuation of study drug, the leukocyte count in these patients returned to 
nOf111a11cve18 without additional111casures -within 2-5 days. 
Median values of haCluatology parameters at baseline 'were 'within 110nnal 
lill1itS in all treatlncnt groups. Thcre was a sn1a11 decrease in the levcls of 
hacl11og1obin and thrOl11bocytes during the trial, wllich 'was cOlnparable mnong 
all treatment groups. Median levels of leukocytes did not changc. Senunlevels 
of thrOlnboplastine, thrOlnbin and fihrinogen were not affccted. :Nlcdian 
concentrations of biochemistry parmneters at baseline 'lVere within the nonnal 
range in all treatment groups and remained within these lhnits at 24 and 48 hours. 
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Table 1. Clinical and angiogruphic characteJistics at hascllnc 
Patient demogruphil'S 
Age (years) 
Male gender (n) 
Diahetes (n) 
Hypertension (n) 
Prt:vjolls MI (0) 
Previolls PTCA or CABO (n) 
Angiognlphic Imrmnctcrs 
Segments to bc treated (n) 
RCA 
LAD 
LeX 
Perfusion gmde, TIMI now (n) 
Grade 0 
Grade I 
Gradc 2 
Grade 3 
Lesion type hy AHA/ACe (n) 
A 
Bl 
B2 
C 
missing 
.-_._-----
Placeho 
n= 11 
5" (7) 
" 
2 
3 
6 
2 
8 
5 
5 
30 mg tid 
n= 16 
65 (8) 
14 
3 
2 
5 
3 
2 
9 
5 
2 
14 
3 
10 
3 
Lefradafiban 
45 Il1g tid 
11= 16 
62 (13) 
II 
6 
5 
3 
3 
R 
5 
14 
2 
5 
6 
3 
60 mg tid 
n=21 
60 (12) 
14 
2 
5 
4 
3 
6 
R 
7 
2 
18 
4 
9 
5 
2 
---.---.--
Por age, the mean values are provided with the :.Iandard deviation in parentheses. 
AHA/Ace = American Heart Association/American College of Cardiology, CABU = coronary mter), 
b}'ptLSS grafting, LAD = left anterior descending .utery. LeX = len drcumtlcx artery, .Ml = myocardial 
infarction, PTCA = percutancolls trunsluminai coronary angioph<;ty, RCA = right coronary llrtery, T1MI = 
Thrombolysis in I\·tyocardial Infarction. 
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Figure 1 
ReloNonship between the 
plasma concentration of 
the active drug frodafiban 
ond the degree of 
fibrinogen receptor 
occupancy (FRO). 
Figure 3 
Relation between the 
degree of fibrinogen 
receptor occupancy (FRO) 
and fnhlb;tton of ex-vivo 
platelet aggregation 
induced bV I mmol/I AOP 
In platelet-rich plasma, 
Each point represents data 
from a subject at a sIngle 
time point during the 48 
hours of ora! treatment 
with lefradafiban 30, 45 or 
60mg tid. 
Figure 4 
Relation between the 
degree of fibrinogen 
receptor occupancy (FRO) 
and ivy bleeding times at 
48 hours after first study 
drug administration. Each 
poInt represents data from 
a subject in the 
lefradafiban 30. 45 or 60 
mg tid group. MIn denotes 
minutes. 
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100 %FRO 30 MG TID 
80 
60 
40 
20 
0 Figure 2 Degree of fibrinogen 
receptor occupancy (FRO) 
during oral administration 
100 %FRO 45 MG TID of lefradafiban 30, 45 and 
60 mg tid, Each line 
80 represents data from an 
Individual patient In one of 
60 the three lefrodafiban groups during the 48 hours 
40 of 0(01 treatment, Each fine is based on FRO data 
obtained at one of the 
20 prespecified sample time 
points (baseline and 2, 4, 
0 72, 24, 36, and 48 hours 
after study drug Initiation), 
100 MG TID 
80 
60 
40 
20 
0 
024 12 24 36 48 
TIME (HRS) 
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Table 2. Efficllcy lind sAfety endpoinls 
Lt'fradafiban 
Placebo 30 lUg tid 45 mg tid 60 lUg tid 
n= 11 11= 16 n= 16 n =21 
Eft1Cllt'y pantlllctcl'S 
Plasma concentratiolllradafiban, o 158 (27) 314 (24) 394 (22) 
Cum.,;; ill ng/ml 
FRO (%) - minimum o 54 74 78 
FRO (%) - median o 71 88 
FRO (%) -maximum o 80 X9 95 
FRO (%) - mean o 69 (12) X3 (6) 87 (5) 
Bleeding time 
At baseline (min) 3.3 4.0 4.1 5.3 
After 48 hours (min) 4.4 7.8 19.2 25.0 
Bleeding complications 
Patients with bleeding, n (%) 1 (9) 7 (44) 7 (44) 15 (71) 
Number of bleeding evenls (n) 8 9 29 
Location ofbkcding (n) 
Vascular puncture site 6 6 15 
Gingival 2 10 
Skin 2 
Haematuria 2 
Severity of bleeding by TIIvll (n) 
Major 
l\·1inor 2 
Insignificant 8 27 
For fradatlban plasma concentration, the means of the maximum fradafiban plasma concentration at steady 
stale (em",,,) arc provided with the relative coeftlcient of variation (%) in parentheses. 
For PRO, the minimum, mcdian and maximulll values are provided, as well as the means with the relativc 
coetlicicnt of\'ariation (%) in parentheses. All FRO values are expressed as arl,.'a under the curve normalised 
per hour. Relative coemcknt ofvariatioll = 100 x (standard deviation/mean). 
FRO = Fibrinogcn Receptor Occupancy, TIMI = Thrombolysis in Myocardial Infiuction. 
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Discussion 
Administration of lefradafiban, an oral prodrug of the GP lib/lIla receptor 
blocker fradafiban, resulted in rapid and effective inhibition of platelet aggregation 
in patients with stable coronary artery disease undergoing elective PTCA. Dosages 
oflefradafiban 30, 45 and (JO mg tid caused a dose-dependent increase in fiadafiban 
plasma levels, increase in FRO and inhibition of platelet aggregation. With the tid 
dosing, a stable FRO was achieved witbin each patient (Figure 2). The level of 
inhibition achieved in patients, 1N110 also received aspirin and heparin, was 
greater than absenTed in volunteers receiving lefradafiban ';;vithout additional 
11lcdicatioll. In the placebo group, platelet aggregation 'was already decreased to 
60%. In the phase I studies, inhibition of platelet aggregation of more than 80% 
'was achieved with lefradafiban doses 0[90 111g tid. 14 Tn the present study, this "'was 
achieved with 45 mg tid. This suggests an interaction between the GP IIb/IIIa 
receptor blocker and aspirin. 
As in other studies with GP IIblIIIa receptor blockers, bleeding occurred 
frequently at these levels of platelet inhibition and was dose-dependent. The 
incidences of bleeding complications in the lefi"adafiban 30 and 45 mg groups were 
similar to the rates observed in studies with other oral GP lIb/IlIa blockers at similar 
levels of platelet inhibitioll,18.19 while even 1110re bleeding occurred in the highest 
dose group (71 %). In studies ,;vith sibrafiball and xemilofiban, a gradual increase 
in bleeding was observed for higher dose levels with a higher degree of platelet 
inhibition. 18,19The results of the logistic regression analysis in the present study 
support these obSClvations \vith an increase in the risk of bleeding by 3% for eVCIY 
increase in FRO with 1 % point. It should be appreciated that the majority of the 
bleedings "nrcre insignificant, "with a low incidence oflninorbleeding c0111plications 
following 11MI classification, and no major bleedings (1hble 2). Fmthermore, all 
patients received aspirin and heparin and underwent invasive coronar:.y procedures. 
I nteractions between the GP IIb/JIIa receptor blocker abciximab and heparin have 
been reported in previous studies.56 As demonstrated in the EPILOG and EPISTENT 
studies, it is likely that fmther reduction of the heparin dose in a weight-adjusted 
l11anne1' 111ight reduce bleeding cOlllplications in patients receiving lefradafiban 
'without decreasing the clinical efficacy.7.B Special care should be given to the 
access site of vascular sheaths. Sheaths should be removed early (4-6 hours) 
following the procedure, after the heparin has been stopped and the activated 
clotting time is 175 seconds or less.7Given the interpatient variability in the 
degree of platelet inhibition observed with oral GP IIb/IIIa TeceptOl' antagonists, 
another potential strategy for reducing bleeding COlllpIicatiolls during longer-tenl1 
therapy could be to nlOnitor the degree of platelet inhibition achieved in individual 
patients by using a platelet-function bedside assay and to titrate the dose to a target 
level of inhibition.20·21 
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,vhile a gradual dose-dependent increa1:lc in bleeding 1\738 observed, as in 
studies ·with sibrafiban and xelnilofihan, 18)19the relation betH"Tccn bleeding tilue and 
% FRO in the present study suggests a threshold effect. The bleeding time was 
not increased at FRO levels less than 70%, ·while a luarked increase was observed 
at higher levels. It should be appreciated, howevel; that measurement of bleeding 
thuc docs not reflect a tendency to spontaneous bleeding in clinical practice. 
In tllTee patients receiving lefradaflbau, a clinically significant drop in 
leukocyte COllnt was observed, although the Ineallicukocyte count did not change 
in the overall population. Leukopenia due to bone InalTOW depression has been 
reportcd for other antiplatelet agents (ticlopidin),22 These, howevel~ occur l110stly 
after 2 to 4 weeks of treatlllent. In the present study) leukopenia occurred 
inul1ediately after the first dose or within 2 days, In all three patients) leukocytes 
returned rapidly in the peripheral blood after discontinuation of study 111edication, 
Leukopenia had not been observed in previous studies with lefradafiban in 
hcalthy volunteers and) thereforc) was an unexpected finding in the present 
study, FoIlmving the observation of the leukopenia in the three patients) an 
alllendnlent was made which increased the frequency of the haeluatology 
evaluations to monitor the safety of the patients and investigate the potential 
underlying pathophysiological l1lCchanisnls, Hmvevel~ no additional patients 
experienced this adverse event. A reccntly-prcsented second phase II study 'with 
lcfradatlban in patients 'with acute coronary syndr0111es has confirn1ed the 
increased incidence of leukopenia) or rather neutropenia I associated 'with 
lefradafiban and provided some insight in the pathophysiological mechanisms 
involvcd,23 In accordance with the present studYI the decrease in neutrophils 
lNas characterised by an early onset (il11111ediately after first study drug 
achninish'ation or "within the next two days) and a fast recoverj,' after discontinuation 
ofIefraclafiban. Based on analysis of blood and bone 111at'1'm\' satl1ples obtained in 
patients 'with neutropenia in that study, it 'was concluded that the observed 
neutropenia did not result fr0111 bone marrmv depression but rather frOll1 a 
reversible redistribution of ncutrophils by margination or clustering. Yeti 1110rc 
investigations are needed to further identify the exact nlechanisnls involved) as 
well as to determine the optilnal duration of surveillance and the possible clinical 
associations, 
The clinical benefit of treatment with GP lib/IlIa receptor blockers in 
patients undergoing percutaneous intervention has been established by several 
studies using different inhibitors,5,6,7.8.9·lOIn the present limited series
l 
all patients 
receiving lefradafiban had a successful PTCA without apparent thrombotic 
complications, 'while acute closure was observed during PTCA in one patient in 
the placebo group. Oral compounds such as lefradafiban offer an opportunity for 
long-term treatlnent "with an effective platelet aggregation inhibit01~ 'which l11ay 
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enhance the early benefit of an intravenous agent and prevent subsequent 
thr01nbotic events in patients at risk. 
Three recently-presented large clinical trials have evaluated this concept of 
long-term oral GP Ilb/Illa inhibition with xemilofiban in patients after percutaneous 
coronary intervention (EXCITE) and 'with orbofiban and sibrafiban in patients after 
acute coronary syndrOll1CS (OPUS-TIMI-16 and SYMPHONy).2J25.26 None of the trials 
showed a clear treatment benefit oflong-term GP Ilb/Illa inhibition therapy, while 
all three trials showed a trend towards an increased mortality in the GP lIb/IlIa 
inhibitor group.2.ol25, 26 In this respect, several points deserve consideration. First, the 
patient populations included in these trials 1v-ere at a relative 1mv risk of recurrent 
thrOlllbotic events. 2.1,25,26 Furthennorc, the phannacokinetic and phannacodynatnic 
profile of these agents is characterised by a steep close-respo11se relations11ip and 
by a short half-life relative to the dosing interval.1s'19.2&r'his 111ay have caused 
widely fluctuating inhibition of platelet aggregation anel allowed complete recavety 
in platelet function between doses in sonIC patients, \vith exposure of activated 
GP lIb/IlIa receptors on the platelet's surface."Adelitionally, recent studies have 
raised the possibility that platelet receptor antagonists l11ay, at low concentrations, 
alter the steric conformation of the GP lIb/IlIa receptor sites and, paradoxically, 
enhance the thrombogenicity of these sites,27.28 Compared with the other oral agents, 
the lefradafiban tid dosing regimen Inay result in higher average fradafiban levels 
with less peak-trough fluctuation and more stahle levels of inhibition of platelet 
aggregation. 
It is a challenge to exploit the potential beneficial antithrombotic effect of oral 
GP lib/IlIa inhibitors in balance with the associated risk ofhaemonhage. Dose-
titration to a target degree of platelet inhibition, lueasured with a rapid platelet-
function assay, nlayhllprove the overall safety and efficacy profile. 20·20 To increase 
the treatment benefit of (oral) GP lIb/IlIa blockers, one may choose to treat 
only patients who arc at high risk of recurrent thrOlllbotic cOlllplications, such as 
those \vho present -with elevated troponin levels and continue on 111edical therapy. 
These patients 1118Y particularly benefit fronl 8 l110re aggressive long-tenn 
therapeutic approach. 29,30 
Lefradafiban in doses up to 45 mg tiel achieved stable FRO levels to more than 
80% in patients with stable coronary artery disease undergoing elective PTCA, with 
an acceptable safety during short-tenn treatl11ent. Thus, these doses 111<1y he 
tested in flnther studies to assess ".,-11ether long-term treatnICnt is indeed beneficial 
in patients with acute coronary syndromes at high risk of thrOlubotic cOluplications, 
without au excess of bleeding C0111p1ications. 
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Abstract 
Aims 
Oral glycoprotein IJb/lIla inhibitors might enhance the early benefit of an 
intravenous agent and prevent subsequent cardiac events in patients with acute 
coronary syndrOlllcs. We assessed the safety and prclhninary efficacy of one 
month h"eatment with three dose levels of the oral GP lib/IlIa blocker lefradafiban 
in patients 'with unstable angina or l11yocardial infarction ,\.,-ithout persistent ST-
elevation. 
Methods 
The Fibrinogen Receptor Occupancy S11.1cly (FROST) was designed as a dose-
escalation trial with 20, 30 and 45 mg lefradafiban tid or placebo. Five hundred 
and thirty-one patients 'were randOlnised in a 3: 1 ratio to lefradafiban or placebo 
in a double-blind luanner. Efficacy 'was assessed by the incidence of death, 
l11yocarclial infarction, COr0l131Y revascularisation and recurrent angina, Safety 'was 
evaluated by the occurrence of bleeding classified according to the TIMI criteria 
and by nleasliring clinicallaboratoIJT paratueters. 
Results 
There was a trend tm\7ards a reduction in cardiac events \\7ith lefradafiban 30 
lUg when cOluparcd with placebo and lefradafiban 20 lUg. The benefit was 
particularly apparent in patients with a positive (~O.l ng/ml) troponin I test at 
baseline and less so in those with a negative test result. In patients receiving 
lefradafiban) the cardiac event rate decreased with increasing minimal levels of 
fibrinogen receptor occupancy. There was a dose-depcndent increase in the 
incidence of bleeding: the composite oflnajor or luinorbleeding occurred in 1 % 
of placcbo patients) 5% of patients receiving lerradafiban 20 mg and in 7% of 
patients receiving 30 mg) with an excessive risk (15%) in the 45 mg group which 
resulted in early discontinuation of this dose level. Gingival and arterial or venous 
puncture site bleedings were Blast C0l1lnlO11 and accounted for more than 60% of 
all haemorrhagic events. There was an increased incidence of neutropenia 
(neutrophils < 1.5xlOf)/I) in the lefradafiban groups (5.2% versus 1.5% in the 
placebo group)) which did not result fr0111 bone lllatTow depression but rather from 
a reversible redistribution of neutrophils by nlargination or clustering. 
Conclusion 
One month treatment with the oral glycoprotein lIb/IIIa inhibitor lefradafiban 
in patients with unstable angina and l1lyocardial infarction 'without persistent ST-
elevation resulted in a decrease in cardiac events with lefradafiban 30 lUg and a 
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dose~dcpcndent increase in haCl110rrhagic events. The observed favourable trend 
tu'wards a reduction in cardiac events in patients with elevated troponin levels 
requires confirmation in a large clinica1 trial. 
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Introduction 
Coronary thrombosis is a pivotal event in the pathogenesis of acute coronaTY 
syndT01l1CS and ischemic cOlllplications resulting fro111 coronary intclvcntions. 1-
3 The final C0l111110n pathway to coronary thrombus fOY1nation involves aggregation 
of platelets via their glycoprotein (GP) lIb/lIla receptors.' Intravenous inhibitors 
of GP IIb/IlIa receptors have delllonstrated efficacy in reducing ischemic 
complications in patients undergoing percutaneous coronmy intervention and in 
those with unstable angina ur In,Yocardial infarction lNithout persistent ST-
elevation.5-13 Studies 1\,-ith these lIb/IlIa inhibitors have s1lO-wn early clinical 
benefit during the short-term period of intravenous arllninistration with no 
additional benefit after the infl11:iions ,;vere stopped. 12-15 Despite intensive nlcdical 
therapy including short-acting GP lIb/lIla inhibitors during the acute phase, 
outconles anlOng patients hospita1i.sed with acute coronary syndromes rcn13in 
unsati1:ifactory with a continuous increase in ischemic events after discontinuation 
of initial therapy, such that the risk of death or myocardial infarction within the 
first month after developll1ent of the acute coronary syndr0111e is as high as 10-
15%.12,)3,16.17 This l11ay reflect inC0111plete heeding of the vessel wall or the 
continuance of an activated haemostatic system for several \\7eeks or months after 
t11e acute event. 1B,1? These data suggest a need for prolonged and profound 
inhibition of platelet aggregation, which might be afforded by oral GP lIb/IlIa 
receptor blockers, in order to enhance the eady benefit achieved by intravenous 
agents and prevent subsequent events. 
Lefradafiban is an ora1ly active prodrl1g ,;,\'hich is l11etabolised in two steps to 
fradafiban, a non-peptide GP IIb/IIIa receptor inhibitor.20 A recently conducted 
first phase II study confirmed that lefradafihan causes a dose-dependent inhibition 
ofplatclet aggregation which was safe when adl11inistered for 4H hours in dosages 
up to 45 lUg tid in patients 'with stable coronary artery disease undergoing 
percutaneous coronary intervention. 21 The present FROST study (Fibrinogen 
Receptor Occupancy STI.ldy) was designed to assess the safety and prelitninary 
efficacy of one month trcatn1Cnt 'with different dose levels of lefradafihan in 
patients admitted with unstable angina or 111yocardial infarction 'without persistent 
ST-elevation. 
Methods 
Study population 
In 41 European centres, patients aged between IB and so years ',,'>'ith either 
unstable angina or non-ST-segl11ent elevation luyocardial infarction -were eligible 
for enroll11ent if they presented within 24 hours of the onset of chest pain and had 
ECG evidence of l11yocardial ischenlia (ST-segillent depression, transient ST-
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segment elevation 01' T-'wave changes). Critetia for exclusion included COnC0111itant 
serious illness C active cancer or significant liver or renal disease \ history of 
cerebrovascular accident or epilepsy, history of cranial or intraspinal surgelYI active 
bleeding, peptic ulcer disease, past or present haemorrhagic diathesis 01' 
gastrointestinal bleeding ·within the preceding 3 111011ths, recent nlajar surgelY or 
organ biopsy, puncture of a non-co111pressible vessel ·within the preceding 3 
·weeks, uncontrolled hypertension (systolic blood pressure above 200 111lnI-lg or 
diastolic blood pressure above 100 mmHg), history of thr01ubocytopenia or 
platelet connt < 100,000 per 1111 \vithin the preceding 24 hOUTSI concurrent use 
of or anticipated need for oral anticoagulationl recent n1yocaTdial infarction or 
receipt of thrombolytic theTapYI ECG abnormalities inteTfering 'with a reliable 
interpretation of the ST~scglllent (e.g. left ventricular hypeTtrophy with n1ajor 
repolarisation changes or left bundle branch block), planned percutaneous 
coronary intervention or coronary bypass surgery "within 24 hours following 
enrohnentl child-bearing potential 1 unwi1lingness to accept blood productsl 
planned administration ofa glycoprotein lIb/IlIa inhibitor or receipt of such agent 
,vithin the preceding 30 daysl or use of an investigational dcvice or drug in the 
preceding 30 days. The protocol was approved by the institutional review board 
at each study centre and all patients gave written infonned conscnt to participate. 
Concomitant therapy 
All patients were treated with aspirin and either unfractionated 01' low-
1110lecular-weight heparinl according to local preference. Aspirin was adluinistered 
orally in a dose of 150-250 mg immediately following the first intake of study drug 
and subsequently in a dose of 100 lUg daily. Intravenous heparin 'was to be given 
as a bolus of70 U/kg (maximum 5000 U), followed by an infusion at a rate ofl5 
U/kg per hour (maximum 1000 U per hour) for 2-5 days to achieve anclmaintain 
an activated partial-thromboplastin titue between 1.5 and 2.0 times the local 
control value. No recon11nendations "were lllade with respect to the dosing ofluw-
molecular-weight heparin whiel1 was given for 2-5 days. Other medications were 
given at the discretion of the treating physician. 
Study design 
The study ,\vas designed as a dose-escalation trial with 20 1 30 and 45 mg 
lefradafiban tid or placebo. \Alithin each dose levell patients "·lere rand01nised in 
a 3:1 ratio to receive lefradafiban or placebo in a double-blind 111annet: These dose 
levels ,vere selected based on results fron1 previous studies vl'ith lefradafihanl to 
achieve and nlaintain luean values of platelet glycoprotein lIb/nla receptor 
inhibition (FRO = fibrinogen receptor occupancy) of 56%1 67% and 75%1 
respectively. Study 111edkation was adn1inistcred as an oral solution 3 times a day 
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and 'was to be continued for 30 days. It 'was not to be taken 'ivithin 2 hours after 
or 1 hour priOT to a Inea1. The first dose was given inlll1cdiately after cllIolnlcnt 
in the study 'while subsequent doses "were given at 8-hour intervals. An additional 
loading dose was adl11inistered 3.5 hours follmving the first dose. 
A Data and Safety Monitoring Board lNas established to continuously lllOuitor 
the data on safety and efficacy and to provide continued surveillance as necessmy 
in caSe of untoward bleeding complications or other adverse events. The decision 
to proceed to a higher dose level-was made after this Board had reviC'i\"red the safety 
profile of the preceding dose level. The protocol did not prespecif'y statistical rules 
for stopping the study. If the Data and Safety Monitoring Board recommended 
adjushnent in the study design or early cessation of the trial or a cmtain dose level, 
the Steering Coml11ittee revie"wed the reC01nnlendation and nlade the final 
decision. 
Clinical and laboratory monitoring 
Patients underwent physical examination and extensive laboratory evaluation 
for haematology, coagulation and biochetnishjT at baseline and at regular intervals 
during hospitalisation and subsequent 3D-day follow-up. Qualitative determination 
of cardiac troponin-I status was perfornled at baseline. The assessment ,,,,Tas 
performed by the local hospital staff using the Gardiac STAn!s"" rapid format 
troponin-Ibedside assay (Spectral Diagnostics Inc, threshold D.) ng/ml). ECGs were 
obtained before enrohnent and both during as we11 as 30 Ininutes after episodes 
of chest pain. Additional EGGs were recorded 2, 3 and 30 days after enrolment. 
Patients were continually assessed for the occurrence of bleeding cOlnplications 
and other adverse events. After hospital discharge, patients returned for a fo11uw-
up visit every 7 days during the first 5 i\7eeks and then at 2 and 6 months after 
enrohnent. 
During enrohnent and follow-up in the 20 mg dose level, it was observed that 
patients receiving lefradafiban Inore frequently exhibited a clinically relevant drop 
in leukocyte count as compared with placebo. 1b obtain a l110re C0111plete overview 
on the OCCUlTence, tirne course and severity of the leukopenia and to provide an 
increased sUl,,Teillance on the safety of study patients, a protocol atllendillent was 
Inade which increased the frequency of the haetnatology evaluations and added 
blood samples to be taken for central analysis to further investigate the potential 
underlying pathophysiological 11lechanisll1s. In patients in \"hOl11 a drop in 
leukocyte count was observed (i.e. value below the lower limit ofno1'111al and/or 
decrease in leukocytes of at least 30% relative to the baseline value), Ineasurements 
were to be continued until leukocyte count had non11alised or returned to 
otherwise 11ledically acceptable values. Fronl these smnples, the incidence of 
neutropenia was re-estimated using absolute cell count cut-off values similar to 
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the ranges defined for tic1opidin. This Inethod accomlllOdates for the relative 
decline in leukocyte count 'which occurs in patients ,\,-ith acute ll1yocardial 
infarction and unstable angina after hospital treahncnt. In two patients puncture 
of hone 111anuw 1vas perfon11cd. Intake of trial l11cdication was discontinued if 
leukocyte count dropped belmv 50% of the 10'weT limit of 11or111a1. 
Pharmacokinetics and pharmacodynamics 
In alllefradafihan dose gronps, blood samples were drawn at baseline and day 
2, as ",,"Tell as during the weekly follow-up visits for detenllination of the fradafiban 
plaslu3 concentration and associated phan118cokinetic parameters. Levels of FRO 
'were calculated from the fradafiball plasma concentration using a phannacokinetic 
1110clel 'whose parameters 'were established fr01n preceding studies.20·21 
ECG core laboratory 
C01nputer-assisted continuous 12-1ead ECG-ischen1ia lnonitoring (ELI ST-
100, Mortara Insh'lI111ents, Milwaukee, U.S.A.) 'was perfonned, stmting itnnlCdiately 
after the intake of the first study lneclication and continuing for 24 hours to 
detect and quantify reCUlTent ischemia, All continuous ECG recordings lNere 
analysed at the ECG core laboratory (Cardialysis BV) by independent revie"wers 
lI11,l"Wa1'e oftreahnent assignnlent. The procedlues of editing "md analysis of the 
continuous ECG recording data as deVeloped and applied by the core laboratory 
have been described in detail else"where.222J The onset of au ischeillic episode "n-Tas 
defined as either ST-depression or S1:elevation of at least 100mV in one or n10rc 
of the 12 ECG leads developing within a lO-minute period and persisting for at least 
1 Ininute. The nUluber of patients 'with recurrent ischelnia, the number of 
ischemic episodes and the ischemic burden in patients "with recurrent ischelllia 
lNcre detennined, 
Study endpoints 
The pritllary safety endpoint in this trial was the occurrence of bleeding 
cOlnplications classified as maj01~ n1inOl~ or insignificant according to the criteria 
of the Thrombolysis in Myocardiallnfilrction (TIMI) Study Group," Mi\jor bleeding 
",\7as defined as intracranial haelllOlThage or bleeding associated with a drop of 3,1 
ml1101l1 (5 g/dl) or l110re in the haemoglobin concentration or of 15 percentage 
points or n101'C in the hematocrit. Bleeding was defined as 111inor if it 'was 
spontaneous and observed as gross haen1aturia or haClnatemesis, or ifblood loss 
was observed with a drop of 1.91111110111 (3 g/dl) or more in haemoglobin or of 10 
percentage points or 1110re in the hematocrit. If no bleeding site ",vas identifiable, 
it drop of 2,5 mmolll (4 g/cll) or more in haemoglobin or ofl2 percentage points 
or l110re in the hematocrit was considered to indicate l11inor bleeding. Blood loss 
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insufficient to 111eet criteria for tuino!' bleeding 'was classified as insignificant. 'Ib 
account fOT transfusion) haCl1lOglobin and hfnl1atocrit values were adjusted if 
patients received packed red blood cells or whole blood within 48 hours prior to 
the measurement by using the method of Landefeld et al. 25 
The efficacy endpoint ,\'-as the COlllposite of any of the fbllmving events 
during the one-l1lOnth h"catmcnt period: death fr0111 any cause, non-fatal 111J.TOCardial 
infarction) any percutaneous coronary intervention or coronary artery bypass 
grafting. Myocardial infarction \\7as considered to have occurred if there was an 
elevation of creatine kinase (CK)-MB or CK above the upper linlit of Hannal in 
at least 2 sanlples ·with one value above 2 times the upper Ihnit of 11on11al. 
Follmv-ing percutaneous anel surgical rev<lscularisation, the elevation of cardiac 
enzyme levels had to be at least 3 and 5 times above the upper limit of normal, 
respectively. Suspected infarctions ,vere assessed by a Glinical Events Committee 
blinded to treatlnent assignment. Secondary endpoints included the recurrence 
of unstable angina during shldy treatl1lent (defined as chest pain with concomitant 
ischeulic EGG changes) as wen as the nU111ber of patients exhibiting recurrent 
ischenlia and the ischenlic burden in patients with ischel11ia as detected and 
quantified by continuolls 12-lead ECG-ischel1lia monitoring within 24 hours after 
the start of study ll1edication. 
Statistical analysis 
Based on an expected rate of study drug discontinuation of25%, the lltU11ber 
of patients to be enrolled in each 1efradafiban group to evaluate the prhnary safety 
outcomes was approxh11ately 100. Therefore, approxil11ately 132 patients were to 
be enrolled in each dose level (99 lefradafiban and 33 placebo). Continuous 
variables are presented as 111eanS with standard deviation, and dichotonl0us 
variables as percentages. Data fr0111 the three placebo groups 'were cOl11bined to 
provide lllOre stable outc0111e esti111ates. Bleeding incidences were detennined at 
72 hours after the last intake of study 111edication in order to provide the Inost 
conservative estitnate of the safety oflefradafiban. The titnes fronl start of study 
treatlnent to the first bleeding event are disp1ayed as K.<:'lp1an-lvleier curves 
censored at 72 hours after the last intake. A nlu1tiple logistic regression analysis 
for predictors ofbleedingi\7as pcrfonncd, which also included the FRO, duration 
of heparin use and Inedian on-treatlncnt aPTT level. Frequencies of the clinical 
efficacy endpoints were detennined on an intention-to-treat basis at 30 days 
after randomisation, as we11 as fr0111 randOl11isation until 72 hours after the 1ast 
intake of shldy nledication to account for the high l1u111ber of patients discontinuing 
study treat1nent. The efficacy parameters ,vere evaluated mnong all patients as 
well as 31110ng patients with elevated troponin-I levels at baseline versus those with 
nonnallevels. 
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FRO-efficacy outcome analysis 
The relation between the level of FRO and the composite of death, myocardial 
infarction and recurrent unstable angina ·was investigated in patients who received 
lefradafiban and had at least one sample for determination of fradafiban plasma 
concentration within 8 hours of last study drug achllinistratioll. The FRO ';\'as 
calculated from up to 4 plasma concentrations. Per patient, the mi11in111111 of the 
FRO values ,vas investigated in relation to cardiac outcome. As this ·was a 
l11cchanistic type of analysis, the frequency of the c0111posite endpoint 'vas 
detennined while patients ,vere still receiving treatlncnt. 
Results 
A total of 531 patients were enrolled between April 1997 and October 1998: 
218 patients received lefradafiban 20 mg tid, 136 lefradafiban 30 mg tid, 47 
1efradafiban 45 mg tid and 130 placebo. In the initial study design, approximately 
132 patients were to be enrolled in each dose level (99 Lefradafiban and 33 
placebo). During enrolment in the first (20 mg) dose level, howeve1; it became 
apparent that lllOre patients than anticipated discontinued trial nledication due 
to revascularisation procedures (PCI with subsequent ticlopidin and CABG). The 
use ofticlopidin together with 1efradafiban IVas excluded by the protocol because 
no interaction data "were avaHable at that time. Th obtain nlOre safety data on this 
dose level, the Data and Safety Monitoring Board advised to increase the group 
size ofthis close level to 300 patients before proceeding to the next (30 mg) dose 
level. The FROST trial was discontinued in October 1998 after 61 patients had been 
enrolled in the 45 mg dose level (47 assigned lefrac1afiban and 14 placebo). At that 
time, the Data and Safety Monitoring Board recOlnmended cessation ofrecfuitment 
and discontinuation oftreahnent in this dose group since 5 (11 %) of 47 patients 
receiving lefi-adafiban 45 mg had had a major bleeding complication. 
There ·were no substantial differences in baseline characteristics among the 
treatment groups (TItble 1): 69% were male, 33% had had a previous Inyocardial 
infarction, 14% had undergone a percutaneous coronary intervention and 11 % 
% remaining on treatment 
100 
---20mg 
_.-. p!ac 
--30mg 
----·45mg 
O~---------------------
o 10 20 days 30 
figure 1 
/(aplan-Meler estimates of the 
probability to continue study 
drug during the 3~-day 
treatment period. 
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Table 1. BaseJine characteristics 
Lefradafihan 
Placebo 20 mg tid 30 mg tid 45 mg tid 
n = 130 n=218 n:::: 136 n = 47 
Age (years) 63 (10) 62 (10) 63 (10) 63 (12) 
Gender (% male) 74 67 68 72 
Weight (kg) 80 (15) 78 (13) 78 (15) 80 (15) 
Height (em) 171 (9) 170 (9) 171 (9) 171 (10) 
SBP (mmHg) 128 (19) 131 (21 ) 131 (22) 121 (19) 
DBP (mmHg) 74 (12) 76 (12) 75 ( 14) 70 (II) 
Heart rate (bpm) 72 (II) 71 (13) 72 (13) 69 (14) 
Diabetes (%) 15 15 21 17 
Current smoker (%) 28 30 26 30 
Previous MI (%) 32 31 38 34 
Previous PCI (%) 12 15 15 II 
Previous CABG (%) 13 II 12 4 
CHF(%) 6 3 4 6 
For continuolls variables, the mean values arc provided with the standard deviation in parentheses. 
CABO:::: coronary artery bypass grafting, CHF = congestive heart failure, DBP :::: diastolic blood 
pressure, MI = myocardial infarction, PCI :::: percutaneous coronary intervention, SBP = systolic 
blood pressure. 
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Table 2. Reasons for early discontinuation from study drug (%) 
Lefl'adnfibflll 
Placebo 20 mg tid 30 mg tid 45 mg tid 
n ~ 130 n~218 n~ 136 11 = 47 
Total of patients 55 % 51 % 58 % 77 % 
Rellsons 
Early stop 45 mg group 2 17 
Adverse event 12 15 23 21 
PCI (ticlopidin/abcLximab) 15 12 12 19 
CABG 12 II 10 6 
Consent withdrawn 0 2 4 2 
Normal angiography 4 2 4 0 
Other JO 10 6 II 
Abbreviations, sec legend to Table I. 
coronaTY artery bypass surgery. In all treatment groups, study drug 'INas 
discontinued prematurely in 1110re than 509-b of patients (FiguTe 1 and 'DIble 2). 
Early discontinuation "'\\'as highest among patients treated "with lefradafiban 45 lUg 
(60%, excluding those discontinued prell1aturely due to the early cessation of the 
trial), followed by patients in the :,0 mg group (58%), with slightly lower rates in 
the placebo and 20 lUg treatment anus (55% and 51 %, respectively). 
Discontinuation occurred lnainly within the first two "w"eeks of study drug 
admini::;tration. The majority of the patients who did not "withdrm\' from study drug 
during this periocl completed the intended 30-day treatment periocl, Among all 
treatment groups, n1<~jor reasons for study drug discontinuation ,vere the 
occurrence of an adverse event (mostly bleeding), planned coronary artery 
bypass surgery and the use of other antiplatelet agents (abciximab, tielopidin) 
during or fbllmving percutancolls coronary intcrvention (Thble 2). 
249 
Chapter 74 
Efficacy results 
Cardiovascular events 
Event rates determined from start of treatment up to 72 hours of study drug 
discontinuation sho'wed a trend to-wards a beneficial effect oflefradafiban 30 111g 
\'\'he11 cOlnpared with placebo and lefradafiban 20 l1lg on the incidence of death 
or 111yocardial (re)infarction according to the Clinical Events C0111l11ittec. \"7hen 
c01npared with placebo, there 'INas a 30% relative reduction in the C0111posite 
endpoint of death, myocardial (re)infarction, PCI or CABG in the lefraclafiban 30 
mggroup (Thble 3). Also, the composite outcome of death, myocardial (re)infarction 
or reclirrent angina leading to rehospitalisation detennined at 72 hours aftel' 
study drug discontinuation 'was reduced in patients receiving lefradafiban 30 111g 
(111ble 3). A shnilar pattern was apparent when the incidence of death, myocardial 
(re)infarction or any recurrent unstable angina was evaluated mnong the four 
treatment groups. At 30 days, the incidence of death or myocardial (re )intarction 
was low and conlparable among all treatnwnt groups, while the reduction in the 
3D-day COll1posite of death , 111yocarclial (re)infarctio111 PCI or CABG 'was less 
pronounced (relative reduction 24% 'when cOlnpared 1\"Tith placebo, 'Pdble 3). 
Efficacy by troponin-I status 
Of the 531 patients entered, 455 (3(;%) had tl"oponin-I assay results available. 
The test result at baseline was positive (::00.1 ng/ml) in 118 (26%) of these patients 
and was negative in 337 (74%) patients. The proportion of patients \vith positive 
versus negative troponin-I assay results 'were comparable atuong the fOllr treat1ncnt 
anns. In each treahnent group, the incidence of the 3D-clay composite endpoint 
of death, myocardial (re )infarction, PCI or CABG was higher among patients 
with a positive troponin-I test result at baseline when cOlllpared with those with 
% Death/MIIPCl/CABG (30 d) Figure 2 Incidence of the composite 
Trop-I (+) Trop-I (-) endpoint of death. MI, PClor CABG at 30-dav fol/ow-up 
50.0 among patients with a positive 
42.1 44.4 troponln-l test result at baseline 
35.7 35.7 (left panel) versus those with a 
:1'0 
negative test result (right 
panel). CABG ~ coronary 
arterv bvpass grafting: MI ~ 
myocardial infarction as 
adjudicated bV the Clinical 
Events CommiHee; PCI = 
24 57 28 9 n 84 percutaneous coronary 
intervention. 
plac 20mg 30mg 45mg 
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Table 3. Efficacy outcomes (%) 
Lcfradafiban 
Placebo 20 mg tid 30 mg tid 45 mg lid 
n ~ 130 n ~ 218 n ~ 136 n =47 
At 72 hOllrs /olloll'illg hut 
study drug administration 
Death/MI 3.1 % 3.2 % 2.2 % 4.3 % 
Death/MI/PCI/CABG 31.5 30.7 22.1 25.5 
Death/MIIAP-rchosp 7.7 6.9 2.9 6.4 
DeathlMIIAP·any 17.7 17.0 4.4 12.8 
A t 3D-day folloll'-up 
DeatlllMl 3.1 4.1 4.4 4.3 
DeatlllMlIPCIICABG 43.1 35.9 32.6 40.4 
Percentages refcr to total number of patients in each trcatment group. P-value (2-sided) provided according to 
Fisher's Exact Test for comparison hetween placebo and lefradafiban 30 mg. AP-any:::: any [eCliITent unstable 
angina pectoris; AP-rehosp :::: recurrent angina pectoris leading to rehospitalization; CABG::: coronary artery 
bypass grafting; MI :::: myocardial infarction as adjudicated by the Clinical Events Committee; PCI :::: 
percutaneous coronary intervention. 
a negative test result (Figure 2). In patients 'with a positive troponin-I as ",veIl as 
in those with a negative test result I the cOlnposite endpoint OCCUlTed 1110st 
frequently in patients receiving placebo l while the event rate decreased with 
increasing doses of lefradafiban l with exception of the 45 111g dose (ver:y sl11a11 
nmnber of patients). The dose-dependent reduction in event rate associated with 
lefradafiban 20 mg and 30 mg appeared greater in patients with a positive 
troponin-I at baseline (ca. 15% and 30%/ respectively) than in those with a 
negative test result (10% and 13%). 
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"- Figure 3 « 30 >- Incldence of the composite 
c 
endpoint of death, ~ 25 ~ 
:;;; Placebo: 16.9% myocardIal infarction or any 
? n=130 recurrent angina in relation to 1ii 20 17.8 i 
" 
16.3 the minimum FRO level. Event 
0 15 HI~[~I::II:l, rates are determIned while ~ 10 patients were still receiving ~ study treatment. AP = any " 5 49 107 recurrent angina; FRO = ' § fibrinogen receptor 
"- 0 occupancy,' Mf = myocardIal ~ Infarction as adjudicated by 0 <40 <50 <60 <70 <80 <90 <100 
the Clinical Events 
Minimum FRO Level in % CommiHee. 
Efficacy by FRO level 
There 'were 356 patients who received lefradafiban and had at least one 
evaluable fradafiban plasma concenhation value for deternlination of the FRO level. 
There 'I\Tas a clear relation between the ll1inilllum FRO level and the observed 
incidence of the composite of death, 111yocardial infarction and any recurrent 
unstable angina (Figure 3). The event rate decreased with increasing 11linimal FRO 
levels. The lm\"rest event rate was found in patients \vith a 111ininlal FRO level of 
at least 70%. In contrast, in patients \\"rith a minimal FRO level below 50%, the 
cardiac event rate appeared higher than in those receiving placebo (Figure 3). 
ECG-ischemia monitoring results 
FOlll' hundred and thirteen patients (78%) had continuous ECG recordings 
suitable for analysis, Duling the 24-hou1' monitoling peliod, ischemic episodes were 
detected in 33 (33%) ofthe 99 placebo patients, 56 (31 %) of the 17B lefradafiban 
20 mg patients, 25 (25%) oftlle 101 lefradafiban 30 mg patients and 16 (46%) of 
the ~15 lefradafiban 45 11lg patients, There were no differences between groups in 
the nU111ber of recurrent ischemic episodes or the anlOunt ofischenlic burden, 
Haemorrhagic events 
A dose-dependent increase in bleeding incidence was observed with the 
l11ajority of the bleedings occurring during the first two weeks of study drug 
adll1inistration (Figure 4). The incidence oftuajor or minor bleeding complications 
was low- in patients receiving placebo (1 %) while it gradually increased with 
higher doses oflefradafiban up to 15% in patients treated with 45 mg tid (Thble 
4), Intracranial haernorrhage occurred in a single patient who was treated with 
thrOlubolysis for acute myocardial infarction while receiving lefradafiban 20 lUg 
(Thble 5). The percentage of patients who required a blood transfusion ranged limn 
1 % in the placebo group to 9% in the 45 lng group with intenllcdiate figures for 
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% with bleeding 
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Figure 4 
Kaplan-Meier estimates of 
the occurrence of any 
bleeding complication. 
Bleeding episodes are 
included up to 72 hours 
following last study drug 
admlnlstratlon. 
the 20 mg and 30 mg groups. A dose-related increase for bleeding complications 
leading to discontinuation from study drug was observed. A similar dose-related 
increase 'was apparent for insignificant bleeding events; the percentage of patients 
in the placebo group experiencing any bleeding 'ivas 19% as compared \vith 39% 
in the 20 mg group! 57% in the 30 mg group and 67% in the 45 mg group CTabie 
4). Among all treatment groups, gingival and arterial or venous puncture site 
bleedings 'were most common and accounted for more than 60% of all 
haemorrhagic events (Thille 5). 
By 111ultiple 10gistic regression analysis (model terms: FRO, age, 'weight and 
esti1nated creatinine clearance as continuous meaSUretllents, as 'well as gender), 
higher levels of FRO and a higher age were founel to be significantly related to an 
increased bleeding incidence, The odds for bleeding increased 'I\lith a factor of 1 ,023 
for every increase in FRO level by 1 % point (95% confidence interval (eI), 1.016-
1.030) and 1.022 fm one year increase in age (95%CI, 1.003-1.044). In addition, 
gender proved to be a significant predictor of bleeding (fenlale versus male, odds 
ratio 1.54 w"ith 95%CI, 1.03-2.46), In separate analyses, no statistically significant 
association 1\Tas found between the occurrence of bleeding and the duration of 
heparin therapy or the tnedian on-treatnlent aPTT level. 
Haematological changes 
Treatment ',"Tith lefradafiban was associated with an increased incidence of 
leukopenia, Ol~ more precisely, neutropenia, The incidence ofJeukopenia, defined 
as leukocyte count below 4xlO"/I, was estimated at 5.7 i jU in the lefradafihan groups 
compared with 2.3% in the placebo group. Neutropenia (neutrophils below 1.5xIQ9/1) 
occurred in 5,2% of the lefradafiban groups and 1.5% of the placebo group. In the 
patients with observed neutropenia, the decrease in neutropbils was characterised 
by an early onset (inlmediately after first study drug administration or within the 
next 2 days) and a fast recovery after discontinuation of lefradafiban (Figure 5). 
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Table 4. Incidence and SCl'ctity ofbkcdlng ennts "uliln hours after study dmg discontinuation (%) 
Lefradafiban 
Bleeding cvent 
TIr'lI! - major 
TIMI - minor 
T1r-.n - major or minor 
Requiring transfusion 
Leading to discontinuation 
Any 
l'laceho 
n =: 130 
% 
0 
2 
19 
20 mg tid 
n =: 21H 
3 % 
5 
2 
5 
39 
Percentages refer to total number of patients in each treatment group. 
TIMl = Thrombolysis in Myocardial Infarction 
Table S. Location of bleeding (%) 
30mg tid 
n = 136 
3 % 
4 
7 
4 
10 
57 
Lcfmdafiban 
Bleeding cvent 
Intracranial 
Retroperitoneal 
Gastrointestinal 
Genitourinary 
Hematoma 
Oral I gingival! epistaxis 
Puncture site 
Placebo 
n = 130 
0 % 
0 
0 
3 
5 
3 
12 
20 mg tid 
n=21S 
% 
7 
5 
9 
15 
19 
Percentages rcler to total numl'>cr ofh1ecdings located at each site. 
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30 mg tid 
n =: 136 
0 % 
0 
10 
10 
9 
31 
29 
45 mg tid 
n=47 
II % 
6 
15 
9 
15 
67 
45 mg tid 
11=47 
0 % 
0 
II 
4 
11 
28 
34 
Neutropenia 
neutrophils (109/1) 
10 start drug 
8 
6 
4 
2 
o~===~~~ 
stop drug 
o days 6 0 
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days 6 
Figure 5 
Neutrophil counts in 
individual patients 
experiencIng neutropenia, 
In relotion to study drug 
start and dIscontinuation. 
Although the clinical SYluptOlUS of chills and fever occurred in patients ·with 
neutropenia) none developed a serious infection or pCf1llancnt neutrophil deficiency. 
Based on central analysis of blood and bone 11lanm\T salnplcs obtained in patients 
with severe neutropenia by independent expert haClnatologists) it "'Nas concluded tl1at 
the observed neutropenia most likely resulted £r0111 a reversible redistribution of 
neutrophils by margination or clustering rather than £1'0111 bone l11arrm\T depression. 
Al! bone marrow samples showed continued cellularity with a deficiency of later-
stage cells of the granulocyte series. There ·was no evidence of aplastic anaemia or 
changes associated with agranulocytosis. In addition) patients ·with neutropenia 
responded to treatment with G-CSF or steroids with prompt normalisation of their 
neutrophil counts. In patients with simuHaneous decrease in other b100d cell 
populations the pattern was consistent with a generalised redistribution but not with 
i1npaired production by or release of cells from the bone marrmv. 
Thrombocytopenia (platelets below 90xlQ'/I) occurred in only 2 (0.5%) of401 
patients treated with lefradafiban. No placebo recipient had thrombocytopenia. 
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Discussion 
In this double-blind, TandOll1iscd, dose-escalation trial of onC-ll1onth GP 
lIb/IlIa inhibition with lefradafiban in patients 'with acute coronary syndrOll1es, 
we observed a decrease in cardiovascular events with lefradafiban 30 lUg and a 
dose-dependent increase in haeJllorrhagic events. 
Safety 
Close relations betlNcen the dose of lefradafiban adlninistered, the plaSllla 
concentration of fradafiban, the fibrinogen receptor occupancy (FRO), and the 
degree of platelet inhibition have been established in previous studies with 
lefradafiban and fradafiban, both in healthy volunteers and in patients 'with 
coronary artery disease. 20·21 
Bleeding 
As in other studies with long-term treatment with oral GP lIb/IlIa receptor 
blockers, bleeding occurred frequently and 'was dose-dependent. Howeve1~ the 
Inajority ufthe bleedings ,\7ere mild or clinically insignificant. The incidences of 
bleeding cOlnplications in the lefradafiban 20 lng and 30 lng groups 'were shnilar 
to the rates observed ,dth other oral GP Ilb/Illa receptor blockers at shnilar levels 
of platelet inhibition.26-30J, while the very high risk of major or minor bleeding in 
the 45 mg group resulted in cessation of recruihnent and discontinuation of 
treatment in this dose group. The results of the 111uHivariable logistic regression 
analysis in the present study support earlier observations with an increase in the 
risk of bleeding of 2.3% for every increase in FRO level by 1 % point. 26.27 The 
magnitude of this association is shnilar to that found in a previous study of 
lefradafiban in patients with stable coronary artery disease undergoing elective 
percutaneous coronary intervcntion. 21 
The clinical pattern of bleeding was largely mucocutaneous: epistaxis, gingival 
bleeding, gastro-intestinal and genito-urinary bleeding, or bruising. No excess 
strokes werc obscrved with lefrac1afiban. This pattern has also been observed with 
othcr GP Ilb/Illa receptor blockers.6,13.26'30), and is shnilar to that seen with 
thro111bocytopcnia and in Glanzmann's thr01nbasthenia. 31 Arterial and venous 
puncture sites were the second lllost comnlOnlocation of bleeding. Other studies 
have dCll10nstrated that bleeding at vascular puncture sites can be reduced hy the 
usc of low-dose I w'eight-adjusted heparin regilnens, early felnoral arterial sheath 
rClnoval and careful access site managenlent. 7,TO,32 Although the protocol 
recolll111ended a low-dose, weight-adjusted heparin regi111en during the early 
phase of lllcdical trcatlnent, no specific heparin dosing reginlen during 
pcrcutaneous coronary intervention was provided. 
Given the intCl"-patient variability in drug level and degree of platelet inhibition 
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observed with oral GP lIb/IlIa receptor antagonists, another potential strategy for 
reducing bleeding complications could be to monitor the degree of platelet 
inhibition achieved in individual patients and to 3c\jnst the close to a target level, 
as is done "Tith anticoagulant therapy':l3.:34 
Neutropenia and thrombocytopenia 
'ItcatnlCnt "with lefradafiban "was associated ",\\"Tith an increased incidence of 
neutropenia,21 \'Vhcrcas leukopenia due to bone Inarruw depression has been 
reported for other antiplatclet agents (ticlopidin).JC, expert analysis of blood and 
bone 11laHOW sa1nplcs obtained in FROST patients revealed that the observed 
neutropenia lllOSt likely did not result fr0111 bone 111alTOW depression but Tathcr 
fTOll1 a reversible redistribution ofllcutrophils by l11argillation or clustering. It \\7as 
reassuring that all patients shmved a fast recovery of neutrophil count after 
discontinuation oflefradafiban/ and that none developed infection or pennanent 
neutrophil deficiency. Yeti nlOre investigations are needed to further elucidate the 
exact nlechanisnls involved I as ,veIl as to detennine the opthnal duration of 
surveillance and the possible clinical associations. 
The incidence ofthr0111bocytopenia associated with lefradafiban (0.5%) 'was 
low and similar to that reported for other oral GP IIb/IIIa receptor blockers.2~ 
Efficacy 
The 30-day incidence of death or non-fatallllyocardial infarction was low in 
this study. The study was not designed to detect differences in clinical outcOllles 
between the treatment groups, yet there 1Nas a trend to-'wards a reduction in 
cardiovascular events in the lefradafiban 30 mg group compared with placebo and 
lefradafiban 20 mg. The sample size for the 45 mg cohort of patients was too small 
to detect a meaningful trend. The reduction in the composite of death, myocardial 
infarction, PCI or CABG was greater in the on-treatment analysis than when the 
endpoint was determined at 30 days. This suggests that the treatment benefit may 
be enhanced in patients who continue on medical therapy.36 In patients undergoing 
PCI or CABG, the post-procedural event rates are very low and no benefit is to be 
expected.28.37 
Patients with a positive troponin-I bedside assay at baseline were at increased 
risk of unfavourable outc0111e. This observation is concordant ,vith the results of 
previous studies which have shown that mnong patients with unstahle anginal 
elevated seHnn troponin-T and troponin-I levels are independent predictors of 
short- and long-tenn risk of adverse cardiac events. 33-41 Ttoponin-T and troponin-
I reflect tninitnal or larger tnyocardial injury due to occlusion of the culprit 
vessel or distal mnholisation of platelet thrombi originating from the culprit 
lesion.4243 As glycoprotein IIh/lIla receptor blockers inhibit thrombus formation 
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at the culprit lesion and facilitate the resolution ofthrOlnbi."A)1 they arc expected 
to be particularly effective in patients 'ivith elevated troponin lcvcls:15,~6 Indeed) 
treatment benefit among FROST patients appeared greatest in those with positive 
truponin-I at baseline. This observation parallels those of the FRlSC and FIUSC 
II trials, and the recently reported truponin substudies of the CAPTURE and 
PRISM trials. 36.38.45.46 The data fron1 the present study therefore support the 
therapeutic concept that elevated troponin-T or troponin-I levels identify the group 
of patients 'with acute corollary syndrOlucs and active thrombosis who are at high 
risk for cardiac events and 'who will benefit 1110St £r0111 a 1110re intensive treattllcnt 
strategy including the administration of GP lIb/IlIa receptor blockers and low-
l11olecular-lNcight heparin. 
The trend towards a reduction in clinical events with lefradafiban 30 lUg in 
this study contrasts 'with the results of recent, large-scale clinical trials oflong-term 
oral GP lIb/lIla inhibition with xemilofiban, orbofiban and sibrafiban in patients 
after PCr. 28) and acute coronatjr syndrOlnes.29.~;o In thi.s respect, several points 
deserve consideration. First, the risk of recurrent ischemic events in the patient 
populations included in these trials Inay have been too Imv to detect benefit of 
long-term GP lIb/IlIa receptor blockade. In the EXCITE trial, xemilofiban or 
placebo was adlllinistered prior to and for sLx nlOnths after PCr. 28 In accordance 
'with the results of previous trials of intravenous glycoprotein lIb/lIla receptor 
blockers, xemi10fiban protected against procedure-related cOlnplications. I"Iowevel~ 
the risk of subsequent events follm\7ing PCI 'was velY law, and no fluther benefit 
was observed. In OPUS-TIMI-16, patients were included for up to 72 hours 
ibllawing an episode of chest pain, 'while ischel11ic ECG changes or positive 
cardiac enzyn::tes were not mandatory for enroltnent.2'] Long-tel'1n treahnent 'with 
orbofiban in this trial resulted in a nlOdest 11 % relative reduction in cardiac 
events at 30 days, pritnarily due to a reduction in urgent coronary intervention. 
In the SYMPHONY trial, patients could be included for up to 7 days after the onset 
of the acute coronary syndrOlne, and had to be stabilised for 1110re than 12 hours 
from the initial presentation.3/) AhlloSt 25% of all patients unden\7ent a percutaneous 
coronalY intervention between the qualifying episode and rand0111isation. No 
benefit 'was observed '''lith sibrafiban after DO days of treatment. All trials shu-wed 
a trend towards an increased nlOrtality in the GP JIb/lIla inhfiJitor treatment groups. 
The phannacokinetic and phannacodynamic profile of the8e agents is 
characterised by a steep dose-response relationship and by a short half-life relative 
to the dosing intervaJ.26?7.29 Thus, the twice-daily dosing regimen in the orbofiban 
and sibrafiban trials n1ay have caused widely fluctuating inhibition of platelet 
aggregatioll,,29.30 This l11ay have allowed complete recovery in platelet function 
between doses in S0111e patients, 'with exposure of activated GP lIb/IlIa receptors 
on the platelet's surface.47 Whereas it has been reported that high peak blood levels 
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of oral GP JIb/IlIa receptor blockers increase the risk ofbleeding.262", recent studies 
of platelet activation have also raised the possibility that platelet receptm 
antagonists 1118YI at Imv concentrations) alter the .steric confonllation of the GP 
lIb/IlIa receptor sites, and paradoxically, enhance the thrOl11bogenicity of these 
sites. 47.48 
In this study, the cardiac event rate decreased 'with increasing l11initllal FRO 
levelsJ "with the }mvest event rate found in patients 'with a luinhnal FRO level of 
at least 70%. In contrast, patients 'with a 111inimal FRO level belm\' 50% appeared 
to have a higher cardiac event rate than patients receiving placebo. These findings 
suggest that an effective treatment with the GP JIb/IlIa receptor antagonist 
lefradafiban can be anticipated with marked levels of inhibition of platelet 
aggregation (i.e. FRO levels of at least 70%). 
It should be emphasised that the present study was not designed and powered 
to definitively evaluate differences in clinical DUtCOlllCS between treatment 
groups. The observed favourable trend in the lefradafiban 20 mg ane! 30 mg 
groups '\Tith a reduction in clinical events requires confinllation in an adequately-
powered clinical trial. 
Conclusion 
It is a challenge to exploit the potential beneficial antithrombotic effect of oral 
GP IIb/Illa inhibitors in relation to the associated risk ofhaenlorrhage,26.49 Dose-
ac,jnstl1lent on the basis of patient characteristics that influence drug levels, such 
as renal function and body 'weight,26,W,30\ as well as dose-titration to a target level 
of platelet inhibition, measured with a Tapid platelet-function assay.33.M), 1nay 
improve the overall safety and efficacy protlle. 1b increase the treatnlCnt benefit 
of(01'a1) GP IIb/Illa receptor blockers, one 111ay choose to treat only patients '\;\Tho 
are at high risk of adverse cardiac events, such as those 'who present 'Nitll elevated 
troponin levels or "who exhibit recurrent ischelllia and continue on Inedical 
therap'y.23.38.4~,46 These patients may particularly benefit from a more aggressive 
therapeutic approach.38.45,46 
Although data from this stuely may suggest that an effective treatment with 
the GP lIb/IlIa receptor antagonist lefradafiban can only be anticipated with 
marked levels of inhibition of platelet aggregation (i.e. FRO levels of at least 70%), 
the level of platelet inhibition needed to prevent recurrent ischemic cardiac 
events, as v,rell as the optinlal duration of treahnent after an acute coronary 
syndr0111e require further investigation. A potential treatlllent strategy for patients 
adnlitted with acute coronary syndromes ,vou1cl include the achninistration of a 
rapid-acting intravenous GP Ilh/lIIa receptor blocker during the acute phase, 
fbllmved by conversion to an orally active preparation of the same compound for 
prolonged outpatient secondary prevention.49 If a patient undergoes percutaneous 
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coronary intervention, it may be advised to continue the oral drug, or to convert 
to the intravenous preparation during and for 12-24 hOUTS follo1ving the 
intervention.5-l0 As the risk ofsuhscqucnt events follm .... Ting pel is 100\T/ no further 
treattncnt with oral GP lIb/nIa receptor blockers seenlS rcql1ired.28.37 The need for 
cOllcOlnitant anticoagulant therapy should be evaluated. 
The intravenous GP IIb/lIla receptor blocker fraclafiban and its orally active 
prod rug lefradafiban, as t'lVO completllcntary preparations of the same c01llpound/ 20 
are suited to be used in such strategy, and l1light be evaluated for their efficacy 
in reducing ischemic cardiac events atuong patients 'with acute coronary syndromes 
in a large clinical trial. 
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MC Alkmam; VAWM Um(I11' (4Z); Sint Francisens Gasthnis, P Nierop (37); 
T\\'eesteden Ziekenhllis, H Baa,-, (Z7); Spaarne Ziekenhnis, EJ Miiller (Z3); 
Acade1nisch Ziekenhuis Rotterdanl~Dijk7,igt, C vel Zwaal1, 1\1L 8i11100ns (22); 
Ziekenhlli, Hilversnm, P de MilliwlO (ZZ); MC Leenwarden, R Breedve1d (14); 
Ziekenhlli, Sint Jansdal, R Dijkgmaf' (IZ); Ziekenhnis De Tjonger,chans, GM 
Jocl"",,,,,,, (7); Sint Clara Ziekenhnis, M Sc1wf)er (5); Ziekenhllis De Weezenlanden, 
H S1Iryaprwwta (4); Hofpoort Ziekenhllis, E Wajon (Z). 
Germany (7 75 patients) 
,Tohannes Gutenberg-UniversWit Mainz, H Dmius (41); Klinikum Nilrnberg 
Siid, M Gatt/vile, W Riego (41); Kliniknm d. Albert-LlIdwigs-Universitiit, C Hol1lbarsch, 
H Liidemw11l (lD); Universitiit Heidelberg, C Bode (7); Stiidtische Kliniken Kassel, 
K-L Ne1liJa1l', U Zeymer (6); St Marien Krankenhaus Siegen, P Sch1lster (4); 
Stiidtische Krankenhaus Traunstein, K Schlotterbeck (4); Stiidtische Kliniken 
Offenbach, F Praetori1l' (1); Kreiskrankenhans Liidenseheid, ]( Hemichs (1). 
United Kingdom (703 patients) 
Antrim Hospital, T 7Jmilon (41); University Hospital Nottingham, RG wilcox 
(Z6); King's Mill Hospital, 1M Rowley (10); Birmingham City Hospital, lIDS Wat,on 
(6); The Royal Alexandra Hospital, IN Findlay (5); Nottingham City Hospital, DC 
Banks (4); Leeds General Infirmary, G Reynold, (3); Royal Victoria Hospital, AL\1 
Adgey (3); North Manchester General Hospital, 1W Swan (Z); Victoria Hospital, M 
Francis (Z); Hartlepool General Hospital, G Tildesley (I). 
France (92 patients) 
Hapital TImon, A Villumiall (Z8); H6pital Notre Dame de !lOll Secours, K 
KIU!1if'e (Z5); Centre Hospitalier de Lorient, P CaZ(lllX (18); Centre Hospitalier 
Cochin, P Ric/ull'd (10); Centre Hospitalier German et Gauthiet; C Myeillsl" (7); 
Centre Hospitalier de Lagny, T DOlil11iez (Z); H6pital de Freyming Merlebach, P 
Dambn'l1c (1); Centre Hospitalier Universitaire de Poitiers, D COiSllC (I), 
Belgium (4 patients) 
H6pital de la Citadelle, J-L Bolalld (4). 
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Summary and conclusions 
Acute coronary syndrOlnes j which include unstable angina, acute l11yocardial 
infarction, and the acute COll1plications of percutaneous coronary intervention, 
are important global public health problems and the leading causes of morbidity 
and lllOrtality in the '''Testcrn V\Todd,l Patients presenting lNith these syndr0111cs 
are at increased short-tcnll and long-tcT1n risk of death) Inyocardial (rc-)infarctioll) 
recurrent anginal congestive heart failurc, alThytlllllias, and the need for coronary 
revasculaTization procedures. As described in chapter I, the developlllcnt of an 
acute coronary ischclllic event is believed to involve a disruption (nlptllTc j 
fissuring or erosion) in atherosclerotic vascular plaque, resulting in activation of 
platelets and the coagulation cascade. Formation of a local thrOlnhus as a response 
to vascular injury can then lead to several consequences: varying degrees of 
vessel occlusion 'with resultant dinlinished coronary blood flmv, distal etnholis111 
of thrOlllbotic Inaterial causing capillary plugging and myocardial necrosis, and 
incorporation of the local thrOlnbus into the growing plaque leading to a progression 
of atherosclerosis?·4 As sUll1111arized in chapter 1, recognition of the pivotal role 
of thro111bosis in the pathophysiologic process of the acute coronary syndrOlnes 
has led to a focus on antitllT01nbotic therapies, specifically anti platelets and 
antithrolnbins. Aggregation of activated platelets plays a central role in the 
process of coron811' thrOlllbosis. 5 Irrespective of the pro-aggregatoly sthnulus, the 
final COnllllOn pathway to platelet aggregation involves bridging of platelets via 
their activated glycoprotein (GP) lIb/IlIa receptors by fibrinogen and other 
adhesive ligands.5 A ne'w class of agents, kn01\1n as GP Ilb/Illa receptor blockers, 
has been designed to block this terminal step and thereby inhibit coronary 
thrombosis. The efficacy of GP lIb/IlIa blockers in reducing ischemic complications 
was clearly shm\rn in a large nUlnber of patients undergoing percutaneous 
coronary revascularization procedures 'with and without stent deploYlnent.&-11 In 
these trials of percutaneous coronary interventions, patients receiving GP lIb/IlIa 
inhihitors had an approximately 30% lo'wer occurrence of the conlposite of death, 
Inyocardial infarction, or need for urgent repeat revascularization 'within 30 days. 
Based on these favorable results, the use of GP lIb/IlIa blockers was extended to 
the mnpiric treatnlent of acute coronary syndrome patients. As reviewed in 
chapter 1, two Inajor treatment strategies, using a variety of agents, have been 
studied. One approach focllses on the lise of medical therapy and the other 
cOlllbines GP lIb/IlIa blockers with percutaneous coronary intervention. 
This thesis addresses several aspects of the clinical evaluation ofGP lib/IlIa 
receptor blockers in patients with acnte coronary syndromes. A number of 
111anl1scripts descrihed in this thesis have been based on data originating from the 
large Platelet glycoprotein lIb/IlIa in Unstable angina: Receptor Suppression 
Using lntegrilin (eptifibatide) Therapy (PURSUIT) tria1. '213 
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PURSUIT compared the GP lib/IlIa inhibitor eptifibatide with placebo in 
addition to standard therapy in 9461 patients with acute coronary syndrOlllcs ·who 
did not have persistent ST-segment elevation. A total of 726 hospitals £r0111 27 
countries in four geographic regions (VVestern Europe, North .A.Jllcrica, Eastern 
Europe, Latin Alllcrica) participated. Patients were eligible for enrolhllcnt if they 
had ischeUlic chest pain ·w"ithin the previous 24 hours and either ECG changes 
suggestive ofischCluia (ST-scgnlCnt depression, T-:wave inversion, or transient ST-
segment elevation) or a creatine kinase-ME fraction above the upper litnit ofnol1nal 
for that hospital. Patients '1vere rand0111ly assigned in doub1e-blind fashion to an 
intravenous bolus and infusion of placebo or 180 ~lg. kg-I bolus plus infusion of 
2.0 fIg. kg' min-1 eptifibatide. Study dmg was to be infhsed over 72 hours, but could 
be continued for up to 96 hours if a percutaneous coronary intervention "'INas 
performed at the end of the 72-hour treatment period. All other treatment 
decisions, including the use of hcparin, other anti-ischemic medications and 
coronary angiography, as 'well as the usc and tilning of percutaneous or surgical 
coronary revascularization, 'were left to the discretion of the treating physician, 
C01npared 'with placebo, treat1ncnt 'with eptifibatide resulted in a statistically 
significant 1,5% absolute reduction in the 30-day C0111posite endpoint of death and 
non-fatal (re )myocardial infarction as adjudicated by an independent Clinical Events 
Conll11ittee blindcd to treatnlent assignl11ent. The composite endpoint "was also 
calculated using the site invcstigator determination of myocardial infarction. 
Clinical endpoint determination: methodology and impact 
Myocardial infarction is a potentially catastrophic event in paticnts presenting 
"with acute coronary syndromes and an important efficacy cndpoint in clinical trials, 
Although myocardial infarction has heen considercd a IIhard" end point, 
determination of myocardial infarction endpoints in clinical trials can be difficult, 
just as in clinical practice, because of conflicting clinical, laboratory, and 
electrocardiographic data. As prevention of IllJ.TOcardial infarction has been the 
primary treatment effect assessed in recent hials of anti platelet and antithronlhotic 
therapies/- I2. 14,18 Clinical Events Conllnittees have becOllle an integral aspect of 
clinical trials of nC\'\' therapies for patients 1Nith acute coronary syndrol1les to 
provide a systematic, unbiased, independent, and standard assessment of this 
endpoint. 19•23 Accordingly, in the PURSUIT trial, a centralized, independent 
Clinical Events Conllnittee systClnatically identified and H(1iudicated all sllspected 
infarctions that occurred after enrolhncnt and through 30-day follow-up, 
In chapters 2 and 3, 'we revic1Ncd the structure of the Clinical Events 
Committee and the event-adjudication process as used in the PURSUIT trial. 
The Clinical Events Committee identified 5005 suspected infhrctiolls, of which 1415 
(2B%) were adjudicated as infarctions, Rcvie';,T of the clinical events classification 
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process raised i1npOliant issues. First, the rates of infarction ,vere higher than those 
reported in prior trials of patients with acute coronary syndromes,l2.l7.l8.24 Second, 
protocol-defined 11lyocardial infarctions were l1nderreported by the site 
investigators. Third/ the site investigator and the Clinical Events Committee 
assessment of infarction disagreed for 983 (20%) of the 5005 patients reviewed by 
the Committee. Most of the disagreenlents reflected investigator 11lisc1assification 
ofpost-enrol1ment myocardial infarctions (as cnrollnlcnt 111yocardial infarctions 
instead) or underreporting of peri-procedural 111yocardial infarctions as 1NC11 as 
myocardial infarctions defined by cardiac cnzylllc elevations '\7ithout clinical or 
ECG evidence of ischemia or infarction. Fourth, the observed trcahllent effect "v-as 
smaller using the Clinical Events Conllllittee adjudicated 11lyocardial infarction 
rates versus site investigator-identified event rates. Finally, in a retrospective 
analysis that excluded cases of lllyocardial infarction that, despite lneeting the 
pre specified endpoint criteria, had conflicting clinical, ECG, and cardiac-enzynle 
data, the treatment effect ·w-as larger than that seen when such cases were 
included. 
Several explanations for these five observations arc provided. In aggregate, 
the findings suggest that Clinical Events C0l1l111ittee adjudication of suspected 
nonfatal myocardial infarction endpoint events is ilnpOltant to provide illdependent, 
unbiased, standard, systematic assessnlent. Hm\TeVel~ the definition of lllyocardial 
infarction and its application in Clinical Events Conll11ittee event adjudication in 
PURSUIT may have been too inclusive of myocardial infarctions defined by 10w-
level enzynle elevations (creatine kinase-ME above once the upper li1llit of 
n01'1nal), \',1hich either represented nnoisen or clinically unimportant events. 
Therefore, Clinical Events C01lllnittee adjudication does have certain limitations; 
in cases in which the clinical history, the cardiac-em-::yme data, and ECG information 
are inconsistent, or cardiac-enzYllle data suspect, the deternlination of myocardial 
infarction nlay require l110re clinical judg111ent although this 111ay decrease the 
objectivity that is ilnportant for event classification, particularly in trials across 
geographic regions and clinical-practice settings. Although the absolute difference 
in infarction rates dete1'lnined by the Clinical Events C0l1n11ittee versus site 
investigators "\Tas s111all, the relative difference was l110re substantial. This caused 
a substantial ilnpact on the statistical outc0111e of the trial. This phen0111enon has 
also been observed in other large clinical trials and HUlst be considered in saIllple-
size and power calculations during design of future trials. Furthe1'1llore it also 
influences how clinical and regulatory bodies interpret trial results. Therefore, the 
Clinical Events COl1unittee process used Hlllst be considered, anlOng other factors, 
"',1hen perf01'lning conlparisons of event rates between trials. 
In PURSUIT, as in other large international trials, there 'were considerable 
variations in 0l1tc0111e of patients iH different geographic regions. 12, 2.5--28 In the 
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initial univariate PURSUIT analysis, the treahncnt effect appeared greater in 
North Alnerica than in i,"{estern Europe, 'while no trcahncnt effect was apparent 
in Latin Anlerica and Eastern Europe. HowevB1~ the confidence intervals for the 
treahncnt effects in these regions ·were wide and overlapping. Due to the large 
llUlllber of patients treated in the various regions, this trial afforded a unique 
opportunity to gain insight into the heterogeneity of the disease and patient 
population, and to study differences in 111cdical practice patterns and treatment 
strategies. Therefore, in chapter 4, i\TC reviewed these regional differences and 
analyzed the factors that 11light conttibute to the geographic vmiations in patient 
outcome and treatment effect. 
Major differences in baseline del1lOgraphics were apparent mnong the four 
regions. Interventional treahnent also varied considerably. After l1ulltivariable 
a(1justment, the pattern of benefit "with eptifibatide was consistent 31110ng the 
regions. In general, the differences in outc0111e and treatment effect were greatest 
when the protocol definition of myocardial infarction (CK-MB> 1 upper normal 
limit) was applied. Under stricter definitions, t11cse differences bec3111e slna11er 
and disappeared with the investigatoris assessment. 
The analysis suggests that the apparent differences in patient outcome and 
eptifibatide treatment effect can be explained largely by differences in baseline 
demographics and adjunctive treahllent strategies, particularly the use and timing 
of coronary intervention, as '\7ell as by the methodology of lnyocardial infarction 
definition and the adjudication process. Therefore, global clinical trials should take 
into account these three hnportant aspects when l11aking observations regarding 
differences in patient outconlC and consistency of the treat111ent effect across a 
ll1ulti-national network. 
Safety of glycoprotein lib/ilia receptor blockers 
In the early trials, GP lIb/IlIa receptor blockade was associated with a 
significantly higher rate of bleeding c0111plications,6.7 but tl1is proved to be largely 
attributable to excessive and prolonged concurrent heparin administration.6.7 All 
of the later trials, incorporating low-dosc, ,\reight-ac,justed heparin regi1nens and 
careful vascular access site managclllCnt, have shown no excess in nlajor 
bleeding.8.11,2? 
An accurate estimation of the risk of bleeding based on clinical evaluation at 
baseline may improve the risk-benefit ratio of GP lib/lIla inhibition therapy in 
patients w-ith non-ST-elevation acute coronary syndromes. In chapter 6, we 
therefore studied bleeding complications among the 9375 patients with acute 
coronary syndroll1es -without persistent ST-elevation receiving placebo or the 
platelet GP lIb/IlIa inhibitor eptifibatide in the PURSUIT trial ancl determined the 
111ultivariable baseline predictors ofspontaneolls or procedure-unrelated bleeding 
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events as well as bleeding complications associated 'with percutaneous coronary 
procedu res. 
Bleeding 'was a common event in patients 'ivith non-ST-elevation acute 
coronary syndromes and 'was increased l";rith eptifibatide anlOng patients who did 
not undergo bypass surgery during hospitalization (31 % cOlllparecl 'with 12% in 
placebo). In nlOst cases (83%) however) bleeding 'Nas nlild. Patients undergoing 
bypass surgery during hospitalization had increased bleeding and accounted for 
approxhnatcly 80% of the patients 1Nith InajaI' bleeding c0111plications, No increase 
in bleeding incidence 'i\"fith cptiflbatide therapy ,\'as observed in patients 'who 
unden\7cnt bypass surge!':,).!. Risk factors for procedure-related blccding includcd 
North Anlclican region, allocation to eptifibatide, felnale gendel~ thc nlaxllnal aPIT 
value and treat1ncnt 1\7ith ticlopidin. 1teat1nent with eptiflbatide was the nl0st 
powerful independent predictor of spontaneous bleeding, followed by older age, 
felnale gendel~ North Alnerican region, the 111axhnal aPT'T value, snl0king status, 
use oftln'Olnbolytics or ticlopidin, and non-caucasian anceshy. These factors were 
used to develop a scoring nOlllOgrall1 that can predict the patientis baseline risk 
of spontancous blecding and detennine to what extent this risk incrcases during 
antithmmbotic therapy, After combining the bleeding 1isk model and the 1isk model 
for prediction of adverse cardiac outcOlne, which is d,escribed in chapter 10, no 
subgroups of patients could be identified with either J low risk of adverse cardiac 
events and a high bleeding risk or a low bleeding risk and a high risk of cardiac 
events. Therefore, in detennining indications for GP lIb/IlIa inhibition therapy, 
the risk ofbleec1ing is of secondary hnportance. 
Because of their potent inhibition of platelet aggregation, the effect of the GP 
lIb/IlIa receptor blockers on the risk of stroke has been a concern, Since stroke 
is infrequent, a combined analysis of 8555 patients from the EPIC, CAPTURE, 
EPILOG and EPISTENT studies was performed to compare stroke rates between 
patients treated with the GP lIb/IlIa receptor blocker ~,bciximab (in addition to 
aspirin and heparin) and those receiving placebo duri~g percutaneous coronary 
, 
intervention. The analysis is presented in chapter 5 and hnplies that abcLxhnab 
in addition to aspirin and heparin does not increase the "overall risk of stroke in 
a diverse population of patients undergoing percutaneous coronary intervention. 
The safety of the GP lIb/IlIa receptor blockers is further supported by the 
ctl1nulative frequency of intracerebral hen10rrhage in the 10 large, placebo-
controlled randomized hials of 0,1 % in both the placebo and the GP lIb/lila blocker 
arn1s.30 FurtheTlnore, ell1ergency bypass surgery was not cOlnplicated by excess 
blecding in these trials. 31 
Glycoprotein lib/fila receptor blockers and coronary intervention 
Therapy with the intravenous GP lIb/IlIa receptor blockers for 11on-S1'-
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elevation acute coronary syndr01nes has becn dCl1lO11strated to reduce the 
composite of death and myocardial infarction by lO~50%.32-34 Howevel~ given the 
established benefit of these agents in the setting of percutaneous coronary 
intervention) there 1Nas uncertainty ahout whether the effect in acute coronary 
syndrOlucs -was confined to patients \\'ho underwent percutaneous coronary 
intervention 1\rhilc Tccciving study drug. There were 3 clinical trials that could 
contribute to addressing this issne. 
Accordingly, in chapter 7, "H"'C analyzed data from the CAPTURE! PURSUIT, 
and PIUSM-PLUS randomized t1iaIs, ",hid studied the effects of the GP IIb/IIIa 
inhibitors abcixhnab/ eptiflbatidc j and tirofiban, respectively, in acute coronary 
syndr01ne patients 'without persistent ST-segment elevation/ 'with a period of 
study drug infusion before a possible percutaneous coronary intervcntion. During 
the period of pharmacological treatnlCnt/ each trial demonstrated a significant 
reduction in the rate of dcath or nonfatal myocardial infarction in patients 
randomized to the GP lIb/IlIa inhibitor compared with placebo. The 3 trials 
cOlnbined showed a 2.5% cvcnt rate in this period in the GP lIb/lIla inhibitor group 
(N=6125) versus 3.8% in placebo (N=6171)/ which ilnplies a 34% relative 
reduction (P < 0.001). Dlning study 111edication/ apercu tancous coronary 
inten7ention 'was perfonncd in 1358 patients assigned GP IIb/IlIa inhibition and 
1396 placebo patients. Thc cvent rate during the first 48 hours aftcr percutaneous 
coronary intervcntion "was also significantly lower in the GP IIb/IIla inhibitor group 
(4.9% vs. 8.0%; 41 % reduction; P < 0.001). No further benefit or rebound effect was 
observed beyond 48 hours after the percutaneous coronary intervention. 
Thus, these data suggest that enhanced platelet inhibition with a GP lib/IlIa 
blocker in addition to aspirin and heparin/ starting inlluediately after achnission/ 
is beneficial to patients 'with acute coronary syndrOlllcs -without persistent ST 
segment elevation. This hypothesis is further investigated in the forthcOlning 
GUSTO-IV-ACS study. In addition/ in those undergoing percutaneous coronary 
intervention/ intensive platelet inhibition protects against myocardial dalllage 
associated \vith the intervention.&-l1 Thus/ to fully explore their heneficial effects/ 
GP lib/lIla inhibitors should be initiated early after hospital admission in patients 
at risk and continued until after the procedure in those undergoing pcrcutaneous 
coronary intervention. 
Studies in patients undergoing percutaneous coronary intervention and 
rcceiving GP IIh/IUa reccptor blockers consistently show a reduction in procedure-
related nlyocardial infarction.6-11 Most infarcts occurred at the tinle ofangioplasty 
and 'were characterized by clevated creatine kinase-MB levels without apparent 
clinical symptonls.&-ll Although studies have shown a direct/ proportional 
relationship between the level ofpost~procedural CK-MB elevation and the risk 
of an adverse clinical outconle during long-term follow-up including death/ 
274 
Summary and Conclusions 
myocardial infarction) and need for repeat revat:icularization procedures,J5-39 the 
relevance of the adver,e prognmtic implicatiom of CK-MB elevation following 
percutaneous coronary intervention renlains huw-ever a controversial issue in 
interventional cardiology. In contrast) the prognostic significance of sI11all 
myocardial infarctions occurring spontaneously in the setting Oflll1stable angina 
or after acute 111yocardial infarction has becn \\Te11 cstablishcd.I,G-<12 
In chapter H) 1VC therefore c0111parcd the relationship bet'w-ecn the level of 
post-procedural (within 48 hours follmdng percutaneous coronary intervention) 
CI<CMB elevation and the risk of death after 6-111onth follow-up in 8838 patients 
undergoing percutaneous coronary intervention 1\Tith the Tclationship bet\\"reen the 
level of CK-MB elevation and 1110Ttality in the 5583 PURSUIT patients "with non-
ST-elevation acute coronaTY syndT0111es 'who "WeTe treated Inedically, In both 
patient gTOUpSI theTe "'Nas a gradual incTease in 6-lllOnth lllOTtality "with higheT CK-
MB levels, The 6~11lonth nloTtality rates were lmver after procedure-Tclated 
conlpared 1vith spontaneous infarcts, Yeti the relative increase in 6-11lOnth l1101tality 
"with each increase in the categoTY of peak CK-MB level "nras of the sanle l11agnitude 
for cardiac enZYlllC elevations after percutaneous corOllary intervention and 
those occurring spontaneously in the setting of acute coronary syndrOllles, 
The strong dose-response relationship bet"';\1"een the 111agnitude of post-
procedural CK-MB elevation and 6-nlOnth 11lo1iality indicates that peri-procedural 
myocardial damage is an illlportallt lllarker of subsequent adverse outcOIne. 
Therefore l prevention of 111yocardial dmnage by GP IIb/Illa receptor blockers is 
likely to be of clinical iluportance and ilnprove the long-tenn outcOIne of patients 
undergoing percutaneous coronary intervention.43-45 A recent lueta-analysis of al1 
studies with abciximab in patients undergoing percutaneous coronary intervention 
supports this concept by shuwing a 30% relative reduction in mortality at (i-
nlonth follow-up in patients treated "with this GP lIb/IlIa inhibitor.43 The 1110st 
ilnpressive effect for mortality reduction is that reported in EPISTENT: I-year 
l110rtality alllongst stented patients was reduced by 58% (from 2.4% for the 
placebo group to 1.0% for the abciximab patients [P~O.03Jl.45 
Risk assessment 
Patients 'who present with chest pain or other sylnptOllls suggestive of an acute 
COrOllalJ.T syndrollle and do not have persistent ST-seglnent elevation on the 
elech'ocardiogranl1 enCOl1lpaSS a heterogeneous group that varies considerably"with 
respect to diagnosis as well as future risk for cardiac events, Early Tisk stratification 
in these patients is illlportant to tailor phanllacological and invasive treahllent to 
an individual need based on the estilllated treatl11ent benefit 'which is usually 
propoTtional to the risk of adverse outcOIne in the absence of a specific therapy, 
AccoTdinglYI an appropriate treatnlent policy should include an estilllate of the 
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risk of adverse OUtCOlllB at baseline, \\'llich can be achieved by application of a Tisk 
stratification protocol that integrates itnportant prognostic features. A l1Ulllher of 
risk 1110dels using baseline charactelistics have been developed for acute myocardial 
infarction \vith ST-segmcnt elevation but risk 1110dclling has been underutilized 
in patients with acute coronary syndrOlllcs 'without persistent ST-segment 
elevation . .:!6·so 
Therefore, in chapter 10, ,ve analyzed the relation bctHTcen baseline 
characteristics and the 30-day incidence of death and the composite of death or 
Inyocanlial (re)infarction in the 9461 PURSUIT patients 'with acute coronary 
syndromes 'without persistent ST-segment elevation, Variables eXalllincd included 
demographics, history, henloclynamic condition, and synlptOlll duration. 110re than 
20 significant predictors for mortality and for the cOlllposite endpoint "were 
identified. Thc nlOst ilnportant baseline determinants of death were age, heart rate, 
systolic blood prcssurc, ST-segment depression, signs of heart failurc, and cardiac 
enzymes. Detenninants of Inortality were generally also predictive of death or 
myocardial (re)infarction. Differences were obflerved, hmvevel~ in the relative 
prognostic importance of predictive variables for nlOltality alone or the cOlnposite 
endpoint. The accuracy of the prediction of the C0111posite endpoint was less than 
ofnlortality. The 1110st important prognofltic factors frOlll this lisk nlOdcl"were lU;ed 
to develop a simple scoring nomograIn to estilllate the lisk of adverse outcome 
at 30 clays. 
COlnplementary, a proportion (15-20%) of patients 1Nho present lNith suspected 
acute coronary syndromes are found to have insignificant coronary artery disease 
1Nhen they undergo coronary angiography.51 ,52 Whereas cOlllplex lesion 111Orphology 
is a p01Nerful predictor of adverse outcOlne in acute coronary syndrOllles,53-56 
long-tenn outc01ne and the efficacy of anti-platelet therapy has not been 'well 
charactelizcd in patients 'with acute coronary syndrOllleS found to have insignificant 
coronary artery disease. 
AccordinglYI in chaptcl' III -we evaluated patients from the PURSUIT trial 
"who undcrwent angiography and compared the clinical profiles l treahllent 
responses, and outcOlncs of those "with insignificant versus significant coronary 
artery disease. or the 5767 patients "with non-ST-segment elevation acute coronary 
syndromes "who Undel"lNcnt in-hospital angiography I augo had significant coronary 
artery disease (any stenosis >50%), 69-i) had mild coronary artery disease (any 
stenosis > 0% to 50%)1 and 6% had no coronary artery disease (no stenosis 
identified). Patients 1Nith suspected acute coronary syndr01lles found to have 
insignificant coronary artery disease during coronary angiography had a low 
risk of adverse outcOll1es. While patients with insignificant coronary mtery disease 
did not appear to benefit from treatment with the GP lIb/IlIa receptor blocker 
eptifibatide, those ,;v"ith significant coronary artery disease \vere shown to have an 
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enhanced treahnent benefit. Baseline clinical characteristics "were used to develop 
a sllllplc scoring n01110grmn that accurately predicted the probability of insignificant 
coronary artery disease for use at hospital presentation. This 110l11ogranl 'was 
validated in a separate population of patients 'with non~ST-scgl11ent elevation 
acute coronary syndrOlllcs. 
In conclusion, early identification of patients "'Idth suspected acute coronary 
syndromes at high and 101;\7 risk of adverse ontcome by incorporating the predictive 
risk models presented in chapters 10 and 11 into the clinical decision-rnaking 
process may help refine triage algorithn1s for acute ischeIllic chest pain and 
determine indications for GP IIh/IITa inhibition thcrapy, 
Folluwing hospital adlnission, the prescncc of transient ischemia during 
subsequent continuous ECG-ischemia monitoring Inay provide ilnportant additional 
information for risk stratification. It had been established that recurrent ischelnia 
detected by Holter nlOnitoring or computer-assisted ECG analysis in patients 'with 
acute coronary syndrOlnes carries an increased risk for an unfavorable ontcome, 
including death and 111yocardial infhrction.57-64 This relationship hetween recurrent 
ischemia and adverse outcome was verified in the PURSUIT EGG-ischemia 
Monitoring Substudy which used a computer-assisted standard 12-1ead ECG-
ischenlia monitoring device, in contrast to previous studies that used 2- or 3-1ead 
Holter and vectorcardiographic lnonitoring. The results of this study are reported 
in chapter 9. 
As cOlllputer-assisted 111ultilead EeG monituring offers an accurate continuous 
rcal-thue measurement ofthc QRS-conlplex and the ST-segll1cnt,6S.M it can be used 
as a non-invasive too1 for on-line risk stratification in patients 'with acute coronary 
syndr01ues,60-64 in contrast to Holter nlOnitoring which is li1nited by a restricted 
nlllllbcr of two or three EGG leads and allows for retrospective analysis only,65.66 
HO'wevel~ studies that eva1uated the relationship between recurrent ischenlia 
detected during continuous nnl1tilead ECG-ische111ia monitoring (or Holter 
monitoring) and adverse outcome havc been lhnited hy small series of patients, 57-
64 By combining data of 3 studies, the analysis presented in chaptel' 12 aitncd to 
pruvide an accurate assessment of the iInpact of recurrent ischemia detected by 
multilead EGG-ischcnlia luonitoring on the occurrence of death and nlyocardial 
infarction in patients achnitted with an acute coronary syndrome, 
'vnth allllost 1000 patients, tl1is analysis currently represents the 1argest 
assessment of the prognostic implications of recurrent ischenlia as detected by 
computer-assisted continuous multi1ead EGG-ischC1nia nlOnitoring in the non-
persistent ST-segnlent e1evation acute coronary syndrOlue patient pupulation. The 
main finding "was a direct proportional relationship between the nU111ber of 
ischemic episodes nornlalized per 24 hours and the probability of cardiac events 
at 5 and 30 clay follow-up. The 30-day composite of death and myocardial infarction 
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occurred in 5.7% of patients ·without episodes and increased to 19.7% in patients 
with:::::: 5 episodes. After ac'iustment for baseline predictors of adverse outcome, 
the relative risk of death or Inyocardial infarction at 5 and 30 days increased by 
25% for each additional ischemic episode per 24 hours. 
Other recent studies have shown that the prognostic infornlation of recurrent 
ischemia during continuous COlllputer-assisted 111ultilead ECG lllOnitoring appears 
to be independent fronl and additive to not only baseline characteristics and 
adlnission ECG but also the biochemical markers oflnyocardial necrosis, including 
creatine kinase-fi1B and h·opol1inlevels. 63.64It can therefore be concluded that fmiher 
integration of Il1u1tilead ECG-ische111ia monitoring systems in coronary care units 
and el1lergency "w"ards should be recommended to illlprove early risk stratification 
in patients adlnitted with an acute coronary syndro111e. 
Over the past decade, the therapeutic endeavour to rapidly identify the 
patients at the highest risk for adverse events to individualize therapy and 
prOIllote ilnproved outcOIne has identified the cardiac-specific troponins to be 
pm\7"Crfl1l and independent predictors of future cardiac events in patients "with acute 
coronary syndromes.6J./5 
The troponin complex is for111ed by three distinct structural proteins (troponin 
I, C, and 1') and is located on the thin filament of the contractile apparatlw in both 
skeletal and cardiac l1UISclc tissue regulating the calcium-dependent interaction 
of myosin and actin.73 Cardiac isoforms for all three troponins, hO'wevel~ are 
encoded each by different genes and can be distinguished by 1110110clonal antibodies 
recognising the aminoacid sequence characteristic of the cardiac isoforms.n,76.77 The 
cardiac isoforms of troponin T and I are exclusively expressed in cardiac Inyocytes. 
Accordingly, the detection of cardiac troponin T and troponin I is conlpletely 
specific for myocardial damage, attributing to these markers a ne'w gold standard,73 
The superiority of cardiac-specific troponins over the ECG as prognostic l11arkers 
is confinned by both prospective and retrospective analyses. lv8 The risk for 
lllyocardial infarction and death increases with increasing sennn troponin 
concentrations and IlIaY be as high as 20% at 30 days and 259-6 within 6 months 
in patients 'with the highest troponin levels.nn,7JJ5.78 
The association between nlinor l11yocardial dalnage represented by troponin 
elevation and unfavorable outcOIne l11ight be explained by the link bet'ween the 
diseased epicardial artery and events occurring in the 111icrocirculation following 
plaque fissure or ruphlre. 79,fJ) The ruptured atherosclerotic plaque disturbs epicardial 
£101\7 and acts as a nidus for platelet deposition and activation.:30.79,eO Distal 
ell1bolization of the plaque-platelet aggregate results in microvascular obstruction 
and lllyocardiainecrosis manifested by troponin clevatiol1. 79 The severity of the 
plaque disruption appears to be directly correlated with the extent oflocal platelet 
activation and epicardial occlusion. Because of the central role platelets play in 
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this cascade of events, considerable effort has been devoted to interrupting this 
vicious cycle with platelet GP lIb/IlIa receptor inhibition, thus limiting the 
frequency, extent and consequences of Inicrovasc111ar embolization. 79 
Indeed, recent evidence from the CAPTURE study and the PRISM study 
suggests that GP IIb/IIla receptor blockers are particularly effective in patients 
-with acute coronary syndr01l1CS and an elevated troponin T or troponin I level. 74.75 
In patients 'Ivith an elevated h-oponin level) GP IIb/Illa receptor blockers have been 
8hO\\1]1 to reduce the high risk of cardiac events to that of patients 1vithout elevated 
troponin levels. ld,75 This applies to thr0111botic cOlnplications arising froll1 
spontaneous plaque disruption as ·well as those associated i\.,-ith intervention-
induced plaque Tuptures,7d,75 
An cillcrgency-departlnent algoritlu11 for triage ofpaticnts 'who prcsent "with 
suspected acute coronary syndr01nes based on the adinission 12-lead ECG) senun 
troponinlevel and continuous l11ultilead ECG-ischeinia Inonitoring is suggested 
in Figurc 3 fr0111 chalJter 12. 
Reccnt clinical trials suggest that patients identificd as having a high risk of 
subsequent cardiac events based on gr-deprcssion on the adinission ECG or an 
elevated troponin T or I level) Il1ay particularly benefit fr0111 a I110re aggressive 
therapeutic approach including adillinish'ation ofa glycoprotein lIb/lIla receptor 
blockel~ a I01N-lnolccular-\\7eight heparin and an early percutaneous coronary 
intervention.74.7581-3J Ifit is itnpossible to perfbnn illUllediate percutaneous coronary 
intervention) high-risk patients Inay still receive a glycoprotein lIb/IlIa blocker 
as there appears to be a bencfit of these agcnts during phannacological treatl11ent 
The meta-analysis presentcd in chapter 7 showed a 34!J6 relative reduction 
(from 3,8% to 2.5% at 72 hours) in the COll1posite endpoint of death or myocardial 
infarction during pharllwcological treatnlent among the full spectrum of patients 
\vith non-ST-elevation acute coronary syndromes. The benefit appears even 
greater in patients ·w·ith an elevated troponin level at admission. 74,75 Patients 
admitted with a low-risk profile and a non-elevated troponin level Shollldllnclergo 
continuous nlulti1ead ECG-ischemia monitoring while receiving standard Inedical 
therapy.7J Measurement oftroponin level should be repeated after approxitnatcly 
8 hours. Patients who stabilize and do not exhibit recurrent ischC111ic episodes have 
a low risk of death and myocardial infarction. In these patients) a non-invasive 
InanagC111ent strategy might be preferred.6.3, 73-75 Early transfer to a low level of care 
and early hospital discharge may result in econ0111ic gains without jeopardizing 
the safety. By contrast) in patients with an initial low-risk profile who do exhibit 
recurrent ischelnia) the risk of adverse outcon1e increases 'with the nUlllber of 
ischelnic episodes, These patients should be considered high-risk even whcn the 
SertllH troponin level is not elevated.6.164 Glycoprotein lIb/IlIa inhibition therapy 
and revascularization should be considered. This would apply even 11101'e to 
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patients "\vho exhibit frequent recurrent i8che111ia as the analysis presented in 
chapter 12 shows that the 3D-day event rate ofahnost 20% in this group surpasses 
the risk associated 'with an early intervention protected by a glycoprotein IIb/IlIa 
blocker: Clearly, the suggested protocol for patient triage needs to be evaluated 
for its safety and efficacy in prospective studies. 
Oral glycoprotein lib/ilia receptor blockers 
Although intravenous GP lib/IlIa inhibitors reduce thrombotic complications 
in patients "with acute coronary syndromes and in those undergoing percutaneous 
coronar:y intervention, platelets remain activated for severallNceks or 1110nths after 
the acute event."" This suggests that prolonged inhibition of platelet aggregation 
by oral GP Ilb/IlIa receptor blockers might provide an additional reduction in 
recurrent events in patients 'Nith acute coronary syndr01ncs, In chaptel's 13 and 
14, we describe the phase II clinical development of lefi'adafiban, an orally active 
prodrug which is metabolised in two steps to fradafiban, a non-peptide GP TIb/lIla 
receptor blocker.66 
Chapter 13 describes the first phase TI study which determined the dose of 
lefradafiban that provides 80% blockade of the GP lib/IlIa receptors (FRO ~ 
Fibrinogen Receptor Occupancy) by fradafiban and studied the pharmacodynamics 
and safety of different doses of lefradafiban when adlninistered for 48 hours in 
64 patients \\Tith stable coronary artery disease undergoing percutaneous 
transhUllinal coronary angioplasty. plasma concentrations of fradafiban increased 
in a dose-dependent llwnner in patients treated 'with lefradafiban. There 'vas a 
close correlation between the plasma concentrations of fradafiban and the FRO 
levels. Levels of FRO increased in a dose-dependent l11anner in patients treated 
with lefradafiban. Median levels of FRO ,\7C1'C 09'0 in the placebo groUPI 71 % in 
patients treated with lefradafiban 30 lUg tid, 85% in patients treated -with 
lefradafiban 45 mg tid and 118% in patients on Leftadafiban 60 mg tid. Fradafiban 
plaslna levels of 170 nghnl ,vere required to achieve 809-tl FRO. There was little 
variation in FRO level within each patient, lNhile the interpatient variability was 
greater alnong patients receiving the lov·;rcr dose than anlong those treated with 
the higher dosages, which reflected the plasl1la concentrationfiFRO relationship. 
Inhibition of platelet aggregation was closely related to FRO. There were no 
major bleeding events. Leftadafiban 60 mg tid resulted in a high (71 %) incidence 
of Inindr and insignificant bleeding. The incidence of bleeding was 44% in the 
lefradafiban 30 and 45 nlg tid groups, cOlupared with 9% in placebo patients. 
Puncture site bleedings were 1110St conlll1on. The odds of bleeding increased by 
3% for every increase in FRO by 1 %. 
Based on the results from this first phase II study we conducted a second study 
which aflsessed, in a double-blind, randOluized mannel~ the safety and preliminary 
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efficacy of one month treatment with three dose levels oflefradafiban (20, 30 and 
45 mg tid versus placebo) in 531 patients ,;\rith acute coronmy syndrOlllcs "'\\"'ithout 
persistent ST~scgtl1cnt elevation. This study is rcpOlted in chaptcl' 14. Although this 
study ·was not po·w-ered to definitively evaluate differences in clinical QutcOlnes 
among treahllcllt groupsJ there \\'as a trend tmvards a reduction in cardiac events 
with lefradafiban 30 mg when compared with placebo and lefradafiban 20 mg. The 
bencfit "was particularly apparent in patients ,;vith a positive (20.1 ng/nll) troponin 
I test at baseline and less so in thm;e with a negative test result. In patients 
receiving lefradafiban, the cardiac event rate decreased with increasing 111ini111al 
levels of fibrinogen receptor occupancy. There was a dose-dependent increase in 
the incidence of bleeding: the composite of major or minor bleeding occurred in 
1 % of placebo patients, 5% of patients receiving lefradafiban 20 mg and in 7% of 
patients receiving 30 mg, ·with an excessive risk (15%) in the 45 mg group which 
resulted in early discontinuation of this dose level. Gingival and arterial or venous 
puncture site bleedings ·were most common and accounted for more than 60% of 
all hae1norrhagic events. There was an increased incidence of neutropenia 
(ncutrophils < 1.5xl09/1) in the lefradafiban groups (5.2% versus 1.5% in the 
placebo group), which did not result from bone marrow depression but rather 
£r0111 a reversible redistribution of neutrophils by margination or clustering. 
Along lNith this study, four large-scale clinical trials evaluated the efficacy of 
10ng-teTln oral GP lIb/IlIa inhibition ,,·lith xelnilofiban, orbofiban and sibrafiban 
in paticnts after percutaneous coronary intervention and acute coronaTY 
syndr0111es.87-69 None of the h·ials shmved benefit oflong-tenn GP lIb/IlIa inhibition 
therapy. On the contrar:,>" there 'vas a higher incidence of the cOl11posite endpoint 
of death or 11lyocardial infarction at the end of the follo1N-UP periods in patients 
treated with an oral GP Ilb/Illa Tcceptor blocker than in those Tcceiving placebo 
(,Tl1ble). The il11pact on nlOrtality alone ,vas cven ,\701'se with an approxinlate 25 % 
relative increase associated with oral GP IIb/Illa inhibition therapy when the data 
of all trials were combined (Thble). 
Several hypotheses can be considered for the lack of benefit of the first 
generation of oral GP IIb/IIla receptor blockers in the light of the benefit of the 
intravenous C0111pounds.87 The pharnlacokinetic and phannacodynamic profiles 
of these agents are characterized by Im\7 bioavailability (5-20%) and the existence 
of peaks and troughs in plasma drug level corresponding to the drug;s short half-
life relative to the dosing interva1.8H{1.91 Accordingly, substantial variability betvveen 
and within patients in the level of platelet inhibition has been observed with the 
oral agentsy·m,91 As such l with a fL"'~:ed dose, SOlne patients Inay have as high as 100% 
inhibition at peak and others as low as 0% to 20% inhibition at trough.87 This may 
result in average levcls of platelet inhibition that are too low· to provide optimal 
protection against HelN thrOlnbotic events. In cOlnparison, the benefit of the 
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Table. Characteristics and outcomes of the four large phase III trials on long-term treatment with oral glycoprotein IIblIIIa receptor blockers 
Mortality (%) Composite of death and MI (%) 
Study acronym Agent Background Patient Number of Follow-up Placebo Low-dose High-dose Placebo Low-dose High-dose 
with aspirin category patients (months) 
EXCITE Xemilofiban Yes PCI 7232 6 1.0 1.7 1.1 8.9 9.2 8.2 
OPUS-TIMI-16 Orbofiban Yes ACS 10288 10 3.7 5.1 4.5 8.1 9.7 9.5 
SYMPHONY-I Sibrafiban No ACS 9169 3 1.8 2.0 2.0 7.0 7.4 7.9 
SYMPHONY-2 Sibrafiban Yes ACS 6637 3 1.3 1.7 2.4 6.1 6.8 8.6 
Total phase III 33326 2.0 2.7 7.3 8.3 
OR (95% CI) 1.35 (1.16-1.60) 1.14 (1.05-1.24) 
ACS = acute coronary syndromes. CI = confidence interval, MI = myocardial infarction. OR = odds ratio. PCI = percutaneous coronary intervention 
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intravenous GP lIb/IlIa receptor blockers has been observed "with high levels 
(> 80%) of inhibition of platelet aggregation. HowevC1; these levels of inhibition 
during long-tenn trcahncllt arc currently associated "H"rith a high incidence of 
bleeding cOlllplications.87-$9 
Additionally, it has been shown that (oral) GP lIb/IlIa inhibitors are both 
antagonists and partial agonists of the GP lIb/IlIa receptOl;" and that at low 
concentrations these agents can dcnlOllstrate an inh-insic activating property, 'which 
can result in fibrinogen binding to the GP lIb/IlIa receptor and consequently in 
platelet aggregation."·95 Thus, it is possible that at trough periods, low blood 
concentrations of the oral GP IIb/IlIa inhibitor induces a prothromhotic state, 
thereby increasing the propensity to new thrombotic events.8! Indeed, several 
subanalyscs have show11 that the excess mortality mainly resulted from increased 
rates oEne"T thromhotic events.87.95 Accordingly, these events may occur early after 
discontinuation ofGP rIb/lIla inhihition therapy.87.95 
Another possihility is that the risk of recurrent ischemic events in the patient 
popUlations included in these trials may have been too low to detect benefit of 
long-term GP lIb/IlIa receptor blockade."" Particularly following percutaneous 
coronary intervention, the event rates are 1m\,. 
Further possibilities include the inability of GP lIb/IlIa receptor blockers to affect 
plaque grm\TthJ inflanunation and rupture, as well as the fact that concomitant 
antithrombin therapy may be required for benefit as observed with the intravenous 
agents. 18 
Finally, decreasing the propensity of platelets to becOlne activatedlnay be 
nlOre effective for long-tcnn prevention of new thrOlllbotic events than direct 
inhibition ofplatclct aggregation, 'which l11ay be nlOst ilnpOltant in the acute phase.87 
Perspective for oral glycoprotein fib/fifo receptor blockers 
Nmver drugs with higher bioavailability and longer half-lives will be associated 
with fewer peaks and troughs in the level of platelet inhibition, thereby providing 
a more stable anti platelet action." The development of drugs with a tight binding 
affinity for the GP IIb/lIIa receptor might also avoid low levels of platelet 
inhibition and the prothrombotic effect seen with the present agents that rapidly 
move on and off the receptor. Studies evaluating these newer agents with tight 
receptor binding are underway.97 
Second, dose-adjustment on the basis of patient characteristics that influence 
drug levels such as renal function and body weight, as well as individual dose-
titration to a target level of platelet inhfuition measured with a bedside rapid platelet-
function assay,9B.<n as is done routinely for 'warfarin, Inay ilnprove the safety 
profile, as 'well as improve cHnical outcOlncs. Furthennore, as the risk of thrombotic 
events declines after an acute episode while the bleeding risk continues, an 
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additional potential strategy may be to Relect only patients at high risk ofrccurrent 
thrOll1botic events. 
Finally, in parallel with the therapeutic exploitation of the GP lIb/IlIa 
receptor path'way there has been improvement in antagonists to the ADP recept01:32 
Therefore j if oral GP IIb/IlIa antagonism 'with the second generation drugs proves 
to be safe and clinically effective, "will this therapy IeIllain 1110re effective than a 
combination of other platelet antagonists (i.e. aspirin plus clopidogrel) and will 
the margin of hnproved efficacy justifY the increased COSt.'?32 
Glycoprotein lib/ilia receptor blockers combined with thrombolytic therapy 
in acute ST-elevation myocardial infarction 
Although prinlary angioplasty is being used to an increasing extent, 
thrombolysis is still the 11108t 1v"idcly used 1110dality of reperfusion therapy in 
patients with acute ST-seglllcnt elevation 111yocardial infarction. Although 
thrombolytic therapy produces an ilnportant survival henefitl 1OJ.101 it has well-
established efficacy as 'well as safety lilllitations. As deRcrihed in chap tel' 11 the 
Iinlitations relate to the prothrOlllbotic cffects of fibrinolytic agents coincident 'with 
a lack of a sound antiplatelet approach." Accordingly, GP lIb/IlIa receptor 
inhibition added to (reduccd-dosc) fibrinolytic therapy luay ilnprove treatment 
outcOlues in patients "with acutc STelevation myocardial infarction. Indeed, 
preclinical and early phase II studies have shown that GP lIb/IlIa inhibition 
accelerates thrOlubolysis and prevents reocc1usion.102,103 
Recently, three large, phase II angiographic studies demonstrated that GP 
lIb/lIla inhibition with abciximab and eptifibatide enhances the rate and extent 
of thrOlnbolysis l producing eadYI marked increases in complete reperfllsion 
(TIMI 3 flow) when combined with reduced-dose fibrinolytic therapy.'<l4-'06 The 
TIMI-14 trial demonstrated that (iO- and gO-minute TIMI 3 flow could be achieved 
in 75% to 80% of patients treated with a cOlnbination of abciximab and a protractcd 
infusion ofhalf.dose alteplase, compared with 57% of patients treated with full-
dose accelerated alteplase alone. 1(1') This inlprovClnent in reperfusion with alteplase 
occurred ,\7ithout an increase in the risk of l11ajor bleeding. ModeRt i111provclllents 
in THvII 3 flow were seen when abcixhllab was cOlnbined with Rtreptokinase l but 
there was an increased risk of bleeding. This pattern was also apparent when 
streptokinase was administered with eptifibatide in another stlldy.107 A possib1e 
explanation for this observation l11ay bc the lllOre profound systmnic disturbances 
of the hemostatic system that occur with a less fibrin-specific fibrinolytic agent 
such as streptokinase. The SPEED (abcbdluab in combination with lmv-dm;e 
reteplase) and INTRO-AMI (eptifibatide added to alteplase) trials endorsed the TIMI-
14 tria1 observations. lOJ·1Cl'> Although achievcl11cnt of rapidl complete and sustained 
restoration of coronary flmv through thc infarct-re1ated artery (TIMI grade 3 
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flnw) is associated \\Tith lower lllOrtality/m,l09 the GUSTO-TV-Acute Myocardial 
Infarction trial, 'Nhich 'will rand0111ize more than 16,000 patients to rcteplasc 
'with or 'without abcixhnab, is underway to evaluate \\Thether the earlier l110re 
cOlnplete repcrfusion observed in the phase II studies translates into hnproved 
survival. Furthennorc, the large sample size of this trial "will allm\T for a 1110re 
statistically robust esthnate of the risk of intracerebral bleeding with the new 
reperfusion reghnen. 
Finally, the use of low-dose fibrinolytic and GP lIb/lIla inhibition as an 
initial phannacological strategy has the potential not only to achieve reperfusion 
in a high proportion of patients but also to support acute-phase intervention. 3D 
V\Tithout the hazard of promoting coronary throlllbosis or inducing serious bleeding 
complications, combined low-dose fibrinolytic and GP lIb/IlIa inhibition has 
considerable potential to bridge the long-tenn gap between mechanical and 
phar111acological reperfnsion therapies. 30 
Further perspectives 
Despite the itnpressive progress in our understanding of the platelet GP 
lIb/IlIa receptor and its role in platelet fi.mction and the improved patient 
outc0111e lNith GP lIb/IlIa receptor blockers in clinical trials, there are several 
unresolved issues,s.3D.32 
More clinical trials are required to detenlline the optilnal l11anagement 
strategy in different risk categories of patients with non-ST-elevation acute 
coronary syndrOll1es. Although data from subanalyses suggest that the intravenous 
GP lIb/HIa receptor blockers are beneficial in these patients during phannacological 
treatment only, especially in those presenting ·with an elevated troponin T or I 
level/d,7£> this observation is investigated in a prospective way in the forthcOlning 
GUSTO-IV-ACS study. In addition, the optimal timing of percutaneous coronary 
intervention needs to be deteIlnined.62.83 
Furthel~ there has not yet been a direct comparison, head-lo-head trial of one 
of the intravenous GP lib/lIla receptor blockers versus al1othel0 The perspectives 
for the oral GP lib/lIla receptor blockers, as well as for the combined use of GP 
IIb/Illa inhibitors and reduced-dose fibrinolytics in the treatment of patients 
presenting v'lith an acute ST-segnlCnt elevation myocardial infarction have been 
described in previous paragraphs. 
Refinetnent of dosing of antiplatelet agents to optimize patient care ·will 
require definition of the extent ofplatclct inhibition necessary to reduce ischenlic 
events and prevent bleeding conlplications in a variety of clinical settings including 
acute coronary syndrOlnes, percutaneous coronary interventions, and long-tenn 
prevention. 110 After definition of the optilnal extent of platelet inhibition, treatment 
can be itnproved by titration of dosage according to the needs of individual 
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patients. no Therefore, correlation between platelet reactivity 01' aggregation, 
111casured by a platelet function assay, and subsequent OUtCOl11C should be an 
inlportant aspect in ongoing clinical Tcscarch and c1inical trials. 110 
A better understanding of the structure and function of the platelet GP 
IIb/IIla receptor has the potential for design of new and better GP IIb/IIla 
receptor antagonists that might selectively target the activated receptor and allm\T 
for a 1110re safe and effective use of these agents. 32 Another question is 1Nhcther 
the interaction of GP IIb/I1la blockers with other integrins, notably the U.v~3' is 
advantageous. 32 
Finally, 1\.,-i11 treatlnent ·with GP IIb/IIla receptor blockers remain 1110re 
effective than other antiplatelet antagonists and rcginlClls and ·will the Inargin of 
hnprovcd efficacy justifY the increased cost? 32 
The potency of effects '\7ith these agents in clinical trials support the view 
that the GP Ilb/I1la receptor blockers have taken the clinician and patient out of 
the era of aspirin nlOnotherapy when platelet inhibition is reql1ired. 32 Continued 
clinical TcscaTch coupled with the completion ofnlOrc clinical trials should allow 
clinicians to offer patients enhanced antiplatelet protection with proven benefits 
and understood risks. 
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Acute cOTonaire syndrOlneu, cen verzalnelnamn voor onstabiele angina 
pectoris, acuut luyocardinfarct en de acute cOlnplicaties van cen percutanc 
coronaire interventic, V01'111en 1110ndiaal gezien f!Cl1 belangrijk prohlcC111 voor de 
gezondheidszorg en zijn de belangrijkstc vcroorzakers vall 1110luiditeit en lllOrtaliteit 
in de westerse wereld. Patienten l11Ct dcze syndrOlllen hcbben zO'wel op korte 
termijn a1800k op lange tennijn een vCThoogd risico op ovcrl\jden, een (recidief) 
myocardinfhrct, recidief angina pectoris, hmifhlen, aritmieell en een noodzakelijke 
coronaire revm>culalisaticprocedure. Zoals beschreven in hoofdshtk I1vorclt de 
ont'wikkeling van cen acuut coronair ischacillisch syndr00111 verondersteld te 
beginnen met disruptie Cruptuul~ fissuur of crosie) van een atherosclerotische 
plaque l hetgeen resulteert in activatie van throll1bocyten en van de sto11ingscascade. 
Ret ontstaan van een locale thrombus als reactie op de vaatwandbcschadiging kan 
vervolgens aanleiding geven tot een "wisselende nlate van vaatocclusie met als gevolg 
verminderde coronaire bloeddoorstrOlning/ elllbolisatie van thr0111botLsch l11ateriaal 
naar distaal resuHerend in obstructie van de capillaire bloeddoorstrOllling en 
necrose van hartspierweefsel/ en incorporatie van de locale thronlbus in de groter 
'wordende plaque resulterend in progressie van de atherosclerose. ZoaIs salncngevat 
in hoofdstnl{ 1 heeft ondcrkenning van de crudale rol van thrombose in de 
pathofysiologie van acutc co1'onaire syndromen geleid tot concentratie op 
antithrombotische therapic/ 111et na111e thrOlnbocytenre111111CrS en anticoagulantia. 
Aggregatie van geactivccrde t11rombocyten speeIt een centrale rol in clit proces van 
coronaire thrombose. Ongeacht de aggregatie-inducerellde stirnulus ""Ivonlt de 
laatste gell1eenschappel~jke stap tot aggregatie van thrOlllbocyten gevormd dooT 
binding van fibrinogeen en andere plasn1a-ei"witten aan gcactiveerde glycoproteinc 
nb/Illa receptoren op Ineerdere thr01llbocyten. Een nicuwe groep geneesmiddelen/ 
bekend als de glycoproteine (GP) lib/IlIa receptor bloldcers, is ontwikkeld 0111 deze 
laatstel gmneenschappelljke stap te blokkeren en daannee coronaire thron1bosc 
te vooTkOlnen. Dc effectiviteit van GP IIb/I1Ia bloklmrs in het verll1inderen van 
ischacll1ischc COll1plicaties is ono111stotelijk vastgestcld bU een groot aantal patienten 
die ccn pcrcutanc coronairc rcvascularisaticprocedure/ al dan niet Inet 
stcntilnplantatic1 ondergingen. In deze studies wcrd bU patienten bchandeld nlet 
GP nb/Illa blokk:ers een reductic van ongeveer 30% bereikt in het sa1nengestclde 
cindpunt van overlijden/ Inyocardinfarct of noodzaak tot een spoeclinterventie 
binncn 30 dagen. Gebaseerd op deze gunstige resultaten werd dc experitncntele 
behandeling met GP lIb/lila blokkers uitgebreid naar patienten met acute 
coronairc syndrOlnen. Zoals beschreven in hoofdstul{ 1 \verden met diverse 
Iniddelcn twcc belangrijkc bchandelingsstratcgieen ondcrzocht. Ecn 
behandc1il1gssh'ategie richt zich op 111edicamenteuzc behandeling en dc andere richt 
zich op GP lIb/IlIa blokkers in cOlnbinatie n1et pcrcutane coronairc interventie. 
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Dit proefschrift behandeIt diverse aspecten van de klillischc cvall1atic van 
GP JIh/IIIa blokkers bU patientcn lllct acute coronairc syndrOluen, Een aautal 
artikelen uit dit proefschrift Zijll gcbasccrd op gcgevens voortvloeiend uit de 
omvangrijke 'Platelet glycoprotein Ilb/IIla in Unstable angina: Receptor 
Suppre"ion Using Integrelin (eptifibatide) Therapy (PURSUIT), stuclie. PURSUIT 
vergeleek eptifibatide met placebo toegevoegd aan cle stanc!aarc!medicatie bij 
9461 patienten l11ct acute coronaire sYllc1rOlllcn zander persisterende ST-segment 
elevatie. In tataal 113111C11 726 ziekenhuizen uit 27 verschi11ende landen in 4 
geografischc rcgiols dcel (\".'est-Europa/ Noord-Amerika, Gost-Europa en Zuid-
Aillcrika). Paticntcn k1\73111Cn in aanlllerking VDor deelname aan de stu die indien 
z~j binncn de voorafgaande 24 LIllI' pijn of) de borst hadden met daarnaast hetzij 
ECG-veranderingen suggestief voor ischaemie (ST-segment depressie, T-top 
inversie, voorbijgaande ST-segl11ent elevatie), het:;dj een creatine kinase-ME [ractie 
hoger dan de bovengrens gehanteerd claar het deshetreffende ziekenhuis. Patienten 
"werden op dubbcl-blinde ';vijze gerandOlnizeerd naar hetz;ij behandeling met 
placebo als illtraveneuze bolus plus infi.ms hetzij behandeling met eptifibatide als 
180 ~lg.kg.-l bolusinjectie plus 2.0 flg.kg.-lmin.-l infuus. De toediening van de 
studicnlcdicatic dicnde l11instens 72 uur te duren. Echtel~ wanneer aan het einde 
van dezc periode van 72 uur een percutane coronaire interventie plaatsvond, 
bestond de mogel~jkheid de infusie te verlengen tot maximaal 96 nUl: De beslissing 
tot andere vonllen van behandcling zoais bijvoorbeeld het toeclienen van heparine 
en andere anti-ischaenlischc nledicatic en het vcnichten van coronair-angiografie, 
maar ook het gebrllik en tijdstip van percutane of chirurgische revascularisatie 
werd geheel overgelatcn aan de behandelcnd cardioloog. In vergelijking Inet 
placebo resnlteerde behandeling Illet eptifibatide in cen statistisch significante 
absolute reductie van 1.5% in het smnengcstclde 30-dagcn eindpunt van I110ltaliteit 
en niet-fataal (recidief)-myocardinfarct, lNclke lNcrd vastgcstcld door cen 
onafhankelijke Eindpnnt VaHdatie Conullissie die geen infonnatie had ovcr de 
,vcrkelijke behandelingsvorm. 
De me thodologie en impact 
van het beoordelen van eindpunten in een klinische studie 
Ecn l11yocardinfarct is een potentieel dodelijke conlplicatie lNelke kan 
optrcdcn bij paticntcn nwt een acuut coronair syndroom en is tevens een 
be1angrUk eindpunt voor het beoordelen van de effectiviteit van een experimentele 
behandeling in klinische studies. Hoewel een myocardinfarct gezien ,\7erd als een 
duidcl~jk Olllschrcvcn eindpunt kan het vaststellen van een myocardinfarct zowel 
in klinische studies als in de klinische praktijk lastig zijn vanwcge elkaar 
tegensprckendc klinische, laboratoriu111, en electrocardiografischc gegevens. 
Daar in reccntc studies 11aar thrombocytenremmende en antithrOlllbotische 
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thcrapicen ele prcventie van myocardillfarct de meest helallgr~jke maat VOOI 
effect van de behandcling 'was, I';ijn Eindpunt Validatie COl1llnissics een essentiecl 
onderdeel ge\vorden van kIinische studies 11aa1' nieuwe thcrapieen voor de 
behandeHng van acute coronaire syndrOlllCn. Dit am het systematisch, 
onhevooroordeeld, onafhankelUk en gestandaardiscerd vaststellen van dit eindpunt 
te kunnen 'waarborgcn, Dientengevolge bcoordeelde in PURSUIT een 
onafhankelUke Eindpunt Validatie Commissie aIle vernlOec1elUke 111yocardinfarctcn 
die optraden tussen het ll10111cnt van inc1usie en 30 dagen later. 
In de hoofdstukken 2 ell 3 'wordt de structulll' van de Einc1punt Validatie 
Commissie en het heoordclingsproces van eindpunten zoals gehanteerd in 
PURSUIT naderbestl1cleerd. Dc Eindpl1nt Valiclatie COlllmissie iclentificccrdc 5005 
vermoedelUke infarcten, waarvan 1415 (2B %) uiteindelijk ·werden beoordeeld als 
zUnde een nlyocardinfarct. Terugkijkend op het beoordeIingsproces vallen eell 
aantal punten op. Thn eerste, het percentage vastgestelde infarcten was hoger dan 
in voorgaande studies Inet een verge1ijkbare patientcnpopulatie. Ten tweede, 
myocardin£'1fcten volgens de definities van het protocol ,\7crden ondergerapporteerd 
door de behandelende cardiologen. len derde verschilde de heoordeIing van 
infarcten door behandelend cardioloog of Eindpun! Validatie C0I11111issic b\j 983 
(20%) van de 5005 patienten die door de Eindpullt VaIidatie C0111111issie werden 
heoordeeld. Ret grootste deel van dit verschil in beoordeling was tc w~iten "owel 
aan misc1assificatie door de behandelende cardiologen van infarct en reeds 
bestaand tijdens inclusie als z\inde infarcten die optraden na inclusic, als ook aan 
de onderrapportage van lllyocardinfarcten rOndOlll coronaire revascularisatie-
procedures en n1yocardinfarcten vastgestcld op basis van enzYlllstijgingen zonder 
klinisch ofelectrocardiografisch hewijs voor ischaemie of infarct. Thn vierde lNas 
het effect van hehandeIing met eptifibatide Ideiner wanneer het infarctpercentage 
volgens de Eindpunt Validatie Conll11issie werd gehanteerd, dan wanneer dit 
percentage volgells de behandelende cardiologen werd gebrl1ikt. Thn slotte, in een 
retrospectieve analyse was het behandeleffect groter wanneer clie illfarcten 
werden uitgesloten die, hoe weI werd voldaan aan de vastgestelde criteria, 
gebaseerd "waren op tegenstrijdige kIinische, electrocardiografische en enz~Ylllatische 
informatie. 
Diverse verl<1aringen voor deze vijf constateringen kunnen worden 
aangeclragell. Sa111envattend kan ,yorden gesteld dat bovenstaande bevindingen 
bevestigen c1at beoordeling vaulllyocardinfhrcering ais eindpl1nt door een Eindpl1nt 
Validatie Conllllissie van belang is om te zorgell voor eell onafhankelijke, 
onbevooroordeelde, ge.standaardiseerde en systell1atische vaststelIing van dit 
eindpunt. Echtel~ met de definitie van 111yocardinfarct (creatine kinase-MB hoger 
dan een111aal de bovengrens) zoals gehanteerd en toegepast binnen PURSUIT zijn 
moge!\ik tevecI n1yocardinfarcten geincludeerd welke lNerden gekeIul1erkt door 
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geringe enzymstUgingcll, 'welke bf vals-positieve uitslagen waren bf klinisch 
onbelangrijke infarctcn repTcsenteerden. Hierdoor heeft vaststelling van 
eindpunten door cen Eindpl1nt Yalidatie C0111111issie tevens 7.cke1'e beperkingcn; 
in gevallen 'waarill klinischc, enzYlnatischc en clectrocardiografische infol'lnatic 
inconsistent is, of indien onzekerheid bcstaat over de juisthcid van 
laboratorhl111uitslagen van verhoogde cardiale enzymen, zan het vaststellcn van 
een myocardinfarct een meer klinischc subjectieve beoordeling vcrciscl1, hoc"weI 
dit de objcctiviteit noodzakelijk voor eindpunt-c1assificatic zou kunnen 
vernlindcrcl1, ll1et name in internationale studies. Hoe"wel het absolute verschil 
in infarctpercentages bepaa1d door de Eindplint Validatie Conllnissie versus de 
behandelend cardiologen klein 'was, 'was het relatieve verschil daarentegen 
dllidelijk groter. Dit oefende een aanzienlijke invloed uit op de statistische 
UitkOlllst van de studie. Dit £en0111een 1110et daarom in aanlnerking 'worden 
genOll1en bij het berekenen vall de grootte van de te onderzoeken populatie 
tUdens het opzetten van toekOlllstige studies. Thvens beinv10edt het de Inanier 
lNaarop de Inedische 'wereld en overheidsinstanties de onderzoeksresliitaten 
beoordelen. Voorts nloet het gehanteerde Eindpunt Valida tic Conll11issie -
beoordelingsproces in aal1111erking lNorden genonlen 'wanneer infarctpercentages 
tussen verschillende studies 'worden vergeleken. 
In PURSUIT bestonden, net als in andere grote internationale studies, 
aanzienlUke verschillen in uitkornsten tussen patienten uit de diverse geografische 
regio'". In de eerstc univariate PURSUIT analyse leek het effect van bchandcling 
in Noord-Alnerika groter dan in "'.\Test-Europa, tenvijl geen effect duidelijk "was in 
Zuid-Amerika en Oost-Europa. Echtel~ de betroLlnrbaarheidsintervallen voor het 
behandeleffect in deze regio's waren groot en overlappend. Dank:z.ij het grote aanta1 
patienten in de diverse regio's bood deze studie de unieke nlogelijkheicl onl 
inzicht te verwerven in de heterogeniteit van de ziekte en patientenpopulatie 
alsn1ede 0111 de verschillen in 111edische praktijkvoering en behandelstrategieen 
te onderzoeken. 
Dientengevolge bestudeerden ,ve in hoofdstul{ 4 deze regionale verschillen 
en analyseenlen we de hlctoren die 1110gelijk bijgedragen hebben aan de 
geografische variaties. Er waren belangrijke verschi11en in de uitgangssituatie van 
patienten uit de verschi11ende regio's. Behandeling Inet coronaiTe interventie 
verschilde ook aanzienl\ik. Na n1ultivariate analyse lNas het patroon van 
behandelvoordeel met eptifibatide consistent over de diverse regio's. In het 
algenlcen 1Naren de verschillen in UitkOlllst van patienten en behandeleffect het 
grootst, w-anneer de definitie van nlyocardinfarct volgens het protocol (CK-MB > 1 
bovengrens van no1'l11aa1) gehanteerd 'werel. Deze verschillen werden kleiner 
lNanncer strengere definities 1Ncrden toegepast en verd-wenen 111ct de beoordeling 
van lllyocardinfarct door de behandelend cardioloog. Dcze analyse laat :;den dat 
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de verschillen in de Uitk0111St van patienten en het effect van behandelillg 111Ct 
eptifibatide grootendeels vcrklaard kunne11 worden door de verschillcll in de 
kenillcrken van patientenpopulatics bij inc1usie en door verschillcn in aanvullendc 
behandeling, lHct name het gebruik en tUdstip van coronairc interventic, ais ook 
door de dcfinitie van myocaTdinfarct en de toepassing cryan in het 
bcoordclingsproccs. Deze drie belangtijkc aspecten 1110cten daar0111 in aanmerking 
\\7ordcn gCl10lnen "'wanneer hi1111e11 intcTnationale klinische studies analyses 
·worden gedaan 11881' verschillell in uitk01llstcn en behandeleffect. 
Veiligheid van gfycoproteine fib/fifo receptor bfokkers 
In de eerste studies ging behandeling met GP IJb/lIIa receptor blokl<ers 
gepaard 111Ct significant lncer bloeciingsc01nplicaties! echter clit bleek grootenc.1eels 
te 'wijten aan ovennatige en langdurige gelijktijdige toediening van hcparine. Alle 
latere studies waarbij Iage-dosis! aan ge'wicht aangepaste heparineschema!s 
toegepast ,verden en w-aarbU intravasculaire toegangs'wegen nwt voorzichtigheid 
'werden behandeld! Iieten geen overschot aan ernstige bloedillgscOll1plicaties 
zien. 
Een schatting van het bloedingsrisico gebaseenl op klinische evaluatie bij 
aankOlllst van de patient 1mn de verhouding tussen risico en voordeel van 
behandeling met GP IIb/IITa receptor blokkers bij patienten met acute coronaire 
syndroll1en zonder persisterende ST-scgnlCnt elevatie gUllstig beinvloeden. In 
hoofustuk 6 bestudeerden we daarOln de bloedingsconlplicaties "Telke optradcn 
bij de 9375 PURSUIT patienten llwt acute coronaire syndronlen! die bf placebo 
Of de GP IIb/IIIa receptor blokker eptifibatide kregen, en bepaalclen we de 
multivariate voorspellende factorcn voor spontane ofniet-intel\rentie gerelateerde 
bloedingen aIsnlede voor bloedingscomplicaties geassocieerd met percutane 
coronaire interventies. 
Bloedingen traden regelmatig 01' bij deze groep patienten. Het percentage 
bloedings-complicaties was hoger in de eptifibatide groep b\j patienten die geen 
bypassoperatie tijdens ziekenhuisopname ondergingen (31 C}fl versus 12 % in de 
placebogroep). Echtcr! in de meeste gevaI1en (83 %) waren deze 
hloedingSCOlllplicaties lliet ernstig. Patienten die een bypassoperatie tUdens 
ziekenhuisopnmlle ondergingen! had den een verhoogd risico op 
bloedingscOlnplicaties en !lamen bij benadering 80% van de ernstigc bloedingen 
vaal' hun rekening. Ret gebrllik van eptifibatide bij cleze patientcn deed het 
aantal bioedingscoll1pIicaties niet toenetnell. Risicofactoren voor interventie-
gerelateerde bloedingscoll1pIicaties waren behandeIing in Noord-Arnerika! 
eptifibatide! vrotn .... Telijk geslacht! de maxhnale aPTT-waarde en behandeling met 
ticlopidine. I3ehandeling met eptifibatide was de sterkste onafhankelijke voorspeller 
van spontane hloedingen! gevoIgd door hogere leeftijd! vrouweIijk geslacht! 
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bchalldeling in Noord~AlllcTika! de l11axhnale aPIT-waardc, rookgclNoontcs ell 
bchandeling met thrOlnbolytica of ticlopidine. Deze [aetoren 'w-eIelen gcbruikt 0111 
cen 110mogranl tc ontwikkelcll -waarmee het basisrisico van cen patient op 
spontane bloedingcll voorspeld ka11 worden en "w-aaflllce bcpaald kan 'worden in 
'welke mate dit risico toeneenlt wanneer gestart 'WDIdt HIet antithr0111botische 
therapie. Na het c0111hi11eren van twee risicOlllodellcn konden geen patienten-
subgroepen gcidclltificeerd worden lllct hetzij cen laag ri8ico op cardiale 
compIicatics en een hoog bloedingsrisico, hctzij cen hoag risico op carcliale 
complicaties en een laag bloedingsrisico. DaaTonl is het hasisrisico op 
bloedingscomplicaties van secundair be1ang bij de indicatiestelling tot behandeling 
met GP lIb/ilia receptor blol<kers. 
Vanwege het krachtig rel11l11ende effect van GP lib/IlIa receptor blokkers 
op de aggrcgatie van thrombocyten, "'INas hct risico op cerebrovasc111air accident 
(GVA) cen punt van zorg. OnlClat de incidentie van eVA laag is, ·werd een 
gecombineerde analyse gec1aan b\j 3555 patienten uit de EPIC, CAPTURE, EPILOG 
en EPISTENT studies om het risico op CVA te bepalen bij patienten behandelc1 
met de GP IIb/IlIa receptor b10kker abciximab (toegevoegd aan aspirine en 
heparine) versus patienten behande1d met placebo, allen tijdens percutane 
coronaire intervclltie. Deze analyse ·worclt beschrevcn in hoofdstuk 5 en laat zien 
dat het totale risico op cen eVA niet verhoogd 1vordt 1\7-anneer abcixhnab worc1t 
toegevoegcl aan aspirins en heparine bij patienten die cen percutane coronaiTc 
interventie ondergaan. 
De veiligheid van GP IIh/I1Ia receptor blokkers 1\'ordt 'lerder ondersteund 
door de cumulatievc incidentie van intracerebrale bloedingcn van 0,1 % in 10 grote, 
placebo-gecontroleerde, gerandonlizeerde studies in zmvel de placebogroep als de 
GP IIb/lIIa behande1groep. Voorts werd acute bypasschirurgie in deze studies niet 
gecompliceerd door een verhoogd b10edingsrisico bU gebruik van GP TIb/IIIa 
receptor blokkers. 
G/ycoproteine lib/ilia receptor b/okkers en coronaire interventie 
Behandeling met intraveneuze GP IIb/IIIa l'eceptor bloHers b(j patienten met 
acute coronaire syndrol11en zonder pcrsistcrende ST-segment elevatie heeft 
geresulteerd in een reductic in het salncngestelde eindpunt van l110rtaliteit en 
myocardinfarct van 10-50%. Echtel~ gezicn het gunstige effect van deze middelen 
bij percutanc coronaire intervenUe bcstond cr onduidelijkheid of het effect bij acute 
coronairc syndromen voorbehouclcn "was aan patienten die een percutane coronaire 
interventie onder studie-l11edicatie ondcrgingcn. Er 'waren 3 klinische studies die 
konden helpen clit vraagstuk op te 10ssen. 
Dientengevolge hebben we in hootdstuk 7 data uit de CAPTURE, PURSUIT 
en PRISM-PLUS stuelies geana1yseerd, welke respectievelijk het effect van de GP 
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lib/lIla receptor blokkers abciximab, eptifibatidc en tirofiban bestudeerden bij de 
behandeling van patientcn nlet acute coronaire syndromen zunder persisterendc 
ST-segl11cnt elcvatic, allen ll1ct cen periode van illfnsie van stuelie llledicatie 
Vaal' cen eventucle percl1tane coronaire interventic, Gedurende deze periode van 
enkel ll1cclicmnenteuzc behandeling liet elk van dcze studies een significante 
reductic zicn in hst gec01nbineerde eindpullt van 1110rtaliteit en nict~fataal 
myocardinfarct in de paticntcngroep gerandomiseerd 11aaf de GP nb/I1Ia receptor 
blokker ten opzichte van de placebogroep. Gecombineerd lieten deze 3 studies een 
eindpunt percentage zien van 2.5% in de GP lib/lIla receptor blokker groep 
(n ~ 6125) in deze periode versus 3.8% in de placebogroep (n ~ 6171), hetgeen een 
relatieve reductic van 34% itnpliceert (p < 0.001). TijdcllS behandeling lnet studie 
nledicatie werd een percutane coronaire interventie verricht bij 1358 patienten 
in de GP lIb/lIIa reccptorblokker groep versus 1396 patienten in de placebogroep. 
Ret eindpunt perccntage binnen de eerstc 48 UUT na percutane coronaire 
interventie ·was \VedCr0111 significant lageT in de GP IIb/lIla receptor blokker groep 
(4.9% versus 8.0%; 41 % reductic; p < 0.001). Noch een additionecl gunstig cffect 
noch een negatief effect werd gezien in dc periode aanvangend 48 lIllr na de 
percutane coronaire interventic. 
Deze data suggereren dat additiollcle throlllbocytenrcnuning 111et GP 
lIb/IlIa receptor blold<ers naast behandeling met aspirine en heparine, gestart direkt 
na opnanw, een gunstig effect heeft bij patienten Inet acute coronaire syndromen 
zonder persistercnde ST-segtllent elevatic. Deze hypothese wordt nader onderzocht 
in de GUSTO-IV-ACS stuelie die binnenkort zal wordcn gerapporteerd. Vcrder kan 
vwrden gesteld dat bij patiellten die vervolgens een percutane coronaire interventic 
ondergaan intensieve thrombocytenreml11ing beschenllend wcrkt tegcn 
111yocardschade ten gevolge van de interventie. Dus, 0111 111axitnaal effect te 
bewerkstelligen, (lient de behancleling met GP llb/Illa receptor bloldcers vroeg na 
ziekellhuisopname te \\'urclen gestart en te worden gecolltinueerd tot na de 
interventie bij patienten die vervolgens een percutane coronairc illterventie 
ondergaan. 
Studies bij patienten die een percutane coronaire intcrventie olldergaall en 
behandeld worden11let GP lIb/lIla receptor blokkers laten allen eell consistente 
reductie in interventie- gerelateerde myocardinfarcten zien. Bet Ineerendeel 
van deze infarcten traden op tijdens de interventie en werden gekennlerkt door 
verhoogde creatine kinase-ME waarden in hct bloed zander duidel~jke klinische 
symptomen. Ondanks het feit dat studies een proportionele relatie hebben laten 
zien tussen de 111ate van creatine kinase-MB clevatie na de interventie encrzijds 
en het risico op een nadeligc klinische prognose bij langdurige follow-up 
(l11ortaliteit, myocardinfarct en noodzaak tot het vcrrichten van coronaire 
revascularisatie) andcrzijds, blijft de betekenis van deze ilnplicatie van creatine 
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kinase~MB elevatie na pcrcutane coronairc illtcrventie cell discussiepunt binnen 
de intervcntiecardiologic, De prognostischc betekenis van k1cine 111yocardinfarcten 
die spontaan optrcdCll tijdens onstabiele angina pectoTis of na cell acuut 
myocardinfarcl staat daarcntegen weI duidelijk vast. 
In hoofdstuk 3 hebben we daamm bij 8838 patienten die een percntane 
coronaiTc interventie ondergingen de Tclatie hlssen de hoogte van de CK~MB stijging 
binncn 48 UUf 11a de interventie en 1110rtaliteit 11a 6 l11aancien follm\T-up dUllr 
vcrgeleken 111et de relatie tussen de hoogte vall de CK-MB stUging en lllortaliteit 
bij 5583 PURSUIT patienten luet acute coronaire syndrOlnen zander pcrsisterencle 
ST-segmcnt cleva tie die l11cdicanlcnten8 ·werdcn behandeld. In beide 
patientengrocpen was st\jging van de CK-IvIB -waarden geassocieerd 111et een 
gclcidelijke toenanlC van de nlOrtaliteit op 6 maandcn. De mortaliteitspercentages 
na 6 111aanc1en 1Naren lager na intcrventie-gerelatecrde infarcten dallna spontane 
inf1u-cten. Echtel~ de relatieve toCna111e in mortaliteit na 6 maanden geassocieerd 
ll1Ct elke stijging in maximale CK-MB v,raarde "'was voor enzYlnstijgingen na 
pcrcutane coronaire interventie cvcn groat als voor spontane enzY111stijgingen bij 
acute coronairc syndromen. 
De sterke relatie tussen de 111ate van enzY111stijging na interventie en 
1110rtaliteit na 6 11laanden suggereert dat myocardschade ontstaan gedurcndc dc 
intervelltie een belangrijke prognostische factor is, geassocieerd l11et een nadelige 
klillische uitkOlllst. Dientengevolge lijkt preventie van nlyocardschade door 
behandeling met GP Ilb/IlIa receptor blokker8 van klinisch be lang om de lange-
tenllijn UitkOlust tc verbeteren van patienten die een percutane corona ire 
interventie ondergaan. Een recente lueta-analyse van alle studies met abcixitllab 
bij patienten die een percutane coronaire intcrventie ondergaan, onderschrijft dit 
concept door te laten zien dat behandeling met deze GP lIb/IlIa receptor b10kker 
tijdens de interventie resulteert in een 30% relatieve reductic in het risico op 
ovcrlijden na 6 maandcn follow-up. De nICcst indruk'\7ekkcnde reductie in 
mortaliteit werel gerapporteerd in de EPISTENT-studie: de leiaars mortaliteit bij 
patienten behandeld nlet een stent was gereduceerd met 58% (van 2.4% in de 
placebogroep tot 1.0% in de abcbdmab-groep; p ~ 0.03). 
Rlslcostratificatie 
Patienten 111et pijn op de borst of met andere klachten suggesticf vaal' een 
acuut coronair syndr00111 en die electrocardiografisch geen persisteTcnde ST-
segment elevatie hebben, vonnen een heterogenc groep met -aanzienlijke variaties 
wat hetreft diagnose en toekOlllstig risico voor cardiale c0111plicatics. Vroege 
risico-stratificatie is bU deze patienten van belallg onl een op ll1aat gesneden 
111edicamentellze en invasieve behandeling aan te kunnen biedcn, gebaseerd op 
het geschatte voordeeI van bchandeling welke 111cestal proportioned verloopt 111et 
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het lisico op een nadclige nitko111st zander die spccifieke therapie. Overecnkomstig 
dient cell gepast hehandelplan tevcns een schatting te gevcll van het basisrisico 
op cen nadeHge nitko111st) hetgeen lean lNorden hercikt door het toepassen van een 
risicostratilicatie-protocol \\'aarin hclangrUke prognostische factoren geintegreerd 
zijn. Diverse risico111odcllen zijn ont'lviklceld voor patienten die zich presenteren 
met cen 111yocardinfarct lllct persisterende ST-segnlcnt elevatic) echter voor 
patientcn 111Ct een aell ut coronair syndroOlll zonder persisterende ST-segnlcnt 
elevatie zijn e1' tot up hedcn slechts weinig 1110dellen ol1t-wikkeld. 
Daar0111 hcbben we in hoofdstuk 10 de relatie onderzocht tnssen enerzijds 
kenn1e1'ken van de patient b~j presentatic en anderzijds mortalitcit 11a 30 dagcn 
alsmede het sa111cngestelde eindpunt van nlOrtaliteit en Inyocardinfarct bij de 9461 
patienten geincludeercl in PURSUIT. Uiteindelijk werden meer clan 20 statistisch 
significante voorspelle1's van mortaliteit en het smnengesteldc eindpunt 
geidentificeerd. De belangrijkste voorspcllers van lllOrtaliteit 'waren leeftijd, 
hartfrequentic, systo1ische bloeddruk, ST-scgu1ent deprcssie, tekenen van hartfalcn 
en stijging van de cardiale enzymen. Voorspellers van nlOrtaliteit 1varen in het 
aIgen1een oak voorspellend Vaal' het sanwngestelde cindpunt van lnortaliteit of 
111yocardinfarct. De helangr\jkste prognostische factoren uit dit risicOlll0dcl 
werden gcbruikt on1 een ecnvoudig nOll1ognull te ont"wikkelen 1\Taanllec het 
risico op ccn cardiale COlllplicatie hinnen 30 dagen geschat kan worden. 
Ecn deel (15-20%) van de paticnten die zich prescnteren l11et een 
venlloedclijk acuut coronair syndroOln blijken b~j coronaiT-angiografic geen 
significante atherosclcrotische Iaesic te hebben. Thnvijl coronair-anatOlnie met 
cOlllplexe laesies geldt als een sterke voorspeller van een slechtc prognose bij acute 
coronaire syndroll1cn, is de lange-termijn uitkomst en de effectiviteit van 
thrOll1bocytenrenul1ende therapic b~j patienten u1et acute coronaire syndromen 
dic geen significantc coronaire lacsies blijken tc hebben nog niet goed vastgesteid. 
DaarOlll evalucerden we in hoofdstuk 11 de gegevens van patienten die 
binnen PURSUIT cen coronai1'-angiografie oudergingen en vergelcken 'ive de 
klinische kenn1c1'kcn, de reaktie op behandeling en de uitkomst van patienten n1ct 
niet-significante coronairsclerosc 111et die van patienten l11Ct significante coronairc 
atherosclerotische laesies. Van de 5767 patienten met acute coronaire syndrOll1en 
zonder persistercnde ST-segl11ent eleva tie dic coronair-angiografie ondergingcn, 
had BB% significante corona ire laesies (l of meerdcre stenosen >50%)1 6% 
matige-ernstigc laesies (stenose >0%::::; 50%) en 6% geen laesies (gecn stenose). 
Patienten verdacht van een aCl1ut coronair synclroOlll die geen significante 
coronaire laesie bij angiografie bleken tc hebben, hadden een laag risico op 
cardiale c01nplicaties. Daar waar patienten n1et niet-significante coronairsclerose 
geen haat hadden van hehandeling met cle GP IIb/II1a blokker eptifibatide, bleek 
het effect van bchandeling bij patienten l11et significante lacsiesjuist toegenOlllen. 
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Klinischc kenlnCrken 'wcTden gebruikt 0111 cen eenvoudig 1l011logrmn tc 
ollt'wikkclen dat nau'wkeurig de 'waaTschijnlijkheid van niet-signitlcant 
coronairlijden voorspelde. Dit n01110granl ka11 gehruikt worden wanneer een 
patient zich in het ;;,iekenhuis presenteert. Het n01110granl werd gevalideerd 
binnen een aparte groep patienten 111et acute co1'o11aire syndr01llCn zander 
persisterende ST-segment elevatie. 
Conc1uderend, een vroege indeling van patienten verdacht van een aCl1ut 
coronair syndro0111 naa1' een hoog- of laag-risicogroep door in het klinische 
heslissingsproces gebrl1ik te llwken van de voorspellende risico-tl1odellen zoals 
\veergegeven in hoofdstul{ 10 ell 111 lmn van nut zUn bU het verflinen van de 
risicostratificatie van acute ischaenlische coronaire syndr0111en en bU het be palen 
van indicaties Vaal' behandeling met een GP lIb/IlIa b10kker 
Na opnanle in het ziekenhuis kan de aalTwezigheid van voorbijgaande 
episodes van isehaenlie tijdens continue ECG-be";Naking belangrUke additionele 
informatie verschaffen voor het proees van risicostratificatie. Het is gebleken dat 
terugkerende episodes van ischaeluie geregistreerd luet Holter-be"waking of 
gecomputeriseerde ECG-analyse bU patienten met een acuut coronair syndroo111 
geassocieerd is lllet een verhoogd risico op overIijden en nlyocardinfarct. Deze 
relatie hlssen terugkerende episodes van ischaemie en een nadelige uitkomst wenl 
geverifieerd in een snbstudie van PURSUIT, "waarbij een compnter-ondersteund, 
12-afleidingen ECG-bewakingssysteem gebruikt werd, dit in tegenstelling tot 
eerdel'e studies waarbij gebruik werd gemaakt van Holter-be"waking met 2- of 3-
afleidingen of vectorcardiografische bewaking. De resultaten van deze stu die 
zijn 'weergegeven in hoofdstuk 9. 
Daar C0111IJutel'-ondersteunde, 111ultilead ECG-registratie de Inogelijkheid 
biedt tot accurate continue on-line 111eting van QRS-c0111plex en ST-seglnent, kan 
het gebruikt \\Torden als een niet-invasiefinsh·un1ent voor on-line risicosh'atificatie 
bij patienten 111et acute eoronairc syndr0111en, elit in tegcnstelling tot HoIter-
registratie welke gelhniteerd wordt door ecn beperkt aantal ECG-atleidingen en 
a11een kan worden gebruikt voor retrospccticve analyse. Echtel~ cerdere studies 
naal' de relatie tussen tcrugkerendc episodes van ischac1nic geregistreerd 111et 
continue nluItiIead ECG-bewaking en prognose \\Tcrden beperkt door k1eine 
patienten-aantallen. Door gcgevens van 3 vcrschillende studies te cOlnbineren, 
tracht de analyse besehTeven in hooiastuk 12 een accurate bepaIing te geven van 
de invloed van terugkerende episodes van ischae111ie zoals geregistreerd met 
mnltHead ECG-bcwaking op het 11Sico op overIijden enlnyocardillfarct b~j patienten 
opgenOlnen lllet eell acuut coronair syndroOlll. 
Deze stu die is l1lC~t bijna 1000 patienten hct grootstc onderzoek naar de 
prognostische betckenis van terugkerende episodes van ischaCll1ie gcregistreerd 
met computel'-ondcrsteulldc nluItilead ECG-bewaking bij patienten nlet acute 
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coronaire sync1romen zundel' persisterende ST-segnwut eleva tic. Dc belangrUJu;te 
bevincling '\7as cell proportionele relatie tussen het aantal episodes van ischacmie 
gedurende 24 UUl' en de leans op het optreden van cardiale cOlllplicatics 11a 5 en 
30 dagcn folluw-up. Het saIllcngestelcle eindpl111t van 1110rtaliteit en l11yocardinfarct 
11a 30 dagcn trad op bij 5.7% van de patienten zundel' episodes van ischaClllie en 
dit pCTcentage steeg 11aaT 19.7% voor patienten 111ct ~5 episodes van ischacluic. 
Na concetic voor paticntkarakteristieken geassocieerd 111et een slechte prognosc 
nan1 het relatieve risico op lllortaliteit en l11yocardinfarct na 5 en 30 dagan lllCt 
tclkens 25% toe voor elke episode van ischaenlie per 24 uue 
Andere recente studies hebben laten zien dat de prognostische betekenis 
van terugkerende episodes van ischaC111ie geregistreerd Inet continue, COlnputer-
ondersteunde, Inultilead ECG-be,\7aking onafhankelUk is van en van toegevoegde 
'waarde is aan niet aIleen de patientkarakteTistieken en het opname-ECG, 111aar 
oak de waarden van hiochen1ische stoffen die necrose van myocarcl\veefsel 
aanduiden, inclusief creatine kinase-ME en troponine. Hieruit kan worden 
geconcludeerd dat verdergaande integra tie van continue, mu1tilead ECG-
be,\vakingssystelnen op hartbewaldngsaH:lclingell en spoedeisende hulp-afdelingen 
nlOet worden aanbevolen 0111 de risicostratificatie van patienten opgenOlnen Inet 
een acuut coronair syndr00111 te verbeteren. 
Orale glycoproteine lib/ilia receptor blokkers 
Hoewel behandeling met intraveneuze GP lIb/IlIa receptor blokkers het 
aautal thrOlubotische cOluplicaties vern1indert bU patienten met acute coronaire 
syndTo111en en bij patienten die een percutane coronaire interventie ondergaan, 
bl~iven tlu0111bocyten gednrende enkele ',"Teken tot maanden na het acute corona ire 
syndro0111 in een geactiveerde staat. Dit snggereert dat langdurige rCl111ning van 
thrombocytenaggregatie middels orale GP lib/lIla receptor blokkers een additionele 
reductie in cardiale C0111plicaties zon kunnen bewerkstelligen bij patienten met 
acute coronaire syndromen. In de hoofdstukken 13 en 14 beschrijven we de fase 
II klinische ontwikkeling van lefradafiban, een pro-drug dat oraal wordt toegedienc1 
en in het lichaatn in twee stappen wordt gen1etaboliseerd tot fradafiban, een 
synthetische GP IIb/llla receptor blokket: 
HoofdstuI, 13 beschrijft de eerste fase II stu die waarin vastgesteld werc1 
welke dosis van lefrac1afiban resulteert in 80% blokkade van de GP lIb/IlIa 
receptoren door fradafiban (FRO = fibrinogen receptor occupancy), en bestudeert 
de farmacodynamiek en veiligheid van verschillende lefradafiban doseringen 
wanneer dit gedurende 48 UUl' 'wordt toegediend aan 64 patienten met stahiel 
coronairlUden die een percutane coronaire angioplastiek ondcrgaan. De toename 
in plasmaconcentratie van fradaftban ·was dosis-afhankelijk van de toediening van 
lefradafiban. Er bestond eell sterke correlatie tussen de plaslllaconcentratie van 
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fradafiban en de FRO-'waarden. Thenanle in FRO-i\7-aarden was dosis-afhankelijk 
van de toediening van lcfradafiban. Medianc FRO-"waarden 'waren 0% in de 
placebogroep, 71 % in de patientengroep behandeld met dde maal daags 30 mg 
lefradafiban, 85% in de paticntengroep behandeld ll1Ct drie maa1 daags 45 lUg en 
88% in de graep behandeld met drie maal daags 60 mg. Fradafiban plasmaspiegels 
va11170 llg/ n11 \\7aren nodig 0111 cell FRO-"waarde van 80% te bereiken. Dc variatie 
in FRO-1Naarde binnen elke patient 'was gering, tcrw-ijI de varia tic tussen 
verschillcndc patienten in de lage doseringsgroep grater \VBS dan in de hoge 
doscringsgrocp, hetgecn de relatic tussen de plasmaconccntratie en FRO-waarde 
i\7ccrspiegeldc. RcmBling van thrOlnbocytenaggregatie was sterk gecorrelccrd 
luct de FRO-\\7aarde. Ernstige bioedingsC0111plicaties traden niet op. I3ehandeling 
ll1et dric 111aal daags lefradafiban 60 111g "was geassocieerd ll1et een hoge incidentie 
(7196) van geringe en niet-significante bloedingen. Dc incidentie van 
bloedingscOl11plicaties "was 44% in de lefradafiban 30 lUg en 45 lUg 
behandelgroepen, vergeleken Inet 9 % in de placehogroep. Bloedingen ter plaatse 
van vasculairc punctieplaatsen waren het nleest frequent. Hct bloedingsrisico naIn 
lllet 3 % toe voor e1ke 1 % toenalllC in FRO-"waarde. 
Gebaseerd op de resultaten van deze eerste fase II studie hehben we een 
twecdc studie uitgevoerd welke op dubbelblinde en gerandOluizeerde nlanier bU 
531 patienten luet acute coronaire synclromen zonder persisterende ST-seg111ent 
cleva tie de veiligheid en effectiviteit onderzocht van een I-maand durende 
behandeling met 3 verschillende lefradafiban doseringen (20 mg, :10 mg en 45 mg 
drie nlaa1 daags versus placebo), Deze studie ';\Tordt gepresenteerd in hoofdstul( 
14. Hoewel deze stuelie niet onhvurpen was onl verschil1en in effectiviteit tussen 
de behande1groepen aan tc tonen, hestand er cen trend tot een reductie in 
cardiale eindpl1nten in de patientengroep behandeld met 30 mg lefradafiban ten 
opzichte van de patientengraepen behandeld met placebo en 20 mg lefradafiban. 
Het gunstige effect was lllet name duidelijk bij patienten met een verhoogde (~O.l 
ng/ml) troponine-l waarde bij aanvang van bchandeling elllninder bU patienten 
zonder verhoogde traponine-I waarde. Bij patienten behandeld lllet lefradafiban 
daalde het percentage cardiale eindpuntcn lllct toenelnende FRO-"'waarden. Er 
bestond een dosis-afhankelUke toenanle in het risico op blocdingscomplicaties. 
Het samengestelde eindpunt van ernstigc en geringe hloedingen trad op hij 1 % 
van de patienten in de p1acebogroep, bij 5% van de patienten behandeldl11et 20 
mg lefradafiban Cll b~j 7% van de patienten behandeld lllet 30 mg, 111et cell 
overmatig bloedingsrisico van 15% in de 45 lng groep waardoor behandeling 
met deze dosering voortijdig werd beeindigd. SI\imvliesbloedingen en bloedingen 
vanuit arterifHe ofvencuze pUllctieplaatsC1l 1Naren het meest frequent en nalllCn 
meet' dan 60% van aUe b10edingsC0111plicatics voor hun rekening. Een verhoogde 
incidentie van neutropcnic (neutrofielen < 1.5xl09 / ltr) werd gcconstateercl in de 
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gec0111binccrdc lcfradafiball groep (5.2 % versus 1.5% in de placcbogrocp)1 hetgeen 
niet het gcvolg ·was van bCelll11crgdepressic, 111a31' cerdcI van cen revcrsibele 
rcdistributie van ncutrofiele granulocyten cloor 111arginatie of clustering. 
Het slothoofdstuk SUlllluary and conclusions bevat uitgcbrcidc 
sanlCllvattingen van de in clit proefschrift heschreven hoofdstukken, 'Levens 
\\7orden recente ontwikkelingen op het gebied van de orale GP lIb/IlIa receptor 
blokkers heschreven alsmede op het gebied van de gecOlnhineerde toediening van 
GP lIb/lIla receptor blokker8 en thwmbolytica bU de behandeling van patienten 
111Ct cen acuut myocardinfarct met ST-elevatie. Tevens worden kart enkele 
mogelijke toekom8tige olltwikl<elingen be8pwken up het gebied van de GP lIb/IlIa 
receptor blokkers en de behancleling van patienten Inet acute coronaire :3yndronlfm. 
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Een proefschrift is het resultaat van salnenwerking Inet anderen. rk '\Vil 
iedereen heclankcn die aan het tot stand k0111Cn van dit proefschrift hccft 
bijgedragen. Enkelcll ·wil ik hier speciaal 110C111en. 
In de cerste plaats bcdank ik mijn prOlllotor Prof. dr. M.L. Shl1oons. Beste 
Maarten, je hebt 1115 de principes van het klinisch onderzoek gelccrd en gafulC 
hct vertrollwen 0111 te opereren binncn cen grote, internationalc groep van 
vooraanstaande onclerzockers. Na een enigszins bchoudende statt l11ijnerzijds is 
011ze smnenwerking de afgelopen jarcn steeds toegen0111cn. Jc hebt 1115 
gcstilnuleerd 0111 met ll1ccrdcre projecten tegelijkcrtijd bCl';ig te zijn en maakte 
het Vaal' 11l~i een uitdaging 0111 voor elk doorjoll bcoordeeld manuscript een nieuwe 
aan te bieden. Hierdoor is hct nlOgelijk geweest dit procfschrift in 2,5 jaar tijd af 
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